OA16399A - Crystalline forms of hydrochloride salt of (4AR, 9A-S)-1-(1H-benzoimidazole-5-car-bonyl)-2, 3, 4, 4A 9, 9A-hexahydro-1H-indeno[2, 1-B] pyridine6-carbonitrile and their use as HSD 1 inhibitors. - Google Patents
Crystalline forms of hydrochloride salt of (4AR, 9A-S)-1-(1H-benzoimidazole-5-car-bonyl)-2, 3, 4, 4A 9, 9A-hexahydro-1H-indeno[2, 1-B] pyridine6-carbonitrile and their use as HSD 1 inhibitors. Download PDFInfo
- Publication number
- OA16399A OA16399A OA1201300181 OA16399A OA 16399 A OA16399 A OA 16399A OA 1201300181 OA1201300181 OA 1201300181 OA 16399 A OA16399 A OA 16399A
- Authority
- OA
- OAPI
- Prior art keywords
- ppm
- compound
- crystalline form
- group
- single crystalline
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 36
- 239000003112 inhibitor Substances 0.000 title abstract description 17
- 150000003840 hydrochlorides Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 528
- 102000004277 11-beta-Hydroxysteroid Dehydrogenases Human genes 0.000 claims abstract description 16
- 108090000874 11-beta-Hydroxysteroid Dehydrogenases Proteins 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 208000008466 Metabolic Disease Diseases 0.000 claims abstract description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 195
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 101
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 52
- 238000001816 cooling Methods 0.000 claims description 50
- 239000000126 substance Substances 0.000 claims description 41
- 238000003756 stirring Methods 0.000 claims description 32
- 239000012458 free base Substances 0.000 claims description 30
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 abstract description 5
- 235000020824 obesity Nutrition 0.000 abstract description 5
- 206010058108 Dyslipidaemia Diseases 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 206010061227 Lipid metabolism disease Diseases 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- -1 heterocyclic amines Chemical class 0.000 description 416
- 238000001819 mass spectrum Methods 0.000 description 271
- 239000000203 mixture Substances 0.000 description 255
- 238000000034 method Methods 0.000 description 209
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 195
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 176
- 239000000243 solution Substances 0.000 description 152
- 239000000543 intermediate Substances 0.000 description 108
- 229910001868 water Inorganic materials 0.000 description 103
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 102
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 99
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 98
- 229910052739 hydrogen Inorganic materials 0.000 description 80
- 239000001257 hydrogen Substances 0.000 description 80
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 79
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 75
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 68
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 67
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 66
- 239000002904 solvent Substances 0.000 description 62
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 58
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 58
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 57
- 238000006243 chemical reaction Methods 0.000 description 56
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 55
- 125000003118 aryl group Chemical group 0.000 description 53
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 51
- 239000002253 acid Substances 0.000 description 49
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 49
- 230000000875 corresponding Effects 0.000 description 48
- 239000000741 silica gel Substances 0.000 description 48
- 229910002027 silica gel Inorganic materials 0.000 description 48
- 239000011780 sodium chloride Substances 0.000 description 48
- 239000012071 phase Substances 0.000 description 47
- COYPLDIXZODDDL-UHFFFAOYSA-N 3H-benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CNC2=C1 COYPLDIXZODDDL-UHFFFAOYSA-N 0.000 description 43
- 239000000460 chlorine Substances 0.000 description 43
- 150000003839 salts Chemical class 0.000 description 43
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 41
- 229910052731 fluorine Inorganic materials 0.000 description 41
- 239000011737 fluorine Substances 0.000 description 38
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 38
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 38
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 37
- 239000007787 solid Substances 0.000 description 37
- 125000004432 carbon atoms Chemical group C* 0.000 description 32
- 229910052801 chlorine Inorganic materials 0.000 description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 31
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 31
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 29
- 125000004093 cyano group Chemical group *C#N 0.000 description 29
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 28
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 28
- 239000003054 catalyst Substances 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
- 229960000583 Acetic Acid Drugs 0.000 description 25
- 235000011054 acetic acid Nutrition 0.000 description 25
- 238000001914 filtration Methods 0.000 description 25
- 239000002244 precipitate Substances 0.000 description 25
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 24
- 239000000284 extract Substances 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 23
- 239000000523 sample Substances 0.000 description 23
- 239000000706 filtrate Substances 0.000 description 22
- ITMCEJHCFYSIIV-UHFFFAOYSA-N Trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 21
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 21
- 150000002431 hydrogen Chemical class 0.000 description 21
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 21
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 239000002585 base Substances 0.000 description 19
- 229910052799 carbon Inorganic materials 0.000 description 19
- 238000007792 addition Methods 0.000 description 18
- 239000012267 brine Substances 0.000 description 18
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 229910052763 palladium Inorganic materials 0.000 description 18
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 17
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 17
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 17
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 17
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 16
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 16
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 16
- 229910052740 iodine Inorganic materials 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 230000001131 transforming Effects 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 15
- MVPPADPHJFYWMZ-UHFFFAOYSA-N Chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 14
- 229910052786 argon Inorganic materials 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 14
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 14
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 14
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 13
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 13
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 13
- 125000003277 amino group Chemical group 0.000 description 13
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 13
- 239000001569 carbon dioxide Substances 0.000 description 13
- 229910002092 carbon dioxide Inorganic materials 0.000 description 13
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 13
- 229910000033 sodium borohydride Inorganic materials 0.000 description 13
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 12
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 12
- 239000000654 additive Substances 0.000 description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 12
- 239000012039 electrophile Substances 0.000 description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 12
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 11
- 150000001408 amides Chemical class 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 11
- 239000008079 hexane Substances 0.000 description 11
- KLGZELKXQMTEMM-UHFFFAOYSA-N hydride Chemical compound [H-] KLGZELKXQMTEMM-UHFFFAOYSA-N 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 125000006239 protecting group Chemical group 0.000 description 11
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 239000002841 Lewis acid Substances 0.000 description 10
- 125000002252 acyl group Chemical group 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 229960000890 hydrocortisone Drugs 0.000 description 10
- 150000007517 lewis acids Chemical class 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 125000004076 pyridyl group Chemical group 0.000 description 10
- 241000894007 species Species 0.000 description 10
- YKIOKAURTKXMSB-UHFFFAOYSA-N Adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 125000004104 aryloxy group Chemical group 0.000 description 9
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 125000002541 furyl group Chemical group 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 9
- 125000005842 heteroatoms Chemical group 0.000 description 9
- 125000001041 indolyl group Chemical group 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- 230000002829 reduced Effects 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 239000002002 slurry Substances 0.000 description 9
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 9
- 125000001544 thienyl group Chemical group 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 8
- XMPZTFVPEKAKFH-UHFFFAOYSA-P Ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 229910019020 PtO2 Inorganic materials 0.000 description 8
- CSRZQMIRAZTJOY-UHFFFAOYSA-N Trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 8
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 8
- 150000001298 alcohols Chemical class 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 239000003125 aqueous solvent Substances 0.000 description 8
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 8
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 229910052802 copper Inorganic materials 0.000 description 8
- 239000010949 copper Substances 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 150000002430 hydrocarbons Chemical group 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 8
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 8
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 8
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 7
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 150000008064 anhydrides Chemical class 0.000 description 7
- 230000003042 antagnostic Effects 0.000 description 7
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 7
- 230000001808 coupling Effects 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- TUCNEACPLKLKNU-UHFFFAOYSA-N ethanone Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 150000002440 hydroxy compounds Chemical class 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 125000004537 indazol-5-yl group Chemical group N1N=CC2=CC(=CC=C12)* 0.000 description 7
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 125000000468 ketone group Chemical group 0.000 description 7
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 7
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 7
- 229910052759 nickel Inorganic materials 0.000 description 7
- 150000002825 nitriles Chemical class 0.000 description 7
- 125000000168 pyrrolyl group Chemical group 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 229910052725 zinc Inorganic materials 0.000 description 7
- 239000011701 zinc Substances 0.000 description 7
- ILAHWRKJUDSMFH-UHFFFAOYSA-N Boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
- WTEOIRVLGSZEPR-UHFFFAOYSA-N Boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 6
- 210000002356 Skeleton Anatomy 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M Sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 230000000996 additive Effects 0.000 description 6
- 239000003513 alkali Substances 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- 150000001491 aromatic compounds Chemical class 0.000 description 6
- 125000004429 atoms Chemical group 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- UGFAIRIUMAVXCW-UHFFFAOYSA-N carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 150000001733 carboxylic acid esters Chemical class 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 125000001841 imino group Chemical group [H]N=* 0.000 description 6
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 6
- 230000001404 mediated Effects 0.000 description 6
- 229940098779 methanesulfonic acid Drugs 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000010948 rhodium Substances 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 6
- WHUPHUJYROLPBP-OLZOCXBDSA-N (4aS,10bR)-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline Chemical compound C1CC2=CC=CC=C2[C@@H]2[C@H]1NCCC2 WHUPHUJYROLPBP-OLZOCXBDSA-N 0.000 description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 5
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 5
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 5
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N Tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 5
- GTLDTDOJJJZVBW-UHFFFAOYSA-N Zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 230000001476 alcoholic Effects 0.000 description 5
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 5
- 229910000085 borane Inorganic materials 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 150000001728 carbonyl compounds Chemical class 0.000 description 5
- 210000004027 cells Anatomy 0.000 description 5
- XFXPMWWXUTWYJX-UHFFFAOYSA-N cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 5
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 5
- 238000006193 diazotization reaction Methods 0.000 description 5
- 229960004132 diethyl ether Drugs 0.000 description 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 150000004820 halides Chemical class 0.000 description 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 125000001624 naphthyl group Chemical group 0.000 description 5
- 239000012038 nucleophile Substances 0.000 description 5
- 229910052703 rhodium Inorganic materials 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- WHUPHUJYROLPBP-STQMWFEESA-N (4aS,10bS)-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline Chemical compound C1CC2=CC=CC=C2[C@H]2[C@H]1NCCC2 WHUPHUJYROLPBP-STQMWFEESA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- KCKZIWSINLBROE-UHFFFAOYSA-N 3,4-dihydro-1H-naphthalen-2-one Chemical class C1=CC=C2CC(=O)CCC2=C1 KCKZIWSINLBROE-UHFFFAOYSA-N 0.000 description 4
- QCNGRUOQNGJXJU-UHFFFAOYSA-N 3-(3-methoxyphenyl)pyridine-2-carboxylic acid Chemical compound COC1=CC=CC(C=2C(=NC=CC=2)C(O)=O)=C1 QCNGRUOQNGJXJU-UHFFFAOYSA-N 0.000 description 4
- KBDIRPOTVAODSA-UHFFFAOYSA-N 3-bromopyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=C1Br KBDIRPOTVAODSA-UHFFFAOYSA-N 0.000 description 4
- LBKFGYZQBSGRHY-UHFFFAOYSA-N 3-hydroxy-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1O LBKFGYZQBSGRHY-UHFFFAOYSA-N 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-Hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- PMXLQNFJWWBNQA-UHFFFAOYSA-N 5,6-dihydrobenzo[f]quinoline Chemical compound C1=CC=C2CCC3=NC=CC=C3C2=C1 PMXLQNFJWWBNQA-UHFFFAOYSA-N 0.000 description 4
- RCUKIURSBATLLJ-UHFFFAOYSA-N 6-methoxyindeno[2,3-b]pyridin-9-one Chemical compound C1=CC=C2C3=CC(OC)=CC=C3C(=O)C2=N1 RCUKIURSBATLLJ-UHFFFAOYSA-N 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K Aluminium chloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- YYLLIJHXUHJATK-UHFFFAOYSA-N Cyclohexyl acetate Chemical compound CC(=O)OC1CCCCC1 YYLLIJHXUHJATK-UHFFFAOYSA-N 0.000 description 4
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 4
- XJLXINKUBYWONI-NNYOXOHSSA-N Nicotinamide adenine dinucleotide phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N Nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N Phosphorus pentoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 4
- 239000007868 Raney catalyst Substances 0.000 description 4
- 229910000564 Raney nickel Inorganic materials 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 229910000090 borane Inorganic materials 0.000 description 4
- 229950005499 carbon tetrachloride Drugs 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- DMJZZSLVPSMWCS-UHFFFAOYSA-N diborane Chemical compound B1[H]B[H]1 DMJZZSLVPSMWCS-UHFFFAOYSA-N 0.000 description 4
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 4
- 125000006575 electron-withdrawing group Chemical group 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- UMJJFEIKYGFCAT-UHFFFAOYSA-N indan-2-one Chemical class C1=CC=C2CC(=O)CC2=C1 UMJJFEIKYGFCAT-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N iodine atom Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 125000002346 iodo group Chemical group I* 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- QMMFVYPAHWMCMS-UHFFFAOYSA-N methyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- YGYAWVDWMABLBF-UHFFFAOYSA-N phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 4
- 150000003378 silver Chemical class 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000005694 sulfonylation reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002076 thermal analysis method Methods 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 3
- MRYASQNSJAHEQV-UHFFFAOYSA-N 1$l^{2}-azolidin-2-one Chemical group O=C1CCC[N]1 MRYASQNSJAHEQV-UHFFFAOYSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 3
- HVRCLXXJIQTXHC-UHFFFAOYSA-N 1-methylindole-3-carboxylic acid Chemical compound C1=CC=C2N(C)C=C(C(O)=O)C2=C1 HVRCLXXJIQTXHC-UHFFFAOYSA-N 0.000 description 3
- ZQDVOTYYCJHZES-UHFFFAOYSA-N 10-bromo-5,6-dihydrobenzo[f]quinoline Chemical compound C1CC2=NC=CC=C2C2=C1C=CC=C2Br ZQDVOTYYCJHZES-UHFFFAOYSA-N 0.000 description 3
- MPOGNEQWFLEINN-UHFFFAOYSA-N 10-methoxy-5,6-dihydrobenzo[f]quinoline Chemical compound C1CC2=NC=CC=C2C2=C1C=CC=C2OC MPOGNEQWFLEINN-UHFFFAOYSA-N 0.000 description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
- NRVIZYWYHXROKA-UHFFFAOYSA-N 1H-imidazo[4,5-b]pyridine-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC=NC2=N1 NRVIZYWYHXROKA-UHFFFAOYSA-N 0.000 description 3
- CINJODFGIBPBSD-UHFFFAOYSA-N 2,3,4,4a,4b,5-hexahydro-1H-indeno[2,1-b]pyridine Chemical compound C1=CCC2C(CCCN3)C3=CC2=C1 CINJODFGIBPBSD-UHFFFAOYSA-N 0.000 description 3
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 3
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
- GUOVBFFLXKJFEE-UHFFFAOYSA-N 2H-benzotriazole-5-carboxylic acid Chemical compound C1=C(C(=O)O)C=CC2=NNN=C21 GUOVBFFLXKJFEE-UHFFFAOYSA-N 0.000 description 3
- WSNZTTIWEUZRFR-UHFFFAOYSA-N 8-bromo-5,6-dihydrobenzo[f]quinoline Chemical compound C1=CC=C2C3=CC=C(Br)C=C3CCC2=N1 WSNZTTIWEUZRFR-UHFFFAOYSA-N 0.000 description 3
- PFWJFKBTIBAASX-UHFFFAOYSA-N 9H-indeno[2,1-b]pyridine Chemical compound C1=CN=C2CC3=CC=CC=C3C2=C1 PFWJFKBTIBAASX-UHFFFAOYSA-N 0.000 description 3
- DOBRDRYODQBAMW-UHFFFAOYSA-N Copper(I) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 3
- 229910016523 CuKa Inorganic materials 0.000 description 3
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- VUVGYHUDAICLFK-UHFFFAOYSA-N Perosmic oxide Chemical compound O=[Os](=O)(=O)=O VUVGYHUDAICLFK-UHFFFAOYSA-N 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M Potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M Sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- AKEJUJNQAAGONA-UHFFFAOYSA-N Sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 3
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- IQPQWNKOIGAROB-UHFFFAOYSA-N [N-]=C=O Chemical compound [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000003377 acid catalyst Substances 0.000 description 3
- 230000002378 acidificating Effects 0.000 description 3
- 150000001345 alkine derivatives Chemical group 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 3
- 230000001396 anti-anti-diuretic Effects 0.000 description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000007819 coupling partner Substances 0.000 description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 150000008049 diazo compounds Chemical class 0.000 description 3
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
- 238000006197 hydroboration reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- AMCNGINELBODDW-UHFFFAOYSA-N lithium;triethylboron(1-) Chemical compound [Li+].CC[B-](CC)CC AMCNGINELBODDW-UHFFFAOYSA-N 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 230000000051 modifying Effects 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 150000007530 organic bases Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- HJKYXKSLRZKNSI-UHFFFAOYSA-I pentapotassium;hydrogen sulfate;oxido sulfate;sulfuric acid Chemical compound [K+].[K+].[K+].[K+].[K+].OS([O-])(=O)=O.[O-]S([O-])(=O)=O.OS(=O)(=O)O[O-].OS(=O)(=O)O[O-] HJKYXKSLRZKNSI-UHFFFAOYSA-I 0.000 description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 3
- 150000003003 phosphines Chemical class 0.000 description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Inorganic materials [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000002577 pseudohalo group Chemical group 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- VQMSRUREDGBWKT-UHFFFAOYSA-N quinoline-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=NC2=C1 VQMSRUREDGBWKT-UHFFFAOYSA-N 0.000 description 3
- 239000003638 reducing agent Substances 0.000 description 3
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 3
- 239000005051 trimethylchlorosilane Substances 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-(1R,3R,4S)-menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 2
- OOERPQACTFFTHC-NEPJUHHUSA-N (4aR,9aS)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine Chemical compound C12=CC=CC=C2C[C@H]2[C@@H]1CCCN2 OOERPQACTFFTHC-NEPJUHHUSA-N 0.000 description 2
- MVCGAPKBAFCOJE-AAEUAGOBSA-N (4aS,10bS)-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-9-amine Chemical compound N1CCC[C@H]2C3=CC(N)=CC=C3CC[C@@H]21 MVCGAPKBAFCOJE-AAEUAGOBSA-N 0.000 description 2
- UNEGVVFVYBAGHI-UHFFFAOYSA-N 1,2,3,4,4a,5,6,6a-octahydrobenzo[f]quinoline Chemical compound C1CC2C=CC=CC2=C2C1NCCC2 UNEGVVFVYBAGHI-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N 1,2-dihydrobenzotriazol-4-one Chemical compound O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- HONDCIFZVSMIJQ-UHFFFAOYSA-N 1,3,4,9-tetrahydroindeno[2,1-b]pyridin-2-one Chemical compound C1=CC=C2C(CCC(N3)=O)=C3CC2=C1 HONDCIFZVSMIJQ-UHFFFAOYSA-N 0.000 description 2
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- DMPZJACLHDWUFS-UHFFFAOYSA-N 1,3-benzothiazole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CSC2=C1 DMPZJACLHDWUFS-UHFFFAOYSA-N 0.000 description 2
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 2
- QNDLALRCXRJUKT-UHFFFAOYSA-N 1-benzyl-4-methyl-2,3,9,9a-tetrahydroindeno[2,1-b]pyridine Chemical compound C1CC(C)=C(C2=CC=CC=C2C2)C2N1CC1=CC=CC=C1 QNDLALRCXRJUKT-UHFFFAOYSA-N 0.000 description 2
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
- KAJLCBKTWRUQOI-UHFFFAOYSA-N 1-methylbenzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N(C)C=NC2=C1 KAJLCBKTWRUQOI-UHFFFAOYSA-N 0.000 description 2
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- OUPXSJMXSGNZJT-UHFFFAOYSA-N 10-[(4-methoxyphenyl)methyl]-5,6-dihydrobenzo[f]quinoline Chemical compound C1=CC(OC)=CC=C1CC1=CC=CC2=C1C1=CC=CN=C1CC2 OUPXSJMXSGNZJT-UHFFFAOYSA-N 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- LFJYOICFZUSPRS-UHFFFAOYSA-N 10b-methyl-5,6-dihydro-3H-benzo[f]quinoline Chemical compound C1CC2=CC=CC=C2C2(C)C1=NCC=C2 LFJYOICFZUSPRS-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- MAVGBUDLHOOROM-UHFFFAOYSA-N 1H-indazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NN=CC2=C1 MAVGBUDLHOOROM-UHFFFAOYSA-N 0.000 description 2
- IENZCGNHSIMFJE-UHFFFAOYSA-N 1H-indole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC=CC2=C1 IENZCGNHSIMFJE-UHFFFAOYSA-N 0.000 description 2
- GHTDODSYDCPOCW-UHFFFAOYSA-N 1H-indole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=CNC2=C1 GHTDODSYDCPOCW-UHFFFAOYSA-N 0.000 description 2
- CRLSHTZUJTXOEL-UHFFFAOYSA-N 2,2-difluoroacetyl fluoride Chemical compound FC(F)C(F)=O CRLSHTZUJTXOEL-UHFFFAOYSA-N 0.000 description 2
- DOSGEBYQRMBTGS-UHFFFAOYSA-N 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCOCC1 DOSGEBYQRMBTGS-UHFFFAOYSA-N 0.000 description 2
- ZEAKWWWXCZMODH-UHFFFAOYSA-N 2-amino-1,3-benzothiazole-6-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2SC(N)=NC2=C1 ZEAKWWWXCZMODH-UHFFFAOYSA-N 0.000 description 2
- QNBMELTXPLGIMF-UHFFFAOYSA-N 2-amino-3H-benzimidazole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2NC(N)=NC2=C1 QNBMELTXPLGIMF-UHFFFAOYSA-N 0.000 description 2
- STRAEOQKYFMDMG-UHFFFAOYSA-N 2-methyl-1H-indole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC(C)=CC2=C1 STRAEOQKYFMDMG-UHFFFAOYSA-N 0.000 description 2
- GZHWABCBKGMLIE-UHFFFAOYSA-N 2-methyl-3H-benzimidazole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2NC(C)=NC2=C1 GZHWABCBKGMLIE-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- YIGYJEWJHOCKSR-UHFFFAOYSA-N 2-oxo-1,3-dihydrobenzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC(=O)NC2=C1 YIGYJEWJHOCKSR-UHFFFAOYSA-N 0.000 description 2
- LLLKBUWXODIMEW-UHFFFAOYSA-N 2-oxo-1,3-dihydroindole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC(=O)CC2=C1 LLLKBUWXODIMEW-UHFFFAOYSA-N 0.000 description 2
- IIKVTJWRBSYRSA-UHFFFAOYSA-N 2-oxo-1,3-dihydroindole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2CC(=O)NC2=C1 IIKVTJWRBSYRSA-UHFFFAOYSA-N 0.000 description 2
- ZJPCUQHSLWJVOS-UHFFFAOYSA-N 2-oxo-1H-quinoxaline-6-carboxylic acid Chemical compound N1C(=O)C=NC2=CC(C(=O)O)=CC=C21 ZJPCUQHSLWJVOS-UHFFFAOYSA-N 0.000 description 2
- USZSGINUZRHINQ-UHFFFAOYSA-N 2-oxo-3H-1,3-benzothiazole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC(=O)SC2=C1 USZSGINUZRHINQ-UHFFFAOYSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- AULKDLUOQCUNOK-UHFFFAOYSA-N 3,5-dichloro-4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(Cl)=C(O)C(Cl)=C1 AULKDLUOQCUNOK-UHFFFAOYSA-N 0.000 description 2
- ICHGAAALDGDCHR-UHFFFAOYSA-N 3-(3-methoxyphenyl)pyridine-2-carbonitrile Chemical compound COC1=CC=CC(C=2C(=NC=CC=2)C#N)=C1 ICHGAAALDGDCHR-UHFFFAOYSA-N 0.000 description 2
- DGDUWZZICMKBNM-UHFFFAOYSA-N 3-(3-methoxyphenyl)pyridine-2-carbonyl chloride Chemical compound COC1=CC=CC(C=2C(=NC=CC=2)C(Cl)=O)=C1 DGDUWZZICMKBNM-UHFFFAOYSA-N 0.000 description 2
- DMGFVJVLVZOSOE-UHFFFAOYSA-N 3-amino-4-chlorobenzoic acid Chemical compound NC1=CC(C(O)=O)=CC=C1Cl DMGFVJVLVZOSOE-UHFFFAOYSA-N 0.000 description 2
- WFSPEVFSRUTRCN-UHFFFAOYSA-N 3-amino-4-fluorobenzoic acid Chemical compound NC1=CC(C(O)=O)=CC=C1F WFSPEVFSRUTRCN-UHFFFAOYSA-N 0.000 description 2
- FDGAEAYZQQCBRN-UHFFFAOYSA-N 3-amino-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1N FDGAEAYZQQCBRN-UHFFFAOYSA-N 0.000 description 2
- XKFIFYROMAAUDL-UHFFFAOYSA-N 3-amino-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1N XKFIFYROMAAUDL-UHFFFAOYSA-N 0.000 description 2
- PHBYNHYLFOEGDK-UHFFFAOYSA-N 3-bromo-2-(2-phenylethyl)pyridine Chemical compound BrC1=CC=CN=C1CCC1=CC=CC=C1 PHBYNHYLFOEGDK-UHFFFAOYSA-N 0.000 description 2
- HCOPIUVJCIZALB-UHFFFAOYSA-N 3-bromopyridine-2-carbonitrile Chemical compound BrC1=CC=CN=C1C#N HCOPIUVJCIZALB-UHFFFAOYSA-N 0.000 description 2
- QGNLHMKIGMZKJX-UHFFFAOYSA-N 3-chloro-4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(Cl)=C1 QGNLHMKIGMZKJX-UHFFFAOYSA-N 0.000 description 2
- ZQLCWPXBHUALQC-UHFFFAOYSA-N 3-hydroxy-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1O ZQLCWPXBHUALQC-UHFFFAOYSA-N 0.000 description 2
- GKPKZMOUMKZJSM-UHFFFAOYSA-N 3-methylbenzimidazole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2N(C)C=NC2=C1 GKPKZMOUMKZJSM-UHFFFAOYSA-N 0.000 description 2
- 229940000641 4-Aminobenzoic Acid Drugs 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-Aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- YIYBPEDZAUFQLO-UHFFFAOYSA-N 4-amino-3-chlorobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1Cl YIYBPEDZAUFQLO-UHFFFAOYSA-N 0.000 description 2
- JSKXHTHMCCDEGD-UHFFFAOYSA-N 4-amino-3-fluorobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1F JSKXHTHMCCDEGD-UHFFFAOYSA-N 0.000 description 2
- JNFGLYJROFAOQP-UHFFFAOYSA-N 4-amino-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1N JNFGLYJROFAOQP-UHFFFAOYSA-N 0.000 description 2
- JMHSCWJIDIKGNZ-UHFFFAOYSA-N 4-carbamoylbenzoic acid Chemical compound NC(=O)C1=CC=C(C(O)=O)C=C1 JMHSCWJIDIKGNZ-UHFFFAOYSA-N 0.000 description 2
- SCPUNJAMWFAYED-UHFFFAOYSA-N 4-chloro-3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C(O)=C1 SCPUNJAMWFAYED-UHFFFAOYSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- CPNMCWQGESOVJT-UHFFFAOYSA-N 4-methyl-9H-indeno[2,1-b]pyridine Chemical compound C1C2=CC=CC=C2C2=C1N=CC=C2C CPNMCWQGESOVJT-UHFFFAOYSA-N 0.000 description 2
- DESZIYLJMFYSDT-UHFFFAOYSA-N 5,6-dihydrobenzo[f]quinolin-9-amine Chemical compound C1=CC=C2C3=CC(N)=CC=C3CCC2=N1 DESZIYLJMFYSDT-UHFFFAOYSA-N 0.000 description 2
- YARVCOSUDNVNIX-UHFFFAOYSA-N 6,6-dimethyl-5H-benzo[f]quinoline Chemical compound C1=CC=C2C(C)(C)CC3=NC=CC=C3C2=C1 YARVCOSUDNVNIX-UHFFFAOYSA-N 0.000 description 2
- PODNOOSZMXLAAP-UHFFFAOYSA-N 7-methoxy-5,6-dihydrobenzo[f]quinoline Chemical compound C1CC2=NC=CC=C2C2=C1C(OC)=CC=C2 PODNOOSZMXLAAP-UHFFFAOYSA-N 0.000 description 2
- BYMLCFMGXFVMTK-UHFFFAOYSA-N 7-nitro-9H-indeno[2,1-b]pyridine Chemical compound C1=CC=C2C3=CC=C([N+](=O)[O-])C=C3CC2=N1 BYMLCFMGXFVMTK-UHFFFAOYSA-N 0.000 description 2
- NMXQEPCXNXZEGR-UHFFFAOYSA-N 8-benzyl-5,6-dihydrobenzo[f]quinoline Chemical compound C=1C=C(C2=CC=CN=C2CC2)C2=CC=1CC1=CC=CC=C1 NMXQEPCXNXZEGR-UHFFFAOYSA-N 0.000 description 2
- SWLHKCMZNDOONO-UHFFFAOYSA-N 8-methoxy-5,6-dihydrobenzo[f]quinoline Chemical compound C1=CC=C2C3=CC=C(OC)C=C3CCC2=N1 SWLHKCMZNDOONO-UHFFFAOYSA-N 0.000 description 2
- ZMJRASKSDVLWJW-UHFFFAOYSA-N 8-phenyl-5,6-dihydrobenzo[f]quinoline Chemical compound C1=C2CCC3=NC=CC=C3C2=CC=C1C1=CC=CC=C1 ZMJRASKSDVLWJW-UHFFFAOYSA-N 0.000 description 2
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-Borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 2
- PXVCIEJTXDBAIL-UHFFFAOYSA-N 9-methoxy-5,6-dihydrobenzo[f]quinoline Chemical compound C1=CC=C2C3=CC(OC)=CC=C3CCC2=N1 PXVCIEJTXDBAIL-UHFFFAOYSA-N 0.000 description 2
- SQULCWLOSYLXFD-UHFFFAOYSA-N 9-nitro-5,6-dihydrobenzo[f]quinoline Chemical compound C1=CC=C2C3=CC([N+](=O)[O-])=CC=C3CCC2=N1 SQULCWLOSYLXFD-UHFFFAOYSA-N 0.000 description 2
- 229940030600 ANTIHYPERTENSIVES Drugs 0.000 description 2
- 229940117913 Acrylamide Drugs 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N Anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- OBZHEBDUNPOCJG-WBXJDKIVSA-N Carbenoxolone Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC(O)=O)C1(C)C OBZHEBDUNPOCJG-WBXJDKIVSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L Copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N DABCO Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 229940030606 DIURETICS Drugs 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N Dess–Martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- WMKGGPCROCCUDY-PHEQNACWSA-N Dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 2
- KVBKAPANDHPRDG-UHFFFAOYSA-N Dibromotetrafluoroethane Chemical compound FC(F)(Br)C(F)(F)Br KVBKAPANDHPRDG-UHFFFAOYSA-N 0.000 description 2
- ZWWCURLKEXEFQT-UHFFFAOYSA-N Dinitrogen pentoxide Chemical compound [O-][N+](=O)O[N+]([O-])=O ZWWCURLKEXEFQT-UHFFFAOYSA-N 0.000 description 2
- CCGKOQOJPYTBIH-UHFFFAOYSA-N Ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N Ethyl iodide Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- JUINSXZKUKVTMD-UHFFFAOYSA-N Hydrazoic acid Chemical compound N=[N+]=[N-] JUINSXZKUKVTMD-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N Indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N Leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M Lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000005004 MAS NMR spectroscopy Methods 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 230000036650 Metabolic stability Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N Methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- 210000001589 Microsomes Anatomy 0.000 description 2
- 210000001853 Microsomes, Liver Anatomy 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-Bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-Methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- 229910017974 NH40H Inorganic materials 0.000 description 2
- QMMRZOWCJAIUJA-UHFFFAOYSA-L Nickel(II) chloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N Phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- AQSJGOWTSHOLKH-UHFFFAOYSA-N Phosphite Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N Phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N Picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M Potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 102000014961 Protein Precursors Human genes 0.000 description 2
- 108010078762 Protein Precursors Proteins 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N Silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N Sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N Sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M Sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N Sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N Trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 229920004482 WACKER® Polymers 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N ZrO2 Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- OZHFEJMMPQKCFJ-UHFFFAOYSA-N [1-(2,2,2-trifluoroacetyl)-2,3,4,4a,9,9a-hexahydroindeno[2,1-b]pyridin-6-yl] trifluoromethanesulfonate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)C=C2C3CCCN(C(=O)C(F)(F)F)C3CC2=C1 OZHFEJMMPQKCFJ-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000010640 amide synthesis reaction Methods 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000001837 anti-cortisol Effects 0.000 description 2
- 230000003276 anti-hypertensive Effects 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- HTJWUNNIRKDDIV-UHFFFAOYSA-N bis(1-adamantyl)-butylphosphane Chemical compound C1C(C2)CC(C3)CC2CC13P(CCCC)C1(C2)CC(C3)CC2CC3C1 HTJWUNNIRKDDIV-UHFFFAOYSA-N 0.000 description 2
- CROBTXVXNQNKKO-UHFFFAOYSA-N borohydride Chemical compound [BH4-] CROBTXVXNQNKKO-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium monoxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229960000530 carbenoxolone Drugs 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- 238000005906 dihydroxylation reaction Methods 0.000 description 2
- KQTXIZHBFFWWFW-UHFFFAOYSA-L disilver;carbonate Chemical compound [Ag]OC(=O)O[Ag] KQTXIZHBFFWWFW-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000007336 electrophilic substitution reaction Methods 0.000 description 2
- 238000006735 epoxidation reaction Methods 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N ethoxyethane;trifluoroborane Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000005669 hydrocyanation reaction Methods 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-O hydron;imidazolidine Chemical compound C1C[NH2+]CN1 WRYCSMQKUKOKBP-UHFFFAOYSA-O 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- ONOJJCTXSDBVSP-UHFFFAOYSA-N imidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound C1=C(C(=O)O)C=CC2=NC=CN21 ONOJJCTXSDBVSP-UHFFFAOYSA-N 0.000 description 2
- TUKDVVKJZVLVTD-UHFFFAOYSA-N imidazo[1,2-a]pyridine-7-carboxylic acid Chemical compound C1=C(C(=O)O)C=CN2C=CN=C21 TUKDVVKJZVLVTD-UHFFFAOYSA-N 0.000 description 2
- 230000000155 isotopic Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NZTNZPDOBQDOSO-UHFFFAOYSA-N lithium;boron(1-) Chemical compound [Li+].[B-] NZTNZPDOBQDOSO-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- QRLHANNSPRAJFN-UHFFFAOYSA-N methyl 3-chloropyridine-2-carboxylate Chemical compound COC(=O)C1=NC=CC=C1Cl QRLHANNSPRAJFN-UHFFFAOYSA-N 0.000 description 2
- STFLVKVIOPWCES-UHFFFAOYSA-N methyl 5,6-dihydrobenzo[f]quinoline-10-carboxylate Chemical compound C1CC2=NC=CC=C2C2=C1C=CC=C2C(=O)OC STFLVKVIOPWCES-UHFFFAOYSA-N 0.000 description 2
- XQVRGALNEOELRG-UHFFFAOYSA-N methyl 5,6-dihydrobenzo[f]quinoline-8-carboxylate Chemical compound C1=CC=C2C3=CC=C(C(=O)OC)C=C3CCC2=N1 XQVRGALNEOELRG-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 2
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 2
- 230000003228 microsomal Effects 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- NLEUXPOVZGDKJI-UHFFFAOYSA-N nickel(2+);dicyanide Chemical compound [Ni+2].N#[C-].N#[C-] NLEUXPOVZGDKJI-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 238000007034 nitrosation reaction Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 238000005949 ozonolysis reaction Methods 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 239000001184 potassium carbonate Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 125000003198 secondary alcohol group Chemical group 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910000144 sodium(I) superoxide Inorganic materials 0.000 description 2
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 2
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 2
- 229910000080 stannane Inorganic materials 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000003509 tertiary alcohols Chemical class 0.000 description 2
- ODGCEQLVLXJUCC-UHFFFAOYSA-N tetrafluoroborate Chemical compound F[B-](F)(F)F ODGCEQLVLXJUCC-UHFFFAOYSA-N 0.000 description 2
- ODGCEQLVLXJUCC-UHFFFAOYSA-O tetrafluoroboric acid Chemical compound [H+].F[B-](F)(F)F ODGCEQLVLXJUCC-UHFFFAOYSA-O 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 2
- MVJKXJPDBTXECY-UHFFFAOYSA-N trifluoroborane;hydrate Chemical compound O.FB(F)F MVJKXJPDBTXECY-UHFFFAOYSA-N 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940075966 (+)- menthol Drugs 0.000 description 1
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2R,3R)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- SYOKIDBDQMKNDQ-HHUWHTLVSA-N (2S)-1-[2-[[(5S,7R)-3-hydroxy-1-adamantyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1C[C@H](C2)CC(C1)(C1)O)C21NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-HHUWHTLVSA-N 0.000 description 1
- XUFXOAAUWZOOIT-WVJZLWNXSA-N (2S,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-WVJZLWNXSA-N 0.000 description 1
- CMIBUZBMZCBCAT-HOTGVXAUSA-N (2S,3S)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@H](C(O)=O)[C@@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HOTGVXAUSA-N 0.000 description 1
- MPDGHEJMBKOTSU-WFJWTYAKSA-N (2S,4aS,6aS,6bR,10S,12aS)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid Chemical compound C12C(=O)C=C3C4C[C@@](C)(C(O)=O)CC[C@]4(C)CC[C@@]3(C)[C@]1(C)CCC1[C@]2(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-WFJWTYAKSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- JONIMGVUGJVFQD-UHFFFAOYSA-N (4-methylphenyl)sulfonylformonitrile Chemical compound CC1=CC=C(S(=O)(=O)C#N)C=C1 JONIMGVUGJVFQD-UHFFFAOYSA-N 0.000 description 1
- JNSDPHBOQXVNJG-MNOVXSKESA-N (4aR,9aS)-1,3,4,4a,9,9a-hexahydroindeno[2,1-b]pyridin-2-one Chemical compound C1=CC=C2[C@H]3CCC(=O)N[C@H]3CC2=C1 JNSDPHBOQXVNJG-MNOVXSKESA-N 0.000 description 1
- MTOPEQZNAQOLKX-QBKBNCOFSA-N (4aR,9aS)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-7-amine;dihydrochloride Chemical compound Cl.Cl.C1CCN[C@H]2CC3=CC(N)=CC=C3[C@H]21 MTOPEQZNAQOLKX-QBKBNCOFSA-N 0.000 description 1
- MVCGAPKBAFCOJE-YPMHNXCESA-N (4aS,10bR)-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-9-amine Chemical compound N1CCC[C@@H]2C3=CC(N)=CC=C3CC[C@@H]21 MVCGAPKBAFCOJE-YPMHNXCESA-N 0.000 description 1
- FOOGLAOFPLQPIT-GJZGRUSLSA-N (4aS,10bS)-10b-ethyl-2,3,4,4a,5,6-hexahydro-1H-benzo[f]quinoline Chemical compound C1CC2=CC=CC=C2[C@@]2(CC)[C@H]1NCCC2 FOOGLAOFPLQPIT-GJZGRUSLSA-N 0.000 description 1
- SZFIVQZEEDBHND-KBPBESRZSA-N (4aS,10bS)-10b-methyl-2,3,4,4a,5,6-hexahydro-1H-benzo[f]quinoline Chemical compound C1CC2=CC=CC=C2[C@@]2(C)[C@H]1NCCC2 SZFIVQZEEDBHND-KBPBESRZSA-N 0.000 description 1
- RBWOUQBZWIGYDQ-GWCFXTLKSA-N (4aS,10bS)-7,9-difluoro-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline Chemical compound N1CCC[C@H]2C3=CC(F)=CC(F)=C3CC[C@@H]21 RBWOUQBZWIGYDQ-GWCFXTLKSA-N 0.000 description 1
- GHNVWCDFSUPLTC-AAEUAGOBSA-N (4aS,10bS)-7-methoxy-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline Chemical compound C([C@H]12)CCN[C@H]1CCC1=C2C=CC=C1OC GHNVWCDFSUPLTC-AAEUAGOBSA-N 0.000 description 1
- ZNMGXPWUYJTMFM-KBPBESRZSA-N (4aS,10bS)-8-methoxy-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline Chemical compound C1CCN[C@H]2CCC3=CC(OC)=CC=C3[C@@H]21 ZNMGXPWUYJTMFM-KBPBESRZSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-L (E)-4-hydroxy-2-oxido-4-oxobut-2-enoate Chemical class OC(=O)\C=C(\[O-])C([O-])=O UWYVPFMHMJIBHE-OWOJBTEDSA-L 0.000 description 1
- NPUZFKMKEFBWLV-SNAWJCMRSA-N (E)-pent-2-ene Chemical group [CH2]C\C=C\C NPUZFKMKEFBWLV-SNAWJCMRSA-N 0.000 description 1
- FHUDAMLDXFJHJE-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-one Chemical compound CC(=O)C(F)(F)F FHUDAMLDXFJHJE-UHFFFAOYSA-N 0.000 description 1
- WHUPHUJYROLPBP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline Chemical compound C1CC2=CC=CC=C2C2C1NCCC2 WHUPHUJYROLPBP-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-Dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PZVRSDBLMSXDCX-UHFFFAOYSA-N 1,3-Benzodioxolyl-N-methylpentanamine Chemical compound CCCC(NC)CC1=CC=C2OCOC2=C1 PZVRSDBLMSXDCX-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-Propanediol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- ZJLMKPKYJBQJNH-UHFFFAOYSA-N 1,3-Propanedithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 description 1
- HHBCEKAWSILOOP-UHFFFAOYSA-N 1,3-dibromo-1,3,5-triazinane-2,4,6-trione Chemical compound BrN1C(=O)NC(=O)N(Br)C1=O HHBCEKAWSILOOP-UHFFFAOYSA-N 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical class O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- UZNQNWYIDSYPLV-UHFFFAOYSA-N 1-(1H-inden-2-yl)pyrrolidine Chemical compound C1CCCN1C1=CC2=CC=CC=C2C1 UZNQNWYIDSYPLV-UHFFFAOYSA-N 0.000 description 1
- YWYAUYAEQBYZFN-UHFFFAOYSA-N 1-(3,4-dihydronaphthalen-2-yl)pyrrolidine Chemical compound C1CCCN1C1=CC2=CC=CC=C2CC1 YWYAUYAEQBYZFN-UHFFFAOYSA-N 0.000 description 1
- AXKODQWYERYHPM-UHFFFAOYSA-M 1-benzyl-4-methyl-9H-indeno[2,1-b]pyridin-1-ium;bromide Chemical compound [Br-].C1=2CC3=CC=CC=C3C=2C(C)=CC=[N+]1CC1=CC=CC=C1 AXKODQWYERYHPM-UHFFFAOYSA-M 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 1-butanal Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-M 1-carboxynaphthalen-2-olate Chemical class C1=CC=CC2=C(C([O-])=O)C(O)=CC=C21 UPHOPMSGKZNELG-UHFFFAOYSA-M 0.000 description 1
- RHHATTYTIYFAKF-UHFFFAOYSA-N 1-ethyl-3,4-dihydro-1H-naphthalen-2-one Chemical compound C1=CC=C2C(CC)C(=O)CCC2=C1 RHHATTYTIYFAKF-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- NXLLJAFDWSUDJZ-UHFFFAOYSA-N 1-methyl-2-oxo-3H-benzimidazole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2NC(=O)N(C)C2=C1 NXLLJAFDWSUDJZ-UHFFFAOYSA-N 0.000 description 1
- VGZQKUJGVYFKBP-UHFFFAOYSA-N 1-methyl-3,4-dihydro-1H-naphthalen-2-one Chemical compound C1=CC=C2C(C)C(=O)CCC2=C1 VGZQKUJGVYFKBP-UHFFFAOYSA-N 0.000 description 1
- SGHWYTLJLHVIBQ-UHFFFAOYSA-N 1-methylbenzotriazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N(C)N=NC2=C1 SGHWYTLJLHVIBQ-UHFFFAOYSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- HBCPLFVMULKZGY-UHFFFAOYSA-N 10-fluoro-5,6-dihydrobenzo[f]quinoline Chemical compound C1CC2=NC=CC=C2C2=C1C=CC=C2F HBCPLFVMULKZGY-UHFFFAOYSA-N 0.000 description 1
- 238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- DNCVTVVLMRHJCJ-UHFFFAOYSA-N 1H-indazole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=NNC2=C1 DNCVTVVLMRHJCJ-UHFFFAOYSA-N 0.000 description 1
- GVUWPJDJXCXRKR-UHFFFAOYSA-N 1H-indeno[2,1-b]pyridine Chemical compound C1=CNC2=CC3=CC=CC=C3C2=C1 GVUWPJDJXCXRKR-UHFFFAOYSA-N 0.000 description 1
- VGJWVEYTYIBXIA-UHFFFAOYSA-N 2,2,2-trifluoroethane-1,1-diol Chemical compound OC(O)C(F)(F)F VGJWVEYTYIBXIA-UHFFFAOYSA-N 0.000 description 1
- WSNDAYQNZRJGMJ-UHFFFAOYSA-N 2,2,2-trifluoroethanone Chemical compound FC(F)(F)[C]=O WSNDAYQNZRJGMJ-UHFFFAOYSA-N 0.000 description 1
- RVWUHFFPEOKYLB-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxidopiperidin-1-ium Chemical compound CC1(C)CCCC(C)(C)[NH+]1[O-] RVWUHFFPEOKYLB-UHFFFAOYSA-N 0.000 description 1
- SLMHHOVQRSSRCV-UHFFFAOYSA-N 2,3-dibromopyridine Chemical compound BrC1=CC=CN=C1Br SLMHHOVQRSSRCV-UHFFFAOYSA-N 0.000 description 1
- MAKFMOSBBNKPMS-UHFFFAOYSA-N 2,3-dichloropyridine Chemical compound ClC1=CC=CN=C1Cl MAKFMOSBBNKPMS-UHFFFAOYSA-N 0.000 description 1
- AAYWIXGLVAEPTP-UHFFFAOYSA-N 2,3-dimethylbutan-2-ylboron Chemical compound [B]C(C)(C)C(C)C AAYWIXGLVAEPTP-UHFFFAOYSA-N 0.000 description 1
- JGFXUYLYPITYGR-UHFFFAOYSA-N 2-(2-diphenylphosphanylphenyl)-N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 JGFXUYLYPITYGR-UHFFFAOYSA-N 0.000 description 1
- NIJWAAUHTPDGOM-UHFFFAOYSA-N 2-(2-phenylethyl)pyridine Chemical compound C=1C=CC=CC=1CCC1=CC=CC=N1 NIJWAAUHTPDGOM-UHFFFAOYSA-N 0.000 description 1
- WFZZMEOXDLWFHI-UHFFFAOYSA-N 2-(3-methoxy-2-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound COC1=CC=CC(B2OC(C)(C)C(C)(C)O2)=C1C WFZZMEOXDLWFHI-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-Aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-Methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N 2-Piperidinone Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- PCFUWBOSXMKGIP-UHFFFAOYSA-N 2-benzylpyridine Chemical group C=1C=CC=NC=1CC1=CC=CC=C1 PCFUWBOSXMKGIP-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- QUSIJPWIXLGKNS-UHFFFAOYSA-M 3,3-dimethylbut-1-en-1-olate Chemical group CC(C)(C)[C-]=C[O-] QUSIJPWIXLGKNS-UHFFFAOYSA-M 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- PRORLQAJNJMGAR-UHFFFAOYSA-N 3-chloro-6-methylpyridazine Chemical compound CC1=CC=C(Cl)N=N1 PRORLQAJNJMGAR-UHFFFAOYSA-N 0.000 description 1
- YDPLFBIGFQFIDB-UHFFFAOYSA-N 3-chloropyridine-2-carbonitrile Chemical compound ClC1=CC=CN=C1C#N YDPLFBIGFQFIDB-UHFFFAOYSA-N 0.000 description 1
- IUSDEKNMCOUBEE-UHFFFAOYSA-N 3-fluoro-4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(F)=C1 IUSDEKNMCOUBEE-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- KEPSJISIUDGGSI-UHFFFAOYSA-N 3H-benzimidazole-5-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2N=CNC2=C1 KEPSJISIUDGGSI-UHFFFAOYSA-N 0.000 description 1
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 description 1
- CWXUCOIJSLPOCZ-UHFFFAOYSA-N 4,4-dimethyl-1,3-dihydronaphthalen-2-one Chemical compound C1=CC=C2C(C)(C)CC(=O)CC2=C1 CWXUCOIJSLPOCZ-UHFFFAOYSA-N 0.000 description 1
- DJSLTDBPKHORNY-UWRQUICRSA-N 4-[[2-butyl-5-[(Z)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)\CC1=CC=CS1 DJSLTDBPKHORNY-UWRQUICRSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- LTFHNKUKQYVHDX-UHFFFAOYSA-N 4-hydroxy-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1O LTFHNKUKQYVHDX-UHFFFAOYSA-N 0.000 description 1
- MHRMWFCQRSOVJX-UHFFFAOYSA-N 5,6-dihydrobenzo[f]quinolin-10-ol Chemical compound C1CC2=NC=CC=C2C2=C1C=CC=C2O MHRMWFCQRSOVJX-UHFFFAOYSA-N 0.000 description 1
- HOUVATQQKYAEBB-UHFFFAOYSA-N 5,7-difluoro-3,4-dihydro-1H-naphthalen-2-one Chemical compound C1CC(=O)CC2=CC(F)=CC(F)=C21 HOUVATQQKYAEBB-UHFFFAOYSA-N 0.000 description 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 1
- IMVDZFOSXJSXFP-UHFFFAOYSA-N 5-chloro-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carbaldehyde Chemical compound CCCC1=NC(Cl)=C(C=O)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1 IMVDZFOSXJSXFP-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- MDAIAXRTLTVEOU-UHFFFAOYSA-N 5-methoxy-3,4-dihydro-1H-naphthalen-2-one Chemical compound C1C(=O)CCC2=C1C=CC=C2OC MDAIAXRTLTVEOU-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N 5-methyl-2-(propan-2-yl)cyclohexan-1-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- BYHKDUFPSJWJDI-UHFFFAOYSA-N 6-bromo-3,4-dihydro-1H-naphthalen-2-one Chemical compound C1C(=O)CCC2=CC(Br)=CC=C21 BYHKDUFPSJWJDI-UHFFFAOYSA-N 0.000 description 1
- RMRKDYNVZWKAFP-UHFFFAOYSA-N 6-methoxy-3,4-dihydro-1H-naphthalen-2-one Chemical compound C1C(=O)CCC2=CC(OC)=CC=C21 RMRKDYNVZWKAFP-UHFFFAOYSA-N 0.000 description 1
- ZHZZGQXASQPFLC-UHFFFAOYSA-N 6-methyl-1H-benzimidazole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C(C)=CC2=C1N=CN2 ZHZZGQXASQPFLC-UHFFFAOYSA-N 0.000 description 1
- PXHXHCGZMYGETE-UHFFFAOYSA-N 7,9-difluoro-5,6-dihydrobenzo[f]quinoline Chemical compound C1=CC=C2C3=CC(F)=CC(F)=C3CCC2=N1 PXHXHCGZMYGETE-UHFFFAOYSA-N 0.000 description 1
- XEAPZXNZOJGVCZ-UHFFFAOYSA-N 7-methoxy-3,4-dihydro-1H-naphthalen-2-one Chemical compound C1CC(=O)CC2=CC(OC)=CC=C21 XEAPZXNZOJGVCZ-UHFFFAOYSA-N 0.000 description 1
- RZYFGKCQFAWNIE-UHFFFAOYSA-N 7-methyl-3H-benzimidazole-5-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC2=C1N=CN2 RZYFGKCQFAWNIE-UHFFFAOYSA-N 0.000 description 1
- BIZFHQDZRNKNAU-UHFFFAOYSA-N 7-nitro-3,4-dihydro-1H-naphthalen-2-one Chemical compound C1CC(=O)CC2=CC([N+](=O)[O-])=CC=C21 BIZFHQDZRNKNAU-UHFFFAOYSA-N 0.000 description 1
- RWEVGLMABSFMKW-UHFFFAOYSA-N 8-bromo-3,4-dihydro-1H-naphthalen-2-one Chemical compound C1CC(=O)CC2=C1C=CC=C2Br RWEVGLMABSFMKW-UHFFFAOYSA-N 0.000 description 1
- MQCCLMXABWLNIF-UHFFFAOYSA-N 8-fluoro-3,4-dihydro-1H-naphthalen-2-one Chemical compound C1CC(=O)CC2=C1C=CC=C2F MQCCLMXABWLNIF-UHFFFAOYSA-N 0.000 description 1
- BTYBORAHYUCUMH-UHFFFAOYSA-N 8-methoxy-3,4-dihydro-1H-naphthalen-2-one Chemical compound C1CC(=O)CC2=C1C=CC=C2OC BTYBORAHYUCUMH-UHFFFAOYSA-N 0.000 description 1
- YPVFJXGWILGXOV-UHFFFAOYSA-N 8-phenyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline Chemical compound C=1C=C2C3CCCNC3CCC2=CC=1C1=CC=CC=C1 YPVFJXGWILGXOV-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- MWFMGBPGAXYFAR-UHFFFAOYSA-N Acetone cyanohydrin Chemical compound CC(C)(O)C#N MWFMGBPGAXYFAR-UHFFFAOYSA-N 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 102000017910 Adrenergic receptor family Human genes 0.000 description 1
- 108060003345 Adrenergic receptor family Proteins 0.000 description 1
- 241000349731 Afzelia bipindensis Species 0.000 description 1
- 229940090865 Aldose reductase inhibitors used in diabetes Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N Alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N Ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 229950010046 Avasimibe Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N Benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N Bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N Bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000007848 Bronsted acid Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 102100000129 CHURC1 Human genes 0.000 description 1
- 101710014631 CHURC1 Proteins 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000073677 Changea Species 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N Chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- FZLWTRLVFXUTLF-UHFFFAOYSA-O ClBr(=O)=O.ClBr(=O)=O.C1=CC=[NH+]C=C1 Chemical compound ClBr(=O)=O.ClBr(=O)=O.C1=CC=[NH+]C=C1 FZLWTRLVFXUTLF-UHFFFAOYSA-O 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L Cobalt(II) chloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 206010057668 Cognitive disease Diseases 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L Copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
- MLIREBYILWEBDM-UHFFFAOYSA-N Cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- QGJUIPDUBHWZPV-YQBUGCKMSA-N DB07465 Chemical compound C([C@@H](C1)C2)[C@@H](C3)C[C@@]1(O)C[C@]23[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-YQBUGCKMSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 101700039720 DPP4 Proteins 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 208000008960 Diabetic Foot Diseases 0.000 description 1
- 229940117389 Dichlorobenzene Drugs 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Dichlothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N Dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N Diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N Diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 102000019622 EC 2.7.1.2 Human genes 0.000 description 1
- 108010021582 EC 2.7.1.2 Proteins 0.000 description 1
- 229960000573 Eprosartan mesylate Drugs 0.000 description 1
- GWQVMPWSEVRGPY-UHFFFAOYSA-N Europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N Ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 102100009984 FAP Human genes 0.000 description 1
- 101710008097 FAP Proteins 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N Fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 Fenofibrate Drugs 0.000 description 1
- 102000027721 Fructose-Bisphosphatase Human genes 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- 101710042131 GCG Proteins 0.000 description 1
- 229960004580 GLIBENCLAMIDE Drugs 0.000 description 1
- 102000025873 GPCR, family 2, glucagon receptor Human genes 0.000 description 1
- 108010063919 GPCR, family 2, glucagon receptor Proteins 0.000 description 1
- 101700071595 GRZ1 Proteins 0.000 description 1
- 108091007473 GSKs Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N Glibenclamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N Glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 102100013220 HEATR6 Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N HF Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 102100015241 HSD11B1 Human genes 0.000 description 1
- 101710013483 HSD11B1 Proteins 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 241000463109 Haloprofundus marisrubri Species 0.000 description 1
- 229940116364 Hard Fat Drugs 0.000 description 1
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- CUILPNURFADTPE-UHFFFAOYSA-N Hypobromous acid Chemical compound BrO CUILPNURFADTPE-UHFFFAOYSA-N 0.000 description 1
- 206010020993 Hypoglycaemia Diseases 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N Iodic acid Chemical compound OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N Irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 102000036849 Islet amyloid polypeptide Human genes 0.000 description 1
- 108010041872 Islet amyloid polypeptide Proteins 0.000 description 1
- 229920004459 Kel-F® PCTFE Polymers 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229960004873 LEVOMENTHOL Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- 229960002397 Linagliptin Drugs 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 229940063718 Lodine Drugs 0.000 description 1
- 238000006644 Lossen rearrangement reaction Methods 0.000 description 1
- 108090000028 MMP12 Proteins 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 229960003105 Metformin Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N N-(p-Tolylsulfonyl)-N'-butylcarbamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 101700075086 NPY2 Proteins 0.000 description 1
- 101700025829 NPY5 Proteins 0.000 description 1
- 101700005832 NPY6R Proteins 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N Nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 Nateglinide Drugs 0.000 description 1
- 206010029149 Nephropathy Diseases 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 206010029331 Neuropathy peripheral Diseases 0.000 description 1
- KGCNVGDHOSFKFT-UHFFFAOYSA-N Nitrosonium tetrafluoroborate Chemical compound [O+]#N.F[B-](F)(F)F KGCNVGDHOSFKFT-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- 238000006036 Oppenauer oxidation reaction Methods 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102100003647 PPARA Human genes 0.000 description 1
- 102100003648 PPARD Human genes 0.000 description 1
- 102100000077 PPARG Human genes 0.000 description 1
- 101700056560 PTP-1 Proteins 0.000 description 1
- BEZDDPMMPIDMGJ-UHFFFAOYSA-N Pentamethylbenzene Chemical compound CC1=CC(C)=C(C)C(C)=C1C BEZDDPMMPIDMGJ-UHFFFAOYSA-N 0.000 description 1
- 238000003527 Peterson olefination reaction Methods 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Phenylacetylene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 1
- PARWUHTVGZSQPD-UHFFFAOYSA-N Phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N Phosphoenolpyruvic acid Natural products OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N Phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
- 229960005095 Pioglitazone Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N Potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N Propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 229940076788 Pyruvate Drugs 0.000 description 1
- AAWZDTNXLSGCEK-WYWMIBKRSA-N Quinic acid Chemical compound O[C@@H]1C[C@](O)(C(O)=O)C[C@@H](O)[C@H]1O AAWZDTNXLSGCEK-WYWMIBKRSA-N 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N Quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038932 Retinopathy Diseases 0.000 description 1
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
- 108060007534 SIGB Proteins 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 238000000297 Sandmeyer reaction Methods 0.000 description 1
- 229960004937 Saxagliptin Drugs 0.000 description 1
- 238000006350 Schiemann fluorination reaction Methods 0.000 description 1
- 238000006085 Schmidt reaction Methods 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N Sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- QRUBYZBWAOOHSV-UHFFFAOYSA-M Silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N Sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 229940083599 Sodium Iodide Drugs 0.000 description 1
- JBUKJLNBQDQXLI-UHFFFAOYSA-N Sodium perborate Chemical compound [Na+].[Na+].O[B-]1(O)OO[B-](O)(O)OO1 JBUKJLNBQDQXLI-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N Sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 description 1
- 229940032330 Sulfuric acid Drugs 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000010928 TGA analysis Methods 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N Tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- RMMXLENWKUUMAY-UHFFFAOYSA-N Telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N Tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N Trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N Trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- HVLLSGMXQDNUAL-UHFFFAOYSA-N Triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N Triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 229940116269 Uric Acid Drugs 0.000 description 1
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 102100005236 ZGLP1 Human genes 0.000 description 1
- 101700078733 ZGLP1 Proteins 0.000 description 1
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N [2,6-di(propan-2-yl)phenyl] N-[2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]sulfamate Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 1
- FDKIDFYIEWFERB-UHFFFAOYSA-N [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol;potassium Chemical compound [K].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 FDKIDFYIEWFERB-UHFFFAOYSA-N 0.000 description 1
- HGMSJMJPXGGEBP-UHFFFAOYSA-N [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium Chemical compound C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 HGMSJMJPXGGEBP-UHFFFAOYSA-N 0.000 description 1
- NNTGAOLTGGLLPE-UHFFFAOYSA-N [Zn+2].[C-]#[C-] Chemical compound [Zn+2].[C-]#[C-] NNTGAOLTGGLLPE-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- OIBNPFSWDGUGEA-UHFFFAOYSA-O [methoxy(methylamino)methylidene]-dimethylazanium Chemical compound CNC(OC)=[N+](C)C OIBNPFSWDGUGEA-UHFFFAOYSA-O 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000003705 antithrombocytic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005002 aryl methyl group Chemical group 0.000 description 1
- 125000005163 aryl sulfanyl group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 108010014210 axokine Proteins 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- UCYRAEIHXSVXPV-UHFFFAOYSA-K bis(trifluoromethylsulfonyloxy)indiganyl trifluoromethanesulfonate Chemical compound [In+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F UCYRAEIHXSVXPV-UHFFFAOYSA-K 0.000 description 1
- 229940090127 blood glucose lowering Alpha glucosidase inhibitors Drugs 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- YLBIBZCIFHPPKA-UHFFFAOYSA-N but-2-yn-1-amine Chemical compound CC#CCN YLBIBZCIFHPPKA-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- 229960004349 candesartan cilexetil Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910052803 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- NIPZPLSTRCTEND-UHFFFAOYSA-N copper;thiophene-2-carboxylic acid Chemical compound [Cu].OC(=O)C1=CC=CS1 NIPZPLSTRCTEND-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000005388 cross polarization Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 230000002074 deregulated Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- CVKBMWWNKUWISK-UHFFFAOYSA-L dichloromethane;dichloropalladium Chemical compound ClCCl.Cl[Pd]Cl CVKBMWWNKUWISK-UHFFFAOYSA-L 0.000 description 1
- YVHPHQBRUPLYOS-UHFFFAOYSA-N dichloromethane;methane Chemical compound C.ClCCl YVHPHQBRUPLYOS-UHFFFAOYSA-N 0.000 description 1
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 1
- VPLLTGLLUHLIHA-UHFFFAOYSA-N dicyclohexyl(phenyl)phosphane Chemical group C1CCCCC1P(C=1C=CC=CC=1)C1CCCCC1 VPLLTGLLUHLIHA-UHFFFAOYSA-N 0.000 description 1
- AOBOMOUUYYHMOX-UHFFFAOYSA-N diethylboron Chemical compound CC[B]CC AOBOMOUUYYHMOX-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- OPCPRUQQEJNFIV-UHFFFAOYSA-N disodium;cyanoboron(1-) Chemical compound [Na+].[Na+].[B-]C#N.[B-]C#N OPCPRUQQEJNFIV-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- JURBTQKVGNFPRJ-UHFFFAOYSA-N ditert-butyl(methyl)phosphane Chemical compound CC(C)(C)P(C)C(C)(C)C JURBTQKVGNFPRJ-UHFFFAOYSA-N 0.000 description 1
- CRHWEIDCXNDTMO-UHFFFAOYSA-N ditert-butylphosphane Chemical compound CC(C)(C)PC(C)(C)C CRHWEIDCXNDTMO-UHFFFAOYSA-N 0.000 description 1
- 230000001882 diuretic Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229940048820 edetates Drugs 0.000 description 1
- 238000007345 electrophilic aromatic substitution reaction Methods 0.000 description 1
- 238000007350 electrophilic reaction Methods 0.000 description 1
- 125000005610 enamide group Chemical group 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethanedisulfonate group Chemical class C(CS(=O)(=O)[O-])S(=O)(=O)[O-] AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- QLXKHBNJTPICNF-QMCAAQAGSA-N ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[(4-methoxyphenyl)methyl]phenoxy]oxan-2-yl]methyl carbonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=CC=CC=C1CC1=CC=C(OC)C=C1 QLXKHBNJTPICNF-QMCAAQAGSA-N 0.000 description 1
- UAOCLDQAQNNEAX-ABMICEGHSA-N ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxan-2-yl]methyl carbonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- KONIYTHNVWYBMP-UHFFFAOYSA-N ethylcyclohexane Chemical compound [CH2-]C[C+]1CCCCC1 KONIYTHNVWYBMP-UHFFFAOYSA-N 0.000 description 1
- NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- DWYMPOCYEZONEA-UHFFFAOYSA-L fluoridophosphate Chemical compound [O-]P([O-])(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-L 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- CYEFKCRAAGLNHW-UHFFFAOYSA-N furan-3-ylboronic acid Chemical compound OB(O)C=1C=COC=1 CYEFKCRAAGLNHW-UHFFFAOYSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 201000001420 glucose metabolism disease Diseases 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- MYSMMEUXKHJYKH-UHFFFAOYSA-O hydron;tricyclohexylphosphane;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1 MYSMMEUXKHJYKH-UHFFFAOYSA-O 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000035879 hyperinsulinaemia Effects 0.000 description 1
- 201000001431 hyperuricemia Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000002519 immonomodulatory Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000006361 intramolecular Friedel-Crafts acylation reaction Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 description 1
- 125000006328 iso-butylcarbonyl group Chemical group [H]C([H])([H])C([H])(C(*)=O)C([H])([H])[H] 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- HMONSXRREGWFKT-UHFFFAOYSA-N lithium;bis(2-methylpropyl)alumanylium;hydride Chemical compound [H-].[H-].[Li+].CC(C)C[Al+]CC(C)C HMONSXRREGWFKT-UHFFFAOYSA-N 0.000 description 1
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 1
- ZEUXAIYYDDCIRX-UHFFFAOYSA-N losartan carboxylic acid Chemical compound CCCCC1=NC(Cl)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1 ZEUXAIYYDDCIRX-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- AHXVKYSOBUHGES-KBPBESRZSA-N methyl (4aS,10bS)-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline-8-carboxylate Chemical compound C1CCN[C@H]2CCC3=CC(C(=O)OC)=CC=C3[C@@H]21 AHXVKYSOBUHGES-KBPBESRZSA-N 0.000 description 1
- 150000005217 methyl ethers Chemical class 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N methylsulfanylbenzene Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- IPLJNQFXJUCRNH-UHFFFAOYSA-L nickel(2+);dibromide Chemical compound [Ni+2].[Br-].[Br-] IPLJNQFXJUCRNH-UHFFFAOYSA-L 0.000 description 1
- UYLRKRLDQUXYKB-UHFFFAOYSA-N nickel;triphenylphosphane Chemical compound [Ni].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UYLRKRLDQUXYKB-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- JCZMXVGQBBATMY-UHFFFAOYSA-N nitro acetate Chemical compound CC(=O)O[N+]([O-])=O JCZMXVGQBBATMY-UHFFFAOYSA-N 0.000 description 1
- RGVZMPONLYFINH-UHFFFAOYSA-N nitronium;tetrafluoroborate Chemical compound O=[N+]=O.F[B-](F)(F)F RGVZMPONLYFINH-UHFFFAOYSA-N 0.000 description 1
- KEJOCWOXCDWNID-UHFFFAOYSA-N nitrosonium Chemical compound [O+]#N KEJOCWOXCDWNID-UHFFFAOYSA-N 0.000 description 1
- IQZPDFORWZTSKT-UHFFFAOYSA-N nitrosulphonic acid Chemical compound OS(=O)(=O)[N+]([O-])=O IQZPDFORWZTSKT-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 125000005482 norpinyl group Chemical group 0.000 description 1
- 230000000269 nucleophilic Effects 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- VPUIJHRNBVHUKJ-UHFFFAOYSA-N oxido(trioxo)osmium Chemical compound [O-][Os](=O)(=O)=O VPUIJHRNBVHUKJ-UHFFFAOYSA-N 0.000 description 1
- UJJLJRQIPMGXEZ-UHFFFAOYSA-M oxolane-2-carboxylate Chemical compound [O-]C(=O)C1CCCO1 UJJLJRQIPMGXEZ-UHFFFAOYSA-M 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- ZOUWOGOTHLRRLS-UHFFFAOYSA-N palladium;phosphane Chemical compound P.[Pd] ZOUWOGOTHLRRLS-UHFFFAOYSA-N 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 150000004976 peroxydisulfates Chemical class 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229940096700 plain lipid modifying drugs Fibrates Drugs 0.000 description 1
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001843 polymethylhydrosiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- VBKNTGMWIPUCRF-UHFFFAOYSA-M potassium;fluoride;hydrofluoride Chemical compound F.[F-].[K+] VBKNTGMWIPUCRF-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- DITHIFQMPPCBCU-UHFFFAOYSA-N propa-1,2-diene Chemical group [CH]=C=C DITHIFQMPPCBCU-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical class CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- NBBJYMSMWIIQGU-UHFFFAOYSA-N propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 239000003881 protein kinase c inhibitor Substances 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 101700063467 pyp1 Proteins 0.000 description 1
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 1
- HBDYSKVKXMUPKV-UHFFFAOYSA-N pyridine;trioxochromium;hydrochloride Chemical compound [H+].[Cl-].O=[Cr](=O)=O.C1=CC=NC=C1 HBDYSKVKXMUPKV-UHFFFAOYSA-N 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical group CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- CIIFKVFOVFJZDM-UHFFFAOYSA-N quinoline-8-carbonitrile Chemical compound C1=CN=C2C(C#N)=CC=CC2=C1 CIIFKVFOVFJZDM-UHFFFAOYSA-N 0.000 description 1
- QRDZFPUVLYEQTA-UHFFFAOYSA-N quinoline-8-carboxylic acid Chemical compound C1=CN=C2C(C(=O)O)=CC=CC2=C1 QRDZFPUVLYEQTA-UHFFFAOYSA-N 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229950011516 remogliflozin etabonate Drugs 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 238000002821 scintillation proximity assay Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 238000003530 single readout Methods 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- NESXXUAWVHXRGX-UHFFFAOYSA-M sodium;1-carboxyethenyl hydrogen phosphate Chemical compound [Na+].OP(O)(=O)OC(=C)C([O-])=O NESXXUAWVHXRGX-UHFFFAOYSA-M 0.000 description 1
- XJIQVZMZXHEYOY-UHFFFAOYSA-N sodium;bis(2-methoxyethoxy)alumanuide Chemical compound [Na+].COCCO[AlH2-]OCCOC XJIQVZMZXHEYOY-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003899 tartaric acid esters Chemical class 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- BYGOPQKDHGXNCD-UHFFFAOYSA-N tripotassium;iron(3+);hexacyanide Chemical compound [K+].[K+].[K+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] BYGOPQKDHGXNCD-UHFFFAOYSA-N 0.000 description 1
- GEPJPYNDFSOARB-UHFFFAOYSA-N tris(4-fluorophenyl)phosphane Chemical compound C1=CC(F)=CC=C1P(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 GEPJPYNDFSOARB-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003424 uricosuric Effects 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- AMKXMADQMVPOCK-UHFFFAOYSA-M zinc;1-methanidyl-4-methoxybenzene;chloride Chemical compound [Zn+]Cl.COC1=CC=C([CH2-])C=C1 AMKXMADQMVPOCK-UHFFFAOYSA-M 0.000 description 1
- YHVLYRZWQLDARE-UHFFFAOYSA-M zinc;ethylbenzene;bromide Chemical compound Br[Zn+].[CH2-]CC1=CC=CC=C1 YHVLYRZWQLDARE-UHFFFAOYSA-M 0.000 description 1
- WRSWIWOVJBYZAW-UHFFFAOYSA-M zinc;methanidylbenzene;bromide Chemical compound Br[Zn+].[CH2-]C1=CC=CC=C1 WRSWIWOVJBYZAW-UHFFFAOYSA-M 0.000 description 1
Abstract
The present invention relates to compounds defined by formula I
Description
Aryi- and heteroarylcarbonyl dérivatives of hexahydroindenopyridine and octahydrobenzoquinoline
Related Applications
This applications claims the benefit of U.S. Provisional Application Serial No. 61/484,995, filed May 11,2011. This applications also claims priority to International Application Serial No. PCT/US2010/055586, filed November 5, 2010. The entire teachings of these two applications are incorporated herein by reference.
Field of the invention
The présent invention relates to hexahydroindenopyridines and octahydrobenzoquinolines and their use as inhibitors of 11ft-hydroxysteroid dehydrogenase 1 (HSD 1 ), to pharmaceutical compositions containing said compounds as well as their use for the treatment of metabolic disorders like metabolic syndrome, diabètes, obesity, and dyslipidemia. In addition, the invention relates to processes for preparing a pharmaceutical composition as well as a compound according to the invention.
Background of the invention
In the literature, compounds which hâve an inhibitory effect on the enzyme 11 β-hydroxysteroid dehydrogenase (HSD) 1 are proposed for the treatment of the metabolic syndrome, in particular diabètes type 2, obesity, and dyslipidemia.
In Bulletin ofthe Chemical Society ofJapan 1959, 32, p. 1005-7 and Journal ofOrganic
Chemistry 1964, 29, p. 1419-24, the compounds of the following structures hâve been disclosed:
In Journal of Organic Chemistry 1984, 49, p. 2504-6 a chromatographie method to separate enantiomers of heterocyclic amines, inter alia the enantiomers of the following racemic compound are disclosed:
In Journal of Médicinal Chemistry 1981, 24, p. 1432-7 the following compound is described as an intermediate in order to separate cis- and trans-isomer:
Aim of the invention
It has been surprisingly found that compounds of the présent invention hâve not only an inhibitory effect on HSD 1 in vitro and/or in vivo but also possess significant metabolic stability which makes them suitable to be used as médicaments. Accordingly, aim of the présent invention is to discover hexahydroîndenopyridines and octahydrobenzoquinolines having an inhibitory effect on HSD 1 in vitro and/or in vivo and possessing suitable pharmacological and pharmacokinetic properties to use them as médicaments.
A further aspect of the présent invention is to provide new pharmaceutical compositions which are suitable for the prévention and/or treatment of metabolic disorders.
A further aspect of the invention relates to the physiologically acceptable salts of the compounds of general formula I according to this invention with inorganic or organic acids or bases.
In a further aspect this invention relates to pharmaceutical compositions, containing at least one compound of general formula I or a physiologically acceptable sait according to the invention, optionally together with one or more inert carriers and/or diluents.
In a further aspect this invention relates to the compounds according to general formula I or the physiologically acceptable salts thereof for treatment or prévention of diseases or conditions which can be influenced by inhibiting the enzyme 11 β-hydroxysteroid dehydrogenase (HSD) 1, such as metabolic disorders.
In a further aspect this invention relates to the use of at least one compound according to general formula I or a physiologically acceptable sait thereof for preparing a pharmaceutical composition which is suitable for the treatment or prévention of diseases or conditions which can be influenced by inhibiting the enzyme 11B-hydroxysteroid dehydrogenase (HSD) 1, such 5 as metabolic disorders.
Other aims of the présent invention will become apparent to the skilled man directly from the foregoing and following remarks.
Brief Description of the Drawinqs
FIG. 1 is an XRPD pattern obtained from a sample of Form I of the compound of formula (II).
FIG. 2 is a 13C SSNMR spectrum obtained from a sample of Form I of the compound of formula 15 (II).
FIG. 3 is a thermal analysis profile obtained from a sample of Form I of the compound of formula (II) determined by DSC measurements.
FIG. 4 is a thermal analysis profile obtained from a sample of Form I of the compound of formula (11) determined by TGA measurements.
FIG. 5 is an XRPD pattern obtained from a sample of Form II of the compound of formula (II).
FIG. 6 is a 13C SSNMR spectrum obtained from a sample of Form II of the compound of formula (II).
FIG. 7 is a thermal analysis profile obtained from a sample of Form II of the compound of formula (II) determined by DSC measurements.
FIG. 8 is a thermal analysis profile obtained from a sample of Form II of the compound of formula (11) determined by TGA measurements.
Detailed description
In a first aspect the présent invention relates to compounds of general formula I
wherein
R1 is selected from the group R1a consisting of phenyl, naphthyl, pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl, wherein in the pyrrolyl, furanyl, thienyl, and pyridyl group optionally 1 or 2 CH groups may be replaced by N, and wherein in the indolyl, benzofuranyl, benzothiophenyl, quinolinyl, and isoquinolinyl group 1 to 3 CH groups may optionally be replaced by N,
2-oxo-l ,2-dihydro-pyridinyl, 4-oxo-1,4-dihydro-pyridinyl, 3-oxo-2,3-dihydropyridazinyl, 3,6-dioxo-1,2,3,6-tetrahydro-pyridazinyl, 2-oxo-1,2-dihydro-pyrimidinyl, 4-oxo-3,4-dihydro-pyrimidinyl, 1,2,3,4-tetrahydro-2,4-dioxo-pyrimidinyl, 2-oxo-1,2dihydro-pyrazinyl, 2,3-dioxo-1,2,3,4-tetrahydro-pyrazinyl, indanyl, 1-oxo-indanyl, 2,3-dihydro-indolyl, 2,3-dihydro-isoindolyl, 2-oxo-2,3-dihydro-indolyl, 1-oxo-2,3-dihydro-isoindolyl, 2,3-dihydrobenzofuranyl, 2-oxo-2,3-dihydro-benzimidazolyl, 2oxo-2,3-dihydro-benzoxazolyl, benzofl ,3]dioxolyl, 2-oxo-benzo[1,3]dioxolyl,
1.2.3.4- tetrahydro-naphthyl, 1,2,3,4-tetrahydro-quinolinyl, 2-oxo-1,2,3,4tetrahydro-quinolinyl, 2-oxo-1,2-dihydro-quinolinyl, 4-oxo-1,4-dihydro-quinolinyl,
1.2.3.4- tetrahydro-isoquinolinyl, 1-oxo-1,2,3,4-tetrahydro-isoquinolinyl, 1-oxo-1,2dihydro-isoquinolinyl, 4-oxo-1,4-dihydro-cinnolinyl, 2-oxo-1,2-dihydro-quinazolinyl, 4-oxo-1,4-dihydro-quinazolinyl, 2,4-dioxo-1,2,3,4-tetrahydro-quinazolinyl, 2-oxo-
1,2-dihydro-quinoxalinyl, 3-oxo-1,2,3,4-tetrahydro-quinoxalinyl, 2,3-dioxo-1,2,3,4tetrahydro-quinoxalinyl, 1-oxo-1,2-dihydro-phthalazinyl, 1,4-dioxo-1,2,3,4tetrahydro-phthalazinyl, chromanyl, coumarinyl, 2,3-dihydro-benzo[1,4]dioxin-yl, 3oxo-3,4-dihydro-benzo[1,4]oxazinyl, tetrazolyî, 2-oxo-2,3-dihydro-benzothiazolyl, and imidazo[1,2-a]pyridinyl, wherein the members of the group R1a are attached to the carbonyl group in formula I via an aromatic carbon atom and wherein the members of the group R1a may optionally be substituted with one R5, one to three identical and/or different R6, and/or one R7, provided that in case R1 is a phenyl group, the substituents R5, R6, and/or R7 are not attached to the carbon atoms next to the carbon atom which is attached to the carbonyl group in formula I;
R2 | is selected from the group R2a consisting of hydrogen, halogen, (het)aryl, cyano, nitro, amino, hydroxy, Ci^-alkyl, C3.6cycloalkyl, C2.6-alkenyl, and C2.e-alkynyl, wherein in each C^-alkyl-, C3.6-cycloalkyl-, C2-6-alkenyl- or C2.6-alkynyl-group one CH2 group may optionally be replaced by CO or SO21 one CH2 group optionally by 0 or NRn and one CH group optionally by N, and wherein each of those groups may optionally be mono- or polyfluorinated and optionally mono- or independently of each other disubstituted with chlorine, C^a-alkyl, cyano, (het)aryl, amino, Ci_3-alkylamino, di-(C1.3-alkyl)amino, hydroxy, Ci.3-alkyloxy, (het)aryloxy, Ci.3-alkylsulfanyi, 0,.3alkylsulfinyl, or C3^-cycloalkyl, wherein one or two CH2 groups of the C3.6cycloalkyI group may optionally be replaced independently of each other by carbonyl, 0 or NRn and one CH group optionally by N, and which may optionally be mono- or independently disubstituted with fluorine or Cj.s-alkyl; |
R3, R4 | are selected independently of each other from the group R3'4a consisting of hydrogen, halogen, Ci.3-alkyl, trifluoromethyl, hydroxy, Ci.3-alkyloxy, and cyano, or R3'4a dénotés R3 and R4 that are bound to adjacent carbon atoms and joined to form a methylenedioxy, ethylenedioxy, or C3.5-alkylene group, each of which may optionally be substituted with one or two groups independently selected from fluorine and methyl, or, together with the carbon atoms they are attached, form a benzo, pyrido, pyrimido, pyrazino, pyridazino, pyrazolo, imidazo, triazolo, oxazolo, thiazolo, isoxazolo, or isothiazolo ring, each of which may optionally be substituted with one or two substituents selected independently from halogen, C,. 3-alkyl, trifluoromethyl, amino, Ci.3-alkylamino, di-fC^-alkylJamino, hydroxy, and Ci.3-alkyloxy; |
R5 | is selected from the group R5a consisting of halogen, (het)aryl, cyano, nitro, amino, hydroxy, C^-alkyl, C3^-cycloalkyl, C2.c-alkenyl, and C2.G-alkynyl, wherein in each group one CH2 group may optionally be replaced by CO or SO2, one CH2 group optionally by 0 or NRN, and one CH group optionally by N, and wherein each group may optionally be mono- or polyfluorinated and optionally mono- or independently of each other disubstituted with chlorine, C^a-alkyl, cyano, (het)aryl, amino, Cvralkylamino, di-(CV3-alkyl)amino, hydroxy, Ci.3-alkyloxy, (het)aryloxy, Ci.3-alkylsulfanyl, Ci_3- |
alkylsulfinyl, or C3.6-cycloalkyl, wherein one or two CH2 groups of the C3.6cycloalkyl group may optionally be replaced independently of each other by carbonyl, 0 or NRn and one CH group optionally by N, and which may optionally be mono- or independently disubstituted with fluorine or Cu-alkyl; | |
R6, RT | are selected independently of each other from the group R6l7a consisting of halogen, Cf.3-alkyl, C2.3-alkynyl, trifluoromethyl, hydroxy, C^-alkyloxy, and cyano, and/or R6i7a dénotés one R6 combined with R7, which are bound to adjacent carbon atoms, that form a methylenedioxy, difluoromethylenedioxy, ethylenedioxy, C3.5alkylene group, or form, together with the carbon atoms they are attached, a pyrazolo, imidazo, oxazolo, isoxazolo, thiazolo, or isothiazolo ring, each of which may optionally be mono- or disubstituted independently of each other with Ci_3alkyl, trifluoromethyl, amino, Ci.3-alkylamino, di-(Ci.3-alky!)amino, hydroxy, Cv3alkyloxy; |
Rn | is selected independently of each other from the group RNa consisting of hydrogen, C^-alkyl, CM-cycloalkyl, C3^-alkenyl, C3.6-alkynyl, (het)aryl, C-malkylcarbonyl, (het)arylcarbonyl, Cvi-alkylaminocarbonyl, di-(C1.3-alkyl)aminocarbonyl, (het)arylaminocarbonyl, CM-alkyloxycarbonyl, C^-alkylsulfonyl and (het)arylsulfonyl, wherein each alkyl, alkenyl and alkynyl group may optionally be mono- or polysubstituted with fluorine and optionally monosubstituted with (het)aryl, cyano, aminocarbonyl, Cva-alkylaminocarbonyl, di-ÎCvs-alkyljaminocarbonyl, carboxy, CM-alkyloxycarbonyl, amino, C;.4-alkylamino, di-(Ci.3-alkyl)amino, Cm-alkylcarbonylamino, hydroxy, C^-alkyloxy, C,^-alkylsulfanyl, Ci_4alkylsulfinyl, or C^-alkylsulfonyl; |
(het)aryl | is selected independently of each other from the group HAa consisting of phenyl, naphthyl, pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl, wherein in the pyrrolyl, furanyl, thienyl, and pyridyl group optionally 1 or 2 CH groups may be replaced by N, and wherein in the indolyl, benzofuranyl, benzothiophenyl, quinolinyl, and isoquinolinyl group 1 to 3 CH groups optionally may be replaced by N, 2-oxo-l ,2-dihydro-pyridinyl, 4-oxo-1,4-dihydro-pyridinyI, 3-oxo-2,3-dihydropyridazinyl, 3,6-dioxo-1,2,3,6-tetrahydro-pyridazinyl, 2-oxo-1,2-dihydro-pyrimidinyl, |
4-oxo-3,4-dihydro-pyrimidinyl, 2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinyl, 2-oxo-1,2dihydro-pyrazinyl, 2,3-dioxo-1,2,3,4-tetrahydro-pyrazinyl, 2-oxo-2,3-dihydroindolyl, 2,3-dihydrobenzo-furanyl, 2-oxo-2,3-dihydro-benzimidazolyl1 2-oxo-2,3dihydro-benzoxazolyl, 2-oxo-1,2-dihydro-quinolinyl, 4-oxo-1,4-dihydro-quinolinyl, 1-oxo-1,2-dihydro-isoquinolinyl, 4-oxo-1,4-dihydro-cinnolinyl, 2-oxo-1,2-dihydroquinazolinyl, 4-oxo-1,4-dihydro-quinazolinyl, 2,4-dioxo-1,2,3,4-tetrahydroquinazolinyl, 2-oxo-1,2-dihydro-quinoxalinyl, 3-oxo-1,2,3,4-tetrahydro-quinoxalinyl, 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl, 1 -oxo-1,2-d i hyd ro-p ht halaziny 1, 1,4dioxo-1,2,3,4-tetrahydro-phthalazinyl, chromanyl, coumarinyl, 2,3-dihydrobenzo[1,4]dioxinyl, 3-oxo-3,4-dihydro-benzo[1,4]oxazinyl, and tetrazolyl, and wherein the above-mentioned (het)aryl groups may optionally be substituted with one to three R10 which may be identical or different;
R10 is selected independently of each other from the group R10a consisting of halogen, C^a-alkyl, difluoromethyl, trifluoromethyl, cyano, aminocarbonyl, Ci-3-alkylaminocarbonyl, di-(Ci-3-alkyl)-aminocarbonyl, carboxy,
CM-alkyloxycarbonyï, nitro, amino, Ci.3-alkylamino, dÎ-(Ci.3-alkyl)amino, acetylamino, methylsulfonylamino, hydroxy, C^-alkyloxy, difluoromethoxy, trifluoromethoxy, methylsulfanyl, methylsulfinyl, methylsulfonyl, aminosulfonyl and phenyl, wherein the phenyl-group may optionally be substituted with 1 or 2 substituents independently of each other selected from fluorine, methyl, methoxy, cyano, and hydroxy;
dénotés 0 or 1 ;
and wherein the aliphatic part of the tricyclic core structure of general formula I is substituted with one or two different or identical groups selected independently of each other from the group R8a consisting of hydrogen, methyl, and ethyl;
the tautomers thereof, the stereoisomers thereof, the mixtures thereof, and the salts thereof, while the following compounds are excluded:
In a further aspect the présent invention relates to a process for preparing the compounds of general formula I, characterized in that a compound of general formula II
wherein the variables R2, R3, R4, and m are defined as hereinbefore and hereinafter, is reacted with a compound of general formula R1-CO-Y, optionally prepared in situ from the corresponding carboxylic acid (Y = OH), wherein R1 is defined as hereinbefore and hereinafter and
Y is a leavïng group and in particular dénotés fluorine, chlorine, bromine, cyano, Ci.4-alkoxy, C2-4-alkenyloxy, C2_4-alkynyloxy, C^alkyIsulfanyl, arylotriazoloxy, heteroarylotriazoloxy, heteroar-N-yl, succinyl-N-oxy, C^alkylcarbonyloxy, di-fC^-alkylJ-aminocarbonyloxy, pyrrolylcarbonyloxy, piperidinylcarbonyloxy, morpholinylcarbonyloxy, [tri-(CV4-alkyl)-carbamimidoyl]oxy, [di-(C-i_4-alkyl)20 amino][di-(Ci.4-alkyl)-iminiumyl]methoxy {= [(CM-alkyl)2N]2C+-O-}, (N,N’-dicyclohexylcarbamidoyl)oxy, di-fC^-alkyloxyJ-phosphoryloxy, bis[di-(CM-alkyl)-amino]phosphoryloxy, [bis(pyrrolidin-1-yl)-phosphoryl]oxy, aryloxy, arylsulfanyl, heterosulfanyl, or heteroaryloxy, while the alkyl, alkenyl, and alkynyl groups mentioned in the définition of the above leaving groups optionally may be mono- or polysubstituted with fluorine, chlorine, C1.3alkyl, or C^-alkoxy, while the aryl groups mentioned in the définition of the above leaving groups, either alone or as part of another group, dénoté phenyl or naphthyl and the heteroaryl groups
A mentioned in the définition of the above groups, either alone or as part of another group, dénoté pyridinyl, pyrimidinyl, triazinyl, imidazolyl, pyrazolyl, triazolyl, or tetrazolyl, whilst both, the aryl and heteroaryl groups, may optionally be mono- or polysubstituted independently of each other with fluorine, chlorine, bromine, C^-alkyl, C^-alkyloxy, nitro, cyano, and/or di-(Ci.3-alkyl)amino, optionally in the presence of a base such as a tertiary or an aromatic amine, e.g. ethyldiisopropyl-amine, triethylamine, imidazole, or pyridine, or an inorganic sait, e.g. potassium carbonate or calcium oxide, and/or another additive such as 4-dimethylaminopyridine or 110 hydroxybenzotriazol, in solvents preferably selected from tetrahydrofuran, 1,2-dimethoxyethane, ether, 1,4-dioxane, Ν,Ν-dimethylformamide, Ν,Ν-dimethylacetamide, N-methylpyrrolidinone, acetonîtrile, ethyl acetate, dichloromethane, 1,2-dichloroethane, toluene, benzene, and hexanes, also aqueous and alcoholic solutions may be usable for some of the combinations listed above, preferably at -10 to 120 °C;
and, if necessary, any protective group used in the reactions described above is cleaved concurrently or subsequently;
if desired, a compound of general formula I thus obtained is resolved into its stereoisomers;
if desired, a compound of general formula I thus obtained is converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof.
Detailed Description of the invention
Uniess otherwise stated, the groups, residues, and substituents, particularly R1, R2, R3, R4, R5, R6, R7, R®, R10, Rn, and m are defined as above and hereinafter. If residues, substituents, or groups occur several fîmes in a compound they may hâve the same or different meanings. Some preferred meanings of groups and substituents of the compounds according to the invention will be given hereinafter.
Preferred embodiments of the invention are characterized by the following définitions:
In a further embodiment of the présent invention is selected from the group R1b consisting of phenyl, naphthyl, pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl,
wherein in the pyrrolyl, furanyl, thienyl, and pyridyl group optionally 1 CH group may be replaced by N, and wherein in the indolyl, benzofuranyl, benzothiophenyl, quinolinyl, and isoquinolinyl groups optionally 1 or 2 CH groups may be replaced by N, indanyl, 2,3-dihydro-indolyl, 2-oxo-2,3-dihydro-indolyl, 2,3-dihydro-benzofuranyl, 2oxo-2,3-dihydro-benzoimidazolyl, 2-oxo-2,3-dihydro-benzothiazolyl, benzo[1,3]d ioxolyl, 1,2,3,4-tetrahydronaphthy 1, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 2-oxo-112-dihydro-quinoxalinyl, 3-oxo-1,2,3,4tetrahydro-quinoxalinyl, chromanyl, and imidazo[1,2-a]pyridinyl, wherein the members of the group R1b are attached to the carbonyl group in formula I via an aromatic carbon atom and wherein the members of the group R1b may optionally be substituted with one R5, one R6, and/or one R7, provided that in case R1 is a phenyl group, the substituents R5, R6, and/or R7 are not attached to the carbon atoms next to the carbon atom which is attached to the carbonyl group in formula I.
In a further embodiment of the présent invention
R1 is selected from the group R1c consisting of phenyl, naphthyl, furanyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, wherein in the indolyl, benzofuranyl, and benzothiophenyl group optionally 1 or 2 CH groups may be replaced by N, indanyl, 2,3-dihydro-indolyl, 2-oxo-2,3-dihydro-indolyI, 2,3-dihydrobenzofuranyl, 2oxo-2,3-dihydro-benzoimidazolyl, 2-oxo-2,3-dihydro-benzothiazolyl, benzo[1,3]dioxolyl, 1,2,3,4-tetrahydroquinolinyl, 2-oxo-1,2-dihydro-quinoxalinyl, chromanyl, and imidazo[1,2-aJpyridinyl, wherein the members of the group R1c are attached to the carbonyl group in formula I via an aromatic carbon atom and wherein the members of the group Rlc may optionally be substituted with one R5, one R6, and/or one R7, provided that in case R1 is a phenyl group, the substituents R5, R6, and/or R7 are not attached to the carbon atoms next to the carbon atom which is attached to the carbonyl group in formula
In a further embodiment of the présent invention
R1 is selected from the group Rld consisting of phenyl, indolyl, 2-oxo-2,3-dihydro-indolyl, benzimidazolyl, indazolyl, imidazo[1,2ajpyridinyl, 2-oxo-2,3-dihydro-benzoimidazolyl, 2-oxo-2,3-dihydro-benzothiazolyl, imidazopyridinyl, benzotriazolyl. benzothiazolyl and 2-oxo-1,2-dihydroquinoxalinyl, wherein the members of the group R1d are attached to the carbonyl group in formula I via an aromatic carbon atom and wherein the members of the group R1d may optionally be substituted with one Rs, one R6, and/or one R7, provided that in case R1 is a phenyl group, the substituents R5, R6, and/or R7 are not attached to the carbon atoms next to the carbon atom which is attached to the carbonyl group in formula I.
In a further embodiment of the présent invention
R1 is selected from the group R1dZ consisting of
4-hydroxy-phenyl, 4-amino-3-methoxy-phenyl, 3-fluoro-4-hydroxy-phenyl, 4amino-3-chloro-phenyl, 3-chloro-4-hydroxy-phenyl, indol-3-yl, indol-5-yl, indol-6-yl, 1 -methyl-indol-3-yl, benzimidazol-5-yl, e-methyl-benzimidazol-S-yl, 7-methylbenzimidazol-S-yl, indazol-5-yl and benzothiazol-6-yl.
In a further embodiment of the présent invention
R1 is selected from the group R'e consisting of
4-hydroxy-phenyl, 4-amino-3-methoxy-phenyl, 3-fiuoro-4-hydroxy-phenyl, 4amino-3-chloro-phenyl, 3-chloro-4-hydroxy-phenyl, indol-3-yl, indol-5-yl, indol-6-yl, 1-methyl-indol-3-yl, benzimidazol-5-yl, indazol-5-yl and benzothiazol-6-yl.
In a further embodiment of the présent invention
R1 is selected from the group R1’ consisting of benzimidazol-S-yl, 6-methyl-benzimidazol-5-yl and ï-methyl-benzimidazol-S-yl.
In a further embodiment of the présent invention
R2 is selected from the group R2b consisting of
hydrogen, halogen, (het)aryl, cyano, nitro, amino, hydroxy, C2.6-alkynyl,
C^-alkyl and CM-cycloalkyl, wherein in the Ci.6-aikyI and C3.G-cycloalkyl group one CH2 group may optionally be replaced by CO or SO2, one CH2 group optionally by O or NRn, and one CH groupoptionally by N, and wherein both of these groups may optionally be mono- or polyfluorinated and optionally mono- or independently of each other disubstituted with chlorine, Cj^-alkyl, cyano, (het)aryl, amino, Cj^-alkylamino, di-(Ct.3-alkyl)amino, hydroxy, Ci_3-alkyloxy, (het)aryloxy, Cj-3-alkylsuifanyl, C^alkylsulfinyl, and/or C3Î-cycloalkyl, wherein in the C3.6-cycloalkyl group one or two CH2 groups may optionally be replaced independently of each other by carbonyl, O or NRn, and one CH group optionally by N, and which may optionally be mono- or independently disubstituted with fluorine or Ci.3alkyl.
In a further embodiment of the présent invention
R2 is selected from the group R2c consisting of hydrogen, fluorine, chlorine, bromine, Cv3-alkyl, C3^-cycloalkylmethyl, cyclopropyl, (het)aryl-methyl, C2-»-alkynyl, (het)aryl, cyano-Ci.3-alkyl, aminocarbonyl-Ci_3-alkyl, Cvs-alkyl-aminocarbonyl-Ci-3-alkyl, di-fC-i.a-alkyQ-aminocarbonyl-Cvs-alkyl, pyrrolidin-l-yl-carbonyl-Cva-alkyl, piperidin-l-yl-carbonyl-Cvs-alkyl, morpholin-4-ylcarbonyl-Cvralkyl, carboxy-Cv3-alkyl, C^-alkyloxy-carbonyl-Ci-s-alkyl, Cvs-alkylcarbonyl-amino-C^-alkyl, N-ÎCva-alkylJ-Cva-alkylcarbonyl-amino-Cioalkyl, 2-oxo-pyrrolidin-1-yl-C1.3-alkyl, 2-oxo-piperidin-1-yl-C1.3-alkyl, 3-oxomorpholin-4-yl-Cu-alkyl, hydroxy-Cvij-alkyl, Cra-alkyloxy-Ci^-alkyl, trifluoromethyl, difluoromethyl, cyano, aminocarbonyl, C^-alkyl-aminocarbonyl, di-(C1.3-alkyl)aminocarbonyl, pyrrolidin-1-yl-carbonyl, piperidin-1-yl-carbonyl, morpholin-4-ylcarbonyl, carboxy, CV3-alkyloxy-carbonyl, amino, C^-alkylamino, C,.3-alkylcarbonylamino, (het)aryl-carbonylamino, N-(Ci.3-alkyl)-Ci_3-alkyl-carbonylamino, N-(C1.3-alkyl)-(het)aryl-carbonylamino, 2-oxo-pyrrolidin-1-yl, 2-oxo-piperidin-1-yl, morpholin-4-yl, 3-oxo-morpholin-4-yl, Ci.3-alkyl-sulfonylamino, N-fCvs-alkyO-C,^alkyl-sulfonylamino, N-fCvs-alkylHhetJaryl-sulfonylamino, hydroxy, CM-alkyloxy, C3.6-cycloalkyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, difluoromethoxy, trifluoromethoxy, (het)aryloxy, cyano-Ci.3-alkyloxy, aminocarbonyl-C^-alkyloxy, Ci.3-alkyl-aminocarbonyl-C1.3
alkyloxy, di-tCi.rj-alkyQ-aminocarbonyl-Cvralkyloxy, pyrrolidin-1 -yl-carbonyl-C^alkyloxy, piperidin-1 -yl-carbonyl-Cva-alkyloxy, morpholin-4-yl-carbonyl-Ci_3-alkyloxy, carboxy-Cvj-alkyloxy, Cvralkyloxy-carbonyl-Cvralkyloxy, hydroxy-Ct.3alkyloxy, Cbralkyloxy-Cï.g-alkyloxy, tetrahydrofuranyl-Cva-alkyloxy, tetrahydropyranyl-Ci-3-alkyloxy, C^-alkylsulfonyl, C3.6-cyc!oalkylsulfonyl, aminosulfonyl, Ci.3-alkyl-aminosulfonyl and di-(Ci.3-alkyl)-aminosulfonyl, wherein the above-mentioned term (het)aryl dénotés phenyl, furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, ail of whîch may optionally be mono- or disubstituted with R10.
In a further embodiment of the présent invention
R2 is selected from the group R2d consisting of hydrogen, fluorine, chlorine, bromine, methyl, ethynyl, cyclopropyl, C3.6-cycloalkylmethyl, phenylmethyl, hydroxy-C^-alkyl, phenyl, cyano, aminocarbonyl, methyiaminocarbonyl, dimethylaminocarbonyl, pyrrolidin-1 -ylcarbonyl, morpholin4-ylcarbonyl, carboxy, methoxycarbonyl, amino, acetylamino, methlysulfonylamino, hydroxy, Ci.3-alkyloxy, phenyloxy, and pyridazinyloxy, while the mentioned phenyl and pyridazinyl groups may optionally be monosubstituted with fluorine, methyl, cyano, or methoxy.
In a further embodiment of the présent invention
R2 is selected from the group R2e consisting of hydrogen, fluorine, bromine, cyclohexylmethyl, phenylmethyl, 4-methoxyphenylmethyl, hydroxymethyl, 2-hydroxyprop-2-yl, phenyl, cyano, aminocarbonyl, methyiaminocarbonyl, dimethylaminocarbonyl, pyrrolidin-1-ylcarbonyl, morpholin4-ylcarbonyl, carboxy, methoxycarbonyl, amino, hydroxy, methoxy, 4methoxyphenoxy, and 6-methyl-pyridazin-3-yloxy.
In a further embodiment of the présent invention
R2
is selected from the group RZf consisting of hydrogen and cyano.
In a further embodiment of the présent invention
R3, R4 are selected independently of each other from the group R3/4b consisting of hydrogen, fluorine, chlorine, Ci.3-alkyl, trifluoromethyI, cyano, hydroxy, and Ον3alkyloxy, or
R3/4b dénotés R3 and R4 that are attached to adjacent carbon atoms and joined to form a methylenedioxy or ethylenedioxy group, or, together with the carbon atoms they are attached, an imidazo, oxazolo, or a thiazolo ring, each of which may optionally be substituted with one or two substituents independently selected from methyl, dimethylamino, hydroxy, and methoxy.
In a further embodiment of the présent invention
R3, R4 are selected independently of each other from the group R3,4c consisting of hydrogen, fluorine, chlorine, methyl, trifluoromethyl, cyano, hydroxy, and methoxy.
In a further embodiment of the présent invention
R3, R4 are selected independently of each other from the group R3/4cZ consisting of hydrogen, fluorine and methyl.
In a further embodiment of the présent invention
R3, R4 are selected independently of each other from the group R3/4d consisting of hydrogen and fluorine.
In a further embodiment of the présent invention
R5 is selected from the group R5b consisting of fluorine, chlorine, bromine, ClJ(-alkyI, C3.6-cycloalkyl-CV3-alkyl, C3.6-cycloalkyl, (het)aryl-Cv3-alkyl, (het)aryl, cyano-Cv3-alkyl, aminocarbonyl-Cvs-alkyl, Cvg-alkylaminocarbonyl-C^-alkyl, di-fCvs-alkylj-aminocarbonyl-Cva-alkyl, pyrrolidin-1 -ylcarbonyl-Cva-alkyl, piperidin-1 -yl-carbonyl-Ci*3-aIkyt, piperazin-1 -yl-carbonyl-C-|.3alkyl, 4-(C1.3-alkyl)-piperazin-1 -yl-carbonyl-Cvs-alkyl, morpholin-4-yl-carbonyl-Ci.3alkyl, carboxy-C^-alkyl, C^-alkyloxy-carbonyl-C^-alkyl, amino-Ci.3-alkyl, Ο-|.3alkylamino-Cva-alkyl, di-ÎC^j-alkylj-amino-Ci.s-alkyl, pyrrolidin-1 -yl-Cu-alkyl, piperidin-1 -yl-Ct-3-alkyl, piperazin-1 -yl-Cvj-alkyl, 4-(Ci.3-alkyl)-piperazin-1-yl-C).316399
alkyl, morpholin-4-yl-C,.3-alkyl, Ci-3-alkylcarbonylamino-C,.3-alkyl, (het)arylcarbonylamino-C,.3-alkyl, 2-oxo-pyrrolidin-1-yl-C1.3-alkyl, 2-oxo-piperidin1-yl-C,.3-alkyl, 2-oxo-piperazin-1-yl-Ci.3-alkyl, S-oxo-piperazin-l-yl-Cvs-alkyl, 2oxo-4-(C,.3-alkyl)-piperazin-1 -yl-C,.3-alkyl, 3-oxo-4-(Ci.3-alkyl)-piperazin-1 -yl-C,.3alkyl, 3-oxo-morpholin-4-yl-C,.3-alkyl, hydroxy-C,.3-alkyl, C,.3-alkyloxy-Ci.3-alkyl, (het)aryloxy-C,.3-alkyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoro-1hydroxyethyl, 2,2,2-trifluoro-1-hydroxy-1-methylethyl, 2,2,2-trifluoro-1-hydroxy-1(trifluoromethyl)ethyl, cyano, aminocarbonyl, C,.3-alkyl-aminocarbonyl, ΰί-(Ο,.3alkyl)-aminocarbonyl, (het)aryl-C,.3-alkylaminocarbonyl, N-(Ci.3-alkyl)-(het)aryl-Ci. 3-alkylaminocarbonyl, (het)arylaminocarbonyl, N-(C,.3-alkyl)-(het)arylaminocarbonyl, pyrrolidin-1-yl-carbonylT piperidin-1-yl-carbonyl, piperazin-1-ylcarbonyl, 4-(C1.3-alkyl)-piperazin-1-yl-carbonyl, morpholin-4-yl-carbonyl, carboxy, Ci.3-alkyloxy-carbonyl, nitro, amino, C,.3-alkylamino, di-(C,.3-alkyl)amino, pyrrolidin-1-yl, piperidîn-1 -yl, piperazin-1 -yl, 4-(C1.3-alkyl)-piperazin-1-yl, 4-(0,.3alkylcarbonyl)-piperazin-1 -yl, 4-(Ci_3-alkyloxycarbonyl)-piperazin-1 -yl, 4-(C,.3alkylsulfonyl)-piperazîn-1-yl, morpholin-4-yl, C,.3-alkyl-carbonylamino, N-(Ci.3alkyl)-C,.3-alkyl-carbonylamino, (het)arylcarbonylamino, N-(C,.3-alkyl)(het)arylcarbonylamino, (het)aryi-C1.3-alkyi-carbonylamino, N-(C,.3-alkyl)-(het)arylCi.3-alkyl-carbonylamino, 2-oxo-pyrrolidin-1 -yl, 2-oxo-piperidin-1-yl, 2-oxopiperazin-1 -yl, 2-oxo-4-(C1.3-alkyl)-piperazin-1-yl, 3-oxo-piperazin-1-yl, 3-oxo-4(Cvs-alkylJ-piperazin-l-yl, 3-oxo-morpholin-4-yl, aminocarbonylamino, N(aminocarbonyl)-Ci.3-alkylamino, C,.3-alkyl-aminocarbonylamino, N-(Ci.3-alkylaminocarbonyl)-Ci.3-alkylamino, N-(di-(Ci.3-alkyl)aminocarbonyl]-Ci.3-alkylamino, di-(C,.3-alkyl)-aminocarbonyl-amino, pyrrolidin-1 -yl-carbonylamîno, pîperidin-1 -ylcarbonylamino, piperazin-1-yl-carbonylamtno, 4-(C1.3-alkyl)-piperazin-1-ylcarbonylamino, morpholin-4-yl-carbonylamino, C,.3-alkyloxy-carbonylamino, N-(Ci. 3-alkyl)-C,.3-alkyloxy-carbonylamino, C,.3-alkyl-sulfonylamino, N-(C,.3-alkyl)-Ci_3alkyl-sulfonylamino, (het)arylsulfonylamino. N-(C,.3-alkyl)-(het)arylsulfonylamino, oxo-imidazolidin-1-yl, hydroxy, C^-alkyloxy, C3.6-cycloalkyl-Ci.3-alkyloxy, (het)aryl0,.3-alkyloxy, C3.6-cycloalkyloxy, (het)aryloxy, cyano-C,.3-alkyloxy, aminocarbonylC,.3-alkyloxy, Ci.3-alkyl-aminocarbonyl-Ci.3-alkyloxy, di-(C,.3-alkyl)-aminocarbonylCi.3-alkyloxy, pyrrolidin-1 -yl-carbonyl-C,.3-alkyloxy, piperidin-1-yl-carbonyl-C,.3alkyloxy, piperazin-1-yl-carbonyl-C,.3-alkyloxy. 4-(C,.3-alkyl)-piperazin-1-ylcarbonyl-C,.3-alkyloxy, morpholin-4-yl-carbonyl-Ci.3-alkyloxy, carboxy-Ci.3alkyloxy, Ci.3-alkyloxy-carbonyl-Ci.3-alkyloxy, amino-Ci.3-alkyloxy, C,.3-alkylaminoCi.3-alkyloxy, di-(C1.3-alkyl)-amino-C,.3-alkyloxy, pyrrolidin-1 -yl-C,,3-alkyloxy, piperidin-1 -yl-C,.3-alkyloxy, piperazin-1-yl-C,.3-alkyloxy, 4-(Ci.3-alkyl)-piperazin-1-
yl-Cva-alkyloxy, morpholin-4-yl-Ci.3-alkyloxy, 2-oxo-pyrrolidin-1-yl-C1.3-alkyloxy, 2oxo-piperidin-1 -yl-Cv3-alkyloxy, 2-oxo-piperazin-1 -yl-Ci.3-alkyloxy, 3-oxopiperazin-1 -yl-Cvj-alkyloxy, 2-oxo-4-(C1.3-alkyl)-piperazin-1 -yl-C^-alkyloxy, 3-oxo4-(Ci.3-alkyl)-piperazin-1-yl-Ci.3-alkyloxyt 3-oxo-morpholin-4-yl-C1.3-alkyloxy, hydroxy-Ci-3-alkyloxy, Ci.3-alkyloxy-Ci.3-alkyloxy, tetrahydrofuran-3-yl-oxy, tetrahydropyran-3-yl-oxy, tetrahydropyran-4-yl-oxy, tetrahydrofuranyl-Cvs-alkyloxy, tetrahydropyranyl-C^-alkyloxy, difluoromethoxy, trifluoromethoxy, C-|.3alkylsulfanyl-Ci.3-alkyloxy, Cv3-alkylsulfinyl-Ci.3-alkyloxy, C1.3-alkylsulfonyl-C1.3alkyloxy, Ci_3-alkylsulfonyl, (het)arylsulfonyl, aminosulfonyl, Ci_3-alkylaminosulfonyl, di-(Ci.3-alkyl)-aminosulfonyl, pyrrolidin-1-yl-sulfonyl, piperidin-1 -ylsulfonyl, morpholin-4-yl-sulfonyl, piperazin-1-yl-sulfonyl, and 4-(Ci.3-alkyl)pïperazin-1 -yl-sulfonyl, wherein the above-mentioned term (het)aryl is defined as hereinbefore or hereinafter.
In a further embodiment of the présent invention
R5 is selected from the group RSc consisting of fluorine, chlorine, C-j^-aikyJ, (het)aryl-Ci.3-alkyl, (het)aryl, aminosulfonyl, amino-Ci.3-alkyl, Cvralkylamino-Cvs-alkyl, di-fCvralkylJ-amino-Ci^-alkyl, pyrrolrdin-1 -yl-C,.—alkyl, morpholin-4-yl-Ci.3-alkyl, C^-alkylcarbonylaminoC^-alkyl, (hefiarylcarbonylamino-Cv-j-alkyl, 2-oxo-pyrrolidin-1 -yl-Ci.3-alkyl, 3-oxo-morpholin-4-y!-Ci.3-alkyl, hydroxy-Ci.3-alkyl, C^-alkyloxy-Csa-alkyl, 2,2,2-trifluoro-1-hydroxyethyl, 2,2,2-trifluoro-1-hydroxy-1-methylethyl, 2,2,2trifluoro-1 -hydroxy-1 -trifluoromethyl-ethyl, trifluoromethyl, cyano, aminocarbonyl, Ci.3-alkyl-aminocarbonyl, di-(Ci.3-alkyl)-aminocarbonyl, (het)arylaminocarbonyl, pyrrolidin-1-yl-carbonyl, piperidin-1-yl-carbonyl, piperazîn-1 -yl-carbonyl, morpholin-4-yl-carbonyl, 4-(C1.3-alkyl)-piperazin-1 -ylcarbonyl, carboxy, C1.3-alkyloxy-carbonyl, amino, Ci.3-alkylamino, di-ÎC,^alkyl)amino, pyrrolidin-1 -yl, piperidin-1-yl, piperazin-1 -yl, morpholin-4-yl, 2oxo-pyrrolidin-1-yl, 2-oxo-piperidin-1-yl, 2-oxo-piperazin-1-yl, 3-oxopiperazin-1 -yl, 3-oxo-morpholin-4-yl, C^-alkyl-carbonylamino, (het)arylcarbonylamino, aminocarbonylamîno, C^j-alkyl-aminocarbonylamino, di-(Ci.3-alkyl)aminocarbonylamino, pyrrolidin-1 -yl-carbonylamino, piperidin-1 -yl-carbonylamino, piperazin-1 -yl-carbonylamino, morpholin-4-ylcarbonylamino, Ci.3-alkyloxy-carbonylamino, hydroxy, C^-alkyloxy,
0/ hydroxy-CV3-aîkyloxyt Cvralkyloxy-Cvralkyloxy, difluoromethoxy, trifluoromethoxy, and (het)aryloxy, wherein the above-mentioned term (het)aryl dénotés phenyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, oxazolyl, isoxazolyl, thienyl, thiazolyl, triazolyl, oxadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl, each of which may optionally be substituted with one or two R10.
In a further embodiment of the présent invention is selected from the group RSd consisting of fluorine, chlorine, Ci_3-alkyl, hydroxy-C;.3-alkyl, aminocarbonyl, Cu-alkylaminocarbonyl, amino, Ci.3-alkylamino, Ci-3-alkyl-carbonylamino, hydroxy, Ci.3-alkyloxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, and aminosulfonyl.
In a further embodiment of the présent invention is selected from the group R5® consisting of fluorine, chlorine, methyl, amino, hydroxy, and methoxy.
In a further embodiment of the présent invention
R6, R7 are selected independently of each other from the group RB/7b consisting of fluorine, chlorine, bromine, C-|.3-alkyl, C2.3-alkynyl, trifluoromethyl, hydroxy, 0^3alkyloxy, and cyano, and/or
RB/7b dénotés one R6 and R7 that are attached to adjacent carbon atoms and joined to form a methylenedioxy, difluoromethylenedioxy, ethylenedioxy, or C3.5alkylene group.
In a further embodiment of the présent invention
R6, R7 are selected independently of each other from the group RG/7c consisting of fluorine, chlorine, methyl, ethyl, trifluoromethyl, hydroxy, methoxy, and ethoxy.
In a further embodiment of the présent invention
R6, R7 are selected independently of each other from the group R6/7d consisting of fluorine, chlorine, methyl, hydroxy, and methoxy.
In a further embodiment of the présent invention
R10 îs selected independently of each other from the group R10b consisting of fluorine, chlorine, bromine, Ci.3-alkyJ, phenyl, difluoromethyl, trifluoromethyl, cyano, aminocarbonyl, C^-alkylaminocarbonyl, di-(C1.3-alkyl)-aminocarbonyl, carboxy, C^-alkyloxycarbonyl, nitro, amino, acetylamino, methylsulfonylamino, hydroxy, C^-alkyloxy, difluoromethoxy, trifluoromethoxy, methylsulfanyl, methylsulfinyl, methylsulfonyl, and aminosulfonyl.
In a further embodiment of the présent invention
R10 is selected independently of each other from the group R10c consisting of fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl, cyano, hydroxy, methoxy, difluoromethoxy, and trifluoromethoxy.
In a further embodiment of the présent invention
R10 is selected Independently of each other from the group R10d consisting of fluorine, methyl, cyano, and methoxy.
In a further embodiment of the présent invention
Rn is selected independently of each other from the group RNb consisting of hydrogen, C^-alkyl, C3Î-cycloalkyl, C3.6-alkenyl, phenyl, C^-alkylcarbonyl, phenylcarbonyl, C^-alkylanninocarbonyl, phenylaminocarbonyl, Ομ4alkyloxycarbonyl, ÛM-alkylsulfonyl, and phenylsulfonyl, wherein the C^-alkyl group optionally may be mono- or polysubstituted with fluorine and optionally monosubstituted with phenyl, cyano, aminocarbonyl, CV3-alkylaminocarbonyl, di-(Ci.3-alkyl)aminocarbonyl, carboxy, Cv^-alkoxycarbonyl, Ci.4-alkylcarbonylamino, hydroxy, or CM-alkoxy.
In a further embodiment of the présent invention
RN is selected independently of each other from the group RNc consisting of hydrogen, phenyl, Ci.4-alkylcarbonyl, phenylcarbonyl, C^-alkylaminocarbonyl, phenylaminocarbonyl, CM-alkyloxycarbonyl, C^-alkylsulfonyl, phenylsulfonyl, and a CM-alkyl group, which optionally may be mono- or polyfluorinated and optionally monosubstituted with hydroxy, Cn-alkoxy, cyano, or phenyl.
In a further embodiment of the présent invention
RN is selected independently of each other from the group RNd consisting of hydrogen, methyl, benzyl, phenyl, acetyl, tert-butoxycarbonyl, and methylsulfonyl.
In a further embodiment of the présent invention
R8 is selected independently of each other from the group R8b consisting of hydrogen and methyl.
In a further embodiment of the présent invention
R® is selected independently of each other from the group RBc consisting of hydrogen.
In a further embodiment of the présent invention m is 0.
Each R1*, R2x, R3'4’, RSx, R®™. RNx, R8x, R10*, m represents a characterized, individual embodiment for the corresponding substituent as described above. Thus given the above définitions, preferred individual embodiments of the first aspect of the invention are fully characterized by the term (R1x, R2*, R3'4*, R5x, R6/7x, RNx, R8x, R10x, m), wherein for each index x an individual figure is given that ranges from a to the highest letter given above. Indices x and m vary independently from each other. Ail individual embodiments described by the term in parantheses with full permutation of the indices x and m, referring to the définitions above, shall be comprîsed by the présent invention.
The following Table 1 shows, exemplarily and in the order of increasing preference from the first line to the last line, such embodiments E-1 to E-36 of the invention that are considered preferred. This means that embodiment E-36, represented by the entries in the last row of Table 1, is the most preferred embodiment.
Table 1 : Preferred embodiments E-1 to E-36 of the invention
R2 | Rs/R4 | R5 | Re/R7 | R10 | RB | rn | m | ||
E-1 | R'b | R2b | p3/4b | R5b | R6/7b | Rl°b | r63 | RNb | 0,1 |
E-2 | R'C | R2e | R3/4c | R5c | r6/7c | Rl°c | R0a | 0,1 | |
E-3 | Rw | R2b | R3Md | r5c | R6/7d | R10d | R0a | RNd | 0,1 |
E-4 | R,b | R2b | ^3/4d | R5d | R6/7d | RWd | R8b | RNd | 0,1 |
E-5 | Rlb | R2b | R3Md | R5e | R6/7d | RWd | Rflb | RNd | 0.1 |
E-6 | R1c | R2b | j^3/4b | RSC | R6/7c | R1°d | R8b | RNd | 0,1 |
E-7 | R1C | R2b | RWb | R5d | R6/7d | RWd | R8b | RNd | 0,1 |
E-8 | R1b | R2e | R3/4c | RSC | rB/7c | R 1°d | R8b | •Λ | 0,1 |
E-9 | R1c | R2b | f^3/4c | R5C | j^6/7c | R1°d | R8b | RNd | 0.1 |
E-10 | R1c | r2c | r3/4c | R5C | R6f7c | R10d | R8b | ★ | 0,1 |
E-11 | R1c | R2c | r3/4c | R5d | R6/7d | RWd | R8b | ★ | 0,1 |
E-12 | Rw | R2C | r3/4c2 | R5C | R6/7c | RWd | R8b | * | 0.1 |
E-13 | R1c | R2b | r3/4c2 | R5C | p6/7c | R10d | R8b | RNd | 0,1 |
E-14 | Rie | r2c | r3/4c2 | r5c | R6/7c | RWd | R8b | 0,1 | |
E-15 | R1c | r2c | r3/4c2 | R5d | R6/7d | RWO | R8b | 0,1 | |
E-16 | R1c | r2c | R3/4d | RSd | R6/7d | R10d | R8b | 0.1 | |
E-17 | R1d | R2C | R3/4d | RSd | p6/7d | RWd | R8b | 0,1 | |
E-18 | Rld | r2c | R3Md | R5e | R6/7d | RWd | R8b | 0,1 | |
E-19 | R’d | R2d | R3/4d | R5e | p6/7d | * | R8b | ♦ | 0,1 |
E-20 | R’d | R2e | R3»d | R5e | R6/7d | R8b | 0,1 | ||
E-21 | R1d2 | R2e | R3/4d | * | ★ | R8b | 0,1 | ||
E-22 | Rie | R2e | R3/4d | * | * | R8b | A | 0,1 | |
E-23 | R1e | R2e | R™ | * | « | * | rBc | « | 0,1 |
Table 1 continued
R1 | R2 | R3/R4 | R5 | R6/R7 | R10 | R® | rn | m | |
E-24 | R1e | R2e | A | A | RBC | _A | 0 | ||
E-25 | R’d | R2' | R3Md | rSC | R6/7d | _A | Reb | A | 0,1 |
E-26 | R1e | R2f | R3Md | * | * | * | R®b | A | 0,1 |
E-27 | R1e | R2f | p3/4d | -* | _* | * | rBC | -* | 0,1 |
E-28 | Rie | R2' | |^3/4d | * | A | A | r8c | A | 0 |
E-29 | R1d2 | r2c | R3Md | RWd | Reb | A | 0,1 | ||
E-30 | R’dZ | R2d | R3Md | _A | _A | R8b | A | 0,1 | |
E-31 | R1d2 | R2e | f^3/4d | Λ | A | Λ | R8b | A | 0,1 |
E-32 | R1d2 | R2' | R3Md | _A | * | A | R8b | A | 0,1 |
E-33 | R1d2 | R2' | R3/4d | _A | _A | A | R8b | A | 0 |
E-34 | R1f | R2’ | R3Md | _* | _A | _* | R8b | ^A | 0,1 |
E-35 | R1f | R2' | p3/4d | _A | _A | _A | R8C | _A | 0,1 |
E-36 | R1f | R2' | R3/4d | * | _A | _A | r8c | A | 0 |
-*means that the respective variable does not exist in the corresponding embodiment the tautomers thereof, the stereoisomers thereof, the mixtures thereof, and the salts thereof, while the following compounds are excluded:
Accordingly, E-24 covers compounds of formula I, wherein
R1 is selected from the group R16 consisting of
4-hydroxy-phenyl, 4-amino-3-methoxy-phenyl, 3-fluoro-4-hydroxy-phenyl, 4amino-3-chloro-phenyl, 3-chloro-4-hydroxy-phenyl, indol-3-yl, indol-5-yl, indol-6-yl, 1-methyl-indol-3-yl, benzimidazol-5-yl, indazol-5-yl and benzothiazol-6-yl,
R2 is selected from the group R2e consisting of hydrogen, fluorine, bromine, cyclohexylmethyl, phenylmethyl, 4-methoxyphenylmethyl, hydroxymethyl, 2-hydroxyprop-2-yl, phenyl, cyano, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, pyrrolidin-1-ylcarbonyl, morpholin4-ylcarbonyl, carboxy, methoxycarbonyl, amino, hydroxy, methoxy, 4methoxyphenoxy, and e-methyl-pyridazin-S-yloxy.
R3, R4 are selected independently of each other from the group R3Md consisting of hydrogen and fluorine,
R8 is selected independently of each other from the group R8c consisting of hydrogen, and m = 0, the tautomers thereof, the stereoisomers thereof, the mixtures thereof, and the salts thereof.
Accordingly, E-28 covers compounds of formula I, wherein
R1 is selected from the group R1e consisting of
4-hydroxy-phenyl, 4-amino-3-methoxy-phenyl, 3-fluoro-4-hydroxy-phenyl, 4amino-3-chloro-phenyl, 3-chloro-4-hydroxy-phenyl, indol-3-yl, indol-5-yl, îndol-6-yl, 1-methyl-indol-3-yl, benzimidazol-5-yl, indazol-5-yl and benzothiazol-6-yl,
R2 is selected from the group R2' consisting of hydrogen and cyano,
R3, R4 are selected independently of each other from the group R3/4d consisting of hydrogen and fluorine,
R3 is selected independently of each other from the group R0C consisting of hydrogen, and m = 0, the tautomers thereof, the stereoisomers thereof, the mixtures thereof, and the salts thereof.
Accordingly, E-33 covers compounds of formula I, wherein
R1 is selected from the group R1d2 consisting of
4-hydroxy-phenyl, 4-amino-3-methoxy-phenyl, 3-fluoro-4-hydroxy-phenyl, 4amino-3-chloro-phenyl, 3-chloro-4-hydroxy-phenyl, indol-3-yl, indol-5-yl, indol-6-yl, 1 -methyl-indol-3-yl, benzimidazol-5-yl, 6-methyl-benzimidazol-5-yl, 7-methyl16399
benzimidazol-5-yl, indazol-5-yl and benzothiazol-6-yl,
Rz is selected from the group R2' consisting of hydrogen and cyano,
R3, R4 are selected independently of each other from the group R3Md consisting of hydrogen and fluorine,
R8 is selected independently of each other from the group RSb consisting of hydrogen and methyl and m = 0, the tautomers thereof, the stereoîsomers thereof, the mixtures thereof, and the salts thereof.
Accordingly, E-36 covers compounds of formula I, wherein
R1 is selected from the group R1f consisting of benzimidazol-5-yl, 6-methyl-benzimidazol-5-yl and 7-methyl-benzimidazol-5-yl,
R2 is selected from the group R2f consisting of hydrogen and cyano,
R3, R4 are selected independently of each other from the group R3Md consisting of hydrogen and fluorine,
R8 is selected independently of each other from the group R8c consisting of hydrogen, and m = 0, the tautomers thereof, the stereoîsomers thereof, the mixtures thereof, and the salts thereof.
Another preferred embodiment of this invention is described by formula l.a
wherein the piperidine substructure and the tetraline (m=1 ) or indane (m=0) substructure form a c/s configured tricyclic core structure, while the variables R1, R2, R3, R4, and m are defined as
Λ'
hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof, and the salts thereof.
A further preferred embodiment of this invention is described by formula l.b
R1
l.b wherein the trïcyclic core structure is R configured at C-10b (for m=1 )/C-4a (for m=0) and S configured at C-4a (for m=1)/C-9a (for m=0), while the variables R1, R2, R3, R4, and m are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof, and the salts thereof.
Accordingly, one embodiment of preferred compounds according to the invention comprises compounds of formula l.b,
R1
l.b wherein
R1 is selected from the group R1e consisting of
4-hydroxy-phenyl, 4-amino-3-methoxy-phenyl. 3-fiuoro-4-hydroxy-phenyl, 4amino-3-chloro-phenyl, 3-chloro-4-hydroxy-phenyl, indol-3-yl, îndol-5-yl, indol-6-yl, 1 -methyl-indol-3-yl, benzimidazol-5-yl, indazol-5-yl and benzothiazol-6-yl,
R2 is selected from the group RZe consisting of hydrogen, fluorine, bromine, cyclohexylmethyl, phenylmethyl, 4-methoxyphenylmethyl, hydroxymethyl, 2-hydroxyprop-2-yl, phenyl, cyano, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, pyrrolidin-1 -ylcarbonyl, morpholin4-ylcarbonyl, carboxy, methoxycarbonyl, amino, hydroxy, methoxy, 4methoxyphenoxy, and 6-methyl-pyridazin-3-yloxy.
R3, R4 are selected independently of each other from the group R3/4d consisting of hydrogen and fluorine,
R8 is selected independently of each other from the group R8c consisting of hydrogen, and m = 0, the tautomers thereof, the stereoisomers thereof, the mixtures thereof, and the salts thereof.
Another embodiment of preferred compounds according to the invention are compounds of formula l.b, wherein
R1 is selected from the group R1e consisting of
4-hydroxy-phenyl, 4-amino-3-methoxy-phenyl, 3-fluoro-4-hydroxy-phenyl, 4amino-3-chloro-phenyl, 3-chloro-4-hydroxy-phenyl, indol-3-yl, indol-5-yl, indot-6-yl, 1-methyl-indol-3-yl, benzimidazol-5-yl, indazol-5-yl and benzothiazol-6-yl,
R2 is selected from the group R2f consisting of hydrogen and cyano,
R3, R4 are selected independently of each other from the group R3/4d consisting of hydrogen and fluorine,
R8 is selected independently of each other from the group RBc consisting of hydrogen, and m = 0, the tautomers thereof, the stereoisomers thereof, the mixtures thereof, and the salts thereof.
Another embodiment of preferred compounds according to the invention are compounds of formula l.b, wherein
R1 is selected from the group R1f consisting of benzimidazol-5-yl, 6-methyl-benzimidazol-5-yl and 7-methyl-benzimidazol-5-yl,
R2 is selected from the group R2' consisting of hydrogen and cyano,
R3, R4 are selected independently of each other from the group R3/4d consisting of hydrogen and fluorine,
R® is selected independently of each other from the group R®c consisting of hydrogen, and m = 0,
Λ the tautomers thereof, the stereoisomers thereof, the mixtures thereof, and the salts thereof.
Regarding the définitions of N-containing heteroaromatic groups, such as (het)aryl possessing one or more nitrogens within its framework, that bear a hydroxy group at the carbon atom adjacent to the nitrogen or another position of the ring which allows a mesomeric interaction with the nitrogen, these groups can form a tautomeric amide substructure which is part of the invention; the tautomeric amide obtained from combining a hydroxy group and an N-containing heteroaromatic may bear substituents other than hydrogen on the amide nitrogen. Examples of such substructures of heteroaromatic groups wherein a tautomeric amide may be formed are depicted in the following compilation:
wherein RN is defined as described above. These tautomeric structures may be annelated to hereroaromatic and aromatic groups like such that are comprised by (het)aryl.
In some embodiments, the présent teachings provide crystalline compounds of the following structural formula (II):
As used herein, crystalline refers to a solid in which molécules are arranged in an orderly repeating pattern in three dimensions. Crystalline compounds of formula (II) can be a single crystalline form or a mixture of different crystalline forms, A single crystalline form means a compound of formula (II) as a single crystal or a plurality of crystals in which each crystal has the same crystal form.
In a particular embodiment, at least a particular percentage by weight of the compound of formula (II) is a single crystalline form. Particular weight percentages include 50%, 52%, 55%, 57%, 60%, 62%, 65%. 67%, 70%. 72%, 75%, 77%, 80%, 82%, 85%, 86%, 87%, 88%, 89%,
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or a percentage between 50% and 100%.
When a particular percentage by weight of the compound of formula (II) is defined as a crystalline form, the-remainder of the compound of formula (II) is some combination of amorphous forms of the compound of formula (II). When a particular percentage by weight of the compound of formula (II) is defined as a single crystalline form, the-remainder of the compound of formula (II) is some combination of amorphous forms of the compound of formula (II) and/or one or more crystalline forms of the compound of formula (II) other than the single crystalline form. Examples of single crystalline forms include Forms I and II of the compound of formula (II), as well as single crystalline forms characterized by one or more properties as discussed herein.
In the following description of particular crystalline forms of the compound of formula (II), embodiments of the invention may be described with reference to a particular crystalline “Form” of the compound of formula (II), However, the particular crystalline forms may also be characterized by one or more of the characteristics of the crystalline forms as described herein, with or without regard to referencing a particular Form.
Form I
In one embodiment, a single crystalline form of the compound of formula (II) is characterized as crystalline Form I. In another embodiment, at least a particular percentage by weight of the compound of formula (II) is crystalline Form I. Particular weight percentages include 50%, 52%, 55%, 57%, 60%, 62%, 65%, 67%. 70%, 72%, 75%, 77%, 80%, 82%, 85%, 86%, 87%, 88%,
89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or a percentage between 50% and 100%.
In some embodiments, the crystalline form is characterized by the X-ray powder diffraction (herein referred to as XRPD) pattern shown in FIG. 1, e.g., with values of 2T angles, d30 spacings and relative intensities as listed in Table 1, obtained using CuKa radiation. In some embodiments, the crystalline form is characterized by one, two, three, four, five or six XRPD peaks at 2T angles selected from 12.5°, 12.9°, 14.8°, 20.0°, 22.2° and 26.1°. In some embodiments, the crystalline form is characterized by at least three XRPD peaks at 2T angles selected from 12.5°, 12.9°, 14.8°, 20.0°, 22.2° and 26.1°. In some embodiments, the crystalline form is characterized by at least four XRPD peaks at 2T angles selected from 12.5°, 12.9°, 14.8°, 20.0°, 22.2° and 26.Γ. In some embodiments, the crystalline form is characterized by at least five XRPD peaks at 2T angles selected from 12.5°, 12.9°, 14.8°, 20.0°, 22.2° and 26.1°.
In some embodiments, the crystalline form is characterized by XRPD peaks at 2T angles of 12.5°, 12.9°, 14.8°, 20.0°, 22.2° and 26.Γ. In some embodiments, the crystalline form is characterized by one, two, three or four major XRPD peaks at 2T angles selected from 12.5°, 14.8°, 22.2° and 26.1°. In some embodiments, the crystalline form is characterized by at least three XRPD peaks at 2T angles selected from 12.5°, 14.8°, 22.2° and 26. Γ. In some embodiments, the crystalline form is characterized by XRPD peaks at 2T angles of 12.5°, 14.8°, 22.2° and 26.1°. In some embodiments, the crystalline form is characterized by one, two, three or four major XRPD peaks at 2T angles selected from 12.5°, 14.8°, 22.2° and 26.1°. In some embodiments, the crystalline form is characterized by major XRPD peaks at 2T angles of 12.5°,
14.8°, 22.2° and 26.1°. It is to be understood that a specified 2T angle means the specified value ±0.1°.
As used herein, major XRPD peak refers to an XRPD peak with a relative intensity greater than 25%. Relative intensity is calculated as a ratio of the peak intensity of the peak of interest 15 versus the peak intensity of the largest peak.
Table 1:XRPD Peaks from FIG. 1
2T H | d-value [A] | Intensity l/lo [%] |
5.77 | 15.30 | 5 |
5.93 | 14.88 | 4 |
6.47 | 13.65 | 17 |
9.81 | 9.01 | 3 |
11.55 | 7.66 | 2 |
11.94 | 7.40 | 5 |
12.54 | 7.05 | 100 |
12.88 | 6.87 | 23 |
14.83 | 5.97 | 31 |
16.04 | 5.52 | 12 |
16.54 | 5.35 | 4 |
17.35 | 5.11 | 5 |
18.67 | 4.75 | 2 |
19.52 | 4.54 | 5 |
19.59 | 4.53 | 5 |
19.98 | 4.44 | 21 |
20.20 | 4.39 | 7 |
20.46 | 4.34 | 5 |
2T n | d-value [A] | Intensity l/l0 [%] |
20.66 | 4.30 | 4 |
20.90 | 4.25 | 3 |
21.14 | 4.20 | 5 |
21.55 | 4.12 | 4 |
22.18 | 4.01 | 49 |
23.14 | 3.84 | 8 |
23.26 | 3.82 | 11 |
23.49 | 3.78 | 10 |
23.99 | 3.71 | 3 |
24.32 | 3.66 | 4 |
24.91 | 3.57 | 9 |
25.02 | 3.56 | 14 |
25.39 | 3.51 | 4 |
26.09 | 3.41 | 60 |
26.52 | 3.36 | 12 |
26.84 | 3.32 | 2 |
27.10 | 3.29 | 1 |
27.33 | 3.26 | 2 |
28.30 | 3.15 | 14 |
29.12 | 3.06 | 3 |
29.91 | 2.98 | 4 |
In sonne embodiments, the crystalline form is characterized by the 13C solid-state nuclear magnetic résonance (herein referred to as SSNMR) pattern shown in FIG. 2, e.g., with chemical shifts as listed in Table 2, obtained using magic angle spinning. In a particular embodiment, the crystalline form is characterized by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17 or 18 13C SSNMR peaks at chemical shifts selected from 170.3 ppm, 146.5 ppm,
142.8 ppm, 135.0 ppm, 130.6 ppm, 128.1 ppm, 122.1 ppm, 116.7 ppm, 115.6 ppm, 112.8 ppm,
109.8 ppm, 107.6 ppm, 44.6 ppm, 43.3 ppm, 41.4 ppm, 30.3 ppm, 26.3 ppm and 23.9 ppm. In one embodiment, the crystalline form is characterized by at least ten 13C SSNMR peaks at chemical shifts selected from 170.3 ppm, 146.5 ppm, 142.8 ppm, 135.0 ppm, 130.6 ppm, 128.1 ppm, 122.1 ppm, 116.7 ppm, 115.6 ppm, 112.8 ppm, 109.8 ppm, 107.6 ppm, 44.6 ppm, 43.3 ppm, 41.4 ppm, 30.3 ppm, 26.3 ppm and 23.9 ppm. In one embodiment, the crystalline form is characterized by at least fifteen 13C SSNMR peaks at chemical shifts selected from 170.3 ppm,
146.5 ppm, 142.8 ppm, 135.0 ppm, 130.6 ppm, 128.1 ppm, 122.1 ppm, 116.7 ppm, 115.6 ppm,
112.8 ppm, 109.8 ppm, 107.6 ppm, 44.6 ppm, 43.3 ppm, 41.4 ppm, 30.3 ppm, 26.3 ppm and 23.9 ppm. In one embodiment, the crystalline form is characterized by 13C SSNMR peaks at chemical shifts of 170.3 ppm, 146.5 ppm, 142.8 ppm, 135.0 ppm, 130.6 ppm, 128.1 ppm, 122.1 ppm, 116.7 ppm, 115.6 ppm, 112.8 ppm, 109.8 ppm, 107.6 ppm, 44.6 ppm, 43.3 ppm, 41.4 ppm, 30.3 ppm, 26.3 ppm and 23.9 ppm.
Table 2. 13C NMR Chemical Shifts from FIG 2
Peak | Chemical Shift (ppm) |
1 | 170.3 |
2 | 148.7 |
3 | 146.5 |
4 | 142.8 |
5 | 135.0 |
6 | 130.6 |
7 | 128.1 |
8 | 122.1 |
9 | 116.7 |
10 | 115.6 |
11 | 112.8 |
12 | 109.8 |
13 | 107.6 |
14 | 54.9 |
15 | 44.6 |
16 | 43.3 |
17 | 41.4 |
18 | 30.3 |
19 | 26.3 |
20 | 23.9 |
In some embodiments, the crystalline form is characterized by an endothermie transition having 10 an onset of about 231.7 ± 0.5°C in the differential scanning (herein referred to as DSC) profile.
In some embodiments, the crystalline form is characterized by a DSC profile as shown in FIG. 3. The profile plots the heat flow as a function of température from a sample containing Form I.
The DSC is performed on the sample using a scanning rate of 10°C/minute.
Form I is also characterized by the thermal gravimétrie analysis (herein referred to as TGA) profile shown in FIG. 4. The profile graphs the percent loss of weight of the sample as a function of température with the température rate change being 10°C/minute. The profile shows
a weight loss of approximately 2.1% as the température of the sample is changea from room température to 150°C, which indicates that Form I is anhydrous.
Form //
In one embodiment, a single crystalline form of the compound of formula (II) is characterized as crystalline Form II. In another embodiment, at least a particular percentage by weight of the compound of formula (II) is crystalline Form II. Particular weight percentages include 50%, 52%, 55%, 57%, 60%, 62%, 65%, 67%, 70%, 72%, 75%, 77%, 80%, 82%, 85%, 86%. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or a percentage between 50% and 100%,
In some embodiments, the crystalline form is characterized by the XRPD pattern shown in FIG. 5, e.g., with values of 2T angles, d-spacings and relative intensities as listed in Table 3, obtained using CuKa radiation. In a particular embodiment, the crystalline form is characterized by one, two, three, four, five, six or seven, eight, nîne, ten, eleven or twelve XRPD peaks at 2T angles selected from 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°. In a particular embodiment, the crystalline form is characterized by at least seven, eight, nïne, ten or eleven XRPD peaks at 2T angles selected from 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°. 21.9°, 23.3°, 25.6e and 26.5°. In some embodiments, the crystalline form is characterized by XRPD peaks at 2T angles of 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°. In some embodiments, the crystalline form is characterized by XRPD peaks at2T angles of 13.7°, 17.6°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°. In some embodiments, the crystalline form is characterized by XRPD peaks at 2T angles of 13.7°, 17.6°, 19.7, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°. In some embodiments, the crystalline form is characterized by XRPD peaks at2T angles of 13.7°, 17.6°, 19.7, 20.9, 21.3e, 21.9°, 23.3°, 25.6’ and 26.5°. In some embodiments, the crystalline form is characterized by XRPD peaks at2T angles of 13.7°, 17.6e, 19.3, 19.7,20.9,21.3°, 21.9°, 23.3°, 25.6° and 26.5°. In some embodiments, the crystalline form is characterized by XRPD peaks at 2T angles of 13.3°, 13.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°. In some embodiments, the crystalline form is characterized by XRPD peaks at 2T angles of 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°. In some embodiments, the crystalline form is characterized by one, two, three, four, five, six or seven major XRPD peaks at 2T angles selected from 13.7e, 17.6°, 21.3e, 21.9e, 23.3e, 25.6e and 26.5e. In some embodiments, the crystalline form is characterized by major XRPD peaks at 2T angles of 13.7e, 17.6e, 21.3e, 21.9e, 23.3e, 25.6e and 26.5e.
Table 3: XRPD Peaks from FIG. 5
21 H | d-value [A] | Intensity l/l0 [%] |
9.79 | 9.03 | 19 |
10.73 | 8.24 | 18 |
12.54 | 7.05 | 3 |
13.31 | 6.65 | 26 |
13.70 | 6.46 | 100 |
14.83 | 5.97 | 2 |
15.71 | 5.63 | 20 |
16.68 | 5.31 | 19 |
17.58 | 5.04 | 40 |
18.41 | 4.82 | 7 |
19.07 | 4.65 | 10 |
19.27 | 4.60 | 33 |
19.66 | 4.51 | 39 |
20.88 | 4.25 | 38 |
21.32 | 4.16 | 48 |
21.56 | 4.12 | 8 |
21.91 | 4.05 | 50 |
22.99 | 3.87 | 10 |
23.29 | 3.82 | 56 |
23.61 | 3.77 | 8 |
24.27 | 3.66 | 19 |
24.89 | 3.57 | 9 |
25.37 | 3.51 | 15 |
25.55 | 3.48 | 40 |
26.05 | 3.42 | 5 |
26.50 | 3.36 | 41 |
26.79 | 3.32 | 10 |
27.68 | 3.22 | 19 |
In some embodiments, the crystalline form is characterized by the 13C SSNMR pattern shown in FIG. 6, e.g., with chemical shifts as listed in Table 4, obtained using magic angle spinning. In a particular embodiment, the crystalline form is characterized by 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 5 13, 14, 15,16, 17 or 18 13C SSNMR peaks at chemical shifts selected from 172.6 ppm, 147.1 ppm 144.1 ppm, 132.9 ppm 129.6 ppm, 125.9 ppm 121.2 ppm, 119.5 ppm, 117.7 ppm, 114.6
ppm, 110.2 ppm, 45.1 ppm, 42.4 ppm, 32.6 ppm, 28.3 ppm and 24.4 ppm. In one embodiment, the crystalline form is characterized by at least ten 13C SSNMR peaks at chemical shifts selected from 172.6 ppm, 147.1 ppm 144.1 ppm, 132.9 ppm 129.6 ppm, 125.9 ppm 121.2 ppm,
119.5 ppm, 117.7 ppm, 114.6 ppm, 110.2 ppm, 45.1 ppm, 42.4 ppm, 32.6 ppm, 28.3 ppm and
24.4 ppm. In one embodiment, the crystalline form is characterized by at least thirteen 13C SSNMR peaks at chemical shifts selected from 172.6 ppm, 147.1 ppm 144.1 ppm, 132.9 ppm
129.6 ppm, 125.9 ppm 121.2 ppm, 119.5 ppm, 117.7 ppm, 114.6 ppm, 110.2 ppm, 45.1 ppm,
42.4 ppm, 32.6 ppm, 28.3 ppm and 24.4 ppm. In one embodiment, the crystalline form is characterized by 13C SSNMR peaks at chemical shifts of 172.6 ppm, 147.1 ppm 144.1 ppm,
132.9 ppm 129.6 ppm, 125.9 ppm 121.2 ppm, 119.5 ppm, 117.7 ppm, 114.6 ppm, 110.2 ppm, 45.1 ppm, 42.4 ppm, 32.6 ppm, 28.3 ppm and 24.4 ppm.
Table 4. 13C NMR Chemical Shifts from FIG 6
Peak | Chemical Shift (ppm) |
1 | 172.6 |
2 | 148.7 |
3 | 147.1 |
4 | 144.1 |
5 | 132.9 |
6 | 129.6 |
7 | 125.9 |
8 | 121.2 |
9 | 119.5 |
10 | 117.7 |
11 | 114.6 |
12 | 110.2 |
13 | 55.0 |
14 | 45.1 |
15 | 42.4 |
16 | 32.6 |
17 | 28.3 |
18 | 24.4 |
In some embodiments, the crystalline form is characterized by an endothermie transition having an onset of about 235.5 ± 0.5°C in the DSC profile. In some embodiments, the crystalline form is characterized by a DSC profile as shown in FIG. 7. The profile plots the heat flow as a function of température from a sample containing Form II. The DSC is performed on the sample using a scanning rate of 10’C/minute.
In some embodiments, the crystalline form is characterized by the thermal gravimétrie analysis (herein referred to as TGA) profile shown in FIG. 8. The profile graphe the percent loss of weight of the sample as a function of température with the température rate change being 10°C/minute, The profile shows a weight loss of approximately 0.1% as the température of the sample is changed from room température to 150°C, which indicates that Form II is anhydrous.
Other embodiments of the invention are directed to a single crystalline form of the compound of formula (II) is characterized by a combination of the aforementioned characteristics of any of the single crystalline forms discussed herein. The characterization can be any combination of one or more of the XRPD, TGA, DSC and SSNMR described for a particular crystalline form. For example, the single crystalline form of the compound of formula (II) can be characterized by any combination of the 2T peaks in an XRPD scan and/or any combination of the chemical shift peaks of an SSNMR spectrum and/or any combination of Information obtained from the DSC déterminations and/or the weight change in a sample obtained by TGA. It is to be understood that the présent teachings include any combination of analytical techniques to characterize a crystalline form.
The présent teachings also include compositions which include any of the compounds described herein, In some embodiments, the présent teachings provide a pharmaceutical composition including any of the compounds described herein and a pharmaceutically acceptable carrier or diluent. In some embodiments, the présent teachings provide a pharmaceutical composition comprising the crystalline compound of Formula (II) and a pharmaceutically acceptable carrier or diluent.
Some terms used above and hereinafter to describe the compounds according to the invention will now be defined more closely.
Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the spécification, however, unless specified to the contrary, the following terms hâve the meaning indicated and the following conventions are adhered to.
In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for exampie C-|.6-alkyl means an alkyl group or radical having 1 to 6 carbon atoms. In general, for groups comprising two or more subgroups, the last named subgroup is the radical attachment point, for example, the substituent aryl-Cva-alkyl- means an aryl group which is bound to a C^-alkyl group, the latter of which is bound to the core or to the group to which the substituent is attached.
In general, the attachment site of a given residue to another group shall be variable, i.e. any capable atom, bearing hydrogens to be replaced, within this residue may be the linking spot to the group being attached, unless otherwise indicated.
Unless specifically indicated, throughout the spécification and the appended daims, a given chemical formula or name shall encompass ail conceivable constitutional isomers and stereoisomers, including enantiomers, diastereomers, cis/trans isomers, E/Z isomers, etc., and mixtures thereof, for example, 1:1 mixtures of enantiomers (termed racemates), mixtures of different proportions of separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvatés thereof such as, for instance, hydrates, including solvatés of the free compounds or solvatés of a sait of the compound.
The phrase pharmaceutically acceptable is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of Sound medical judgment, suitable for use in contact with the tissues of human beings and animais without excessive toxicity, irritation, allergie response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.
The term substituted as used herein means that any one or more hydrogens on the designated atom is replaced with a sélection from the indicated group, provided that the designated atom’s viable valence number is not exceeded, and that the substitution results in a stable compound.
The term partially unsaturated as used herein means that in the designated group or moiety 1, 2, or more, preferably 1 or 2, double bonds are présent. Preferably, as used herein, the term partially unsaturated does not cover fully unsaturated groups or moieties.
The term halogen dénotés an atom selected from the group consisting of F, Cl, Br, and I.
The term Ci.n-alkyl, wherein n may hâve a value of 1 to 18, dénotés a saturated, branched or unbranched hydrocarbon group with 1 to n C atoms. Examples of such groups include methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyI, n-pentyl, iso-pentyl, neo-pentyl, tert-pentyl, n-hexyl, iso-hexyl, etc..
The term Ci.n-alkylene wherein n is an integer of 1 to n, either alone or in combination with another radical, dénotés an acyclic, straight or branched chain divalent alkyl radical containing 1 to n carbon atoms. For example, the term Cm-alkylene includes ~(CH2)~. -(CH2-CH2)-, (CH(CH3))-, -(CH2-CH2-CH2)-, -(C(CH3)2)-, -(CH(CH2CH3))-, -(CH(CH3)-CH2)-, -(CH2-CH(CH3))-, -(CH2-CH2-CH2-CH2)-, -(CH2-CH2-CH(CH3))-, -(CH{CH3)-CH2-CH2)-, -(CH2-CH(CH3)-CH2)-, (CH2-C(CH3)2)-, -(C(CH3)2-CH2)-, -(CH(CH3)-CH(CH3))-, -(CH2-CH(CH2CH3))-, -(CH(CH2CH3)CH2)-, -(CH(CH2CH2CH3))-, -(CHCH(CH3)2)-, and -C(CH3)(CH2CH3)-.
The term C^-alkenyl, wherein n has a value of 3 to 10, dénotés a branched or unbranched hydrocarbon group with 2 to n C atoms and a C=C double bond. Examples of such groups include ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, etc..
The term C2.n-alkynyl, wherein n has a value of 3 to 10, dénotés a branched or unbranched hydrocarbon group with 2 to n C atoms and a C=C triple bond. Examples of such groups include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, etc. Unless otherwise stated alkynyl groups are connected to the remainder of the molécule via the C atom in position 1. Therefore terms such as 1-propynyl, 2-propynyl, 1-butynyl, etc. are équivalent to the terms 1-propyn-1-yl, 2-propyn-1-yl, 1-butyn-1-yl, etc.. This also applies analogously to C2.nalkenyl groups.
The term Ci.n-alkoxy dénotés a Cm-alkyl-0 group, wherein C^n-alkyl is as hereinbefore defined. Examples of such groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, iso-pentoxy, neo-pentoxy, tert-pentoxy, n-hexoxy, iso-hexoxy, etc..
The term C^-alkylcarbonyl dénotés a C1.n-alkyl-C(=O) group, wherein Ci.n-alkyl is as hereinbefore defined. Examples of such groups include methylcarbonyl, ethylcarbonyl, npropylcarbonyl, iso-propylcarbonyl, n-butylcarbonyl, iso-butylcarbonyl, sec-butylcarbonyl, tertbutylcarbonyl, n-pentylcarbonyl, iso-pentylcarbonyl, neo-pentylcarbonyl, tert-pentyl-carbonyl, nhexylcarbonyl, iso-hexylcarbonyl, etc..
The term C3.n-cycloalkyl dénotés a saturated mono-, bi-, tri- or spirocarbocyclic group with 3 to n C atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo[3.2.1 Joctyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, adamantyl, etc.. Preferably the term C3.7-cycloalkyl dénotés saturated monocyclic groups.
The term C5.n-cycloalkenyl dénotés a Cg.n-cycloalkyl group which is as hereinbefore defined and additionally has at least one C=C double bond.
The term C3.n-cycloalkylcarbonyl dénotés a C3.n-cycloalkyl-C(=0) group wherein C3.n-cyclo-alkyl is as hereinbefore defined.
The term C3.n-heterocycloalkyl dénotés a saturated mono-, bi-, tri- or spirocarbocyclic group, which is as hereinbefore defined, with 3-m to n-m C atoms, wherein m carbon atoms are replaced with m heteroatoms independently selected from N, NRn, O, S, SO, and SO2. Examples of such groups include aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, 1,3-dioxanyl, 1,4-dioxanyl, thiomorpholinyl, azepanyl, oxepanyl, thiepanyl, 1-aza-bicyclo[2.2.2]octane, 1,4-diaza-bicyclo[2.2.2]octane, etc.. Preferably, the term heterocycloalkyl dénotés saturated monocyclic C5^-cycloalkyl groups wherein one or two carbon atoms are replaced with N and/or O.
The term tri-(CM-alkyl)silyl comprises silyl groups which hâve identical or two or three different alkyl groups.
The term di-fCvralkylJamino comprises amino groups which hâve two identical or different alkyl groups.
If groups or residues are optionally substituted, this applies to any form of the group or residue. For instance, if an alkyl group is optionally mono- or polyfluorinated this comprises also alkyl residues which are part of larger groups, e.g. alkyloxy, alkylcarbonyl, alkoxyalkyl, etc., or if a (het)aryl group is optionally mono- or polysubstituted with a certain substituent or a set of substituents this also includes (het)aryl groups which are part of larger groups, e.g. (het)aryl-Ci. n-alkyl, (het)aryloxy, (het)aryloxy-Ci.n-alkyl, (het)aryl-Ci.n-alkyloxy, etc.. Accordingly, in cases where e.g. Rz or R5 has, for example, the meaning (het)aryloxy, while (het)aryl residues are optionally mono- or polyfluorinated and (het)aryl dénotés inter alia phenyl, the meanings mono-, di-, tri-, tetra-, and pentafluorophenoxy are also comprised. The same applies to groups or residues in which a part of the group or residue is replaced by another group, e.g. a CH2 group is optionally replaced by O, S, NRn, CO, or SO2. For instance, a residue having inter alia the meaning hydroxy-Ci.3-alkyl in which a CH2 group is optionally replaced by CO (= carbonyl), this also comprises carboxy, carboxymethyl, hydroxymethylcarbonyl, 1-hydroxy-2-oxo-ethyl, carboxyethyl, 2-carboxyethyl, 1-carboxyethyl, hydroxymethylcarbonylmethyl, 1-hydroxy-2-oxopropyl, hydroxyethylcarbonyl, (2-hydroxyethyl)carbonyl, hydroxy-3-oxo-propyl, 1-hydroxy-3-oxo-
propyl, 2-hydroxy-3-oxo-propyl, (l-hydroxyethyl)-carbonyl, 2-hydroxy-1-oxo-prop-2-yl, hydroxy2-oxo-prop-2-yl and 3-hydroxy-1-oxo-prop-2-yl. Analogously, a définition such as Ci.n-alkyl wherein one or more CHZ groups are optionally replaced by, for example, carbonyl and which is optionally substituted with e.g. hydroxy or amino also comprises explicit residues having no CH and/or CH2 group, e.g. carboxy and aminocarbonyl.
Ail atoms/elements described herein, including atoms that are part of a group, comprise ail stable isotopic forms of the respective element. For instance, whenever hydrogen is mentioned, either explicitly or as part of a group such as methyl, this includes hydrogen and deuterium as stable isotopic forms of the element hydrogen.
The compounds according to the invention may be obtained using methods of synthesis known in princtple. Preferably, the compounds are obtained by the foliowing methods according to the invention which are described in more detail hereinafter.
A general route to access the core structures of the compounds of the invention is given in Scheme 1 employing a tricyclic pyridine as precursor for the tricyclic piperidine framework; R2, R3, R\ and m hâve the meanings as defined hereinbefore and hereinafter. The tricyclic pyridine may be obtained from 2-indanones (m=0) or 2-tetralones (m=1) and propargylamine or a dérivative thereof by combining the two starting compounds in the presence of a catalyst, such as salis or complexes of gold and copper, preferably NaAuCL and CuCI2 (see J. Org. Chem. 2003, 68, 6959-6966). The reaction is usually run in alcohols, such as éthanol, at températures of 20 to 120 °C through conventional heating or microwave irradiation. The pyridine structure obtained is transformed to the piperidine dérivative by réduction with hydrogen in the presence of a transition métal catalyst, such as PtO2, Pt/C, Pd/C, Rh/C, Raney-Ni, or mixtures thereof. Alcohols, e.g. methanol and éthanol, ethyl acetate, acetic acid, water, ether, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, Ν,Ν-dimethylacetamide, N-methylpyrrolidinone, hexanes, methylcyclohexane, or mixtures thereof are among the preferred solvents, optionally used in combination with additives, such as acid, e.g. trifluoroacetic acid, hydrochloric acid, and sulfuric acid, at températures of 10 to 150 ’C, preferably 20 to 80 °C, and hydrogen pressures of 1 to 150 bar, preferably 1 to 20 bar. Alternatively, the réduction may be accomplished, after transforming the pyridine into a pyridinium ion by N-alkylation, N-acylation, or N-sulfonylation, by treatment with a hydride source such as NaBH4 or LiAIH4. The latter reagent is preferably employed in hydrocarbons, ether, tetrahydrofuran, 1,4-dioxane, benzene, ortoluene, while the former is preferably used in alcohols, e.g. methanol or éthanol, and water, optionally combined with a co-solvent such as tetrahydrofuran, 1,4-dioxane, or N-methylpyrrolidinone and an additive such as acid, e.g. acetic acid, or base, e.g. sodium hydroxide.
Scheme 1. Strategy 1 to build the tricyclic skeleton
Another viable synthetic route to the tricyclic pyridine precursor described in Scheme 1 is delineated in Scheme 2; R2, R3, R4, and m hâve the meanings as defined hereinbefore and hereinafter. Transition métal catalyzed coupling of a phenylmethyl (for m=0) or phenethyl (for m=1) métal dérivative with a 2,3-dihalo or pseudohalo pyridine furnishes a requisite intermediate. Suited métal residues in the phenylalkyl métal dérivative may be e.g. MgCI, MgBr, B(OH)2, B(0CMe2CMe2O), BF3K, ZnCI, ZnBr, or Znl, and suited halo or pseudohalo at the pyridine is preferably Cl, Br, I, F3CSO3, p-TolSO3, and MeSO3. Depending on the coupling partners, different catalysts may be suitable which are predominantly derived from Pd, Ni, Cu, or Fe. Pd(PPh3)4, Pd[1,1’-bis(diphenylphosphino)ferrocene)]CI2, Pd(PPh3)2Cl2, Ni(PPh3)2CI2, or Pd on C, nanoparticles of Pd or Fe, Pd(ll), Ni(ll), Fe(ll), or Fe(lll) salts, such as Pd(O2CCH3)2, PdCI2, NiCI2, or FeCI3) optionally combined with a 2-(optionally substituted phenyljphenyldicyclohexyl or di-ferf-butylphosphine, triphenylphosphîne, tritolylphosphine, trifurylphosphine, tri-tert-butyl-phosphine, tricyclohexylphosphine, a 1,3-diaryl imidazolidinium sait, or a 1,3-diaryl dihydroimidazolidinium sait, are a few more often employed catalysts. The couplings are preferably conducted in toluene, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,Ndimethylformamide, Ν,Ν-dimethylacetamide, N-methylpyrrolidinone, or mixtures thereof, which, depending on the coupling partners, are optionally combined with alcohol, e.g. methanol, water, alkali métal salts, such as LiCI, NaOH, Na2CO3, K2CO3, Cs2CO3, NaO2CCH31 or K3PO4, ammonium salts, e.g. Bu4NCI, or silver salts, e.g. AgO3SCF3, at températures of -10 to 150 °C. The subséquent cyclization of the benzyl- or phenethylpyridine to the tricyclic pyridine structure may be accomplished by anothertransition métal catalyzed reaction, preferably Pd, e.g derived from Pd(O2CC3)2 or Pd(O2CCMe3)2, and a phosphine ligand, such as e.g. di-tert-butyl-methylphosphine, tricyclohexylphosphine, triphenyl-phosphine, tri(4-fluorophenyl)phosphine, or 2-(2dimethylaminophenyl)phenyl-diphenyl-phosphine. The cyclization is most preferably carried out in the presence of a potassium sait, e.g. K2CO3 or KO2CCH3, optionally combined with a silver sait, e.g. Ag2CO3 or AgO3SCF3, and/or pivalic acid in Ν,Ν-dimethylacetamide at 40 to 160 °C (see e.g. Tetrahedron 2008, 64,6015-20 and référencés quoted therein).
Scheme 2. Strategy 2 to build the tricyclic skeleton
X, Y = e.g. Cl, Br, I, O3SCF3
M = e.g. MgCI/Br/l, B(OH)2, BF3K, ZnCI/Br/l,
An alternative strategy to access the tricyclic pyridine precursor described in Scheme 1 is described in Scheme 3; R2, R3, R4, and m hâve the meanings as defined hereinbefore and hereinafter. A transition métal catalyzed coupling of a phenyl métal dérivative, métal is e.g. MgCI, MgBr, B(OH)2, B(OCMe2CMe2O), BF3K, ZnCI, ZnBr, or Znl, with a pyridine-2-carboxylic acid dérivative or a 3-halogen or pseudohalogen substituted pyridine-2-carboxylic acid dérivative (m=0) or pyrid-2-ylacetic acid dérivative (m=1 ), carboxylic acid dérivative preferably is carboxylic acid, carboxylic ester, or carbonitrile, provides the first intermediate. Depending on the coupling partners, different catalysts may be suitable, which are preferably derived from Pd, e.g. Pd(PPh3)4, Pd[1,r-bis(diphenylphosphino)ferrocene]CI2, Pd(PPh3)2CI2, Pd on C, nanoparticles of Pd, Pd(11) salts such as Pd(O2CCH3)2 or PdCI2, optionally combined with a 2(optionally substituted phenyl)phenyl-dicyclohexyl or di-tert-butyl-phosphine, triphenylphosphine, tritolylphosphine, trifurylphosphine, tri-tert-butyl-phosphine, tricyclohexylphosphine, a 1,3-diaryl imidazolidinium sait, or a 1,3-diaryl dîhydroimidazolidinium sait, optionally in the presence of alkali métal salts, such as LÎCI, NaOH, NaO'Bu, KO'Bu, Na2CO3, K2CO3, Cs2CO3, NaO2CCH3, or K3PO4, ammonium salts, e.g. Bu4NCI, and/or silver salts, e.g. AgO3SCF3, preferably employed in toluene, tetrahydrofuran, 1,4-dioxane, N,Ndimethylformamide, Ν,Ν-dimethylacetamide, N-methylpyrrolidinone, or mixtures thereof, which are optionally combined with water, at -10 to 150 °C. Subséquent intramolecular Friedel-Crafts acylation establishes the tricyclic pyridine scaffold by activating the carboxy functionality, e.g. carboxylic acid, anhydride, mixed anhydride, or ester, carbonyl chloride, or nitrile, with a Lewis acid, depending on the kind of carboxy group and the electronic nature of the benzene substructure, e.g. hydrobromic acid, hydrochloric acid, sulfuric acid, phosphoric acid, trifluoroacetic acid, methanesulfonic acid, toluenesulfonic acid, trifluormethanesulfonic acid, SnCI4, FeCI3, AIBr3l AICI3, SbCI5, BCI31 BF3, ZnCI2, montmorillonites, POCI3, and PCI5, preferably in an inert solvent, e.g. acetonitrile, dichloromethane, 1,2-dichloromethane, 1,4-dioxane, 1,216399
dimethoxyethane, hydrocarbons, nitrobenzene, or chlorobenzene, at 0 to 180 °C. Réduction of the keto group formed thereafter is preferably conducted with hydrogen in the présence of a transition métal catalyst, e.g. Pd/C, Pd(OH)Zl PtO2, Pt/C, or Rh/C, in alcohol, e.g. methanol, glycol, or éthanol, water, acetic acid, ethyl acetate, N-methylpyrrolidinone, tetrahydrofuran, 1,45 dioxane, ether, or mixtures thereof, optionally in the presence of acid, e.g. hydrochloric acid, at to 180 °C, preferably 20 to 120 °C, and hydrogen pressures of 1 to 100 bar, preferably 1 to 10 bar. Alternative^, réduction of the keto group may be accomplished with a hydride, e.g. triethylsilane, borane, sodium borohydride, or lithium aluminum hydride, optionally in the presence of a Lewis acid, e.g. BF3, AICI3, lnCI3, SnCI4, FeCI3, ZnCI2, acetic acid, trifluoroacetic acid, hydrochloric acid, methanesulfonic acid, or trifluoromethanesulfonic acid, at 0 to 140 °C.
Scheme 3. Strategy 3 to build the tricyclic skeleton
Y = e.g. Cl, Br, I, OSO2CF3
X = e.g. OH, OCM-alkyl, or CN for COX
X preferably introduced after coupling: Cl, anhydride residue, mixed anhydride residue
M = e.g. MgCI/Br/l, B(OH)Z, BF3K, ZnCI/Br/l,
Scheme 4 describes a strategy suited for accessing the scaffold of compounds of the invention wherein m equals 0; Rz, R3, and R4 hâve the meanings as defined hereinbefore and hereinafter. The phenyl-pyridyl structure is assembled by a transition métal catalyzed coupling as described in Scheme 3. A nucleophilic phenyl group, bearing M, and an electrophilic pyridine group, bearing Y, are used for this purpose, though, the aromatic building blocks may be employed with opposite reactivity, i.e. phenyl bears Y and pyridine M, providing the same coupling product. The compound obtained bears two potential leaving groups, preferably fluorine, chlorine, bromine, arylsulfonate, nitro, or arylsulfonyl, one on each (hetero)aromatic ring adjacent to the phenyl-pyridyl bond. A dianionic methylene synthon, e.g. malonic acid, malonic diester, malodinitrile, cyanoacetic acid, or cyanoacetic ester, combined with a base, e.g.
Cs2CO3, K2CO3, Na2CO3, KO'Bu, NaOEt, NaOMe, NEt31 ’Pr2NEt, 1,8-diazabicyclo[5.4.0]-undec16399
7-ene, consecutively replaces both leaving groups by aromatîc nucleophîlic substitutions to establish the indenopyridine framework. N-Methylpyrrolidinone, Ν,Ν-dimethylacetamide, N,Ndimethylfomnamide, alcohol, e.g. éthanol, isopropanol, or tert-butanol, water, dimethyl sulfoxide, 1,4-dioxane, tetra hydrofuran, or mixtures thereof are among the preferred solvents for this transformation, which is preferably conducted at 0 to 180 °C. The carboxylic electronwithdrawing groups are removed by hydrolysis with base, e.g. NaOH or KOH, or acid, e.g. HCl or H2SO41 in aqueous or alcoholic solution to form the carboxy group which decarboxylates spontaneously or by heating in the acidic or basic medium. This proceeding is particularly suited for compounds bearing one or more electron-withdrawing groups on the phenyl ring.
Scheme 4. Strategy 4 to build the tricyclic skeleton
Y = e.g. Cl, Br, I, OSO2CF3
M = e.g. MgCI/Br/l, B(OH)2, B(OCMe2CMe2O), BF3K, ZnCI/Br/l
LG = leaving group, e.g. F, Cl, Br
EWG = electron-withdrawing group, e.g. CO2H, CO^^^-alkyl, CN, NOZ, SO2Ph, SOjC^-alkyl
Scheme 5 outlines the assembly of the tricyclic scaffoid of the invention starting from the corresponding pyrrolidine enamine of 2-indanones or 2-tetralones and acryl amide; R2, R3, R4, and m hâve the meanings as defined hereinbefore and hereinafter. The desired tricyclic structure as a dihydropyridinone is obtained by heating the two reaction partners at 60 to 150 °C. Réduction of the double bond with hydrogen in the presence of a transition métal, such as palladium on carbon, or with a hydride source, such as a trialkylsilane, e.g. triethylsilane, borohydride, e.g. NaBH4, NaBH(O2CCH3)3, or NaH3BCN, or alanate, e.g. LiAIH4, optionally in the presence of an additive, such as a Lewis acid, e.g. acetic acid, trifluoroacetic acid, AICI31 or BF3*OEt2, provides then the tricyclic piperidinone. Eventual amide réduction is preferably achieved with a hydride source, e.g. NaBH4 combîned with acetic acid in 1,4-dioxane, LiAIH4 in tetrahydrofuran or ether, or sodium dihydrobis(2-methoxyethoxy)aluminate in ethylene glycol dimethyl ether, at 0 to 100 °C.
Scheme 5. Strategy 5 to buîld the tricyclic skeleton
Another generally applicable approach to access the core structures of the compounds of the invention is based on an electrophilic aromatic substitution reaction (Scheme 6); Rz, R3, R4, and m hâve the meanings as defined hereinbefore and hereinafter, Thereby the aromatic part of the molécule reacts with a positively charged carbon atom of the piperidine ring to form the tricyclic framework. The reactive intermediate bearing the positively charged carbon atom in the azacycle may be generated by the addition of a Lewis acid to an olefinic bond or a carbonyl group or by the activation of an appropriately positioned leaving group, such as Cl, Br, I, OH, O3SCF3, 03SMe, or O3S-p-Tol. A huge number of Lewis acids hâve been described for this classical reaction that may also be employed here. The following énumération is supposed to give a few more widely used of them: hydrobromic acid, hydroiodic acid, hydrochloric acid, sulfuric acid, phosphoric acid, Ρ4Ο10, trifluoroacetic acid, methanesulfonicacid, toluenesulfonic acid, trifluormethanesulfonic acid, Sc(O3SCF3)3, lnCI3, lnBr3, SnCI41 FeCI3, AIBr3, AICI3, SbCI5, BCI3, BF3i ZnCI2, montmorillonites, POCI3, and PCI5. Depending on the inclination of the leaving group to be substituted and the electronic nature of the aromatic ring, a more or less powerful acid catalyst has to be used. Besides the acid catalysts mentioned, silver salts, e.g. AgO3SCF3, may be useful in the reactions using halides as leaving group. Preferred solvents are hydrocarbons such as hexane or cyclohexane, chlorinated hydrocarbons, such as dichloromethane or 1,2-dichloroethane, perfluorinated hydrocarbons, nitrobenzene, acetonitrile, chlorinated benzenes, heteroaromatics, such as quinoline, 1,2-dimethoxyethane, 1,4-dioxane, ether, ionic liquids, water, aceticacid, or mixtures thereof, though, not ail of these solvents are usable with ail above listed Lewis acids. The reactions are carried out between -10 and 220 “C, preferably between 20 °C and 180 ’C. The reactions may also be conducted under microwave irradiation.
Scheme 6. Strategy 6 to build the tricyclic skeleton
LG = leaving group such as Cl, Br, I, OH, O3SCF3, O3STol, O3SCH3, or =0
The synthetic routes presented may rely on the use of protecting groups. Suitable protecting groups for the respective functionalities and their removal are described hereinafter and may analogously be employed (see also: Protecting Groups, Philip J. Kocienski, 3,d édition, Georg Thieme Verlag, Stuttgart, 2004 and référencés quoted therein).
In the following a few feasible derivatizations of compounds of general formula I or precursors thereof, obtained as described above, bearing certain functional groups to assemble other compounds of general formula I or precursors thereof are vicariously summarized. This compilation is by no means meant to be complété but is only supposed to give some possibilities by way of example.
If in the process of manufacture according to the invention a compound of general formula I or a precursor thereof is obtained which contains an amino, alkylamino, or imino group, this may be converted by acylation or sulfonylation into a corresponding acyl or sulfonyl compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains a hydroxy group, this may be converted by acylation or sulfonylation into a corresponding acyl or sulfonyl compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains a hydroxy group, this may be converted by alkylation into a corresponding ether of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains an amino, alkylamino, or imino group, this may be converted by alkylation or reductive alkylation into a corresponding alkyl compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains a nitro group, this may be converted by réduction into a corresponding amino compound.
If a compound of general formula I or a precursor thereof is obtained which contains an imino group, this may be converted by nitrosation and subséquent réduction into a corresponding Namino-imino compound.
If a compound of general formula I or a precursor thereof is obtained which contains a C^alkyloxycarbonyl group, this may be converted by cleavage of the ester into the corresponding carboxy compound.
If a compound of general formula I or a precursor thereof is obtained which contains a carboxy group, this may be converted into a corresponding ester of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains a carboxy or ester group, this may be converted by reaction with an amine into a corresponding amide of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains an aromatic substructure, this may be derivatized with a chlorine, bromine, or iodine atom or a nitro, sulfonic acid, chlorosulfonyl, or acyl group by an electrophilic substitution reaction to a corresponding compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains an amino group that is attached to an aromatic or a heteroaromatic group, this may be transformed into a corresponding cyano, fluoro, chloro, bromo, iodo, hydroxy, mercapto, or azido derivatized compound of general formula I or a precursor thereof by diazotization and subséquent replacement of the diazo group with cyanide, fluoride, chloride, bromide, iodide, hydroxide, alkyl or hydrogen sulfide, or azide, respectively.
If a compound of general formula I or a precursor thereof is obtained which contains an amino group that is attached to an aromatic or a heteroaromatic group, this may be converted into a corresponding aryl derivatized aromatic compound of general formula I or a precursor thereof by diazotization of the amino group and subséquent replacement of the resulting diazo group with an appropriate aryl nucleophile mediated by a suited transition métal species.
If a compound of general formula I or a precursor thereof is obtained which contains a chloro, bromo, or iodo atom, or a trifluoromethylsulfonyloxy, mesyloxy, or tosyloxy group which is attached to an aromatic or a heteroaromatic group, this may be converted into a corresponding aryl, alkenyl, alkynyl, or alkyl derivatized compound of general formula I or a precursor thereof by replacement of the respective group by aryl, alkenyl, alkynyl, or alkyl using a transition métal species mediated process.
If a compound of general formula I or a precursor thereof is obtained which contains a chloro, bromo, or iodo atom, or a trifluoromethylsulfonyloxy, mesyloxy, or tosyloxy group which is attached to an aromatic or a heteroaromatic group, this may be replaced with cyano to give a corresponding aromatic compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains a chloro, bromo, or iodo atom, or a trifluoromethylsulfonyloxy, mesyloxy, or tosyloxy group which is attached to an aromatic or a heteroaromatic group, this may be replaced with hydrogen to give a corresponding aromatic compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains two heteroatoms at adjacent carbon atoms that are amino and hydroxy, amino, or mercapto, these heteroatoms may be linked via a carboxy carbon atom to form a cyclic amidine, imino ester, or imino thioester substructure that may be part of an aromatic ring.
If a compound of general formula I or a precursor thereof is obtained which contains a cyano group, this may be converted by réduction into an aminoalkyl derivatized compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains a cyano group, this may be converted into an N-hydroxycarbamimidoyl group by the treatment with hydroxylamine.
If a compound of general formula I is obtained which contains an N-hydroxycarbamimidoyl group, this may be converted to an oxadiazole derivatized compound of general formula I or a precursor thereof by the treatment with a carboxylic or related group.
If a compound of general formula I or a precursor thereof is obtaîned which contains an aminocarbonyl group, this may be converted by déhydration into a corresponding cyano compound of general formula or a precursor thereof I.
If a compound of general formula I or a precursor thereof is obtaîned which contains a keto or aldehydic group, this may be converted by réduction into a corresponding hydroxy compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtaîned which contains a carboxylic acid or aminocarbonyl group, this may be converted by a rearrangement reaction into a corresponding amino derivatized compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtaîned which contains a keto or aldéhyde group, this may be converted into an alkenyl derivatized compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtaîned which contains an olefinic C=C double or a C=C triple bond, this may be reduced to give the corresponding saturated compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtaîned which contains a keto or aldehydic group, this may be converted into a corresponding tertiary or secondary hydroxy compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtaîned which contains a carboxylic ester group, this may be converted into a tertiary alcohol by the addition of two équivalents of an organo métal compound.
If a compound of general formula I or a precursor thereof is obtaîned which contains a primary or secondary hydroxy group, this may be converted by oxidation into a corresponding carbonyl compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtaîned which contains an olefinic bond, this may be converted into a corresponding hydroxy compound of general formula I or a precursor thereof by hydroboration followed by oxidation.
If a compound of general formula I or a precursor thereof is obtained which contains an olefinic bond, this may be converted by dihydroxylation into a corresponding 1,2-dihydroxy compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains an olefinic bond, this may be converted by ozonolysis into a corresponding carbonyl compound compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains an olefinic bond, this may be converted into a corresponding hydroxy compound of general formula I or a precursor thereof by epoxidation followed by oxirane opening with a hydride source.
If a compound of general formula I or a precursor thereof is obtained which contains an olefinic bond, this may be converted by Wacker oxidation into a corresponding carbonyl compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains an olefinic bond, this may be converted by hydrocyanation into a corresponding cyano compound of general formula I or a precursor thereof.
If a compound of general formula I or a precursor thereof is obtained which contains a cyano group, this may be converted by water addition into a corresponding aminocarbonyl compound of general formula I or a precursor thereof.
The subséquent estérification is optionally carried out in a solvent such as methylene chloride, Ν,Ν-dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, 1,4-dioxane, or mixtures thereof or particularly advantageously in the corresponding alcohol optionally in the presence of an acid, e.g. hydrochloric acid, or a dehydrating agent, e.g. isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, phosphores trichloride, phosphores pentoxide, N,N'-carbonyldiimidazole, Ν,Ν'-dicyclohexylcarbodiimide, triphenylphosphine combined with carbon tetrachloride, or combinations thereof optionally in the presence of 4-dimethylaminopyridine and/or 1-hydroxybenzotriazole. The reactions are conducted between 0 and 150 °C, preferably between 0 and 80 °C.
The ester formation may also be carried out by reacting a compound which contains a carboxy group with a corresponding alkyl halide in the presence of a base.
The subséquent acylation or sulfonylation is optionally carried out in a solvent such as methylene chloride, N.N-dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, 1,4-dioxane, or mixtures thereof with a corresponding acyl or sulfonyl electrophile, optionally in the presence of a tertiary organic base, an inorganic base, or a dehydrating agent. Routinely used agents are e.g. isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, phosphorus trichloride, phosphorus pentoxide, Ν,Ν’-dicyclohexylcarbodiimide, Ν,Ν'-carbonyldiimidazole, triphenylphosphine combined with carbon tetrachloride, or combinations thereof that may be employed in the presence of 4dimethylaminopyridine and/or 1-hydroxybenzotriazole at températures between 0 and 150 °C, preferably between 0 and 80 °C.
The subséquent alkylation is optionally carried out in methylene chloride, N,Ndimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, 1,4-dioxane, or mixtures thereof with an alkylating agent such as a corresponding halide or sulfonic acid ester, e.g. methyl iodide, ethyl bromide, dimethyl sulfate, or benzyl chloride, optionally in the presence of a tertiary organic base or an inorganic base at températures between 0 and 150 ’C, preferably between 0 and 100 °C.
The subséquent reductive alkylation is carried out with a corresponding carbonyl compound such as formaldéhyde, acetaldehyde, propionaldéhyde, acetone, or butyraldéhyde in the presence of a complex métal hydride, such as sodium borohydride, lithium borohydride, sodium triacetoxyborohydride, or sodium cyanoborohydride, conveniently at a pH of 6-7 and ambient température, or using hydrogen in the presence of a transition métal catalyst, e.g. palladium on charcoal, at hydrogen pressures of 1 to 5 bar. Méthylation may also be carried out in the presence of formic acid as reducing agent at elevated température, e.g. between 60 and 120 °C.
The subséquent réduction of a nitro group is carried out, for example, with hydrogen and a catalyst such as palladium on carbon, platinum dioxide, or Raney nickel, or using other reducing agents such as tin(ll) chloride, iron, or zinc optionally in the presence of an acid such as acetic acid.
The subséquent nitrosation of an imino group followed by réduction to obtain an N-amino-imino compound is carried out, for example, with an alkyl nitrite such as isoamyl nitrite to form the Nnitroso-imino compound that is then reduced to the N-amino-imino compound using, for example, zinc in the presence of an acid such as acetic acid.
The subséquent cleaving of a Cn-alkyloxycarbonyl group to obtain the carboxy group is carned out, for example, by hydrolysis with an acid such as hydrochloric acid or sulfuric acid or an alkali métal hydroxide such as lithium hydroxide, sodium hydroxide, or potassium hydroxide. The tertbutyl group is preferably removed by treatment with a strong acid, e.g. trifluoroacetic acid or hydrochloric acid, in an inert solvent such as dichloromethane, 1,4-dioxane, or ethyl acétate.
The subséquent amide formation is carried out by reacting a corresponding reactive carboxylic acid dérivative with a corresponding amine in a solvent such as methylene chloride, N,Ndimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, 1,4-dioxane, or mixtures thereof, or without an solvent in an excess of the amine, optionally in the presence of a tertiary organic base, an inorganic base, 4-dimethylaminopyridine, and/or 1-hydroxy-benzotriazole, at températures between 0 and 150 °C, preferably between 0 and 80 °C. Using the carboxylic acid may lead to the desired amide by in situ activation of the carboxy function with e.g. isobutyl chloroformate, thionyl chloride, oxalyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, Ν,Ν'-carbonyldiimidazole, triphenylphosphine combined with carbon tetrachloride, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluroborate, Ν,Ν'-dicyclohexylcarbodiimide, or combinations thereof.
The subséquent introduction of a chlorine, bromine, or iodine atom into an aromatic substructure may be carried out by reacting the aromatic compound with an appropriate electrophile of the respective halogen atom. Suited chlorine and bromine electrophiles may be e.g. N-halosuccinimide, HOCI, HOBr, tert-BuOCI, fert-BuOBr, chlorine, bromine, dibromoisocyanuric acid, pyridinium dichlorobromate, pyridinium tribromide, or sulfuryl chloride that may be used alone or in combination with an acid, e.g. hydrochloric acid, hydrobromic acid, tetrafluoroboric acid, triflic acid, sulfuric acid, or acetic acid, or a Lewis acid, e.g. iron(lll) halide, boron trifluoride hydrate, boron trifluoride etherate, or aluminum halide. Further useful combinations may be LiBr and ceric ammonium nitrate, KCI or KBr with Oxone®, or KBr and sodium perborate. Suited iodine electrophiles may be generated from iodine and an oxidizing agent such as nitric acid, sulfur trioxide, manganèse dioxide, HIO3, hydrogen peroxide, sodium periodate, peroxydisulfates, and Oxone®. Further suited iodine electrophiles may be e.g. iodine chloride, dichloroiodates, and N-iodosuccinimide. These iodine electrophiles are optionally used without an additive or in the presence of an acid such as acetic acid, trifluoroacetic acid, or sulfuric acid or a Lewis acid such as boron trifluoride hydrate or copper salts. If a nitro group is to be introduced appropriate nitro electrophile sources may be, for instance, nitric acid, acetyl nitrate, ceric ammonium nitrate, sodium nitrate, N2O5, alkyl nitrate, and nitronium tetrafluoroborate. Some of these reagents may be used without an additive, though, several of them are better used in combination with an acid, e.g. sulfuric acid or triflic acid, acetic
anhydride, trifluoroacetic anhydride, Lewis acid, e.g. ytterbium triflate or iron acetate, PZO5, or a base. The SO3H group may be inlroduced by reacting the aromatic compound with, for example, concentrated sulfuric acid, SO31 CISO3K, or CISO2NMe2 combined with indium triflate. Reacting the aromatic compound with CISO3H gives the corresponding chlorosulfonylated dérivative that may be hydrolyzed to the sulfonic acid. Acylating the aromatic part is conducted using an acyl electrophile that may be generated from the respective acyl halide, e.g. chloride, or acyl anhydride and a Lewis acid such as aluminum halide, diethylaluminum halide, indium halide, iron(lll) halide, tin(IV) halide, boron trifluoride, titanium(IV) halide, or a Bronsted acid, e.g. sulfuric acid or triflic acid. The formyl group is preferably introduced using the so-called
Vilsmeier or Vilsmeier-Haack conditions: dialkylformamide combined with phosgene, thionyl chloride, POCI31 or oxalyl chloride. Preferred solvents for the electrophilic substitutions described may differ dependîng on the electrophile employed; in the following some more generally applicable are mentioned: methylene chloride, 1,2-dichloroethane, chlorobenzene, dichlorobenzene, ether, 1,4-dioxane, fluorinated hydrocarbons, hexanes, quinoline, and acetonitrile. Températures preferably applied range from 0 to 180 °C.
The subséquent replacement of an amino group that is attached to an aromatic or a heteroaromatic group is initiated by diazotization of the amino group using a nitrous acid or nitrosonium source or équivalent such as a nitrite sait combined with an acid, e.g. sodium nitrite and hydrochloric acid, nitrosonium tetrafluoroborate, or an alkylnitrite, e.g. ferf-butyl nitrite or /so-amyl nitrite. The diazotization is optionally carried out in methylene chloride, 1,2dichloroethane, Ν,Ν-dimethylformamide, N-methylpyrrolidinone, benzene, toluene, chlorobenzene, tetrahydrofuran, water, ethyl acetate, alcohol, ether, 1,2-dimethoxyethane, 1,4dioxane, or mixtures thereof at températures between -10 and 100 °C (diazotization of amino groups is detailed in, for example, Angew. Chem. Int. Ed. 1976, 15, 251). The subséquent displacement of the diazo group with a cyano group, chlorine, or bromine atom using copper cyanide, chloride, or bromide, respectively, is known as the Sandmeyer reaction (see e.g. March's Advanced Organic Chemistry, Michael B. Smith and Jerry March, John Wiley & Sons Inc., 6. Ed., New Jersey, 2007 and references quoted thereîn); the reaction is optionally conducted between -10 and 120 °C in one of the solvents or mixtures mentioned above. The replacement of the diazo group with a fluorine atom may be achieved with a tetrafluoroborate sait or tetrafluoroboric acid and heating to 20 to 160 °C; the reaction is known as the Schiemann reaction, lodine may be introduced by treatment of the diazo compound with an iodide sait, e.g. sodium iodide, preferably using water or an aqueous solvent mixture at températures between 0 and 120 °C. The diazo group is replaced with hydroxy using water or an aqueous solvent mixture at températures between 0 and 180 “C. The reaction usually works without further additives but the addition of copper oxide or strong acid may be advantageous. Mercapto or alkylmercapto may be introduced via their corresponding disulfide salts or dialkyldisulfides at températures between 0 and 120 °C; depending on the sulfur species used an inert solvent or aqueous solvent System may be preferred (see e.g. Synth. Commun. 2001, 31, 1857 and référencés quoted therein).
The subséquent replacement of an amino group that is attached to an aromatic or a heteroaromatic group by an aryl group may be accomplished via the corresponding diazo compound obtainable as described above. The reaction with an aryl nucleophile, preferably an aryl boronic acid, boronic ester, trifluoroborate, zinc halide, or stannane, is conducted in the presence of a transition métal species derived from palladium, nickel, rhodium, copper, or iron, preferably palladium. The active catalyst may be a complex of the transition métal with ligands such as e.g. phosphines, phosphites, imdiazole carbenes, imidazolidine carbenes, dibenzylideneacetone, allyl, or nitriles, an elemental form of the transition métal such as palladium on carbon or nanoparticles, or salts such as chloride, bromide, acetate, or trifluoroacetate. The diazo compound is preferably employed as its tetrafluoroborate sait optionally in water, N-methylpyrrolidinone, Ν,Ν-dimethylformamide, methylene chloride, benzene, toluene, tetrahydrofuran, ethyl acetate, alcohol, ether, 1,2-dimethoxyethane, 1,4dioxane, or mixtures thereof at températures between 10 and 180 °C, preferably between 20 and 140 °C.
The subséquent replacement of a chloro, bromo, or iodo atom or a trifluoromethylsulfonyloxy, mesyloxy, or tosyloxy group that is attached to an aromatic or a heteroaromatic group with an aryl, alkenyl, alkynyl, or alkyl residue is preferably mediated by a transition métal species derived from palladium, nickel, copper, or iron. The active catalyst may be a complex of the transition métal with ligands such as phosphines, e.g. tri-tert-butylphosphine, tricyclohexylphosphine, 2-(substituted phenyl)phenyl-dicyclohexylphosphines, 2-(substituted phenyl)phenyl-di-tert-butylphosphines, 1,1'-bis(diphenylphosphino)ferrocene, triphenylphosphine, tritolylphosphine, or trifuryl-phosphine, phosphites, 1,3-disubstituted imdiazole carbenes, 1,3-disubstituted imidazolidine carbenes, dibenzylideneacetone, allyl, or nitriles, an elemental form of the transition métal such as palladium on carbon or nanoparticles of iron or palladium, or a sait such as fluorîde, chloride, bromide, acetate, triflate, or trifluoroacetate. The replacement reaction is preferably conducted with a trifluoroborate, boronic acid, or boronic ester (Suzuki or Suzuki-type reaction), zinc halide (Negishi or Negishi-type reaction), stannane (Stille or Stille-type reaction), silane (Hiyama or Hiyama-type reaction), magnésium halide (Kumada or Kumada-type reaction) of the aryl, alkenyl, or alkyl residue to be introduced. The terminal alkyne is preferably used as such or as its zinc acetylide dérivative. Depending on the nature of the electrophilic and nucleophilic reaction partners additives such as halide salts, e.g. lithium chloride, potassium fluoride, tetrabutylammonium fluoride, hydroxide sources such as potassium hydroxide or potassium carbonate, silver salts such as silver oxide or triflate, and/or copper salts such as copper chloride or copper thiophene-2-carboxylate may be advantageous or even essential. Copper iodide is a preferred additive in the coupling with terminal alkynes (Sonogashira reaction). The coupling reactions are preferably conducted in benzene, toluene, ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, N,Ndimethylformamide, Ν,Ν-dimethylacetamide, N-methylpyrrolidinone, alcohol, water, or mixtures thereof, though, depending on the nucleophile some of them are less or not suited at ail. Preferred températures are in the range from -10 to 180 °C.
The subséquent replacement of a chlorine, bromîne, or iodine atom or a mesyloxy, trifluoromethylsulfonyloxy, or tosyloxy group that Is attached to an aromatic or a heteroaromatic group with a cyano group is preferably achieved via a transition métal mediated process. Copper, nickel, and palladium are the most frequently employed metals for this transformation and used as éléments, salts, or complexes in combination with a cyanide source. Copper iodide, copper sulfate, copper cyanide, nickel chloride, nickel bromide, nickel cyanide, bis(triphenylphosphine)nickel dtchloride, palladium on carbon, tetrakisitriphenylphosphinejpalladium, tris(dibenzylideneacetone)dipalladium, palladium acetate, palladium trifluoroacetate, palladium chloride, palladium cyanide, optionally combined with a ligand, such as tricyclohexylphosphine, tri-tert-butyl-phosphine, triphenylphosphine, 1,1’bis(diphenylphosphino)ferrocene, diadamantyl-n-buty!-phosphine, or Xantphos, are among the catalysts that are routinely employed. Common cyanide sources are sodium cyanide, potassium cyanide, zinc cyanide, copper cyanide, nickel cyanide, potassium hexacyanoferrate, and acetone cyanohydrin. The reactions are preferably carried out in Ν,Ν-dimethylformamide, N,Ndimethylacetamide, N-methylpyrrolidinone, dimethylsulfoxide, pyridine, acetonitrile, quinoline, toluene, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, or mixtures thereof, at 20 to 280 °C, preferably at 60 to 200 °C. Additives, such as zinc, sodium carbonate, potassium iodide, water, and pyridine, and or the use of microwave irradiation may be advantageous to some of the reaction conditions.
The subséquent replacement of a chlorine, bromine. or iodine atom or a trifluoromethylsulfonyloxy, mesyloxy, or tosyloxy group that is attached to an aromatic or a heteroaromatic group with a hydrogen atom is preferably mediated by a transition métal species derived from palladium, nickel, platinum, or rhodium. The active catalyst may be a complex of the transition métal with ligands, an elemental form, or a sait of the transition métal as mentioned above. Raney nickel or palladium on carbon are among the preferred catalyst species. Suited hydrogen sources may be hydrogen, preferably at pressures of 1 to 10 bar,
silanes, e.g. trialkoxysilane or polymethylhydrosiloxane, boranes, hydrides, e.g. alkali métal borohydride, formic acid, or formates, e.g. ammonium formate. The reactions are preferably carried out in N.N-dimethylformamide, Ν,Ν-dimethylacetamide, N-methylpyrrolidinone, benzene, toluene, tetrahydrofuran, water, ethyl acetate, alcohol, ether, 1,2-dimethoxyethane, 1,4-dioxane, or mixtures thereof at -10 to 180 ’C, more preferably at 20 to 140 °C.
The subséquent cyclization slarting from a compound bearing two heteroatoms at adjacent carbon atoms is optionally conducted with a carboxy équivalent such as nîtrile, carboxylic chloride or fluoride, carboxylic acid, ketene, carboxylic ester, or carboxylic thioester. The overall transformation comprises two reaction steps: attachment of the carboxy équivalent to one of the two heteroatoms followed by cyclization with the other heteroatom. The first step is an amide formation with the amino functionality that may be carried out as described hereinbefore. The ensuing reaction step, cyclization with the second heteroatom, may be accomplished by heating in the presence of an acid, e.g. acetic acid, trifluoroacetic acid, sulfuric acid, or hydrochloric acid, or a base, e.g. sodium hydroxide, sodium ethoxide, or sodium tert-butoxide. The use of dehydrating reagents such as anhydrides, e.g. acetic anhydride, orthoesters, e.g. trimethyl orthoformate, thionyl chloride, phosgene, diphosgene, triphosgene, phosphorous oxychloride, phosphorous pentachloride, dialkylcarbodiimides, combinations with phosphines, e.g. triphenylphosphine or trialkylphosphine with dialkyl azodicarboxylates, bromine, iodine, or 1,2dihaloethanes, e.g. 1,2-dibromotetrafluoroethane, may be advantageous. The reactions are preferably carried out in inert solvents or mixtures such as methylene chloride, 1,2-dichloroethane, benzene, toluene, tetrahydrofuran, ether, or combinations thereof, though, cyclization in the presence of an acid or a base may also be conducted in water or an alcohol, e.g. methanol, éthanol, fso-propanol, or tert-butanol, or combinations with these solvents. The reactions are carried out at températures between 0 and 200 °C, preferably between 20 and 140 °C.
The subséquent réduction of a cyano group to obtain an aminomethyl group is preferably conducted with hydrogen in the presence of a transition métal species or with a hydride. Suited transition metals may be derived from palladium, nickel, platinum, rhodium, or ruthénium such as palladium on charcoal, palladium hydroxide, platinum oxide, or Raney nickel that may be used in solvents such as ethyl acetate, alcohols, e.g. methanol or éthanol, dichloromethane, tetrahydrofuran, ether, benzene, toluene, Ν,Ν-dimethylformamide, or N-methylpyrrolidinone at hydrogen pressures between 1 and 10 bar and at températures between 0 and 160 °C. Additives such as acids, e.g. hydrochloric acid, methanesulfonic acid, sulfuric acid, or acetic acid, may be bénéficiai for the réduction with transition métal catalysts. Among the preferred hydride sources are e.g. borohydrides, e.g. sodium borohydride, potassium tri-sec-butylboro-
hydride, borane, or lithium triethylborohydride, and alanates, e.g. lithium aluminum hydride or diisobutylaluminum hydride. Some of these reagents are best used in combination with nickel chloride or cobalt chloride as sodium borohydride. These reagents may be used in e.g. tetrahydrofuran, ether, 1,4-dioxane, 1,2-dimethoxyethane, dichloromethane, 1,2-dichloroethane, benzene, or toluene; some are also compatible with alcoholic or aqueous solutions. Preferred reaction températures range from -80 to 160 °C, more preferred from -40 to 80 °C.
The subséquent formation of a N-hydroxycarbamimidoyl group from a cyano group may be carrîed out by the treatment of the cyano compound with hydroxylamine. The reaction is preferably conducted in aqueous or alcoholic solvents at températures between 0 and 140 °C.
The subséquent formation of an oxadiazole from an N-hydroxycarbamimidoyl is conducted with a carboxy équivalent such as nitrile, carboxylic chloride or fluoride, carboxylic acid, ketene, carboxylic ester, or carboxylic thioester. The transformation is related to the formation of a ring starting from two heteroatoms at adjacent carbon atoms described above and may be carrîed out analogously.
The subséquent formation of a cyano group from an aminocarbonyl group is preferably conducted by using a dehydrating reagent such as anhydride, e.g. acetic anhydride, trifluoroacetic anhydride, or triflic anhydride, phosgene, thionyl chloride, oxalyl chloride, POCI3, PCI5, P4O1o, triphenylphosphite, or triphenyl- or trialkylphosphine combined with tetrachloromethane, 1,2-dibromotetrafluoroethane, or bromine. The reactions are preferably carrîed out in dichloromethane, 1,2-dichloroethane, hexanes, ether, 1,4-dioxane, benzene, toluene, acetonitrile, mixtures thereof, orwithout a solvent at températures between 0 and 140 °C. Additives such as amines, e.g. pyridine or triethylamine, or Ν,Ν-dimethylformamide may be bénéficiai.
The subséquent réduction of a keto or an aldehydic group to obtain a secondary or primary alcohol may be carrîed out with a complex métal hydride such as sodium borohydride, lithium borohydride, lithium triethylborohydride, diisobutylaluminum hydride, or lithium aluminum hydride. The réductions may be conducted in e.g. dichloromethane, 1,2-dichloroethane, hexanes, ether, 1,4-dioxane, tetrahydrofuran, Ν,Ν-dimethylformamide, N-methylpyrrolidone, benzene, toluene, alcohols, e.g. methanol, water, or mixtures thereof, though, not ail reducing agents are compatible with ail of these solvents. Preferred températures range from -80 to 140 °C depending on the reducing power of the reagent. Alternatively, hydrogen in the presence of a transition métal catalyst may be used for the réduction.
The subséquent conversion of a carboxy group into an amino group by rearrangement may be accomplished by heating an acyl azide resulting in the formation of an isocyanate (Curtius rearrangement). The isocyanate may be hydrolyzed to produce the free amine or converted into a urea or carbamate dérivative by treatment with an amine or an alcohol, respectively. The acyl azide may be obtained by treating an appropriate acyl electrophile, e.g. acyl chloride, carboxylic anhydride, or carboxylic ester, with an azide source, such as e.g. sodium azide or trimethylsilyl azide, in a solvent such as 1,4-dioxane, 1,2-dimethoxyethane, acetonitrile, tetrahydrofuran, dichloromethane, 1,2-dichloroethane, N-methylpyrrolidinone, Ν,Ν-dimethylformamide, toluene, benzene, hexanes, or mixtures thereof; water or alcohols may be usable in certain cases as well. The reactions are routinely carried oui between -10 and 120 °C. Alternative^, the acyl electrophile may be generated in situ from the acid and then converted into the acyl azide: diphenylphosphoryl azide in the presence of a base, e.g. triethylamine or ethyldiisopropylamine, in a solvent such as acetonitrile, benzene, toluene, or an alcohol at elevated température has proven to be an effective reagent for this direct conversion. The direct conversion may also be achieved with hydrazoic acid and an acid catalyst such as sulfuric acid in e.g. chloroform at elevated températures (Schmidt reaction). Another method to accomplish this overall transformation is the Lossen rearrangement: starting from an acyl electrophile such as acyl chloride the corresponding suited hydroxamic acid dérivative is formed that in turn rearranges to give the isocyanate and then the amine by heating and/or treatment with a base, e.g. sodium hydroxide (see e.g. J. Org. Chem. 1997, 62, 3858 and Synthesis 1990, 1143 and references quoted therein).
An unsubstituted carboxylic amîde may be converted into an amine by the so-called Hoffmann rearrangement. Among the suited reagents for this transformation are NaOBr, bromine combined with sodium methoxide, N-bromosuccinimide and sodium methoxide, Phl(O2CCF3)2, 25 and Phl(OH)OTs (Ts is 4-tolylsulfonyl).
The subséquent conversion of an aldehydic or a keto functionality into an olefin may be accomplished by, for example, the so-called Wittig reaction and modifications thereof, Peterson olefination, and Julia reaction and modifications thereof. These reactions hâve large precedence in organic synthèses and are detailed in e.g. March's Advanced Organic Chemistry, Michael B. Smith and Jerry March, John Wiley & Sons Inc., 6. Ed., New Jersey, 2007 and references quoted therein.
The subséquent réduction of a C=C double or C=C triple bond is preferably conducted with hydrogen in the presence of a transition meta! species derived from palladium, nickel, platinum, ruthénium, or rhodium, preferably Raney nickel, palladium on charcoal, platinum oxide, and RhCI(PPh)3. The reactions are preferably carried out in methylene chloride, N,N16399 dimethylformamide, Ν,Ν-dimethylacetamide, N-methylpyrrolidinone, benzene, toluene, tetrahydrofuran, water, ethyl acetate, alcohol, ether, 1,2-dimethoxyethane, 1,4-dioxane, or mixtures thereof, at 0 to 180 °C, more preferabiy at 20 to 140 °C, and hydrogen pressures of 1 to 10 bar, preferabiy 1 to 5 bar.
The subséquent transformation of an aldéhyde or a ketone to a secondary or tertiary alcohol is preferabiy accomplished by addition of a carbon nucleophile, e.g. alkyl, allyl, alkenyl, aryl, or alkynyl lithium, magnésium, or cérium compound, in tetrahydrofuran, ether, 1,4-dioxane, 1,2dimethoxyethane, toluene, hexanes, or mixtures thereof, at -80 to 80 °C.
The subséquent transformation of a carboxylic ester into a tertiary hydroxy group is preferabiy conducted with two or more équivalents of a carbon nucleophile, e.g. alkyl, allyl, alkenyl, aryl, or alkynyl lithium, magnésium, or cérium compound, in tetrahydrofuran, ether, 1,4-dioxane, 1,2dimethoxyethane, toluene, hexanes, or mixtures thereof, at températures of -80 to 80 °C.
The subséquent oxidation of a primary or secondary hydroxy compound may be achieved by using an oxidîzing agent, such as dimethyl sulfoxide combined with e.g. oxalyl chloride, acetic anhydride, SO3*pyridine, or dicyclohexylcarbodiimide, pyridinium chlorochromate (PCC), pyrdidinium dichromate (PDC), Dess-Martin periodinane, manganèse dioxide, 2,2,6,6tetramethylpiperidine-N-oxide (TEMPO) optionally combined with a co-oxidant, or tetrapropylammonium perrhutenate (TPAP) combined with a co-oxidant such as N-methylmorpholine-N-oxide, which are optionally used in the presence of a base, e.g. triethylamine, preferabiy in toluene, dichloromethane, or 1,2-dichloroethane, at -70 to 60 °C. Alternative^, the transformation may be performed as an Oppenauer oxidation with e.g. AI(OtBu)3 and acetone.
The subséquent hydroboration and oxidation of an olefinic bond is conducted with a borane, e.g. borane complexed with tetrahydrofuran, trimethylamine, or dimethyl sulfide, diethylborane, thexylborane, 9-borabicyclo[3.3.1]nonane, NaBH4 combined with BF3 or TiCI4, or dtchloroborane, preferabiy used in tetrahydrofuran at -20 to 60 °C. The hydroboration product is subsequently treated with e.g. hydrogen peroxide and sodium hydroxide in an aqueous solution to replace the boron group in the intermediate with hydroxy.
The subséquent dihydroxylation of an olefinic bond is preferabiy conducted with osmium tetroxide or potassium osmate combined with a co-oxidant, e.g. N-methyl-morpholine-N-oxide or K3Fe(CN)6, preferabiy in water combined with tBuOH, tetrahydrofuran, and/or 1,4-dioxane, at -20 to 60 ’C.
The subséquent cleavage of an olefinic bond by ozonolysis is conducted with ozone, preferably in dichloromethane at -50 to -78 ‘0. The intermediate obtained thereafter may be transformed into a carbonyl compound by treatment with e.g. dimethyl sulfide, zinc combined with acetic acid, hydrogen in the presence of palladium, or triphenylphosphine. Treatment of the intermediate with sodium borohydride or lithium aluminum hydride affords the corresponding hydroxy compound.
The subséquent epoxidation of an olefinic bond is preferably conducted with mchloroperbenzoic acid (mCPBA), hydrogen peroxide combined with formic acid or acetic acid, or Oxone® combined with acetone or 1,1,1-trifluoroacetone, preferably in dichloromethane at -20 to 40 °C. The oxirane ring can be opened with a hydride source such as lithium aluminum hydride or lithium triethylborohydride in an inert solvent, e.g. tetrahydrofuran, to furnish the hydroxy compound.
The subséquent Wacker oxidation of an olefinic bond is preferably conducted with PdCI2 and CuCI or CuCI2, in the presence of oxygen, in an aqueous solvent to provide the corresponding carbonyl compound.
The subséquent hydrocyanation of an olefinic bond can be conducted with 4-tolylsulfonyl cyanide in the presence of phenylsilane and a cobalt catalyst (see e.g. Angew. Chem. 2007, 119, 4603-6).
The subséquent formai water addition to cyano groups can be done by treating an aqueous solution of the nitrile with a strong acid, e.g. sulfuric acid or hydrochloric acid, or a base, e.g. NaOH or KOH, optionally at elevated température, preferably at 0 to 140 °C. Alternative^, this transformation can be achieved in an aqueous solution with a transition métal catalyst such as PdCI2.
In the reactions described hereinbefore, any reactive group présent, such as hydroxy, carbonyl, carboxy, amino, alkylamino, or imino, may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.
For example, a protecting group for a hydroxy group may be a trimethylsilyl, tertbutyldimethylsilyl, triisopropylsilyl, acetyl, pivaloyl, benzoyl, methyl, terf-butyl, allyl, trityl, benzyl, 4-methoxybenzyl, tetrahydropyranyl, methoxymethyl, ethoxymethyl, or 2trimethylsilylethoxymethyl group,protecting groups for a carboxy group may be trimethylsilyl, methyl, ethyl, tert-butyl, allyl, benzyl, or tetrahydropyranyl,
protecting groups for a ketone or aldéhyde may be a ketal or acetal, respectively, e.g. derived from methanol, ethylene glycol, propane-1,3-diol, or propane-1,3-dithiol, protecting groups for an amino, alkylamino, or imino group may be methyl, formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, benzyl, 4methoxybenzyl, or 2,4-dimethoxybenzyl and for the amino group additionally phthalyl and tetrachlorophthalyl, and protecting groups for a termina! alkyne may be trimethylsilyI, trisopropylsilyl, tertbutyldimethylsilyl, or 2-hydroxy-prop-2-yl.
Any acyl protecting group may be cleaved, for example, hydrolytically in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water, or 1,4-dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid, or sulfuric acid or in the presence of an alkali métal base such as lithium hydroxide, sodium hydroxide, or potassium hydroxide at températures between 0 and 120 °C, preferably between 10 and 100 ’C. The transformation may be conducted aprotically with e.g. iodotrimethylsilane in dichloromethane or 1,2-dichlorethane at -70 to 60 °C. Trifluoroacetyl is also cleaved by treating with an acid such as hydrochloric acid optionally in a solvent such as acetic acid at températures between 50 and 120 ’C or by treating with aqueous sodium hydroxide solution optionally in an additional solvent such as tetrahydrofuran or methanol at températures between 0 and 80 ’C.
Any acetal or ketal protecting group used may be cleaved, for example, hydrolytically in an aqueous solvent, e.g. water, isopropanol/water, acetic acid/water, tetrahydrofuran/water, or 1,4dioxane/water, in the presence of an acid such as acetic acid, trifluoroacetic acid, hydrochloric acid, or sulfuric acid at températures between 0 and 120 ’C, preferably between 10 and 100 ’C. Iodotrimethylsilane in dichloromethane is a variant to achieve this transformation aprotically.
A trimethyIsilyl group is cleaved, for example, in water, an aqueous solvent mixture or an alcohol, such as methanol or éthanol, in the presence of a base such as lithium hydroxide, sodium hydroxide, potassium carbonate, or sodium methoxide. Acids such as e.g. hydrochloric acid, trifluoroacetic acid, or acetic acid may also be suitable. The cleavage usually takes place at comparatively low températures, e.g. between -60 and 60 ’C. Silyl groups other than trimethylsilyl are preferentially cleaved in the presence of an acid, e.g. trifluoroacetic acid, hydrochloric acid, or sulfuric acid, at températures between 0 and 100 ’C. A particularly suited cleaving method for silyl groups is based on the use of fluoride salts, e.g. tetrabutylammonium
fluoride, hydrogen fluoride, or potassium fluoride, in organic solvents, such as for example diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, toluene, benzene, 1,2dichloroethane, or dichloromethane at températures between -20 and 100 °C.
A benzyl, methoxybenzyl, or benzyloxycarbonyl group is advantageously cleaved hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium on carbon or palladium hydroxide, in a solvent such as methanol, éthanol, ethyl acetate, acetic acid or mixtures thereof optionally in the presence of an acid such as hydrochloric acid at températures between 0 and 100 °C, preferably between 20 and 60 ’C, and at hydrogen pressures of 1 to 10 bar, preferably 3 to 5 bar. Trimethylsilyl iodide, boron trichloride, or boron trifluoride in the presence of a scavenger such as anisol, thioanisol, or pentamethylbenzene may also be used with benzylether dérivatives. An electron-rich benzyl residue such as methoxybenzyl may also be cleaved oxidatively with e.g. 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) or ceric ammonium nitrate (CAN) preferably in an alcoholic or aqueous solvent at températures between 10 and 120 °C. A 2,4-dimethoxybenzyl group is preferably cleaved in trifluoroacetic acid in the presence of a scavenger such as anisole.
A tert-butyl or tert-butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid, sulfuric acid, or hydrochloric acid or by treating with iodotrimethylsilane optionally using a solvent such as methylene chloride, 1,4-dioxane, methanol, isopropanol, water, or diethylether.
A methyl group at an tertiary amine may be cleaved by the treatment with 1-chloroethyl chloroformate or vinyl chloroformate. Hydrobromic acid and boron tribromide are particularly suited for the cleavage of methylethers.
The compounds of general formula I may be resolved into their enantiomers and/or diastereomers as mentioned before. Thus, for example, cis/trans mixtures may be resolved into their cis and trans isomers and racemic compounds may be separated into their enantiomers.
The cis/trans mixtures may be resolved, for example, by chromatography into the cis and trans isomers thereof. The compounds of general formula I which occur as racemates may be separated by methods known perse (cf. Allinger N. L. and Eliel E. L. in Topics in Stereochemistry, Vol. 6, Wiley Interscience, 1971) into their optical antipodes and diastereomeric mixtures of compounds of general formula I may be resolved into their diastereomers by taking advantage of their different physico-chemical properties using methods
known per se, e.g. chromatography and/or fractional crystallization; if the compounds obtained thereafter are racemates, they may be resolved into the enantiomers as mentioned above.
The racemates are preferably resolved by column chromatography on chiral phases or by crystallization from an optically active solvent or by reacting with an optically active substance which forms salts or dérivatives such as esters or amides with the racemic compound. Salts may be formed with enantiomerically pure acids for basîc compounds and with enantiomerically pure bases for acidic compounds. Diastereomeric dérivatives are formed with enantiomerically pure auxiliary compounds, e.g. acids, their activated dérivatives, or alcohols. Séparation of the diastereomeric mixture of salts or dérivatives thus obtained may be achieved by taking advantage of their different physico-chemical properties, e.g. différences in solubility; the free antipodes may be released from the pure diastereomeric salts or dérivatives by the action of suitable agents, Optically active acids in common use for such a purpose are e.g. the D- and L-forms of tartaric acid, dibenzoyltartaric acid, ditoloyitartaric acid, malic acid, mandelic acid, camphorsulfonic acid, glutamic acid, aspartic acid, or quinic acid. Optically active alcohols applicable as auxiliary resîdues may be, for example, (+) or (-)-menthol and optically active acyl groups in amides may be, for example, (+)- or (-)-menthyloxycarbonyl.
As mentioned above, the compounds of formula I may be converted into salts, particularly for pharmaceutical use into the pharmaceutically acceptable salts. As used herein, pharmaceutically acceptable salts refer to dérivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, minerai or organic acid salts of basic resîdues such as amines, alkali or organic salts of acidic resîdues such as carboxylic acids, and the like. For example, such salts include acétates, ascorbates, benzenesulfonates (besylates), benzoates, bicarbonates, bitartrates, bromides/hydrobromides, Caedetates/edetates, camsylates, carbonates, chlorides/hydrochlorides, citrates, ethane disulfonates (edisylates), estolates, esylates, fumarates, gluceptates, gluconates, glutamates, glycolates, glycollylarsanilates, hexylresorcinates, hydrabamines, hydroxymaleates, hydroxynaphthoates, iodides, isothionates, lactates, lactobionates, malates, maleates, mandelates, methanesulfonates, mucates, napsylates, nitrates, oxalates, pamoates, pantothenates, phenylacetates, phosphates/diphosphates, polygalacturonates, propionates, salicylates, stéarates, subacetates, succinates, sulfamides, sulfates, tannates, tartrates, teoclates, toluenesulfonates (tosylates), triethiodides, ammonium, benzathines, chloroprocaines, cholines, diethanolamines, ethylenediamines, meglumines, and procaines. Further pharmaceutically acceptable salts can be formed with cations from metals like aluminum, calcium, lithium, magnésium, potassium, sodium, zinc, and the like (also see
Pharmaceutical salts, Berge, S.M. et al., J. Pharm. Sci., (1977), 66, 1-19). Some of the salts mentioned above may also be useful for purifying or isolating the compounds of the invention.
The pharmaceutically acceptable salts of the présent invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, éthanol, isopropanol, or acetonitrile, or a mixture thereof.
Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the présent invention (e.g. trifluoroacetate salts), also comprise a part of the invention.
The compounds according to the invention are advantageously also obtainable using the methods described in the examples that follow, which may also be combined for this purpose with methods known to the skilled man from the literature.
In some embodiments, the présent teachings also provide methods for producing crystalline forms of a compound represented by the following structural formula (II):
Ni
In some embodiments, the présent teachings provide methods for producing crystalline form I of a compound represented by structural formula (II). In some embodiments, the présent teachings provide methods for producing crystalline form II of a compound represented by structural formula (II).
In some embodiments, the method for producing crystalline form I of a compound represented by structural formula (II) includes dissolving a free base represented by the following structural formula (III):
n:
(III)
in éthanol at a température below about 30°C; protonating the dissolved free base with hydrochloric acid (e.g., in an aqueous solution, such as a 30-40 wt % aqueous solution, e.g., a 36.5 wt % aqueous solution); and allowing crystalline form I to form by cooling the protonated dissolved free base (e.g., at a température below about 30°C).
For example, in some embodiments, the method includes dissolving the free base in éthanol at 20-30°C, protonating the dissolved free base with hydrochloric acid (e.g., in an aqueous solution, such as a 30-40 wt % aqueous solution, e.g., a 36.5 wt % aqueous solution), and allowing crystalline form l to form at a température at -5° to 5°C (or dissolving at about room température and crystallizing at about 0°C). In some embodiments, the method includes dissolving the free base in éthanol at about room température, protonating the dissolved free base with hydrochloric acid (e.g., in an aqueous solution, such as a 30-40 wt % aqueous solution, e.g., a 36.5 wt % aqueous solution), and allowing crystalline form I to form at room température over a period of at least six hours, e.g., at least eight hours, e.g., at least ten hours. In still other embodiments, the method includes dissolving the free base in éthanol at a température above about 30°C, protonating the dissolved free base with hydrochloric acid (e.g., in an aqueous solution, such as a 30-40 wt % aqueous solution, e.g., a 36.5 wt % aqueous solution) at a température below about 30°C, and allowing crystalline form I to form at a température below about 30°C.
In some embodiments, the method for producing crystalline form II of a compound represented by structural formula (II) includes contacting a compound represented by structural formula (II) (e.g., crystalline form I of a compound represented by structural formula (II)) with éthanol (e.g., 200 proof absolute éthanol) to form a suspension, and stirring the suspension for a period of time sufficient to form crystalline form II. In some embodiments, a period of time suffîcient to form crystalline form II is at least about three days, at least about four days, at least about five days, at least about six days, or at least about one week.
In some embodiments, the method for producing crystalline form II of a compound represented by structural formula (II) includes dissolving a compound represented by structural formula (II) in ethyl acetate at a température above about 40eC (e.g., at least about 50°C or from 40°-60°C); and allowing crystalline form II to form by cooling the dissolved compound (e.g., at a température below about 30°C or at or below about room température).
In some embodiments, the method for producing crystalline form II of a compound represented by structural formula (II) includes dissolving a free base represented by structural formula (III) in isopropanol at a température above about 40°C (e.g., above about 50°C, above about 60°C, or even at or above about 75°C); protonating the dissolved free base with hydrochloric acid (e.g., in isopropanol); and allowing crystalline form II to form by cooling the dissolved protonated free base (e.g., at a température below about 15°C, below about 10°C or below about 5°C). Alternatively, the free base is dissolved at a température between 50°-70°C and form II is formed atO°-15°C.
In some embodiments, the method for producing crystalline form II of a compound represented by structural formula (II) includes dissolving a free base represented by structural formula (III) in éthanol (e.g., 200 proof absolute éthanol) at a température of above about 40°C (e.g., at or above about 50°C); protonating the dissolved free base with hydrochloric acid (e.g., in éthanol, such as 200 proof absolute éthanol); maintaining the dissolved protonated free base at the elevated température for at least two hours and allowing crystalline form II to form by cooling the dissolved protonated free base (e.g., at a température below about 15°C, below about 10°C, below about 5°C, or even at or below about 0°C). Alternatively, the free base is dissolved at 45°-70<>C, the dissolved protonated free base is maintained at 45°-70°C for 2-3 hours and form Il is formed at between 0°-25°C orfrom 0°-15°C.
In some embodiments, the methods for producing crystalline forms of a compound represented by structural formula (II) further include the use of one or more seed crystals (e.g., seed crystals of crystalline form I or crystalline form II.
As already mentioned, the compounds of general formula I and the compounds of formula (II) according to the invention and the physiologîcally acceptable salts thereof hâve valuable pharmacological properties, particularly an inhibitory effect on the enzyme 11ft-hydroxysteroid dehydrogenase (HSD) 1.
Biological Examples
a) The biological properties (inhibitory activity on 11B-hydroxysteroid dehydrogenase 1 ) of the new compounds may be investigated as follows:
In vitro inhibition of 11 β-HSDI by test compounds is determined with HTRF (Homogeneous Time-Resolved Fluorescence) technology (cisbio international, France) detecting cortisol generated from cortisterone by human lîver microsomes. Briefly, compounds are incubated for 1 hour at 37°C in Tris buffer (20 mM tris, 5 mM EDTA, pH 6.0) containing NADPH (200μΜ) and cortisone (80nM). Cortisol generated in the reaction is then detected with a compétitive immunoassay, involving two HTRF conjugales: cortisol linked to XL665 and anti-cortisol
) 65 antibody labeled with Europium cryptate. The incubation period for détection reaction is typically 2 hours. The amount of cortisol is determined by reading the time-resolved fluorescence of the wells (Ex 320/75 nm; Em 615/8.5 nm and 665/7.5 nm). The ratio of the two émission signais is then calculated (Em665*10000/Em615). Each assay contains incubations with vehicle controls instead of compound as controls for non-inhibited cortisol génération (100% CTL; ’high values') and incubations with carbenoxolone as controls for fully inhibited enzyme and cortisol background (0% CTL; ’low values'). Each assay also contains a calibration curve with cortisol to transform the fluorescent data into cortisol concentrations. Percent inhibition (%CTL) of each compound is determined relative to the carbenoxolone signal and IC50 curves are generated.
The compounds of general formula I according to the invention tested as described above for example hâve IC50 values below 10000 nM, particularly below 1000 nM, most preferably below 500 nM.
Table 2. Inhibitory activity on Ιΐβ-HSD 1 of Examples compiled in the experimental part
Example | IC50 [nM] | Example | IC50 [nM] | Example | IC50 [nM] | Example | IC50 [nM] |
1 | 106 | 32 | 954 | 63 | 1337 | 94 | 90 |
2 | 65 | 33 | 676 | 64 | 2871 | 95 | 1033 |
3 | 1380 | 34 | 651 | 65 | 212 | 96 | 1107 |
4 | 573 | 35 | 3137 | 66 | 631 | 97 | 526 |
5 | 861 | 36 | 310 | 67 | 722 | 98 | 1252 |
6 | 296 | 37 | 150 | 68 | 435 | 99 | 3523 |
7 | 410 | 38 | 1474 | 69 | 371 | 100 | 850 |
8 | 342 | 39 | 1515 | 70 | 350 | 101 | 712 |
9 | 481 | 40 | 2148 | 71 | 915 | 102 | 3119 |
10 | 321 | 41 | 1121 | 72 | 656 | 103 | 670 |
11 | 94 | 42 | 418 | 73 | 447 | 104 | 847 |
12 | 367 | 43 | 1629 | 74 | 1960 | 105 | 263 |
13 | 257 | 44 | 2151 | 75 | 324 | 106 | 31 |
14 | 405 | 45 | 1066 | 76 | 933 | 107 | 26 |
15 | 1617 | 46 | 3618 | 77 | 685 | 108 | 150 |
16 | 1412 | 47 | 2157 | 78 | 257 | 109 | 1458 |
17 | 2107 | 48 | 514 | 79 | 650 | 110 | 1561 |
18 | 1027 | 49 | 1469 | 80 | 1971 | 111 | 1376 |
19 | 1902 | 50 | 4266 | 81 | 1730 | 112 | 724 |
20 | 227 | 51 | 2867 | 82 | 1338 | 113 | 2658 |
Example | IC50 [nM] | Example | IC50 [nM] | Example | IC50 [nM] | Example | IC50 [nM] |
21 | 1132 | 52 | 1595 | 83 | 2058 | 114 | 185 |
22 | 123 | 53 | 979 | 84 | 2067 | 115 | 2077 |
23 | 551 | 54 | 471 | 85 | 1625 | 116 | 1795 |
24 | 1794 | 55 | 4680 | 86 | 2110 | 117 | 1654 |
25 | 475 | 56 | 356 | 87 | 8854 | 118 | 1067 |
26 | 1512 | 57 | 969 | 88 | 705 | 119 | 365 |
27 | 297 | 58 | 1112 | 89 | 1319 | 120 | 383 |
28 | 2504 | 59 | 2095 | 90 | 2255 | 121 | 4439 |
29 | 831 | 60 | 1051 | 91 | 244 | 122 | 230 |
30 | 2210 | 61 | 821 | 92 | 884 | 123 | 644 |
31 | 469 | 62 | 940 | 93 | 121 | 124 | 1322 |
125 | 484 | 137 | 1119 | 149 | 141 | 161 | 212 |
126 | 1758 | 138 | 1054 | 150 | 674 | 162 | 354 |
127 | 1129 | 139 | 484 | 151 | 188 | 163 | 67 |
128 | 1917 | 140 | 1622 | 152 | 24 | 164 | 1315 |
129 | 1490 | 141 | 326 | 153 | 48 | 165 | 449 |
130 | 1137 | 142 | 996 | 154 | 449 | 166 | 182 |
131 | 6428 | 143 | 1409 | 155 | 83 | 167 | 573 |
132 | 320 | 144 | 609 | 156 | 432 | 168 | 313 |
133 | 854 | 145 | 777 | 157 | 1155 | 169 | 429 |
134 | 389 | 146 | 55 | 158 | 998 | 170 | 248 |
135 | 585 | 147 | 1738 | 159 | 1786 | 171 | 218 |
136 | 527 | 148 | 214 | 160 | 367 | 174 | 67 |
b) The inhibitory activity on 11β-hydroxysteroid dehydrogenase 1 of the new compounds may also be investigated as follows:
The inhibition of a microsomal préparation of 1Ιβ-HSDI by compounds of the invention is measured essentially as previously described (K. Solly, S.S. Mundt, H.J. Zokian, G.J. Ding, A. Hermanowski-Vosatka, B. Strulovici, and W. Zheng, High-Throughput Screening of 11-BetaHydroxyseroid Dehydrogenase Type 1 in Scintillation Proximity Assay Format. Assay Drug Dev Technol 3 (2005) 377-384). Ail reactions are carried out at room température in 96 well clear flexible PET Microbeta plates (PerkinElmer). The assay begins by dispensing 49 pl of substrate solution (50 mM HEPES, pH 7.4,100 mM KCi, 5 mM NaCI, 2 mM MgCI2, 2 mM NADPH and
160 nIVI [3H]cortîsone (1 Ci/mmol)) and mixing in 1 pL of the test compounds in DMSO zX
previously diluted in half-log incréments (8 points) starting at 0.1 mM. After a 10 minute preincubation, 50 pL of enzyme solution containing microsomes isolated from CHO cells overexpressing human 11B-HSD1 (10-20 pg/ml of total protein) is added, and the plates are incubated for 90 minutes at room température. The reaction is stopped by adding 50 pl of the
SPA beads suspension containing 10 μΜ 18B-glycyrrhetinic acid, 5 mg/ml protein A coated YSi SPA beads (GE Healthcare) and 3.3 pg/ml of anti-cortisol antibody (East Coast Biologics) in Superblock buffer (Bio-Rad), The plates are shaken for 120 minutes at room température, and the SPA signal corresponding to [3H]cortisol is measured on a Microbeta plate reader.
Table 3. Inhibitory activity on 11B-HSD 1 of Examples compiled in the experimental part
Example | IC50 [nM] | Example | IC50 [nM] | Example | IC50 [nM] |
172 | 5.6 | 173 | 18.6 | 174 | 3.6 |
175 | 58.4 | 176 | 46.5 | 177 | >100 |
c) The metabolic stability of the new compounds may be investigated as follows:
The metabolic dégradation of the test compound is assayed at 37 °C with pooled liver microsomes from various species. The final incubation volume of 100 pl per time point contains TRIS buffer pH 7.6 at room température (0.1 M), magnésium chloride (5 mM), microsomal protein (0.5 mg/mL) and the test compound at a final concentration of 1 μΜ. Following a short preîncubation period at 37°C, the reactions are initiated by addition of betanicotinamide adenine dinucleotide phosphate, reduced form (NADPH, 1 mM), and terminated by transferring an aliquot into solvent after different time points. After centrifugation (10000 g, 5 min), an aliquot of the supernatant is assayed by LC-MS/MS for the amount of parent compound. The half-life is determined by the slope of the semi-logarithmic plot of the concentration-time profile.
Table 4. Stability in human liver microsomes of Examples compiled in the experimental part
Example | tu [min] | Example | t» [min] | Example | t» [min] |
1 | >90 | 42 | >90 | 108 | >90 |
2 | 29 | 91 | >90 | 146 | >45 |
10 | >45 | 93 | >90 | 148 | >90 |
11 | 38 | 105 | 22 | 152 | >90 |
20 | >90 | 106 | >90 | 153 | >90 |
37 | >90 | 107 | >90 | 155 | 28 |
In view of theirability to inhibit the enzyme 11 β-hydroxysteroid dehydrogenase (HSD) 1, the compounds of general formula I according to the invention and the corresponding pharmaceutically acceptable salts thereof, as well as the compounds of formula (II) are theoretically suitable for the treatment and/or preventative treatment of ail those conditions or diseases which may be affected by the inhibition of the 11 β-hydroxysteroid dehydrogenase (HSD) 1 activity. Therefore, compounds according to the invention are particularly suitable for the prévention or treatment of diseases, particularly metabolic disorders, or conditions such as type 1 and type 2 diabètes mellitus, complications of diabètes (such as e.g. retinopathy, nephropathy or neuropathies, diabetic foot, ulcers, macroangiopathies, slow or poor wound healing), metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin résistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, edema and hyperuricaemia. These substances may also be suitable for preventing beta-cell degeneration such as e.g. apoptosis or necrosis of pancreatic beta-cells. The substances may also be suitable for improving or restoring the functionality of pancreatic cells, and also of increasing the number and size of pancreatic beta-cells. The compounds according to the invention may also be used as diuretics or antihypertensives and are suitable for the prévention and treatment of acute rénal failure.
Additionally, inhibition of 11 β-hydroxysteroid dehydrogenase (HSD) 1 has been shown to lower intraocular pressure in subjects with ocular hypertension, therefore the compounds could be used to treat glaucoma.
In view of the rôle of 11 β-hydroxysteroid dehydrogenase (HSD) 1 in modulating cortisol levels for interaction with the glucocorticoid receptor and the known rôle of excess glucocorticoids in bone loss, the compounds may hâve bénéficiai effects agaînst osteoporosis.
Stress and/or glucocorticoids hâve been shown to influence cognitive function, and excess cortisol has been associated with brain neuronal loss or dysfunction. Treatment with an 11 βhydroxysteroid dehydrogenase (HSD) 1 inhibitor may resuit in amelioration or prévention of cognitive impairment. Such compounds may also be useful in treating anxiety or dépréssion.
The dynamic interaction between the immune System and the HPA (hypothalamopituitaryadrenal) axis is known, and glucocorticoids help balance between cell-mediated responses and humoral responses. The immune reaction is typîcally biased towards a humoral response in certain disease states, such as tuberculosis, leprosy, and psoriasis. More appropriate would be a cell-based response. An 11 β-hydroxysteroid dehydrogenase (HSD) 1 inhibitor would bolster a
temporal immune response in association with immunization to ensure that a cell based response would be obtaîned, and as such could be useful in immunomodulation.
In particular, the compounds according to the invention, including the physiologically acceptable salts thereof, are suitable for the prévention or treatment of diabètes, particularly type 1 and type 2 diabètes mellitus, and/or diabetic complications.
In a further aspect of the présent invention the présent invention relates to methods for the treatment or prévention of above mentioned diseases and conditions, which method comprises the administration of an effective amount of a compound of general formula I to a human being. In a further embodiment, the présent teachings relate to methods for the treatment or prévention of above mentioned diseases and conditions, which method comprises the administration of an effective amount of a compound of formula (II) to a human being.
The dosage required to achieve the corresponding activity for treatment or prévention usually dépends on the compound which is to be administered, the patient, the nature and gravity of the illness or condition and the method and frequency of administration and is for the patient's doctor to décidé. Expediently, the dosage may be from 1 to 100 mg, preferably 1 to 30 mg, by intravenous route, and 1 to 1000 mg, preferably 1 to 100 mg, by oral route, in each case administered 1 to 4 times a day.
The actual pharmaceutically effective amount or therapeutic dosage will of course dépend on factors known by those skilled in the art such as âge and weight of the patient, route of administration and severity of disease. In any case the combination will be administered at dosages and in a manner which allows a pharmaceutically effective amount to be delivered based upon patient's unique condition.
Suitable préparations for administering the compounds of formula I will be apparent to those with ordinary skill in the art and include for example tablets, pills, capsules, suppositories, lozenges, troches, solutions, syrups, élixirs, sachets, injectables, inhalatives, powders, etc.. The content of the pharmaceutically active compound(s) should be in the range from 0.1 to 95 wt.%, preferably 5.0 to 90 wt.-% of the composition as a whole.
Suitable tablets may be obtaîned, for example, by mixing one or more compounds according to formula I with known excipients, for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants. The tablets may also consist of several layers.
For this purpose, the compounds of formula I prepared according to the invention may be formulated, optionally together with other active substances, together with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnésium stéarate, citric acid, tartaric acid, water, polyvinylpyrrolidone, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof.
The compounds according to the invention may also be used in conjunction with other active substances, particularly for the treatment and/or prévention of the diseases and conditions mentioned above. Other active substances which are suitable for such combinations include, for example, those which potentiate the therapeutic effect of an 11 β-hydroxysteroid dehydrogenase (HSD) 1 antagonist according to the invention with respect to one of the indications mentioned and/or which allow the dosage of an 11 β-hydroxysteroid dehydrogenase (HSD) 1 antagonist according to the invention to be reduced. Therapeutic agents which are suitable for such a combination include, for example, antidiabetic agents such as metformin, sulfonylureas (e.g. glibenclamide, tolbutamide, glimepiride), nateglinide, repaglinide, thiazolidinedîones (e.g. rosiglitazone, pioglitazone), SGLT 2 inhibitors (e.g. dapagliflozin, remogliflozin etabonate, sergliflozin, canagliflozin, 1-chloro-4-^-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)benzyl]-benzene), PPAR-gamma-agonists (e.g. Gl 262570) and antagonists, PPARgamma/alpha modulators (e.g. KRP 297), alpha-glucosidase inhibitors (e.g. acarbose, voglibose), DPPIV inhibitors (e.g. Sitagliptin, Vildagliptin, Saxagliptin, Alogliptin, Linagliptin), alpha2-antagonists, insulin and insulin analogues, GLP-1 and GLP-1 analogues (e.g. exendrn-
4) or amylin. The list also includes inhibitors of protein tyrosinephosphatase 1, substances that affect deregulated glucose production in the liver, such as e.g. inhibitors of glucose-6phosphatase, or fructose-1,6-bisphosphatase, glycogen phosphorylase, glucagon receptor antagonists and inhibitors of phosphoenol pyruvate carboxykinase, glycogen synthase kinase or pyruvate dehydrokinase and glucokinase activators, lipid lowering agents such as for example HMG-CoA-reductase inhibitors (e.g. simvastatin, atorvastatin), fibrates (e.g. bezafibrate, fenofibrate), nicotinic acid and the dérivatives thereof, PPAR-alpha agonists, PPAR-delta agonists, ACAT inhibitors (e.g. avasimibe) or cholestérol absorption inhibitors such as, for example, ezetimibe, bile acid-binding substances such as, for example, cholestyramine, inhibitors of ileac bile acid transport, HDL-raising compounds such as CETP inhibitors or ABC1 regulators or active substances for treating obesity, such as sibutramine or tetrahydrolipostatin, SDRIs, axokine, leptin, leptin mimetics, antagonists of the cannabinoidl receptor, MCH-1 receptor antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists or B3-agonists such as SB-418790 or AD-9677 and agonists of the 5HT2c receptor.
Moreover, combinations with drugs for influencing high blood pressure, chronic heart failure or atherosclerosis such as e.g. A-ll antagonists or ACE inhibitors, ECE inhibitors, diuretics, Bblockers, Ca-antagonists, centrally acting antihypertensives, antagonists of the alpha-25 adrenergic receptor, inhibitors of neutral endopeptidase, thrombocyte aggregation inhibitors and others or combinations thereof are suitable, Examples of angiotensin II receptor antagonists are candesartan cilexetil, potassium losartan, eprosartan mesylate, valsartan, telmisartan, irbesartan, EXP-3174, L-158809, EXP-3312, olmesartan, medoxomil, taso-sartan, KT-3-671, GA-0113, RU-64276, EMD-90423, BR-9701, etc.. Angiotensin II receptor antagonists are preferably used for the treatment or prévention of high blood pressure and complications of diabètes, often combined with a diuretic such as hydrochlorothiazide.
A combination with uric acid synthesis inhibitors or uricosurics is suitable for the treatment or prévention of goût.
A combination with GABA-receptor antagonists, Na-channel blockers, topiramat, protein-kinase C inhibitors, advanced glycation end product inhibitors or aldose reductase inhibitors may be used for the treatment or prévention of complications of diabètes.
The dosage for the combination partners mentioned above is usefully 1/5 of the lowest dose normally recommended up to 1/1 of the normally recommended dose.
Therefore, in another aspect, this invention relates to the use of a compound according to the invention or a physiologically acceptable sait of such a compound combined with at least one of the active substances described above as a combination partner, for preparing a pharmaceutical composition which is suitable for the treatment or prévention of diseases or conditions which can be affected by inhibiting the enzyme 11 B-hydroxysteroid dehydrogenase (HSD) 1. These are preferably metabolic diseases, particularly one of the diseases or conditions listed above, most particularly diabètes or diabetic complications.
The use of the compound according to the invention, or a physiologically acceptable sait thereof, in combination with another active substance may take place simultaneously or at staggered times, but particularly within a short space of time. If they are administered simultaneously, the two active substances are given to the patient together; while if they are used at staggered times the two active substances are given to the patient within a period of less than or equal to 12 hours, but particularly less than or equal to 6 hours.
Consequently, in another aspect, this invention relates to a pharmaceutical composition which comprises a compound according to the invention or a physiologically acceptable sait of such a compound and at least one of the active substances described above as combination partners, optionally together with one or more inert carriers and/or diluents.
Thus, for example, a pharmaceutical composition according to the invention comprises a combination of a compound of formula I according to the invention or a physiologically acceptable sait of such a compound and at least one angiotensin II receptor antagonist optionally together with one or more inert carriers and/or diluents.
The compound according to the invention, or a physiologically acceptable sait thereof, and the additional active substance to be combined therewith may both be présent together in one formulation, for example a tablet or capsule, or separately in two identical or different formulations, for example as a so-called kit-of-parts.
The Examples that follow are intended to illustrate the présent invention without restricting it:
Analytical HPLC and TLC parameters employed for characterization of products:
method 1 | Merck Cromolith Speed ROD, | method 2 | Waters Xbridge C18, | ||||
column | RP18e, 50x4.6 mm | column | 30*4.6 mm, | 2.5 pm | |||
mobile | A: water + 0.1% HCO2H | mobile | A: water + 0.1% NH3 | ||||
phase | B: acetonitrile + 0.1% HCO2H | phase | B: methanol | ||||
TIME (min) | A% | B% | TIME (min) | A% | B% | ||
0.00 | 90 | 10 | 0 | 90 | 10 | ||
4.50 | 10 | 90 | 0.15 | 90 | 10 | ||
5.00 | 10 | 90 | 4.00 | 0 | 100 | ||
5.50 | 90 | 10 | 4.40 | 0 | 100 | ||
4.55 | 90 | 10 | |||||
5.00 | 90 | 10 | |||||
flow rate | 1.5 mL/min | flow rate | 1.6 mL/min | ||||
wavelength | UV 220, 230, or 254 nm | wavelength | UV 220, 230, or 254 nm |
method 3 column | Sunfrre C18, 50*4.6 mm, 3.5 pm, 40°C | method 4 column | Sunfire C18, 50*4.6 mm, 3.5 pm, 40°C |
mobile phase | A: water + 0.1% F3CCO2H B: methanol | mobile phase | A: water + 0.1% F3CCO2H B: methanol | ||
TIME (min) | A% | B% | TIME (min) | A% | B% |
0.00 | 95 | 5 | 0.00 | 95 | 5 |
1.30 | 0 | 100 | 1.30 | 0 | 100 |
3.00 | 0 | 100 | 2.50 | 0 | 100 |
4.00 | 95 | 5 | 2.60 | 95 | 5 |
flow rate | 1.5 mL/min | flow rate | 1.5 mL/min | ||
wavelength | UV 210-500 nm | wavelength | UV 210-500 nm |
method 5 column | Waters Xbridge C18, 50*2.1 mm, 1.7 pm, 60 °C | TLC were conducted on Polygram® S IL G/UV254 plates coated with 0.2 mm silica gel |
mobile phase | A: water + 0.032% NH4OH; B: acetonitrile | |
TIME (min) | A% | B% |
0 | 95 | 5 |
2.00 | 0 | 100 |
2.50 | 0 | 100 |
2.60 | 95 | 5 |
flow rate | 1.3 mL/min | |
wavelength | UV 210-500 nm |
method 6 column | StableBond SB-C18 30*4.6 mm, 1.8 pm | method 7 column | YMC-PACK ODS-AQ 50*2.0 mm, 5pm, 50 °C | ||
mobile phase | A: water + 0.1% F3CCO2H B: methanol | mobile phase | A: water + 0.0375% F3CCO2H B: acetonitrile + 0.0187% F3CCO2H | ||
TIME (min) | A% | B% | |||
0,00 | 90 | 10 | |||
1.80 | 0 | 100 | TIME (min) | A% | B% |
2.00 | 0 | 100 | 0 | 90 | 10 |
2.15 | 90 | 10 | 2.2 | 20 | 80 |
2.35 | 90 | 10 | 2.5 | 20 | 80 |
flow rate | 1.75 mL/min | flow rate | 1.0 mL/min | ||
wavelength | UV 220, 230, or 254 nm wavelength | UV 220 nm |
In the following, whenever a benzoimidazole bearing a hydrogen on one of its two nitrogens is part of a molécule both tauomeric structures, 1H-benzoimidazole and 3H-benzoimidazole, are meant, though, only one is explicitly named or drawn.
Intermediates 1 and 2:
c/s-1.2.3,4,4a,5,6,10b-Octahydro-benzofflquinoline and trans-1,2,3,4,4a,5,6,10b-Octahydrobenzofflquinoline
Step 1: 5,6-dihydro-benzo[f]quinoline
Propargylamîne (5 mL) is added to a flask charged with a stir bar, 2-tetralone (10.00 g), NaAuCI4*2H2O (0.65 g), and éthanol (50 mL) (caution: a very exothermic reaction may evolve afterwards -> keep an ice bath at hand). The resulting mixture is stirred at room température for 15 min and then at reflux température for 1 h. Aftercooling the mixture to room température, the solvent is evaporated and the residue is chromatographed on silica gel (cyclohexane/ethyl acetate 60:40) to afford the title compound as an oil. Yield: 6.78 g (56% of theory); LC (method 1): = 1.81 min; Mass spectrum (ESI*): m/z = 182 [M+Hf.
Alternative^, the reaction may be conducted in a microwave oven heating with microwave irradiation to 100 °C for 10 min.
Step 2: cis- and trans-1.2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline
A mixture of 5,6-dihydro-benzo[f]quinoline (8.78 g), PtO2 (1.00 g), and acetic acid is shaken under hydrogen atmosphère (10 bar) at room température for 24 h (in case the transformation is not complété after this time, another portion of PtO2 (0.20 g) is added and shaking under hydrogen is continued until completion). The catalyst is separated by filtration and the solvent is evaporated. The residue is taken up in 2 M aqueous NaOH solution and the resulting mixture is extracted with ethyl acetate. The combined extracts are dried (MgSOJ and concentrated. The residue is chromatographed on silica gel (dichloromethane/methanol containing 1% NH3 95:5->80:20) to afford the two title compounds separated. c/s-1,2,3,4,4a,5,6,10b-Octahydro-benzo[f]quinoline: Yield: 6.30 g (69% of theory); LC (method 1): tR = 1.85 min; Mass spectrum (ESf): m/z = 188 [M+Hf; Ή NMR (400 MHz. DMSO-dc) d
1.30-1.45 (m, 2H), 1.57-1.66 (m, 1H). 1.66-1.76 (m, 1H), 1.84-1.97 (m, 1H), 1.99-2.10 (m, 1H). 2.59-2.79 (m, 4H), 2.83-2.92 (m, 1H), 3.03-3.10 (m, 1H), 3.27 (broad s, 1H and water), 7.007.11 (m, 3H), 7.15-7.19 (m, 1H).
Alternatively, c/s-1,2,3,4,43,5,6,10b-octahydro-benzo[f]quinoline may be obtained in a departure of the synthesis described in J. Heterocyclic Chem. 1996, 33, 983-5 by conducting the enamide réduction with H2 (3 bar) and 10% palladium on carbon in methanol containing 5% acetic acid. trans-1,2,3,4,48,5,6,1 Ob-Octahydro-benzo[f]quinoline: Yield: 0.41 g (5% of theory); Mass spectrum (ESC): m/z = 188 [M+H]+; 1H NMR (400 MHz, DMSO-d6) d 1.20-1.33 (m, 1H), 1.671.89 (m, 3H), 1.98-2.07 (m, 1H), ca. 2.47-2.55 (2H, m) superimposed on DMSO-d5 signal, 2.592.68 (m, 1H), 2.70-2.80 (m, 2H), 2.82-2.90 (m, 2H), 3.12-3.20 (m, 1H). 7.05-7.18 (m, 3H), 7.257.31 (m, 1H).
Alternatively, trans-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline may be obtained as described in J. Heterocyclic Chem. 1996, 33, 983-5.
Alternatively, 5,6-dihydro-benzo[f]quinoline may be obtained as follows:
Step 3: 3-bromo-2-phenethyl-pyridine
Tetrakis(triphenylphosphine)palladium(0) (2.0 g) is added to a flask charged with a stir bar, phenethylzinc bromide (0.5 mol/L in tetrahydrofuran, 100 mL), 2,3-dibromopyridine (10.50 g), and tetrahydrofuran (100 ml) and kept under argon atmosphère at room température. The resulting mixture is stirred at room température for 3 h and at 40 °C for another 16 h. After cooling the mixture to room température, the solvent is evaporated and the residue is chromatographed on siiica gel (cyclohexane/ethyl acetate 90:10—>75:25) to afford the tïtle compound as an oil that solidified upon treatment with ether. Yield: 9.32 g (81% of theory); LC (method 1): tR = 4.28 min; Mass spectrum (EST): m/z = 262/264 (Br) [M+Hf.
Step 4: 5,6-dïhydro-benzo[f]quinoline
N,N-Dimethylacetamide (15 mL) is added to a flask charged with a stir bar, 3-bromo-2phenethyl-pyridine (3.34 g), freshly dried K2CO3 (3.52 g), palladium(ll) acetate (0.14 g), and tricyclohexylphosphonium tetrafluoroborate (0.47 g) and kept under argon atmosphère at room température. The flask is put into a 150 °C hot oil bath and the mixture is stirred therein for 2 h. After cooling the mixture to room température, the solvent is evaporated and the residue is chromatographed twice on siiica gel (1. dichloromethane/methanol 98:2; 2. cyclohexane/ethyl acetate 90:10—>50:50) to afford the title compound as an oil. Yield: 1.51 g (65% of theory); LC (method 1): tR ~ 1.83 min; Mass spectrum (ESl·): m/z = 182 [Μ+ΗΓ.
Intermediates 3 and 4 c/s-7-Methoxv-1,2,3,4,48.5,6,1 Ob-octahydro-benzofflquinoline and frans-7-Methoxy1,2,3,4,4a,5,6,10b-octahydro-benzoff]quinoline
The title compounds are obtained following a route analogous to that described in Step 1 and Step 2 for Intermediates 1 and 2 employing 5-methoxy-2-tetralone and propargylamine in Step 1 and 7-methoxy-5,6-dihydro-benzo[f]quinoline in Step 2.
Step 1: 7-methoxy-5,6-dihydro-benzo[f]quinoline; Yield: 55% of theory; Mass spectrum (EST): m/z = 212 [M+Hf.
Step 2: c/s-7-methoxy-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline; Yield: 54% of theory; LC (method 1 ): tR = 2.02 min; Mass spectrum (EST): m/z = 218 [M+H]+.
trans-7-methoxy-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline; Yield: 20% of theory; Mass spectrum (EST): m/z = 218 [M+Hf.
Intermediates 5 and 6 c/s-IO-Methoxy-I^.S^^a.S.e.lOb-octahvdro-benzofflquinoline and trans-10-Methoxv1,2,3,4,4a,5.6,10b-octahydro-benzoiflquinoline
The title compounds are obtained following a route analogous to that described in Step 1 and Step 2 for Intermediates 1 and 2 employing 8-methoxy-2-tetralone and propargylamine in Step 1 and 10-methoxy-5,6-dihydro-benzo[f]quinoline in Step 2.
Step 1: 10-methoxy-5,6-dihydro-benzo[f]quinoline; Yield: 54% of theory; LC (method 1): tR = 2.02 min; Mass spectrum (ESI+): m/z = 212 [M+Hf.
Step 2: c/s-IO-methoxy-I^.SAâa.S.e.lOb-octahydro-benzofflquinoline; Yield: 50% of theory; Mass spectrum (EST): m/z = 218 [M+Hf.
frans-10-methoxy-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline; Yield: 11% of theory; Mass spectrum (ESf): m/z = 218 [Μ+ΗΓ.
Intermediates 7 and 8 c/s-10b-Methvl-1.2,3.4,48.5,6,10b-octahydro-benzoffîquinoline and trans-1 Ob-Methyl1,2,3,4,4a,5,6,1Ob-octahvdro-benzofflquinoline
NH
The title compounds are obtained following a route analogous to that described in Step 1 and Step 2 for Intermediates 1 and 2.
Step 1: 10b-methyl-3,5,6,10b-tetrahydro-benzo[f]quinoline
Propargylamine (0.21 mL) is added to a microwave oven suited vessel charged with a stir bar, 1-methyl-2-tetralone (0.50 mL), NaAuCI4*2H2O (27 mg), and éthanol (3 mL) (caution: a very exothermic reaction may evolve afterwards -> keep an ice bath at hand). The resulting mixture is stirred under microwave irradiation at 100 ’C for 10 min. After cooling the mixture to room température, the solvent is evaporated and the residue is chromatographed on silica gel (cyclohexane/ethyl acetate 25:75->0:100) to afford the title compound as an oil. Yield: 0.29 g (50% of theory); LC (method 1): tR = 1.78 min; Mass spectrum (EST): m/z = 198 [M+H]+.
Step 2: c/s-10b-methyl-1,2,3,4,48,5,6,10b-octahydro-benzo[f]quinoline and frans-10b-methyl1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline
A mixture of 10b-methyl-3,5,6,10b-tetrahydro-benzo[f]quinoline (8.78 g), 10% Pd on carbon (1.00 g), acetic acid (0.3 mL), and methanol (10 mL) is shaken under hydrogen atmosphère (3 bar) at room température for 14 h. The catalyst is separated by filtration and the solvent is evaporated. The residue is taken up in half-concentrated aqueous Na2CO3 solution and the resulting mixture is extracted with ethyl acetate. The combined extracts are dried (MgSO4) and then concentrated to afford the two title compounds in a ca. 3:1 mixture (cis/trans). Yield: 0.24 g (86% of theory); LC (method 1): tR = 1.92 min (trans-IOb-methyl-I^.S^^a.S.ô.lOb-octahydrobenzo[f]quinoline) and tR = 2.02 min (c/s-10b-methyl-1,2,3,4,4a,5,6,1 Ob-octahydrobenzo[f]quinoline); Mass spectrum (EST): m/z = 202 [M+Hf.
Intermediates 9 and 10 c/s-9-Methoxy-1,2,3,4,4a,5.6,10b-octahydro-benzo[f|quinoline and trans-9-Methoxy1,2,3,4,4a,5,6,10b-octahvdro-benzofflquinoline
O.
NH
The title compounds are obtained following a route analogous to that described in Step 1 and Step 2 for Intermediates 1 and 2 employing 7-methoxy-2-tetralone and propargylamine in Step 1 and 9-methoxy-5,6-dihydro-benzo[f]quinoline in Step 2.
Step 1: 9-methoxy-5,6-dihydro-benzo[f]quinoline; Yield: 58% of theory; LC (method 1): tR = 1.99 min; Mass spectrum (ESl*): m/z = 212 [M+Hf.
Step 2: c/s-G-methoxy-V.a.Ma.S.ejOb-octahydro-benzolfjqiiinoline; Yield: 19% of theory; Mass spectrum (EST): m/z = 218 [M+Hf.
irans-9-methoxy-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline; Yield: 22% of theory; Mass spectrum (ESl*): m/z = 218 [M+Hf.
Intermediates 11 and 12 c/s-7,9-Difluoro-1,2.3.4,4a,5,6,10b-octahvdro-benzo[f1quinoline and /rans-7,9-Difluoro1,2,3,4,4a,5,6.10b-octahydro-benzofflquinoline
The title compounds are obtained foliowing a route analogous to that described in Step 1 and Step 2 for Intermediates 1 and 2 employing 5,7-difluoro-2-tetralone and propargylamine in Step 1 and /.G-difluoro-S.G-dihydro-benzotfIquinoline in Step 2.
Step 1: 7,9-difluoro-5,6-dihydro-benzo[f]quinoline; Yield: 53% of theory; LC (method 1): tR = 2.54 min; Mass spectrum (ESl*): m/z = 224 [M+Hf.
Step 2: c/s-7,9-difluoro-1,2,3,4,4a,5l6l10b-octahydro-benzo[f]quinoline; Yield: 38% of theory; TLC: r( = 0.37 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (ESl*): m/z = 218 [M+Hf.
/rans-7,9-difluoro-1,2,3,4,4a,5,6,10b-octahydro-benzo[f|qutnoline; Yield: 26% of theory; TLC: r( = 0.37 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (ESl*): m/z - 224 [M+Hf.
Intermediates 13 and 14 c/s-8-Methoxy-1,2,3,4,4a,5,6,10b-octahvdro-benzo[flquinoline and frans-8-Methoxy1,2,3,4,4a, 5,6,10b-octahydro-benzo[flquinoline
The title compounds are obtained foliowing a route analogous to that described in Step 1 and Step 2 for Intermediates 1 and 2 employing 6-methoxy-2-tetralone and propargylamine in Step 1 and 8-methoxy-5,6-dihydro-benzo[f]quinoline in Step 2.
Step 1: 8-methoxy-5,6-dihydro-benzo[f]quinoline; Yield: 14% of theory; LC (method 1): tR = 1,95 min; Mass spectrum (ESl*): m/z = 212 [M+Hf.
Step2: c/s-8-methoxy-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline; Yield: 52% of theory; TLC: rf = 0.22 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (EST): m/z = 218 [M+Hf.
trans-8-methoxy-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quÎnoline; Yield: 21% of theory; TLC: rf = 0.28 (silica gel, CH2Cl2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (ESI*): m/z = 218 [M+Hf.
Intermediates 15 and 16 cfs-10-Fluoro-1,2.3.4.4a,5,6.10b-octahvdro-benzoff1quinoline and trans-10-Fluoro1,2,3,4,4a, 5,6,10b-octahydro-benzo[f|quinoline
NH
The title compounds are obtained foilowing a route analogous to that described in Step 1 and Step 2 for Intermediates 1 and 2 employing 8-fluoro-2-tetralone and propargylamine in Step 1 and 10-fluoro-5,6-dihydro-benzo[f]quinolîne în Step 2.
Step 1: 10-fluoro-5,6'dihydro-benzo[f]quinoline; Yield: 55% of theory; Mass spectrum (ESI*): m/z = 200 [M+H]+.
Step 2: c/s-10-fluoro-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline; Yield: 63% of theory; TLC: rf = 0.38 (silica gel, CH2Clz/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (ESI*): m/z= 206 [M+HJ*.
irans-10-fluoro-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline; Yield: 13% of theory; TLC: rt = 0.46 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (ESI*): m/z = 206 [M+Hf.
Intermediates 17 and 18 cfs-8-Phenvl-1,2,3,4,4a,5.6,10b-octahvdro-benzo[f|quinoline and frans-8-Phenyl1,2.3.4,4a,5,6,10b-octahydro-benzo[flquinoline
Br ° Step 1
Br
NH
Step 1: 8-bromo-5,6-dihydro-benzo[f]quinoline
The title compound is prepared from 6-bromo-2-tetralone and propargylamine following a procedure analogous to that described in Step 1 of Intermediates 1 and 2. Yield: 69% of theory; Mass spectrum (ESI*): m/z = 260/262 (Br) [M+Hf.
Step 2: 8-phenyl-5,6-dihydro-benzo[f]quinoline
A flask charged with a stir bar, 8-bromo-5,6-dihydro-benzo[f]quinoline (0.28 g), phenylboronic acid (0.24 g), 2 M aqueous Na2CO3 solution (1.1 mL), and N,N-dimethylformamide (3 ml) is sparged with argon at room température for 10 min. [1,r-Bis(diphenylphosphino)ferrocenejdichloropalladium dichloromethane complex (30 mg) is then added and the resulting mixture is heated to 90 °C and stirred at this température for 4 h. After cooling the mixture to room température, ethyl acetate and water are added and the mixture is filtered over Celite. The organic phase of the filtrate is separated and washed with brine and dried (Na2SO4). The solvent is evaporated and the residue is chromatographed on silica gel (cyclohexane/ethyl acetate 1:1) to afford the title compound as a solid. Yield: 0.24 g (ca. 80% pure); LC (method 1): tR = 3.16 min; Mass spectrum (EST): m/z = 258 [M+Hf.
Step3: c/s-8-phenyl-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline and trans-8-phenyl1,2,3,4,4a,5,6,10b'Octahydro-benzo[f]quinoline
The title compounds are prepared from 8-phenyl-5,6-dihydro-benzo[f]quinoline following a procedure analogous to that described in Step 2 of Intermediates 1 and 2. c/S“8Phenyl-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline: Yield: 56% of theory; Mass spectrum (ESI+): m/z = 206 [M+Hf.
trans-B-Phenyl-I^.S^^a.S.e.lOb-octahydro-benzotfJquinoline: Yield: 11% of theory; Mass spectrum (ESl+): m/z = 206 [M+Hf.
Intermediates 19 and 20 c/s-1,2,3,4,4a,5,6,10b-Octahydro-benzo[flquinoline-8-carboxylic acid methyl ester and trans-
Step 1: 5,6-dihydro-benzo[f]quinoline-8-carboxylic acid methyl ester
A flask charged with 8-bromo-5,6-dihydro-benzo[f]quinoline (4.00 g), triethylamine (3.0 mL), [1,r-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (0.63 g), N,N-dimethylformamide (5 mL), and methanol (20 ml) is flushed with argon for 5 min and with carbon monoxide for another 5 min. The mixture is then heated to 80 °C under carbon monoxide atmosphère (4 bar) and shaken at this température ovemight. After cooling to room température, the mixture is filtered and concentrated under reduced pressure. The residue is taken up in ethyl acetate and washed with water and brine and dried (NaïSCTi). The solvent is
evaporated and the residue is chromatographed on silica gel (cyclohexane/ethyi acetate
1:1 —*0:1 ) to afford the title compound as a solid. Yield: 3.16 g (86% of theory): LC (method 1): tR = 2.18 min; Mass spectrum (EST): m/z = 240 [M+H]+.
Step 2: c/s-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline-8-carboxylic acid methyl ester and frans-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline-8-carboxylic acid methyl ester
The title compounds are prepared from 5,6-dihydro-benzo[f]quinoline-8-carboxylic acid methyl ester following a procedure analogous to that described in Step 2 of Intermediates 1 and 2. c/s-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline-8-carboxylic acid methyl ester: Yield: 79% of theory; LC (method 1 ): tR = 1.93 min; Mass spectrum (ESI+): m/z = 246 [M+Hf.
trans-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline-8-carboxylic acid methyl ester: Yield: 10% of theory; Mass spectrum (EST): m/z = 246 [M+H]+.
Intermediates 21 and 22 c/s-8-BenzyM ,2,3.4.4a.5,6,10b-octahydro-benzo[f]quinoline and c/s-8-Cvclohexvlmethyl1,2,3,4,4a,5,6.1 Ob-octahvdro-benzofflquÎnoline
Step 1: 8-Benzyl-5,6-dihydro-benzo[f]quinoline
Benzylzinc bromide (0.5 mol/L in tetrahydrofuran, 7.7 mL) is added to a flask charged with a stir bar, tetrakis(triphenylphosphine)palladium(0) (53 mg), and 8-bromo-5,6-dihydrobenzo[f|quinoline (0.20 g) and kept under argon atmosphère at room température. The resulting solution is heated to reflux température and stirred at this température for 6 h. After cooling the solution to room température, aqueous NH4CI solution is added and the resulting mixture is extracted with ethyl acetate. The combined extracts are washed with brine and dried (Na2SO4). The solvent is evaporated and the residue is chromatographed on silica gel (cyclohexane/ethyi acetate 4.Ί—>1:1) to afford the title compound as an oil. Yield: 0.17 g (81% of theory); LC (method 1): tR = 3.08 min; Mass spectrum (EST): m/z = 272 [M+H]T
Step 2: c/s-e-benzyl-I^.S^Aa.SAIOb-octahydro-benzoffJquinoline and c/s-8-cyclohexylmethyl-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline
The title compounds are prepared from 8-benzyl-5,6-dihydro-benzo[f]quinoline following a procedure analogous to that described in Step 2 of Intermediates 1 and 2 and obtained in a ca. 30:70 mixture that is used as such in the next reaction step. Yield: 81% of theory (ca. 30:70 mixture).
G/s-8-Benzyl-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline: LC-MS (method 1): tR = 2.91 min; Mass spectrum (EST): m/z = 278 [M+Hf.
c/s-e-Cyclohexyl-methyl-I^.S^^a.S.e.lOb-octahydro-benzotflquinoline: LC-MS (method 1): tR = 3.41 min; Mass spectrum (ESf): m/z = 284 [M+Hf.
Intermediate 23 c/s-4-( 1 H-Benzoimidazole-5-carbonyl)-1.2,3.4,4a,5.6.10b-octahvdro-benzo[f|quino1ine-10carboxylic acid methyl ester
Step 1:10-bromo-5,6-dihydro-benzo[f]quinoline
The title compound is prepared from 8-bromo-2-tetralone and propargylamine following a procedure analogous to that described in Step 1 of Intermediates 1 and 2. Yield: 49% of theory ; LC (method 1): tR = 2.68 min; Mass spectrum (ESf): m/z = 260/262 (Br) [M+Hf.
Step 2: 5,6-dihydro-benzo[f]quinoline-10-carboxylic acid methyl ester
The title compound is prepared from 10-bromo-5,6-dihydro-benzo[f]quinoline following a procedure analogous to that described in Step 1 of Intermediates 19 and 20. Yield: 84% of theory ; LC (method 1): tR = 1.95 min; Mass spectrum (EST): m/z = 240 [M+Hf.
Step 3: 0/5-1,2,3,4,48,5,6,10b-octahydro-benzo[f]quinoline-10-carboxylic acid methyl ester The title compound is prepared from 5,6-dihydro-benzo[f]quinoline-10-carboxylic acid methyl ester following a procedure analogous to that described in Step 2 of Intermediates 1 and 2. Yield: 52% of theory ; LC (method 1 ): tR = 2.07 min; Mass spectrum (ESI+): m/z = 246 [M+Hf. Step 4: c/s-4-(1H-benzoimidazole-5-carbonyl)-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline10-carboxylic acid methyl ester
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and cisI^.SA^a.S.e.lOb-octahydro-benzoIfJquinoline-IO-carboxylic acid methyl ester following a procedure analogous to that described in Example 1. Yield: 43% of theory; TLC: rf = 0.30 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (ESl·): m/z = 390 [M+Hf.
Intermediate 24 cis-10-(4-Methoxv-benzvl)-1l2,3,4,4a,5,6,10b-octahydro-benzo[f|quinoline
Step 1:10-(4-methoxy-benzyl)-5,6-dihydro-benzo[f]quinoline
The title compound is prepared from 4-methoxybenzylzinc chloride and 10-bromo-5,6-dihydrobenzo[f]quînoline following a procedure analogous to that described in Step 1 of Intermediates 21 and 22. Yield: 85% of theory; LC (method 1): tR = 3.09 min; Mass spectrum (ESI+): m/z = 302 [M+Hf.
Step 2: c/s-10-(4-methoxy-benzyl)-1,2,3,4,43,5,6,1Ob-octahydro-benzo[f]quinoline
The title compound is prepared from 10-(4-methoxy-benzyl)-5,6-dihydro-benzo[f]quinoline following a procedure analogous to that described in Step 2 of Intermediates 1 and 2. Yield: 12% of theory; LC-MS (method 1 ): tR = 2.82 min; Mass spectrum (ESl+): m/z = 308 [M+Hf.
Intermediate 25 c/s-6.6-Dimethvl-1.2.3.4,4a,5.6,10b-octahvdro-benzo[f]quinoline
Step 1: 6,6-dimethyl-5,6-dihydro-benzo[f]quinoline
The title compound is prepared from 4,4-dimethyl-3,4-dihydro-1H-naphthalen-2-one and propargylamine following a procedure analogous to that described in Step 1 of Intermediates 1 and 2. Yield: 49% of theory; LC (method 1): tR = 2.40 min; Mass spectrum (ESI*): m/z = 210 [M+Hf.
Step 2: c/s-6,6-Dimethyl-1 ,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline
The title compounds is prepared from 6,6-dimethyl-5,6-dihydro-benzo[f]quinoline following a procedure analogous to that described in Step 2 of Intermediates 1 and 2. Yield: 72% of theory; LC-MS (method 1): tR = 2.38 min; Mass spectrum (EST): m/z = 216 [M+Hf.
intermediate 26 c/s-4-( 1 H-Benzoimidazole-5-carbonyl)-1.2,3,4,48,5,6,10b-octahydro-benzo[f|quinoline-10carboxylic acid
The title compound is prepared from c/s-4-(1H-benzoimidazole-5-carbonyl)-1,2,3,4,4a,5, 6,10boctahydro-benzo[f]quinoline-10-carboxylic acid methyl ester following a procedure analogous to that described in Example 35 except for stirring the solution at 50 °C. Yield: 69% of theory; Mass spectrum (ESl·): m/z = 376 [M+Hf.
Intermediate 27 c/s-S-Î^Methoxv-phenoxvl-I^.S^^a.S.e.lOb-octahydro-benzoiflquinoline
Step 1 : c/s-2,2,2-trifluoro-1 -(8-methoxy-2,3,4a,5,6,10b-hexahydro-1 H-benzo[f]quinolin-4-yl)ethanone
Trifluoroacetic anhydride (0.75 mL) is added to a solution of c/$-8-methoxy-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline (0.79 g) and triethylamine (0.90 mL) in dichloromethane (10 mL) chilled in an ice bath. The cooling bath is removed and the solution is stirred at room température overnight. Water and dichloromethane are then added and stirring is continued for another 30 min. The organic phase is separated and washed with aqueous NaHCOa solution and dried (Na2SO.;). The solvent is evaporated to afford the title compound as a solid. Yield: 100% of theory; LC (method 1): tR = 4.38 min; Mass spectrum (EST): m/z = 3.14 [M+H]+. Step 2: c/s-2,2,2-trifluoro-1 -(8-hydroxy-2,3,4a,5,6,10b-hexahydro-1 H-benzo[f]quiπolin-4-yI)ethanone
The title compound is prepared from c/s-2,2,2-trifluoro-1-(8-methoxy-2,3,4a,5,6,10b-hexahydro1H-benzo[f]quinolîn-4-yl)-ethanone following a procedure analogous to that described in Example 7. Yield: 93% of theory; LC (method 1): tR = 3.58 min; Mass spectrum (EST): m/z 300 [M+Hf.
Step 3: c/s-2,2,2-trifluoro-1-[8-(4-methoxy-phenoxy)-2,3,4a,5,6,10b-hexahydro-1Hbenzo[f]quinolin-4-yl]-ethanone
A mixture of c/s-2,212-trifluoro-1-(8-hydroxy-2,3l4a,5,6,10b-hexahydro-1H-benzo[f]quinolin-4-yl)ethanone (0.98 g), 4-methoxyphenylboronic acid (1.00 g), pyridine (1.30 mL), copper(ll) acetate (0.60 g), molecular sieves 3A (3.60 g), and dichloromethane (15 mL) is stirred in air at room température overnight. The mixture is diluted with dichloromethane and filtered over Celite. The filtrate is concentrated and the residue is chromatographed on silica gel (dichloromethane/methanol containing 1% NH3 99:1->95:5) to give the title compound as a coloriess resin-like solid. Yield: 1.05 g (79% of theory); LC (method 1): tR = 5.00 min; Mass speclrum (ESP): m/z = 406 [M+H]+.
Step 4: c/s-8-(4-methoxy-phenoxy)-1,2,3,4,4a,5,6,1Ob-octahydro-benzo[f]quinoline
M aqueous NaOH solution (10 mL) is added to a solution of c/s-2,2,2-trifluoro-1-[8-(4methoxy-phenoxy)-2,3,4a,5,6,10b-hexahydro-1H-benzo[f]quinolin-4-yl]-ethanone (0.95 g) in tetrahydrofuran (10 mL)at room température. The resulting solution is stirred at 35 °C overnight and then cooled to room température. The solution is extracted with ethyl acetate, the combined extracts are washed with brine and dried (Na2SO4). The solvent is evaporated and the residue is chromatographed on silica gel (dichloromethane/methanol containing 1% NH3 95:5—>70:30) to give the title compound as a coloriess resin-like solid. Yield: 0.64 g (88% of theory); LC (method 1): tR = 2.75 min; Mass spectrum (EST): m/z = 310 [M+H]+.
Intermediates 28 and 29 c/S“1.2,3.4,4a,5,6.10b-Octahydro-benzofflquinolin-9-vlamine and trans-1,2,3,4,4a,5,6,10bOctahvdro-benzoiflauinolin-9-ylamine
Step 1: 9-nitro-5,6-dihydro-benzo[f]quinoline
The title compound is prepared from 7-nitro-2-tetralone and propargylamine following a procedure analogous to that described in Step 1 of Intermediates 1 and 2. Yield: 41% of theory; LC (method 1): tR - 2.20 min; Mass spectrum (ESP): m/z = 227 [M+Hp.
Step 2: 9-amino-5,6-dihydro-benzo[f]quinoline
A mixture of 9-nitro-5,6-dihydro-benzo[f]quinoline (1.90 g), 10% palladium on carbon (0.20 g), and methanol (10 mL) is shaken under hydrogen atmosphère (3 bar) at room température for 3 h. The catalyst is then separated by filtration and the filtrate is concentrated to give an oil that is submitted to the next reaction without further purification. Yield: 1.67 g (crude); Mass spectrum (ESI4): m/z = 197 [M+H]4.
Step 3: c/s-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinolin-9-ylamine and transV.S.A^a.S.e.lOb-octahydro-benzofflquinolin-g-ylamine
The tille compounds are prepared from 9-amino-5,6-dihydro-benzo[f]quinoline following a procedure analogous to that described in Step 2 of Intermediates 1 and 2. c/s-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinolin-9-ylannine: Yield: 40% of theory; LC (method
2): tR = 2.50 min; Mass spectrum (ESC): m/z = 203 [M+H]4.
trans-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinolin-9-ylamine: Yield: 24% of theory; LC (method 2): tR = 2.70 min; Mass spectrum (ESI4): m/z = 203 [M+H]4.
Intermediate 30 ¢/5-1,2.3,4,43,5.6.10b-Qctahvdro-benzo[f]quinoline-9-carbonitri le
Sodium nitrite (0.12 g) dissolved in water (0.7 mL) is added dropwise to a solution of cis1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinolin-9-ylamine (0.36 g) in half-concentrated sulfuric acid (0.6 ml) cooled to ca. -5 °C. The solution is stirred for 15 min in the cooling bath prior to the addition of urea (30 mg). The resulting solution is added to a vigorously stirred solution of sodium cyanide (0.32 g) and copper(l) cyanide (0.19 g) in water (1.4 mL) cooled to ca. -5 °C. The mixture is stirred in the cooling bath for another 10 min and then the cooling bath is removed. After stirring at room température for 10 min, the mixture is heated to 70 °C and stirred at this température for 1 h. The mixture is cooled to room température, basified with 4 M NaOH solution (1.5 mL), and extracted with dichloromethane, The combined extracts are dried (Na2SO4) and the solvent is evaporated. The residue is chromatographed on silica gel [dichloromethane/(dichloromethane/methanol/NH4OH 50:48:2) 80:20-»40:60] to give the title compound as a resin-like solid. Yield: 0.12 g (31% of theory); Mass spectrum (ESI4): m/z = 213 [M+H]4.
Intermediate 31 trans-1,2,3,4,4a,5,6,10b-Octahvdro-benzo[f1quinoline-9-carbonitrile
The title compound is prepared from trans-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinolin-9ylamine following a procedure analogous to that described for Intermediate 30. Yield: 22% of theory; LC (method 1): tR = 1.64 min; Mass spectrum (ESI4): m/z = 213 [M+H]4.
Intermediate 32 c/s-10-(6-Methvl-pyridazin-3-vloxv)-1,2.3,4,4a,5,6,10b-octahvdro-benzofflquinoIine
Step 1: 5,6-dihydro-benzo[f]quînolin-10-oI
The title compound is prepared from 10-methoxy-5,6-dihydro-benzo[f]quinoline following a procedure analogous to that described for Example 7. Yield: 94% of theory; LC (method 1 ): tR = 1.48 min; Mass spectrum (ESI*): m/z = 198 [M+H]+.
Step 2: c/s-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinolin-10-ol
The title compound is prepared from 5,6-dihydro-benzo[f]quinolin-10-ol following a procedure analogous to that described in Step 2 of Intermediates 1 and 2. Yield: 60% of theory; LC (method 2): tR = 2.71 min; Mass spectrum (ESf): m/z = 204 [M+Hf.
Step 3: c/s-10-hydroxy-2,3,4a,5,6,10b-hexahydro-1H-benzo[f]quinoline-4-carboxylic acid tertbutyl ester
Di-terf-butyl dicarbonate (0.69 g) is added to a solution of c/s-1,2,3,4,4a,5,6,1 Ob-octahydrobenzo[f]quinolin-10-ol (0.64 g) and triethylamine (0.5 mL) in dichloromethane (25 mL) at room température. The solution is stirred at room température overnight and then diluted with dichloromethane. The resulting solution is washed with 2 M aqueous citric acid and brine, dried (Na2SO4), and concentrated. The residue is treated with lîttle methanol and the precipitate formed thereafter is separated by filtration and dried to give the title compound as a colorless solid. Yield: 0.35 g (37% of theory); LC (method 1 ): tR = 4.20 min; Mass spectrum (ESI+): m/z = 304 [M+H]+.
Step 4: c/s-10-(6-methyl-pyridazin-3-yloxy)-2,3,4a,5,6,10b-hexahydro-1H-benzo[f]quinoline-4carboxylic acid tert-butyl ester
A mixture of c/s-10-hydroxy-2,3,4a,5,6,10b-hexahydro-1H-benzo[f]quinoline-4-carboxylic acid tert-butyl ester (0.40 g), 3-chloro-6-methyl-pyridazine (0.13 g), césium carbonate (0.35 g), and N-methylpyrrolidinone (5 mL) is stirred at 150 °C for 1.5 h. After cooling to room température, the mixture is diluted with ethyl acetate and washed with water and brine and dried (Na2SO4). The solvent is evaporated and the residue is chromatographed on silica gel (cyclohexane/ethyl
acetate 3:1—>1:2) togive the title compound. Yield: 0.14 g (impure); LC (method 1): tR = 4.19 min; Mass spectrum (ESΓ): m/z = 396 [M+Hf.
Step 5: c/s-10-(6-methyl-pyridazin-3-yloxy)-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline Hydrochloric acid (4 mol/L in 1,4-dioxane, 0.7 mL) is added to a solution of c/s-10-(6-methylpyridazin-3-yloxy)-2,3,4a,5,6,10b-hexahydro-1H-benzo[f]quinoline-4-carboxylic acid tert-butyl ester (0.13 g) in dichloromethane (5 mL) at room température. The solution is stirred at room température for 2 h and then concentrated to give the crude title compound as its hydrochloric acid sait that is used without further purification. Yield: 0.12 g (crude); LC (method 1 ): tR = 1.90 min; Mass spectrum (EST): m/z = 296 [M+Hf.
Intermediate 33 cis-2,3,4,4al9,9a-Hexahvdro-1H-indeno[2,1-b1pyridine
Step 1: 1,3,4,9-tetrahydro-indeno[2,1 -b]pyridin-2-one
A mixture of 1 -( 1 H-inden-2-yl)-pyrrolidine (5.34 g) and acrylamide (6.15 g) is stirred in argon atmosphère at 100 °C for 30 min. The température is then rised to 130 °C and stirring continued for another 15 min. After cooling to room température, water (50 mL) and acetic acid (5 drops) are added and the mixture is stirred for 30 min. The mixture is filtered and the organic phase of the filtrate is separated and washed with brine. After drying (MgSO4) and evaporating the solvent, the residue is chromatographed on silica gel (cyclohexane/ethyl acetate 1:1-> 0:1) to give a brown solid that is triturated with ethyl acetate and dried to afford the title compound. Yield: 1.12 g (21% of theory); Mass spectrum (EST): m/z = 186 [M+Hf.
Step 2: c/'s-1,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-2-one
A mixture of 1,3,4,9-tetrahydro-indeno[2,1-b]pyridin-2-one (1.10 g), 10% palladium on carbon (0.15 g), acetic acid (0.75 mL), and methanol (20 mL) is shaken under hydrogen atmosphère (3 bar) at room température for 6 h. The catalyst is then separated by filtration and the filtrate is concentrated. The residue is triturated with terf-butyl methyl ether and dried to give the title compound as a colorless solid. Yield: 0.99 g (89% of theory); LC (method 1): tR - 2.53 min; Mass spectrum (ESI+): m/z = 188 [M+Hf.
Step 3: c/s-2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1-b]pyridine
Lithium aluminum hydride (1 mol/L in tetrahydrofuran, 12 mL) is added to a solution of cis1,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-2-one (0.95 g) in tetrahydrofuran (15 mL) at room température. The resulting solution is heated to reflux température and stirred at this température for 2 h. After cooling to room température, the solution is poured into ice-cold water, 1 M aqueous NaOH solution and ethyl acetate are added, and the resulting mixture is filtered over Celite. The aqueous phase of the filtrate is separated and extracted with ethyl acetate and the extracts are combined with the organic phase of the filtrate. The organic phase is washed with brine and dried (MgSO4). The solvent is evaporated to give the title compound as a colorless solid. Yield: 0.83 g (94% of theory); LC (method 1): tR = 1.29 min; Mass spectrum (Ε3Γ): m/z = 174 [M+Hf.
Alternatively, Intermediate 33 is obtained as follows:
Step 4: 9H-indeno[2,1-b]pyridine
The title compound is prepared from 2-indanone and propargylamine following a procedure analogous to that described in Step 1 of Intermediates 1 and 2. Yield: 56% of theory; Mass spectrum (ESf): m/z = 168 [M+Hf.
Step 5: c/$-2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1-b]pyridine
A mixture of 9H-indeno[2,1-b]pyridine (0.20 g), PtO2 (70 mg), concentrated aqueous hydrochloric acid (0.1 mL), and éthanol (10 mL) is shaken under hydrogen atmosphère (2 bar) at room température for 16 h (in case the transformation is not complété after this time another portion of PtO2 (30 mg) is added and shaking under hydrogen is continued until complété). The catalyst is separated by filtration and the solvent is evaporated to give the crude title compound as its hydrochloric acid sait that is used without further purification. Yield: 0.25 g (crude); Mass spectrum (ESI+): m/z = 174 [M+Hf.
Intermediates 34 and 35 c/s-1-(1H-Benzoimidazole-5-carbonvl)-2.3.4.4a,9,9a-hexahvdro-1H-indeno[2.1-blpyridine-6carboxylic acid methyl ester and c/s-1-(lH-Benzoimidazole-5-carbonvl)-2,3,4.4a,9.9ahexahydro-1H-indeno[2.1-blpyridine-7-carboxylic acid methyl ester
Step 1: 2,2,2-trifluoro-1-(c/s-2,3,4,4a,9l9a-hexahydro-indeno[2,1-b]pyridin-1-yl)-ethanone
The title compound is prepared from c/s-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1“b]pyridine following a procedure analogous to that described in Step 1 of Intermediate 27. Yield: 76% of theory; Mass spectrum (EST): m/z = 270 [M+Hf.
Step 2: Cfs-1-(6-bromo-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl)-2,2,2“trifluoroethanone and c/s-1-(7-bromo-2,3,4,4a,919a-hexahydro-indeno[211-b]pyridin-1-yl)-2,2,2-trifluoroethanone
Bromine (0.80 mL) is added to a suspension of 2,2,2-trifluoro-1-(c/s-2,3,4,4a,9,9a-hexahydrO' indeno[2,1-b]pyridin-1-yl)-ethanone (4.00 g) in water (32 mL) at room température. The mixture is heated to 70 °C and stirred at this température for 4 h. After cooling to room température, aqueous Na2S2O3 solution is added and the resulting mixture is extracted with dichloromethane. The combined extracts are dried (Na2SO«) and the solvent is removed under reduced pressure. The residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 1:1 ) to give a mixture of the two title compounds and small amounts of further monobrominated isomers. Yield: 3,40 g (66% of theory); LC (method 1): tR = 4.70 min; Mass spectrum (Ε5Γ): m/z = 348/350 (Br) [M+Hf.
Step 3: c/s-6-bromo-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine and c/s-7-bromo2,3,4,4a,9,9a-hexahydro-1H-indeno[2r1-b]pyridine
The title compounds are prepared from the compound mixture in Step 2 above following a procedure analogous to that described in Step 4 of Intermediate 27 and submitted as an isomeric mixture to the next step. Yield: 69% of theory.
Step 4: c/s-(1H-benzoimidazol-5-yl)-(6-bromo-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1ylfmethanone and cZs-( 1 H'benzoimidazol-5-yl)-(7-bromo-2,3,4,4a,9,9a-hexahydro-indeno[2,1b]py ridin-1 -ylfmethanone
The title compounds are prepared from the isomeric mixture in Step 3 above following a procedure analogous to that described for Example 1 and submitted as an isomeric mixture to the next step. Yield: 85% of theory (ca. 85% pure); Mass spectrum (ESI+): m/z = 396/398 (Br) [M+Hf.
Step 5: c/s-1 -( 1 H-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1 b]pyridine-6-carboxylic acid methyl ester and c/s-1-(1H-benzoimidazole-5-carbonyl)2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine-7-carboxylic acid methyl ester
The title compounds are prepared from the isomeric mixture obtaîned in Step 4 above following a procedure analogous to that described in Step 1 of Intermediates 19 and 20 and submitted as an isomeric mixture to the next step. Yield: 80% of theory (ca. 90% pure); Mass spectrum (EST): m/z = 376 [M+Hf.
Intermediates 36 and 37 (4a-R.9a-S)-6-Bromo-2.3.4,4a.9,9a-hexahydro-1H-indeno[2,1-blpyridine and (4a-ff,9a-S)-7Bromo-2.3,4,4a,9,9a-hexahvdro-lH-indeno[2.1-b1pyridine
The title compounds are prepared as described in Step 3 of Intermediates 34 and 35 and the obtained isomeric mixture (2.2 g) is submitted to SFC on chiral phase (column: DAICEL IC 250x20 mm, 5 pm; mobile phase: methanol containing 0.2% diethylamine/sc carbon dioxide 20:80; flow rate: 70 mL/min) to give pure (4a-R,9a-S)-7-bromo-2,3,4,4a,9,9a-hexahydro-1Hindeno[2,1-b]pyridine [0.23 g; LC (chiral SFC as described): tR = 16.27 min] and a mixture of (4a-R,9a-S)-6-bromo-2,3l4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine with its enantiomer and another isomer which is submitted to a second SFC on chiral phase (column: DAICEL ADH 250x20 mm, 5 pm; mobile phase: isopropanol containing 0.2% diethylamine/sc carbon dioxide 15:85; flow rate: 70 mL/min) to afford pure (4a-/?,9a-S)-6-bromo-2l3,4,4a,9l9a-hexahydro-1Hindeno[2,1-b]pyridine [0.21 g; LC (second chiral SFC as described): tR = 20.30 min].
Intermediate 38 (1H-Benzoimidazol-5-vlHf4a-/?,9a-S)-6-bromo-2,3,4.4a,9,9a-hexahvdro-indenof2.1-b1pyridin-1yll-methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and (4a-R,9a-S)-6bromo-2,3,4,4a,9,9a-hexahydro-lH-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1. Yield: 95% of theory; LC (method 1): tR = 2.83 min; Mass spectrum (ESI*): m/z = 396/398 (Br) [M+H]+.
Intermediate 39 (1H-Benzoimidazol-5-vlH(4a-R9a-S)-7-bromo-2.3.4,4a,9.9a-hexahydro-indeno[2,1-blpyridin-1yll-methanone
The tille compound is prepared from 1H-benzoimidazole-5-carboxylic acid and (4a-R,9a-S)-7bromo^.S^^a.g^a-hexahydro-lH-indeno^.l-bjpyridine following a procedure analogous to
that described in Example 1. Yield: 94% of theory; LC (method 1): tR = 2.88 min; Mass spectrum (EST): m/z = 396/398 (Br) [M+Hf.
Intermediate 40 trans-1 Ob-Ethyl-1,2,3,4.4a.5,6.10b-octahydro-benzoffîquinoline
NH
Step 1: 1-ethyl'2-tetralone
Ethyl iodide (0.81 mL) is added to a solution of 1-(3,4-dihydro-naphthalen-2-yl)-pyrrolidine (2.05 g) in acetonitrile (20 mL). The solution is heated to reflux température and stirred at this température for 4 h. Another portion of ethyl iodide (0.3 mL) is then added and stirring continued overnight. After cooling to room température, the solution is concentrated and treated with water and 2 M aqueous citric acid. The resulting mixture is heated to 50 °C and stirred at this température for 15 min. After cooling to room température, the mixture is extracted with ethyl acetate and the combined extracts are washed with aqueous NaHCOg solution and brine and dried (Na2SO4). The solvent is evaporated and the residue is chromatographed on silica gel (cyclohexane/ethyl acetate 98:2—*80:20) to afford the title compound as an oil. Yield: 0.20 g (11% of theory); Mass spectrum (ESl·): m/z = 175 [M+H]+.
Step 2:10b“ethyl-3,5,6,10b-tetrahydro-benzo[f]quinoline
The title compound is obtained from propargylamine and 1-ethyl-2-tetralone following a procedure analogous to that described in Step 1 for Intermediates 7 and 8. Yield: 19% of theory; LC (method 1): tR = 2.06 min; Mass spectrum (ESI+): m/z = 212 [M+H]+.
Step 3: trans-10b-ethyl-1,2,3,4,4a,5,6,10b-octahydro-benzo[f|quinoline
The title compound is obtained from 10b“ethyl-3,5,6,10b-tetrahydro-benzo[f]quinoline following a procedure analogous to that described in Step 2 for Intermediates 7 and 8. Yield: 67% of theory; TLC: rf = 0.45 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (EST): m/z = 216 [M+Hf.
Intermediate 41 c/s-6-Methoxv-2,3,4,4a,9,9a-hexahvdro-1H-indeno{2,1-b1pyridine
ο
Step 1: 3-(3-methoxy-phenyl)-pyridine-2-carbonitrile
A flask charged with a stir bar, 3-chloro-2-cyanopyridine (8.16 g), 3-methoxyphenylboronic acid (13.42 g), K3PO4 (25.00 g), and toluene (100 mL) is sparged with argon for 10 min. Palladium(ll) acetate (0.13 g) and n-butyl-di-(1-adamantyl)-phosphine (0.42 g) are added and the resulting mixture is put in a 100 °C hot oil bath and stirred in there for 3.5 h. After cooling to room température, ethyl acetate (250 mL) is added and the mixture is washed with 2 M aqueous
NaOH solution and brine. The organic phase is dried (Na2SO4) and the solvent is evaporated. The residue is triturated with methanol and dried to give the title compound as a colorless solid. Yield: 12.05 g (97% of theory); LC (method 1 ): tR = 3.32 min; Mass spectrum (ESl·): m/z = 211 [M+H]+.
Step 2: 3-(3-methoxy-phenyl)-pyridine-2-carboxylic acid
A mixture of 3-(3-methoxyphenyl)-pyridine-2-carbonitrile (12.00 g), 15 M aqueous NaOH solution (40 mL), and methanol (60 mL) is stirred at reflux température for 7 h. After cooling to room température, most of the methanol is evaporated and the residue is cooled in an ice bath and adjusted to pH value ca. 4-5 by the careful addition of concentrated hydrochloric acid. The resulting mixture is concentrated to ca. 50 ml by évaporation and extracted with dichloromethane/methanol (9:1) several times. The aqueous phase is then adjusted to pH value 2-3 using concentrated hydrochloric acid and extracted again with dichloromethane/methanol (9:1). The combined extracts are dried (Na2SO4) and the solvent is evaporated to give the title compound as a foam-like solid. Yield: 11.88 g (91 % of theory); LC (method 1 ): tR = 1.70 min; Mass spectrum (EST): m/z = 230 [M+H]+.
Step 3: 3-(3-methoxy-phenyl)-pyridine-2-carbonyl chloride
Thionyl chloride (8 mL) and Ν,Ν-dimethylformamide (few drops) are added to a solution of 3-(3methoxy-phenyl)-pyridine-2-carboxylic acid (11.86 g) in dichloromethane (80 mL). The mixture is heated to 40 °C and stirred at this température overnight. The solution is then concentrated
and the residue is taken up in toluene and concentrated again to give the crude title compound that is used without further purification in the next step. Yield: 12.80 g (crude).
Step 4: 6-methoxy-indeno[2,1 -b]pyridin-9-one
Aluminum chloride (7.33 g) is added to a solution of 3-(3-methoxy-phenyl)-pyridine-2-carbonyl chloride (crude, 5.40 g) in dichloromethane (100 mL) chilled in an ice bath. The cooling bath is removed and the mixture is stirred at room température overnight. The mixture is then poured on crushed ice and the resulting mixture is extracted with dichloromethane. The combined extracts are washed with aqueous NaHCO3 solution and dried (Na2SO4). The solvent is evaporated and the residue is triturated with a mixture of cyclohexane and ethyl acetate (1:1 ) and dried to give the title compound as a yellowish solid. Yield: 3.00 g (65% of theory); LC (method 1): tR = 2.84 min; Mass spectrum (ESl·): m/z = 212 [M+H]*.
Step 5: c/s-6-methoxy-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine
A mixture of 6-methoxy-indeno[2,1-b]pyridin-9-one (2.00 g), 10% palladium on carbon (0.30 g), 4 M aqueous hydrochloric acid (6 mL), and methanol (100 mL) is shaken under hydrogen atmosphère (3 bar) at room température for 4 h. PtO2 (0,20 g) is then added and shaking is continued under hydrogen atmosphère (1 bar) at room température for another 36 h. The catalysts are separated by filtration and the filtrate is concentrated. The residue is basified by the addition of 2 M aqueous NaOH solution and the resulting mixture is extracted with ethyl acetate. The combined extracts are washed with brine, dried (Na2SO4), and the solvent is evaporated. The residue is chromatographed on silica gel (dichloromethane/methanol containing 1% NH3 90:10—>75:25) to give the title compound as a colorless oil. Yield: 1.00 g (52% of theory); LC (method 1 ): tR = 1.50 min; Mass spectrum (ESf): m/z = 204 [M+H]+.
Intermediate 42
Trifluoromethanesulfonic acid c/s-1-(1-trifluoromethanesulfonyl-1H-benzoimidazole-5-carbonvl)2.3,4,4a,9.9a-hexahydro-1H-indenof2.1-b1pyridin-6-yl ester and Trifluoro-methanesulfonic acid c/s-1-(3-trifluoromethanesulfonvl-3H-benzoimidazole-5-carbonvl)-2.3.4,4a,9,9a-hexahydro-1Hindeno[2.1-blpyridin-6-yl ester
Trifluoromethanesulfonic anhydride (0.60 mL) dissolved in dichloromethane (3 mL) is added dropwise to a solution of (1H-benzoimÎdazol-5-yl)-(c/s-6-hydroxy-2,3,4,4a,9,9a-hexahydroindeno[2,1-b]pyridin-1-yl)-methanone (0.45 g) and pyridine (0.40 mL) in dichloromethane (10 mL) cooled to -10 °C. The solution is stirred in the cooling bath for 1 h and then diluted with
dichloromethane. The solution is washed with aqueous citric acid and aqueous NaHCO3 solution and dried (Na2SO4). The solvent is evaporated to give the two title compounds as a mixture that is used as such in the next step. Yield: 0.72 g (89% of theory); LC (method 1 ): tR = 4.75 min; Mass spectrum (EST): m/z = 598 [M+Hf.
Intermediate 43 c/s-2.3,4,4a.9.9a-Hexahydro-1H-indeno[2,1-bÎPvridin-7-vlamine
Step 1: 7-nitro-9H-indeno[2,1-b]pyridine
A ca. 10 ’C-cold mixture of nitric acid (65%, 1.1 mL) and sulfuric acid (96%, 1.6 mL) is added dropwise to a solution of 9H-indeno[2,1-b]pyndine (2.44 g) in sulfuric acid (96%, 3 mL) chilled in an ice bath. The solution is stirred in the cooling bath for 1 h and poured then onto crushed ice. The precipitate formed is separated by filtration and the filtrate is neutralized using 4 M aqueous NaOH solution. The precipitate formed is separated by filtration and combined with the precipitate separated before. The precipitate is triturated with acetone and dried to give the title compound as a solid. Yield: 2.64 g (85% of theory); LC (method 1): tR = 2.93 min; Mass spectrum (ESI+): m/z = 213 [M+Hf.
Step 2: c/s-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-7-ylamine
A mixture of 7-nitro-9H-indeno[2,1-b]pyridine (3.25 g), 10% palladium on carbon (0.35 g), and methanol (50 mL) is shaken under hydrogen atmosphère (3 bar) at room température for 22 h. PtO2 (0.50 g) and 4 M aqueous hydrochloric acid (3.2 mL) are then added and shaking is continued under hydrogen atmosphère (1 bar) at room température for another 22 h. The catalysts are separated by filtration and the filtrate is concentrated to give the crude title compound as its hydrochloric acid sait that is used without further purification or transformed to the free base by treatment with aqueous NaOH solution and extraction into ethyl acetate. Yield: 4.20 g (ca. 80% pure); LC (method 1): tR =0.52 min; Mass spectrum (ESI+): m/z = 189 [M+Hf.
Intermediate 44 c/s-2,3,4,4a,9,9a-Hexahvdro-1H-indeno[2,1-blpvridin-7-ol
Sodium nitrite (92 mg) dissolved in water (0.5 mL) is added dropwise to a solution of cis2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-7-ylamine dihydrochloride (0.30 g) in halfconcentrated sulfuric acid (0.6 ml) chilled in an ice bath. The solution is stirred for 15 min in the cooling bath prior to the addition of half-concentrated sulfuric acid (5 ml). The resulting solution
is heated to 120 6C and stirred at this température for 3 h. The mixture is cooled to room température, diluted with water, and basified with 4 M NaOH, The resulting mixture is extracted with ethyl acetate and the combined extracts are dried (Na2SO4). The solvent is evaporated and the residue is chromatographed on silica gel [dichloromethane/ (dichloromethane/methanol/NH4OH 50:48:2) 80:20-+40:60] to give the title compound. Yield:
0.07 g (32% of theory); LC (method 1 ): tR =0.83 min; Mass spectrum (ESf): m/z = 190 [M+H]+.
Intermediate 45 c/s-4-Methvl-2,3,4,4a,9,9a-hexahvdro-1 H-indenoi2,1-blpyridine
Step 1: 4-methyl-9H-indeno[2,1-b]pyridine
The title compound is prepared from indan-2-one and but-2-ynylamine following a procedure analogous to that described in Step 1 of Intermediates 1 and 2; the reaction is carried out in a microwave oven at 100 °C for 12 min. Yield: 22% of theory; LC (method 1 ): tR = 1.98 min; Mass spectrum (ESI+): m/z =182 [M+Hf.
Step 2: 1-benzyl-4-methyl-9H-indeno[2,1-b]pyridinium bromide
A mixture of 4-methyl-9H-indeno[2,1-b]pyridine (0.64 g) and benzyl bromide (0.42 mL) in acetone (5 mL) is stirred at reflux température for 4 h. After cooling to room température, the precipitate is separated by filtration, washed with little diethyl ether, and dried to give the title compound as a beige solid. Yield: 0.93 g (75% of theory); LC (method 1 ): tR = 2.49 min; Mass spectrum (ESI+): m/z = 272 [M-Br]\
Step 3: 1 -benzyl-4-methyl-2,3,9,9a-tetrahydro-1 H-indeno[2,1 -b]pyridine
Sodium borohydride (0.15 g) is added to a suspension of 1-benzyl-4-methyl-9H-indeno[2,1bjpyridinium bromide (0.92 g) in éthanol (10 mL) chilled in an ice bath. The cooling bath is removed and the mixture is stirred at room température for 1 h and at 60 °C for 2 h. More sodium borohydride (0.18 g) is added and stirring is continued at reflux température for 4 h. After the addition of another portion of sodium borohydride (0.10 g), the mixture is stirred at reflux température overnight. After cooling to room température, ice-cold water is added and the precipitate is separated by filtration. The precipitate is dissolved in ether, the resulting solution is dried (Na2SO4), and the solvent is evaporated to afford the crude product that is used without further purification. Yield: 0.66 g (crude); Mass spectrum (ESI+): m/z = 276 [M+H]‘.
Step 4: c/s-4-methyl-2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1 -b]pyridine
A mixture of 1-benzyl-4-methyl-2,3,9,9a-tetrahydro-1 H-indeno[2,1-b]pyridine (0.65 g), Pd(OH)2 (200 mg), and éthanol (10 mL) is shaken under hydrogen atmosphère (5 bar) at room température for 16 h. Another portion of Pd(OH)2 (100 mg) is then added and shaking under hydrogen atmosphère (5 bar) is continued overnight. The catalyst is separated by filtration and the solvent is evaporated to give the crude title compound that is used without further purification. Yield: 0.43 g (crude).
Intermediate 46 cÂs-2,3,4,4a,9,9a-Hexahvdro-1H-indeno[2,1-b1pyridine-6-carbonitrile
Step 1: 2,2,2-trifluoro-1-(c/s-6-methoxy-2,3,414a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl)ethanone
Trifluoroacetîc anhydride (4.5 mL) is added dropwise to a solution of c/s-6-methoxy2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine (5.0 g), triethylamine (5.6 mL), and 4dimethylaminopyridine (ca. 5 mol%) in dichloromethane (60 mL) maintained below 10 °C. The solution is stirred with cooling for 1 h and at room température for 2 h. The solution is diluted with dichloromethane (100 mL) and aqueous NaHCO3 solution and then stirred vigorously for 15 min. The organîc phase is separated, washed with 1 M hydrochloric acid (25 mL) and water (50 mL), and dried (MgSO4). The solvent is evaporated to afford the title compound as an oil. Yield: 8.1 g (quantitative); LC (method 1): tR = 4.24 min; Mass spectrum (ESl+): m/z = 300 [M+H]+. Step 2: 2,2,2-trifluoro-1-(c/s-6-hydroxy-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl)ethanone
Boron tribromide (1 mol/L in heptane, 27 mL) is added to a solution of 2,2,2-trifluoro-1-(c/s-6methoxy-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl)-ethanone (8.1 g) in dichloromethane (120 mL) chilled in an ice bath. The resulting mixture is warmed in the cooling bath to room température overnight. The solution is cooled again in an ice bath, diluted with dichloromethane (50 mL), and then 25% aqueous K2CO3 (20 mL) is carefully added. The mixture is stirred for 30 min and then acidified by the addition of 4 M aqueous hydrochloric acid (60 mL). The organic phase is separated, washed with 1 M aqueous hydrochloric acid (40 mL),
and dried (MgSO4). The solvent is evaporated to give the title compound as a solid. Yield: 7.3 g (95% of theory); LC (method 1): tR = 3.43 min; Mass spectrum (ESl*): m/z = 286 [M+H]*.
Step 3: trifluoro-methanesulfonic acid c/s-1-(2,2,2-trifluoro-acetyl)-2,3,4,4a.9,9a-hexahydro-1Hindeno[2,1-b]pyridin-6-yl ester
Trifluoromethanesulfonic anhydride (5.6 mL) is added dropwise to a solution of 2,2,2-trifluoro-1(c/s-6-hydroxy-213,4,4a,9,9a-hexahydro-indeno[2,1 -bjpyridin-1 -yl)-ethanone (7.3 g), triethylamine (7.2 mL), and 4-dimethylaminopyridine (50 mg) in dichloromethane (60 mL) chilled in an ice bath. The solution is stirred with cooling for 1 h and at room température for 2 h. Water (100 mL) and dichloromethane (100 mL) are then added and the organic phase is separated. The organic phase is washed with water (50 mL), dried (MgSO4), and concentrated to give the title compound as a dark oil. Yield: 10.7 g (quantitative); TLC: rf = 0.50 (silica gel, cyclohexane/ethyl acetate 3:1); Mass spectrum (ESl*): m/z = 418 [M+H]*.
Step 4: c/s-1-(2,2,2-trifluoroacetyl)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine-6carbonitrile
A flask charged with a stir bar, zinc cyanide (5.0 g), trifluoro-methanesulfonic acid c/s-1-(2,2,2trifluoro-acetyl^.S^^a.g^a-hexahydro-IH-indenop.l-bJpyridin-e-yl ester (10.7 g), and N,Ndimethylformamide (60 mL) is sparged with argon for 5 min. Tetrakis(triphenylphosphine)palladium(O) (4.0 g) is then added and the resulting mixture is stirred at 100 °C for 2 h. After cooling to room température, water is added and the resulting mixture is extracted with ethyl acetate. The combined extract is washed with brine, dried (MgSO4), and concentrated. The residue is chromatographed on silica gel (ethyl acetate/cyclohexane 1:9—>4:1) to give the title compound as a solid. Yield: 5.5 g (73% of theory); TLC: r, - 0.25 (silica gel, cyclohexane/ethyl acetate 3:1); Mass spectrum (ESC): m/z = 295 [M+H]*.
Step 5: c/s-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine-6-carbonitrile
A solution of c/s-1-(2,2,2-trifluoroacetyl)-2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1-b]pyridine-6carbonitrile (5.50 g) and 4 M NaOH solution (5.6 mL) in methanol (30 mL) is stirred at room température for 2 h. Brine (150 mL) is then added and the resulting mixture is extracted with ethyl acetate (3x75 mL). The combined extract is dried (MgSO4) and concentrated to give the title compound as an oil that solidified upon standing. Yield: 3.70 g (quantitative); Mass spectrum (ESl*): m/z = 295 [M+H]*.
The racemîc mixture may be separated by SFC on chiral phase (column: Daicel ADH 250 x 20 mm, 5 pm; mobile phase: isopropanol containing 0.2% diethylamine/sc carbon dioxide 20:80; flow rate: 70 mL/min) to give
1. (4a-/?>9a-S)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine-6-carbonitrile, yield: 1.60 g (43% of theory), LC (analytical SFC on chiral phase: column: Daicel ADH 250 x 4.6 mm; mobile phase: isopropanol containing 0.2% diethylamine/sc carbon dioxide 20:80; flow rate: 4 mL/min): tR = 4.05 min.
2. (4a-S,9a-R)-2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1 -bJpyridine-6-carbonitrile, yield: 1.70 g (46% of theory), LC (analytical SFC on chiral phase: column: Daicel ADH 250 x 4.6 mm; mobile phase: isopropanol containing 0.2% diethylamine/sc carbon dioxide 20:80; flow rate: 4 mL/min): tR = 2.81 min.
The enantiomerically pure (ee >99%) Intermediate 46 is also obtained employing the foilowing protocols:
O O
O O
tep 1: 3-chloro-pyridine-2-carboxylic acid methyl ester
An autoclave is charged with 2,3-dichloropyridine (2.5 kg), degassed methanoi (12.5 L), and triethylamine (3.42 kg). A catalyst solution [prepared as follows: a flask is charged with palladium acetate (19 g), 1,3-bis(diphenylphosphino)propane (38.5 g), and methanoi (1 L). The mixture is stirred at 20-25 °C until palladium acetate is completely dissolved (ca. 30 min)] is added. After purging the apparatus with nitrogen twice and carbon monoxide twice, the mixture is stirred under carbon monoxide atmosphère (100 psi) at 60-65 °C for 20 h. After cooling to room température, the mixture is filtered over Celite and the filtrate is concentrated.
Steps 2/3: 3-(3-methoxy-phenyl)-pyridine-2-carboxylic acid
100
2-Methyl-tetrahydrofuran (500 mL) is added to crude 3-chloro-pyridine-2-carboxylic acid methyl ester (58.0 g) and the resulting solution is washed with water (200 mL) and 5% aqueous sodium chloride solution (200 mL) and concentrated (to ca, 450 mL total volume). 3Methoxybenzeneboronic acid (61.6 g) and potassium phosphate (143.3 g) are added and the resulting mixture is sparged with nitrogen for 20 min. Palladium acetate (0.76 g) and diadamantyl-n-butyl-phosphine (2.42 g) are added and the resulting mixture is heated to 80 °C and stirred at this température for 12 h. After cooling to room température, the mixture is washed with water (300 mL) and 1 mol/L aqueous NaOH solution (200 mL). The organic phase is diluted with methanol (100 mL) and 30% aqueous NaOH solution (27.04 g) is added at such a rate that the solution température maintained below 40 °C. The resulting mixture is stirred at room température for 2 h and then diluted with water (100 mL) and methyl tert-butyl ether (100 mL). The etheral layer is separated and concentrated hydrochloric acid (60 mL) is added to the aqueous phase (pH value ca. 2-3). The aqueous phase is extracted with dichloromethane (2x 250 mL) and the combined extract is diluted with toluene (6 L). The organic solution is concentrated at below 40 °C and the crude title compound is used as is for the next step. Steps 4/5:6-methoxy-indeno[2,1-b]pyridin-9-one
Thionyl chloride (0.95 L) is added over 30 min to a solution of 3-(3-methoxy-phenyl)-pyridine-2carboxylic acid (crude product; 2.0 kg) and N,N-dimethylformamide (34 mL) in dichloromethane (9 L) at 40 °C. The addition vessel is rinsed with dichloromethane (1 L) and the solution is stirred at 40 °C for 2 h. The solution is diluted with toluene (10 L) and most of the solvent is evaporated (residual toluene ca. 2 L). Dichloromethane (10 L) is added to obtain a homogeneous solution. The solution is heated to 35 °C and added over 30 min to a vessel charged with aluminum chloride (1.75 kg) and dichloromethane (10 L) while keeping mild reflux. The mixture is stirred at 40 °C for 30 min and then cooled to 0 °C. Water (4 L) is added at such a rate that the solution température maintained below 40 °C. The aqueous layer is adjusted to pH value 2.5-3.5 using 2 M aqueous NaOH solution and the resulting mixture is stirred for 15 min. The organic layer is separated and the aqueous layer is extracted with dichloromethane (2x). The combined organic phase is concentrated (to ca. 10 L) and toluene (10 L) is added to the residue. The residual amount of dichloromethane is evaporated and the precipitate is separated and washed with toluene (2 L) and heptane (4 L) and dried under vacuum to give the title compound.
Step 6: c/s-6-methoxy-2,3,4.4a,9,9a-hexahydro-1 H-indeno[2,1 -b]pyridine
A mixture of sulfuric acid (98%, 6 kg), water (6 L), and methanol (6 L) is added to an autoclave charged with 6-methoxy-indeno[2,1-b]pyridin-9-one (1.2 kg) and wet 10% palladium on carbon (50%, 0.48 kg). The autoclave is purged with nitrogen and filled then with hydrogen (100 psi). The mixture is heated to 60 °C and maintained at this température and hydrogen pressure until the starting material is completeiy consumed (2-12 h). The mixture is cooled to 50-55 °C and
101 filtered over Celite. TheCelite is washed with a warm 1:1 mixture of water and methanol sevaral times (total 20 L). The combined filtrate is added to an autoclave charged with wet 10% palladium on carbon (50%, 0.96 kg). The autoclave is purged with nitrogen and filled then with hydrogen (100 psi). The mixture is heated to 60 °C and maintained at this température and hydrogen pressure until the intermediate is completely consumed (12-24 h). The mixture is cooled to ambient température and filtered over Celite. The Celite is washed with a mixture of methanol and water (5 L/5 L). The combined filtrate is cooled to 0-10 °C and the pH value is adjusted to 10-11 using 30% aqueous NaOH solution while maintaîning the solution température below 40 °C. Water (10 L) is added and the resulting mixture is extracted with dichloromethane (2x 5 L). The combined extract is washed with 10% aqueous NaCI solution and concentrated. The residue is taken up twice in methyl ethyl ketone and concentrated again to give the crude title compound.
Step 7: (4a-R,9a-S)-6-methoxy-2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1 -bjpyridine Di-p-toluoyl-D-tartaric acid (403 g) is added to crude CiS-6-methoxy-2,3,4,4a,9,9a-hexahydro1H-indeno[2,1-bjpyridine (ca. 0.53 kg of pure compound) dissolved in methyl ethyl ketone (5.3 L). The solution is heated to 50 °C and some seeds are added. The mixture is stirred at 50 °C for 1 h and at 15 °C overnight. The resulting slurry is filtered to give a white solid (386 g, 95% de). The solid is taken up in dichloromethane (6 L) and 10% aqueous NaOH solution is added. The resulting mixture is stirred at room température for 1 h. The organic phase is separated and concentrated to give the title compound. Yield: 170 g (95% ee).
Step 8: (4a-R,9a-S)-2,2,2-trifluoro-1 -(6-methoxy-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin1-yl)-ethanone
A vessel charged with 4-dimethylaminopyridine (6.9 g), triethylamine (0.24 L), (4a-/?,9a-S)-6methoxy-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1 -bjpyridine (231 g), and dichloromethane (2.3 L) is cooled to 10-15 °C. Trifluoroacetic anhydride (0.21 L) is added at such a rate that the solution température maintained below 25 °C. The mixture is heated to 20-25 °C and stirred at this température for 1 h. Salurated aqueous NaHCO3 solution (1.5 L) is added and the resulting mixture is stirred for 15 min. The organic layer is separated, washed with 1 M aqueous HCl solution (1.2 L) and water (0.9 L), concentrated, and azeotropically dried using dichloromethane to give the title compound.
Step 9: (4a-R,9a-S)-2,2,2-trifluoro-1 -(6-hydroxy-2,3,4,4a,9,9a-hexahydro-indeno[2,1 -b]pyridin-1 yl)-ethanone
Boron tribromrde (0.14 kg) is added to a solution of (4a-R,9a-S)-2,2,2-trifluoro-1-(6-methoxy2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl)-ethanone (0.34 kg) in dichloromethane (5.7 L) cooled to 10-15 °C at such a rate that the solution tempeerature maintained below 25 °C. The solution is stirred at 20-25 °C for 5 h. The solution is poured into water (1.7 L) at such a rate that the solution température maintained below 35 °C and the resulting mixture is stirred for 30 min.
102
The organic phase is separated, washed with water (1,3 L), and concentrated. The residue is azetropically dried with dichloromethane to give the title compound.
Step 10: (4a-R,9a-S)-trifluoro-methanesulfonic acid 1-(2,2,2-trifluoro-acetyl)-2,3,4,4a,9,9ahexahydro-1 H-indeno[2,1 -b]pyridin-6-yl ester
Trifluoromethanesulfonic anhydride (0.23 L) is added to a solution of 4-dimethylamino-pyridine (6.9 g), triethylamine (0.24 L), and (4a-/?,9a-S)-2,2,2-trifluoro-1-(6-hydroxy-2,3,4,4a,9.9ahexahydro-indeno[2,1-b]pyridin-1-yl)-ethanone (0.32 kg) in dichloromethane (3.4 L) cooled to 05 °C at such a rate that the solution température maintained between 0 and 5 °C. After stirring the solution for 30 min at 0-5 ’C, water (1.2 L) is added at such a rate that the solution température maintained 0-5 ’C. After stirring for 15 min, the organic phase is separated, washed with water (1.2 L), and concentrated. The residue is passed through a plug of silica gel (ethyl acetate/hexane 1:2) to give the title compound as an oil. Yield: 0.42 kg (98% of theory). Step 11 : (4a-f?,9a-S)-1-(2,2,2-trifluoro-acetyl)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1b]pyridine-6-carbonitrile
A mixture of (4a-/?,9a-S)-trifluoro-methanesulfonic acid 1-(2,2,2-trifluoro-acetyl)-2,3,4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridin-6-yl ester (189 g), zinc cyanide (79.8 g), and N,Ndïmethylformamide (1.9 L) is purged with nitrogen for 15 min. Tris(dibenzylideneacetone)dipalladium(0)(16.6 g) and 1,T-bis(diphenylphosphino)ferrocene (25.1 g) are added and the resulting mixture is purged with nitrogen at room température. The mixture is heated to 80 ’C and stirred at this température for 12 h. After cooling to room température, water (2 L) and ethyl acetate (2 L) are added and the resulting mixture is stirred for 10 min. The organic phase is separated and the aqueous phase is extracted with ethyl acetate. The combined organic phase is washed with water (4x 1 L) and concentrated. The residue is passed through a plug of silica gel (hexane/ethyl acetate 2:1.5) to give the title compound as a solid. Yield: 133 g (quantitative).
Steps 12/13: (4a-R,9a-S)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine-6-carbonitrile 2 M aqueous NaOH solution (300 mL) is added to a slurry of (4a-/?,9a-S)-1-(2,2,2-trifluoroacetyl)-2,3,4,4a,9,9a-hexahydro-lH-indeno[2,1-b]pyridine-6-carbonitrile (135 g) in methanol (600 mL) at such a rate that the slurry température maintained below 40 ’C. The mixture is stirred at room température for 2 h and diluted then with water (300 mL) and dichloromethane (600 mL). The organic phase is separated and the aqueous phase is extracted with dichloromethane (2x 500 mL). The combined organic phase is washed with 10% aqueous NaCI solution and concentrated to give the crude title compound as an oil (90 g, 93-95% ee). The crude title compound (90 g) in isopropanol (540 mL) is heated to 50 ’C and di-benzoyi-D-tartaric acid (109 g) is added. The resulting mixture is stirred at 90 ’C for 1 h and at room température for 2 h. The precipitate is separated and washed with isopropanol (3x 50 mL). The precipitate is taken up in dichloromethane (1 L)and the resulting mixture is treated with 2 M aqueous NaOH
103 solution (500 mL). The mixture is stirred at room température for 1 h. The organic phase is separated, washed with 10% aqueous NaCI solution (500 mL), and concentrated to give the title compound as an oil. Yield: 80 g (>99% ee).
Intermediate 47 c/s-6-Phenyl-2,3,4,4a,9.9a-hexahydro-1 H-indeno[2,1 -blpyridine
Step 1: c/s-2,2,2-trifiuoro-1-(6-phenyl-2l3,4,4al9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl)ethanone
The title compound is prepared from trifluoro-methanesulfonic acid c/s-1 -(2,2,2-trifluoro-acetyl)2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-6-yl ester and phenylboronic acid following a procedure analogous to that described in Step 2 of Intermediates 17 and 18. Yield: 70% of theory; LC (method 1): tR =5.02 min; Mass spectrum (EST): m/z = 346 [M+Hf.
Step 2: c/s-6-phenyl-2,3,4,4al9l9a-hexahydro-1H-indeno[2,1-b]pyridine
The title compound is prepared from c/s-2,2,2-trifluoro-1-(6-phenyl-2,3,4,4a,9,9a-hexahydroindeno^J-bjpyridin-l-ylJ-ethanone following a procedure analogous to that described in Step 5 of Intermediate 46. Yield: 60% of theory; LC (method 1 ): tR = 2.70 min; Mass spectrum (EST): m/z = 250 [M+Hf.
Intermediate 48 cis-6-Furan-3-vl-2,3,4,4a,9.9a-hexahvdro-1 H-indeno[2,1 -blpyridine
Step 1: c/s-2,2,2-lrifluoro-1-(6-furan-3-yl-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl)ethanone
The title compound is prepared from trifluoro-methanesulfonic acid c/s-1-(2,2,2-trifluoro-acetyl)2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-6-yl ester and furan-3-yl-boronic acid following a procedure analogous to that described in Step 2 of Intermediates 17 and 18. Yield: 61% of theory; LC (method 1): lR =4.60 min; Mass spectrum (ESl*): m/z = 336 [M+H]*.
Step 2: c/s-6-furan-3-yl-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine
104
The title compound is prepared from c/s^^^-trifluoro-l-ÎS-furan-S-yl^^.A^a^.Oa-hexahydroindeno[2,1-b]pyridin-1-yl)-ethanone following a procedure analogous to that described in Step 5 of Intermediate 46. Yield: 93% of theory; LC (method 1): tR = 2.27 min; Mass spectrum (ESI+): m/z = 240 [M+H]+.
Intermediate 49 c/s-6-(1-Methvl-1H-pvrazol-4-vl)-2,3,4,4a.9.9a-hexahvdro-1H-indeno[2,1-b]pyridine
Step 1: c/s^^^-trifluoro-l-te-fl-methyl-IH-pyrazol^-yO^^^^a^.ga-hexahydro-indeno^.lb]py rid i n-1 -yl]-ethanone
The title compound is prepared from trifluoro-methanesulfonic acid c/s-1-(2,2,2-trifluoro-acetyl)2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-6-yl ester and l-methyl-pyrazol-4-yl-boronic acid following a procedure analogous to that described in Step 2 of Intermediates 17 and 18. Yield: 32% of theory; LC (method 1 ): tR = 3.88 min; Mass spectrum (EST): m/z = 350 [M+H]+. Step 2: c/'s-6-(1-methyl-1H-pyrazol-4-yl)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine The title compound is prepared from c/s-2,2,2-triiluoro-1-[6-(1-methyl-1H-pyrazol-4-yl)2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl]-ethanone following a procedure analogous to that described in Step 5 of Intermediate 46. Yield: quantitative; LC (method 1 ): tR = 1.70 min; Mass spectrum (ESI+): m/z= 254 [M+H]*.
Intermediate 50 c/s-6-Methvl-2.3,4,4a,9<9a-hexahydro-1H-indenoÎ2.1-blpyridine
Step 1: c/s-2,2,2-trifluoro-1-(6-methyl-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl)ethanone
Tetrakis(triphenylphosphine)pal!adium(0) (17 mg) is added to a flask charged with a stir bar, trifluoromethanesulfonic acid c/s-1-(2,2.2-trifluoro-acetyl)-2l3,4,4a19.9a-hexahydro-1 Hindeno[2,1-b]pyridin-6-yl ester (200 mg), trimethylboroxine (81 pL), K3PO4 (0.15 g), and 1,4dioxane (4 mL) under argon atmosphère at room température. The reaction mixture is heated to 100 °C and stirred at this température overnight. Another portion of trimethylboroxine (40 pL)
and tetrakis(triphenylphosphine)palladium(0) (17 mg) is then added and stirring is continued at 100 “C. The addition of further amounts of trimethylboroxine and tetrakis(triphenylphosphine)palladium(O) is repeated after each 6 h of stirring until the starting material is completely consumed. After cooling to room température, water is added and the resulting mixture is extracted with ethyl acetate. The combined extract is dried (Na2SO4) and concentrated and the residue is chromatographed on silica gel (dichloromethane/methanol 1:0—>9:1 ) to give the title compound. Yield: 50 mg (37% of theory); LC (method 1 ): tR — 4.62 min; Mass spectrum (ESP): m/z = 284 [M+Hf.
Step 2: c/s-6-methyl-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine
The title compound is prepared from c/s-2,2,2'trifluoro-1-(6-methyl-2,3,4,4a,9,9a-hexahydroindeno[2,1-b]pyridin-1-yl)-ethanone following a procedure analogous to that described in Step 5 of Intermediate 46. Yield: 94% of theory; LC (method 1): tR = 1.91 min; Mass spectrum (ESP): m/z = 188 [M+Hf.
Intermediate 51 c/s-(3H-Benzoimidazol-5-vl)-r6-(3,6-dihvdro-2H-pvran-4-vl)-2.3,4.4a.9.9a-hexahvdro-indeno[2,1blpyridin-1-vH-methanone
Step 1: 1-[c/s-6-(3,6-dihydro-2H-pyran-4-yl)-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl]2,2,2-trifluoro-ethanone
A flask charged with a stir bar, trifluoromethanesulfonic acid 1-(2,2,2-trifluoro-acetyl)2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-6-yl ester (0.20 g), 3,6-dihydro-2H-pyran-4boronic acid pinacol ester (0.23 g), césium carbonate (2 mol/L in water, 0.7 mL), tetrahydrofuran (4 ml), and toluene (1 mL) is sparged with argon for 5 min. Bis(1 ,Tdiphenylphosphinojferrocene-dichloropalladium (44 mg) is added and the mixture is heated to
100 °C. After stirring at 100 °C overnight, another portion of 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester (0.05 g) and bis(1 ,T-diphenylphosphino)ferrocene-dichloropalladium (20 mg) is added and stirring is continued at 100 °C for 5 h. After cooling to room température, the mixture is diluted with ethyl acetate, washed with aqueous NH4CI solution, dried (Na2SO4), and
X
concentrated. The residue is chromatographed on silica gel (dichloromethane/methanol 1:0-+9:1) togive the title compound. Yield: 0.16 g (impure); LC (method 1): tR = 4.36 min; Mass spectrum (EST): m/z =352 [M+H|*.
Step 2: cis-6-(3,6-dihydro-2H-pyran-4-yl)-2,3,4,4a,919a-hexahydro-1H-indeno[2,1-b]pyridine
The title compound is prepared from 1-[c/s-6-(3,6-dihydro-2H-pyran-4-yl)-2,3,4,4a,9,9ahexahydro-indeno[2t1-b]pyridin-1-yl]-2,2,2-trifluoro-ethanone foilowing a procedure analogous to that described in Step 5of Intermediate 46. Yield: 37% of theory; LC (method 1): tR = 1.97 min; Mass spectrum (ESI*): m/z =256 [M+H]*.
Step 3: c/s-(3H-benzoimidazol-5-yl)-[6-(316-dihydro-2H-pyran-4-yl)-2,3,4,4a,919a-hexahydro10 indeno[2,1 -b] pyridin -1 -yl]-methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and c/s-6-(3,6dihydro-2H-pyran-4-yl)-2,3l4,4al9,9a-hexahydro-1H-indeno[2,1-b]pyridine foilowing a procedure analogous to that described in Example 1. Yield: 69% of theory; LC (method 1 ): tR = 2.65 min; Mass spectrum (Ε5Γ): m/z = 400 [M+H]*.
Intermediate 52 c/s-(3H-Benzoimidazol-5-vl)-(6-cvclopent-1-envl-2.3.4,4a.9,9a-hexahydro-indeno[2,1-b]pvridin1-ylbmethanone
Step 1: 1-(c/s-6-cyclopent-1-enyl-2l3l4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl)-2,2,220 trifluoro-ethanone
The title compound is prepared from trifluoro-methanesulfonic acid 1-(2,2,2-trifluoro-acetyl)2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-6-yl ester and cyclopentenyl-1-boronic acid pinacol ester foilowing a procedure analogous to that described in Step 1 of Intermediate 51.
Yield: 31% of theory; LC (method 1): tR = 5.34 min; Mass spectrum (EST): m/z = 336 [M+H]*.
Step 2: c/s-6-cyclopent-1-enyl-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine
The title compound is prepared from 1-(c/s-6-cyclopent-1-enyl-2,3,4,4a,9,9a-hexahydroindeno[2,1 -bjpyridin-1 -yl)-2,2,2-trifluoro-ethanone foilowing a procedure analogous to that
107 described in Step 5 of Intermediate 46. Yield: quantitative; LC (method 1); tR = 2.73 min; Mass spectrum (ESI+): m/z - 240 [M+Hf.
Step 3: c/s-(3H-benzoimidazol-5-yl)-(6-cyclopent-1-enyl-2,3,4,4a,9,9a-hexahydro-indeno[2,1b]pyridin-1-yl)-methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and c/s-6-cyclopent1-enyl-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1. Yield: 49% of theory; LC (method 1 ): tR = 2.64 min; Mass spectrum (ESI+): m/z = 384 [M+Hf.
Intermediate 53
N-(c/s-2.3,4.4a,9.9a-Hexahvdro-1H-indeno[2,1-bIpvridin-7-vl)-acetamide
Step 1: c/s-7-amino-2,3,4,4al9,9a-hexahydro-indeno[2,1-b]pyridine-1 -carboxylic acid tert-butyl ester
The title compound is prepared from c/s-2,3,4,4al9,9a-hexahydro-1H-indeno[2,1-b]pyridin-7ylamine and di-tert-butyl dicarbonate following a procedure analogous to that described in Step 3 of Intermediate 32. Yield: 25% of theory; LC (method 1): tR = 2.69 min; Mass spectrum (ESI+): m/z = 289 [M+Hf.
Step 2: c/s-7-acetylamino-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridine-1-carboxylic acid tertbutyl ester
Acetic anhydride (50 pL) is added to a solution of c/s-7-amino-2,3,4,4a,9,9a-hexahydroindeno[2,1-b]pyridine-1-carboxylicacid tert-butyl ester (140 mg) and triethylamine (70 pL) in dichloromethane (3 mL) at room température. The solution is stirred for 1 h at room température and then aqueous NaHCO3 solution is added. The mixture is stirred vigorously for 20 min and then extracted with dichloromethane. The combined extract is concentrated and the residue is chromatographed (cyclohexane/ethyl acetate 7:3—>1:9) to give the title compound. Yield: 100 mg (62% of theory); LC (method 1): tR =3.60 min.
Step 3: N-(c/s-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-7-yl)-acetamide
The title compound is prepared from c/s-7-acetylamîno-2,3,4,4a,9,9a-hexahydro-indeno[2,1blpyridine-1-carboxylic acid tert-butyl ester following a procedure analogous to that described in
108
Step 5 of Intermediate 32. Yield: quantitative; LC (method 1 ): tR = 0.92 min; Mass spectrum (ESI+): m/z = 231 [M+Hf.
Intermediate 54
N-(c/s-2.3,4,4a.9.9a-Hexahydro-1H-indenoi2<1-blpvridin-7-v1)-methanesulfonannide
Step 1: c/s-7-methanesulfonylamino-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridine-1-carboxylic acid tert-butyl ester
Methylsulfonyl chloride (42 pL) is added to a solution of c/s-7-amino-2,3,414a,9,9a-hexahydroindeno[2,1-b]pyridine-1-carboxylicacid tert-butyl ester (160 mg) and triethylamine (76 pL) in dichloromethane (3 mL) at room température. The solution is stirred for 1 h at room température and then aqueous NaHCO3 solution is added. The mixture is stirred vigorously for 20 min and then extracted with dichloromethane. The combined extract is concentrated and the residue is chromatographed (cyclohexane/ethyl acetate 7:3—* 1:9) to give the title compound. Yield: 120 mg (59% of theory); LC (method 1): tR =3.80 min; Mass spectrum (EST): m/z = 365 [M-H]‘. Step 2: N-(c/s-2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1 -b]pyridin-7-yl)-methanesulfonamide The title compound is prepared from c/s-7-methanesulfonylamino-2,3,4,4a,9,9a-hexahydroindeno[2,1-b]pyridine-1-carboxylicacid tert-butyl ester following a procedure analogous to that described in Step 5 of Intermediate 32. Yield: quantitative; LC (method 1): tR = 0.97 min; Mass spectrum (ESI+): m/z = 267 [M+Hf.
Intermediate 55 c/s-7-Nitro-2.3,4.4a,9,9a-hexahvdro-1H-indeno[2,1-blpyridin-6-ol
A ca. 10 °C-cold mixture of nitric acid (65%, 0.36 mL) and sulfuric acid (96%, 0.55 mL) is added dropwise to a solution of trifluoro-methanesulfonic acid c/s-1-(2,2,2-trifluoro-acetyl)2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-6-yl ester (2.00 g) in sulfuric acid (96%, 12 mL) chilled in an ice bath. The solution is stirred in the cooling bath for 1 h and poured then onto crushed ice. The precipitate formed is separated by filtration and taken up in methanol (10 mL). The resulting solution is treated with saturated aqueous K2CO3 solution (alternative^ NaOH is used) until the trifluoromethylsulfonyl and trifluoroacetyl group are cleaved off (TLC or HPLC).
109
Water is then added and the resulting mixture is extracted with ethyl acetate. The combined extract is concentrated to give the crude title compound that is used without further purification. Yield: 1.10 g (crude); LC (method 1): tR = 1.44 min; Mass spectrum (EST): m/z = 235 [M+H]+.
Intermediate 56 c/s-6-Methoxy-7-methvl-2,3,4,4a,9,9a-hexahydro-1 H-indenof2,1 -b] p y ri d i n e
The title compound is prepared from 3-bromo-pyridine-2-carboxylic acid and 4-methyl-3methoxyboronic acid following the synthetic sequence and protocols described for Intermediate 41; since 3-bromo-pyridine-2-carboxylic acid instead of 3-bromo-pyridine-2-carbonitrile is used for the Suzuki-Miyaura coupling (Step 1 of Intermediate 41), hydrolysis of the nitrile (Step 2 of Intermediate 41 ) is omitted, LC (method 7): tR = 0.74 min; Mass spectrum (ESI+): m/z = 218 [M+Hf.
Intermediate 57 c/s-6-Methoxy-5-methvl-2.3,4,4a.9.9a-hexahvdro-1H-indenof2.1-b|pyridine
The title compound is prepared from 3-bromo-pyridine-2-carboxylic acid and 2-(3-methoxy-2methyl-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (may be prepared as in WO 2001053268 described) following the synthetic sequence and protocols described for Intermediate 41; since 3-bromo-pyridine-2-carboxylic acid instead of 3-bromo-pyridine-2carbonitrile is used for the Suzuki-Miyaura coupling (Step 1 of Intermediate 41), hydrolysis of the nitrile (Step 2 of Intermediate 41 ) is omitted.
Intermediate 58
Trifluoromethanesulfonic acid c/s-7-methvl-1-(1-trifluoromethanesulfonvl-1H-benzoimidazole-5carbonvl )-2,3,4,4a,9,9a-hexahvdro-1H-indeno[2,1-blpyridin-6-vl ester and Trifluoromethanesulfonic acid c/s-7-methvl-1-(3-trifluoromethanesulfonyl-3H-benzoimidazole-5carbonyl)-2.3.4,4a,9,9a-hexahvdro-1H-indeno[2.1-b1pvridin-6-yl ester
110
The tille compounds are prepared from (1H-benzoimidazol-5-yl)-(c/s-6-hydroxy-7-methyl2l3l4,4a,9,9a-hexahydro-indeno[2l1-b]pyridin-1-yl)-methanone following a procedure analogous to that described in Intermediate 42 and used as a mixture in the following step.
Intermediate 59 (1H-Benzoimidazol-5-vl)-(c/s-6-methoxv-5-methvl-2,3,4,4a.9,9a-hexahvdro-indenof2,1-b]pyridinΙ-νΠ-methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and c/‘s-6-methoxy-5methyl-2,3,4,4a,9,9a-hexahydro-1H-indeno(2,1-b]pyridine following a procedure analogous to that described in Example 1.
Intermediate 60 (1H-BenzoimidazoÎ-5-yl)-(crs-6-hvdroxy-5-methvl-2.3,4.4a.9.9a-hexahydro-indenor2.1-blpyridin1-vl)-methanone
The title compound is prepared from (1 H-benzoimidazol-5-yl)-(cis-6-methoxy-5-methyl2,3,4,4al9l9a-hexahyciro-indeno[2l1-b]pyridin-1-yl)-methanone following a procedure analogous to that described in Example 7.
Intermediate 61
Trifluoromethanesulfonic acid c/'s-5-methvl-1-(1-trifluoromethanesulfonyl-1H-benzoimidazole-5carbonvl)-2,3,4,4a.9.9a-hexahvdro-1H-indenof2,1-blpyridin-6-vl ester and Trifluoromethanesulfonic acid c/s-5-methvl-1-(3-trifluoromethanesulfonyl-3H-benzoimidazole-5carbonvl)-2.3,4,4a.9,9a-hexahydro-1H-indenof2.1-blpyridin-6-vl ester
The title compounds are prepared from (1H-benzoimidazol-5-yl)-(c/s-6-hydroxy-5-methyl2,3,4,4al9,9a-hexahydro-indeno[2>1-b]pyridin-1-yl)-methanonefollowing a procedure analogous to that described in Intermediate 42 and used as a mixture in the following step.
111
Example 1 (1H-Benzoimidazol-5-vl)-(c/s-2,3t4a,5,6,10b-hexahvdro-1H-benzo[f1quinolin-4-yl)-methanone
2-(1H-Benzotriazol-1-yl)-1,1l3,3-tetramethyluronium tetrafluoroborate (0.50 g; alternatively, 2-(7aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate may be used) is added toa solution of 1H-benzoimidazole-5-carboxylic acid (0.23 g) and ethyl-diisopropyl-amine (0.50 mL) in Ν,Ν-dimethylformarnide (2 mL) at room température. The solution is stirred for 20 min priorto the additionof c/s-I^^^Aa.S.e.lOb-octahydro-benzotfJquinoline (0.30 g) dissolved in Ν,Ν-dimethylformarnide (2 mL). The resulting solution is stirred at room température for 3 h. 32% aqueous ammonia (1 mL) in methanol (2 mL) is then added and the mixture is stirred for another 30 min. The mixture is diluled with ethyl acetate and washed with water and brine and dried (Na2SO4). The solvent is evaporated and the residue is chromatographed on silica gel (dichloromethane/methanol containing 1% NH3 95:5->80:20) to afford the title compound as a foam-like solid that is triturated with ether and dried to give a colorless solid [alternatively, the product may be purified by HPLC on reversed phase (MeOH/H2O)]. Yield: 0.38 g (80% of theory); LC (method 1 ): tR = 2.53 min; Mass spectrum (ESl*): m/z = 332 [M+H]+; 1H NMR (400 MHz, DMSO-de, mixture of 2 rotamers) d 1.52-1.82 (m, 4H), 1.82-1.94 (m, 1H), 2.24-ca. 2.48 (m, 1.5H), 2.71-3.02 (m, 3H), 3.03-3.18 (m, 0.5H), 3.50-3.65 (m, 0.5H), 3.88-4.05 (m, 0.5H), 4.39-4.56 (m, 0.5H), 4.83-4.99 (m, 0.5H), 6.89-7.20 (m. 4H), 7.21-7.27 (m. 1H), 7.56-7.70 (m, 2H), 8.23-8.35 (m, 1H), 12.58 (broad s, 1H).
Example 2 (1H-Benzoimidazol-5-vl)-[(4a-S,10b-F?)-2,3, 4a.5.6,10b-hexahvdro-1H-benzorflquinolin-4-yl1methanone
The title compound is obtained by chromatographing a racemic mixture of (1H-benzoimidazol-5· yl)-(c/s-2,3,4a,5,6,10b-hexahydro-1H-benzo[f]quinolin-4-yl)-methanone (100 mg) on chiral phase (SFC; column: 1x ASH 250 x 10 mm, 5 pm; mobile phase: methanol containing 0.2% diethylamine/sc carbon dioxide 25:75; flow rate: 10 mL/min). Yield: 48 mg; LC (SFC; column: Daicel ASH 250 x 4.6 mm, 5 pm; mobile phase: methanol containing 0.2% diethylamine/sc
112 carbon dioxide 25:75; flow rate: 4 mL/min): tR = 2.73 min; Mass spectrum (ESI ): m/z = 332 [M+H]*; for 1H NMR see Example 1.
Example 3 f 1 H-Benzoimidazol-5-yl)-[(4a-R,10b-S)-2,3, 4a,5,6,1Qb-hexahvdro-1 H-benzorflquinolin-4-νΠmethanone
The title compound is obtained by chromatographing a racemic mixture of (1 H-benzoimidazol-5yl)-(cis-2,3,4a,5,6,10b-hexahydro-1H-benzo[f|quinolin-4-yl)-methanone (100 mg) on chiral phase (SFC; column: 1x ASH 250 x 10 mm, 5 pm; mobile phase: methanol containing 0.2% diethylamine/sc carbon dioxide 25:75; flow rate: 10 mL/min). Yield: 45 mg; LC (SFC; column: Daicel ASH 250 x 4,6 mm, 5 pm; mobile phase: methanol containing 0.2% diethylamine/sc carbon dioxide 25:75; flow rate: 4 mL/min): tR = 2.13 min; Mass spectrum (EST): m/z = 332 [M+Hf; for 1H NMR see Example 1.
Example 4 (1H-Benzoimidazol-5-vl)-(trans-2,3,4a,5,6,10b-hexahydro-1H-benzoiflquinolin-4-vl)-methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and trans1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 31% of theory; TLC: rf = 0.40 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (ESI+): m/z = 332 [M+Hf; 1H NMR (400 MHz, DMSO-d6) d 1.32-1.46 (m, 1H), 1.53-1.76 (m, 2H), 2.14-2.24 (m, 1H), 2.30-2.43 (m, 1H), ca. 2.49-2.56 superimposed by D3CSOCHD2 signal (m, 1H), 2.77-2.93 (m, 2H), 3.03-3.13 (m, 1H), ca. 3.253.34 superimposed by H2O signal (m, 1 H), 3.34-3.43 (m, 1 H), 3.67-3.76 (m, 1 H), 7.07-7.19 (m, 3H), 7.26-7.32 (m, 2H), 7.59-7.70 (m, 2H), 8.30 (s, 1 H), 12.60 (broad s, 1H).
Example 5
4-(c/s-2,3.4a.5,6,10b-Hexahydro-1H-benzoff]quinoline-4-carbonyl)-benzamide
113
The title compound is prepared from terephthalamic acid and c/s-1,2,3,4,48,5,6,10b-octahydrobenzo[f]quinoline foliowing a procedure analogous to that described in Example 1. Yield: 58% of theory; LC (method 1): tR = 3.16 min; Mass spectrum (EST): m/z = 335 [M+Hf.
Example 6 ( 1 H-Benzoiinidazol-5-vl)-(c/s-7-methoxy-2,3,4a,5,6,1Ob-hexahvdro-1 H-benzoiflquinolin-4-νΠmethanone
The title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and c/s-7-methoxy1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline foliowing a procedure analogous to that described in Example 1. Yield: 85% of theory; LC (method 1 ): tR = 2.62 min; Mass spectrum (EST): m/z = 362 [M+Hf.
Example 7 (1H-Benzoimidazol-5-vl)-fc/s-7-hvdroxv-2,3.4a.5,6,10b-hexahvdro-1H-benzo[flquinolin-4-vlT methanone
Boron tribromide (1 mol/L in dichloromethane, 0.5 mL) is added to a solution of(1H-benzoimidazol-5-yl)-(c/s-7-methoxy-2l3,4a,5,6,10b-hexahydro-1H-benzo[f]quinolin-4-yl)-methanone (60 mg) in dichloromethane (5 mL) at room température. The resulting solution is stirred at room température for 2 h. Aqueous half-saturated NaHCO3 solution is added and the resulting neutral mixture is extracted with dichloromethane and dichloromethane/methanol (95:5). The combined extracts are washed with brine and dried (Na2SO4). The solvent is evaporated and the residue is triturated with diethyl ether and dried to give the title compound as a colorless solid. Yield: 30 mg (52% of theory); TLC: rf = 0.45 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (ESI+): m/z= 348 [M+Hf.
114
Example 8 (IH-Benzoimidazol-S-ylHc/s-IO-methoxy-Z.S^a.S.e.lOb-hexahvdro-IH-benzoIflquinolirM-yl)methanone
The title compound is preparedfrom 1 H-benzoimidazole-5-carboxylic acid and c/s-10-methoxy1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 55% of theory; LC (method 1): tR = 2.67 min; Mass spectrum (EST): m/z =362 [M+H]+.
Example 9 ( 1 H-Benzoimidazol-5-ylH transi 0-methoxy-2,3,4a,5,6,10b-hexahydro-1 H-benzofflquinolin-4-vl)methanone
The title compound is preparedfrom 1H-benzoimidazole-5-carboxylic acid and irans-10methoxy-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 51% of theory; LC (method 2): tR = 3.63 min; Mass spectrum (ESI+): m/z = 362 [M+HJ*.
Example 10 (1H-Benzoimidazol-5-vlHcis-10b-methvl-2,3,4a,5,6,10b-hexahvdro-1H-benzoif|quinolin-4-yQmethanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and an isomeric mixture of c/s-10b-methyl-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline and trans-10b-methyl1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 yielding a mixture of Example 10 and Example 11 which is separated by HPLCon reversed phase (MeOH/H2O/NH40H). Yield: 20% of theory; LC (method 2): tR = 3.40 min; Mass spectrum (EST): m/z = 346 [M+H]+; ’H NMR (400 MHz, DMSO-d6, mixture of 2 rotamersjd 1.33 (s, 3H), 1.42-1.53 (m, 2H), 1.62-1.78 (m, 1H), 2.15-2.23 (m, 1H), 2.27-2.35 (m, 1H), 2.75-2.90 (m, 3H), 3.07-3.18 (m, 1H), 3.43-3.49 (m, 1H), 3.69-3.77 (m, 1H), 7.04-7.18 (m,
115
3H), 7.20-7.34 (m, 2H), 7.56 (broad s, 0.75H), 7.58 (broad s, 0.25H), 7.67 (broad s, 0.75H), 7.69 (broad s, 0.25H), 8.29 (s, 1H), 12.53-12.62 (m, 1H).
Example 11 ( 1 H-Benzoimidazol-5-yl)-( transi 0b-methyl-2,3.4a.5,6.10b-hexahydro-1 H-benzoif|quinolin-4-vl)methanone
The title compound is preparedfrom 1H-benzoimidazole-5-carboxylic acid and an isomeric mixture of c/s-10b-methyl-1,2,3,4,4a,5,6,1 Ob-octahydro-benzo[f]quinoline and trans-10b-methyl-
1,2,3,4,48,5,6,1 Ob-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 yielding a mixture of Example 10 and Example 11 which is separated by HPLC on reversed phase (MeOH/H2O/NH4OH). Yield: 15% of theory; LC (method 2): tR = 3.26 min; Mass spectrum (EST): m/z - 346 [M+H]+.
Example 12 ( 1 H-Benzoimidazol-5-vl)-f trans-7-methoxy-2.3.4a.5,6,10b-hexahydro-1 H-benzofflquinolin-4-vQmethanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and trans-7-methoxy1,2,3,4,43,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 49% of theory; LC (method 1): tR = 2.68 min; Mass spectrum (EST): m/z = 362 [M+Hf.
Example 13 (1 H-Benzoimidazol-5-yl)-( c/s-1 Q-hydroxy-2.3,4a,5,6,10b-hexahydro-1H-benzo[flquinolin-4-yi)methanone
The title compound is prepared from (1H-benzoimidazol-5-yl)-(c/s-10-methoxy-2,314a,5,6,10bhexahydro-1H-benzo[f]quinolin-4-yl)-methanone following a procedure analogous to that
117
Example 17 (1H-Benzoimidazol-5-vl)-(frans-9-hvdroxv-2.3.4a,5,6,10b-hexahydro-1H-benzo[flquinolin-4-vl)methanone
The title compound is prepared from (IH-benzoimidazol-S-ylHtrans-g-methoxy^î.S^a.S.e.lObhexahydro-1H-benzo[f]quinolin-4-yl)-methanone following a procedure analogous to that described in Example 7. Yield: 61% of theory; LC (method 1): tR = 2.10 min; Mass spectrum (ESC): m/z = 348 [M+Hf.
Example 18 ( 1 H-Benzoimidazol-5-vl)-( trans-10-hydroxv-2,3.4a,5,6,1Ob-hexahydro-1 H-benzoiflquinolin-4-γΙ)methanone
The title compound is prepared from (1H-benzoimidazol-5-yl)-(/rans-10-methoxy-2,3,4a,5,6r10bhexahydro-1H-benzo[f]quinolin-4-yl)-methanone following a procedure analogous to that described in Example 7. Yield: 14% of theory; LC (method 1): tR = 2.33 min; Mass spectrum (EST): m/z = 348 [M+Hf.
Example 19 (1H-Benzoimidazol-5-vl)-(frans-7-hvdroxy-2,3,4a,5.6.10b-hexahvdro-1H-benzo[flquinolin-4-Yl)methanone
The title compound is prepared from (1H-benzoimidazol-5-yl)-(trans-7-methoxy-2,3,4a,5,6,10bhexahydro-1H-benzo[f]quinolin-4-yl)-methanone following a procedure analogous to that described in Example 7. Yield: 36% of theory; LC (method 1): tR = 2.19 min; Mass spectrum (ESC): m/z = 348 [M+Hf.
116 described in Example 7. Yield: 68% of theory; LC (method 1): tR = 2.25 min; Mass spectrum (EST): m/z = 348 [M+Hf.
Example 14 (1H-Benzoimidazol-5-vl)-(c/s-9-methoxv-2,3,4a,5,6.10b-hexahvdro-1H-benzo[f|quinolin-4-yl)methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and c/s-9-methoxy1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 69% of theory; LC (method 1): tR = 2.55 min; Mass spectrum (EST): m/z = 362[M+H]\
Example 15 (1H-Benzoimidazol-5-vlHfrans-9-methoxv-2,3,4a,5,6,10b-hexahvdro-1H-benzofflquinolin-4-vDmethanone
The title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and trans-9-methoxy-
1,2,3,4,43,5,6,1 Ob-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 77% of theory; LC (method 1): tR = 2.61 min; Mass spectrum (ESI+): m/z = 362 [M+H]*.
Example 16 (1 H-Benzoimidazol-5-yl)-(c/s-9-hydroxy-2.3,4a,5,6,10b-hexahydro-lH-benzo[flquinolin-4-yl)methanone
The title compound is prepared from (1H-benzoimidazol-5-yl)-(c/s-9-methoxy-2,3,4a,5,6, 10bhexahydro-1H-benzo[f]quinolin-4-yl)-methanone following a procedure analogous to that described in Example 7. Yield: 58% of theory; LC (method 1 ): tR = 2.08 min; Mass spectrum (ESI+): m/z = 348 [M+H]4.
118
Example 20 (1H-Benzoimidazol-5-vl)-(c/s-7,9-difluoro-2,3.4a,5,6,10b-hexahvdro-1H-benzo[f1auinolin-4-yl)methanone
The title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and c/s-7,9-difluoro1,2,3,4,43,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 72% of theory; TLC: rr = 0.37 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (ESI+): m/z = 368 [M+H]+.
Example 21 (1H-Benzoimidazol-5-vl)-(frans-7.9-difluoro-2.3.4a.5,6,10b-hexahydro-1H-benzofnquinolin-4-yl)methanone
The title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and trans-7,9difluoro-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 70% of theory; TLC: rf= 0.43 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (ESI+): m/z = 368 [M+H]+.
Example 22 (1H-Benzoimidazol-5-yl)-(c/s-8-methoxy-2,3,4a,5.6,10b-hexahydro-1 H-benzofflquinolin-4-yl)methanone
The tille compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and c/s-8-methoxy1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 78% of theory; LC (method 1): tR = 2.54 min; Mass spectrum (ESI+): m/z = 362 [Μ+ΗΓ.
119
Example 23 ( 1 H-Benzoimidazoi-5-vl)-(trans-8-methoxy-2,3,4a.5,6,10b-hexahydro-1 H-benzoiflquinolin-4-νΠmethanone
The title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and frans-8-methoxy1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 71% of theory; LC (method 1 ): tR = 2.61 min; Mass spectrum (ESI+): m/z = 362 [M+Hf.
Example 24 (1H-Benzoimidazol-5-vl)-(trar7s-8-hvdroxv-2,3,4a,5.6,10b-hexahvdro-1H-benzo[flquinolin-4-yl)methanone
The title compound is prepared from (1H-benzoimidazol-5-yl)-(/rans-8-methoxy-2,3,4a,5,6,10bhexahydro-1H-benzo[f]quinolin-4-yl)-methanone following a procedure analogous to that described in Example 7. Yield: 48% of theory; LC (method 1): tR = 2.07 min; Mass spectrum (EST): m/z = 348 [M+Hf.
Example 25 ( 1 H-Benzoimidazol-5-yl)--(c/s-8-hvdroxv-2,3,4a.5,6110b-hexahvdro-1 H-benzo[flquinolin-4-vl)methanone
The title compound is prepared from (1H-benzoimidazol-5-yl)-(c/s-8-methoxy-2,3,4a,5,6,10bhexahydro-1H-benzo[f]quinolin-4-yl)-methanone following a procedure analogous to that described in Example 7. Yield: 39% of theory; LC (method 1): tR = 2.03 min; Mass spectrum (ESI+): m/z = 348 [M+Hf.
120
Example 26 (IH-Benzoimidazol-S-vD-drans-IO-fluoro-S.SAa.S.G.IOb-hexahvdro-IH-benzofflquinolin-â-vl)methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and trans-10-fluoro-
1,2,3,4,48,5,6,1 Ob-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 41% of theory; LC (method 1 ): tR = 2.76 min; Mass spectrum (ESC*): m/z = 350 [M+H]4.
Example 27 (1H-Benzoimidazol-5-yl)-(c/s-10-fluoro-2,3,4a,5,6.10b-hexahydro-1H-benzo[flquinolin-4-vl)methanone
The title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and c/s-10-fluoro1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 75% of theory; LC (method 1): tR = 2.66 min; Mass spectrum (ESI+): m/z = 350 [M+H]+.
Example 28 (1H-Benzoimidazol-5-vl)-(frans-8-phenvl-2,3,4a,5,6,10b-hexahvdro-1H-benzo[flquinolin-4-yl)methanone
The title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and trans-8-phenyl1,2,3,4,4a,5,6,1 Ob-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 19% of theory; TLC: rf = 0.43 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (EST): m/z = 408 [M+H]4.
121
Example 29 (1H-Benzoimidazoi-5-vl)-(c/s-8-phenyl-2,3.4a.5.6.10b-hexahydro-1H-benzo[flquinolin-4-vQmethanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and c/s-8-phenyl1,2,3,4,4a,5,6,1 Ob-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 29% of theory; TLC: rf = 0.49 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (ESI+): m/z = 408 [M+Hf.
Example 30 (c/s-2.3.4a,5,6,10b-Hexahydro-1H-benzo[nauinolin-4-vl)-(1H-imidazo[4,5-blpyridin-5-yl)methanone
The title compound is prepared from 1H-imidazo[4,5-b]pyridine-5-carboxylic acid and c/s1,2,3,4,4a,5,6,1 Ob-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 (2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 57% of theory; LC (method 3): tR = 2.10 min; Mass spectrum (ESC): m/z = 333 [M+H]+.
Example 31 (c/s-2,3,4a.5,6.10b-Hexahvdro-1H-benzorflquinolin-4-vD-imidazo[1,2-a1pvridin-6-yl-methanone
The title compound is prepared from imidazo[1,2-a]pyridine-6-carboxylic acid and cis1,2,3,4,4a,5,6,1 Ob-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 72% of theory; LC (method 3): tR = 1.82 min; Mass spectrum (ESC): m/z = 335 [M+Hf.
122
Example 32
6-(c/s-2.3,4a,5.6.10b-Hexahydro-1H-benzo[f1quinoline-4-carbonvl)-3H-benzothiazol-2-one
The title compound is prepared from 2-oxo-2,3-dihydro-benzothiazole-6-carboxylic acid and c/s-
1,2,3,4,48,5,6,1 Ob-octahydra-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 56% of theory; LC (method 3): tR = 2.32 min; Mass spectrum (ESP): m/z = 365 [M+H]+.
Example 33 c/s-4-(1 H-Benzoimidazole-5-carbonyl)-1.2,3.4,4a.5,6,10b-octahvdro-benzo[f]quinoline-8-
The title compound is prepared from 1H-benzoimidazole-5-carboxylicacid and c/s1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline-8-carboxylic acid methyl ester following a procedure analogous to that described in Example 1. Yield: 92% of theory; LC (method 1): tR = 2.57 min; Mass spectrum (ESP): m/z = 390 [M+Hf.
Example 34 (1H-Benzoimidazol-5-yl}-(c/s-8-hvdroxvmethyl-2,3,4a.5,6,10b-hexahydro-lH-benzorflquinolin-4vl)-methanone
Lithium aluminum hydride (1 mol/L in tetrahydrofuran, 0.5 mL) is added to a solution of c/s-4(1H-benzoimidazole-5-carbonyl)-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline-8-carboxylic acid methyl ester(150 mg) in tetrahydrofuran (6 mL) cooled to -10 °C. The resulting solution is stirred for 2 h while warming to ca. -3 °C in the cooling bath. Little water is added carefully and the resulting mixture is filtered over Celite. The filtrate is diluted with ethyl acetate and dried (MgSOA The solvent is evaporated and the residue is triturated with ethyl acetate and dried to
give the title compound as a solid. Yield: 56 mg (40% of theory); LC (method 1 ); tR = 2.03 min; Mass spectrum (ESΓ): m/z = 362 [M+H]+.
Example 35 c/s-4-( 1 H-Benzoinnidazole-5-carbonvl)-1,2,3,4,4a,5,6,10b-octahvdro-benzo[flquinoline-8carboxylic acid
M aqueous NaOH solution (15 mL) is added to a solution of c/s-4-(1H-benzoimidazole-5carbonyl)-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline-8-carboxylic acid methyl ester (1.60 g) in tetrahydrofuran (15 mL) at room température. The resulting solution is stirred at room température for 5 h. The solution is concentrated under reduced pressure and water (100 mL) is added to the residue. 1 M Aqueous hydrochloric acid (15 mL) is then added and the precipitate formed is separated by filtration. The precipitate is washed with water and diethyl ether and dried to afford the title compound as a solid. Yield: 1.24 g (80% of theory); LC (method 1 ): tR = 2.09 min; Mass spectrum (ESI+): m/z = 376 [M+H]+.
Example 36 cfs-4-(1H-Benzoimidazole-5-carbonyl)-1,2,3,4,4a,5,6,10b-octahvdro-benzorf|quinoline-8carboxylic acid methylamide
O
The title compound is prepared from c/s-4-(1H-benzoimidazole-5-carbonyl)-1,2,3,4,4a,5,6,10b20 octahydro-benzo[f]quinoline-8-carboxylic acid and methylamine (2 mol/L in tetrahydrofuran) following a procedure analogous to that described in Example 1. Yield: 75% of theory; LC (method 1): tR = 1.91 min; Mass spectrum (ESl·): m/z= 389 [M+Hf.
Example 37 c/s-4-(1H-Benzoimidazole-5-carbonvl)-1.2,3,4,4a,5,6,10b-octahydro-benzo[f|quinoline-8
carboxylic acid amide
O
124
The title compound is prepared from c/s-4-(1H-benzoimidazole-5-carbonyl)-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline-8-carboxylic acid and ammonia (28% in water) following a procedure analogous to that described in Example 1. Yield: 58% of theory; LC (method 1 ): tR = 1.78 min; Mass spectrum (ESl*): m/z = 375 [M+H]+.
Example 38 α$-4-(1Η-Β6ηζοίηΓ^3ζοΐ6-5·θ3ώοηνΙΜ,2.3.4.43,5,6,10ΰ·οοί3ΐΊνΰΓθ-06ηζοίίΚιυΪηοΙΐηθ-8-
The title compound is prepared from c/s-4-(1H-benzoimidazole-5-carbonyl)-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline-8-carboxylic acid and dimethylamine (2 mol/L in tetrahydrofuran) following a procedure analogous to that described in Example 1. Yield: 20% of theory; LC (method 1): tR = 2.08 min; Mass spectrum (ESl*): m/z = 403 [M+H]+.
Example 39 (1Η-Β6ηζοίηηΐό3ζοΙ-5-νΠ-ίο/5-8·(ρνπΌ^Ιπ6-1-θ3ώοηνΙ)-2,3·43·5.6,10^ΐΊ6Χ3ΐΊνάΓθ-1Ηbenzofflquinolin-4-vll-methanone
The title compound is prepared from c/s-4-(1H-benzoimidazole-5-carbonyl)-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline-8-carboxylic acid and pyrrolidine following a procedure analogous to that described in Example 1. Yield: 57% of theory; LC (method 1 ): tR = 2.27 min; Mass spectrum (ESl·): m/z= 429 [M+Hf.
Example 40 (1H-Benzoimidazol-5-vl)-[cis-8-(morpholine-4-carbonyl)-2,3,4a,5.6.10b-hexahydro-1Hbenzoiflauinolin-4-yl]-methanone
The title compound is prepared from c/s-4-(1H-benzoimidazole-5-carbonyl)-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline-8-carboxylic acid and morpholine following a procedure analogous
125 to that described in Example 1. Yield: 63% of theory; LC (method 1 ): tR = 2.05 min; Mass spectrum (Ε3Γ): m/z = 445 [M+Hf.
Example 41 (1H-Benzoimidazol-5-viyrc/s-8-(1-hvdroxy-1-methvl-ethvn-2.3.4a,5,6,10b-hexahvdro-1Hbenzo[f]quinolin-4-yl1-methanone
MeMgBr [1.4 mol/L in toluene/tetrahydrofuran (3:1), 1.1 mL] is added to a solution of c/s-4-(1Hbenzoimidazole-5Carbonyl)-1,2,3,4,4a,5,6,10b-octahydrO'benzo[f]quinoline-8-carboxylic acid methyl ester (200 mg) in tetrahydrofuran (4 mL) cooled to -10 °C. The resulting solution is stirred with cooling for 3 h before another portion of MeMgBr [1.4 mol/L in toluene/tetrahydrofuran (3:1 ), 0.8 mL] is added. The solution is warmed in the cooling bath to room température overnight. The solution is poured into ice-cold water and the resulting mixture is filtered over Celite. The filtrate is diluted with ethyl acetate and the organic phase is separated, washed with brine, and dried (MgSO4). The solvent is evaporated and the residue is chromatographed on silica gel [dichloromethane/ (dichloromethane/methanol/7 M NH3 in methanol 50:48:2) 88:12->50:50] to furnish the title compound as a colorless solid. Yield: 59 mg (29% of theory); LC (method 1 ): tn = 2.27 min; Mass spectrum (ESI*): m/z = 390 [M+H]+.
Example 42 c/s-4-(1H-Benzoimidazole-5-carbonvl)-1,2,3,4,4a.5,6,10b-octahvdro-benzo[f]quinoline-8carbonitrile
Trifluoroacetic anhydride (0.4 mL) is added to a solution of c/s-4-(1 H-benzoimidazole-5carbonylj-I^.S^^a.S.G.IOb-octahydro-benzoffiquinoline-B-carboxylic acid amide (140 mg) and triethylamine (0.6 mL) in dichloromethane (4 mL) chilled in an ice bath. The cooling bath is removed and the solution is stirred at room température for 3 h. Another portion of trifluoroacetic anhydride (0.4 mL) and triethylamine (0.6 mL)are then added and stirring is continued at 35 °C overnight. The solution is diluted with dichloromethane and washed with water and brine. After drying (MgSO4), the solvent is evaporated and the residue is chromatographed on silica gel (dichloromethane/methanol 20:1—* 1:1 ) to furnish the title compound as a yellowish solid. Yield: 50 mg (38% of theory); Mass spectrum (ESI‘): m/z = 357 [M+H]*.
126
Example 43 të-Amino-benzothiazol-G-vlHc/s-Z.S^a.SO.IOb-hexahydro-IH-benzorflquinolin^-vD-methanone
The title compound is prepared from 2-amino-benzothiazole-6-carboxylic acid and cîs1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 24% of theory; LC (method 4): tR = 1.80 min; Mass spectrum (ESI+): m/z = 364 [M+H]\
Example 44 (c/s-2.3.4a.5.6.10b-Hexahvdro-1H-benzorf|quinolin-4-vlM3-hvdroxv-4-methvl-phenyl)methanone
The title compound is prepared from 3-hydroxy-4-methyl-benzoic acid and cis1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 77% of theory; LC (method 4): tR = 2.00 min; Mass spectrum (EST): m/z = 322 [M+H]\
Example 45 (3-Amino-4-methoxy-phenvl)-(c/'5-2,3,4a,5,6,10b-hexahvdro-1H-benzofflquinolin-4-vl)methanone
The title compound is prepared from 3-amino-4-methoxy-benzoic acid and c/s1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 63% of theory; LC (method 4): tR = 1.79 min; Mass spectrum (EST): m/z = 337 [M+H]+.
127
Example 46 (c/'s-2,3.4a,5,6,10b-Hexahvdro-1H-benzoff]quinolin-4-vO-(2-methvl-1H-indol-5-yl)-methanone
The title compound is prepared from 2-methyl-1H-indole-5-carboxylic acid and c/s1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline foilowing a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 46% of theory; LC (method 4): tR = 2.03 min; Mass spectrum (EST): m/z = 345 [M+H]*.
Example 47
5-(c/'s-2,3,4a,5,6JOb-Hexahydro-1H-benzorflquinoline-4-carbonvl)-1-methvl-1,3-dihydrobenzoimidazol-2-one
The title compound is prepared from 1-methyl-2-oxo-2,3-dihydro-1H-benzoimidazole-5carboxylie acid and c/s-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline foilowing a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate is used]. Yield: 15% of theory; LC (method 4): tR = 1.92 min; Mass spectrum (ESI*): m/z = 362 [M+H]*.
Example 48 (c/s-2,3,4a,5.6,1 Ob-Hexahydro-1 H-benzo[f]quinolin-4-yl)-( 1 H-indol-6-yl)-methanone
The tille compound is prepared from 1 H-indole-6-carboxylic acid and c/s-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline foilowing a procedure analogous to that described in Example 1 [2(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-fluorophosphate is used]. Yield:
27% of theory; LC (method 4): tR = 2.01 min; Mass spectrum (ESI*): m/z = 331 [M+H]*.
128
Example 49
5-(c/s-2,3,4a,5,6,10b-Hexahydro-1H-benzo[f]quinoline-4-carbonyl)-1,3-dihydro-indol-2-one
The title compound is prepared from 2-oxo-2,3-dihydro-1 H-indole-5-carboxylic acid and c/s1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinolinefollowing a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotnazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 25% of theory; LC (method 4): tR = 1.90 min; Mass spectrum (ESI+): m/z = 347 [M+Hf,
Example 50
6-(c/s-2,3,4a,5,6.10b-Hexahvdro-1H-benzofflquinoline-4-carbonyl)-1,3-dihydro-indol-2-one
The title compound is prepared from 2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid and cis1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 12% of theory; LC (method 4): tR = 1.90 min; Mass spectrum (ESI+): m/z = 347 [M+H]+.
Example 51 (c/s-2,3,4a,5,6.10b-Hexahydro-1H-benzoff]quinolin-4-vl)-(1-methvl-1 H-benzoimidazol-5-yl)methanone
The title compound is prepared from 1 -methyl-1 H-benzoimidazole-5-carboxylic acid and cis1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 83% of theory; LC (method 5): tR = 1.05 min; Mass spectrum (ESl·): m/z = 346 [M+Hf.
129
Example 52 (cis-2.3,4a,5,6,10b-Hexahydro-1H-benzo[f]quinolin-4-yl)-(1-methyl-1H-benzotriazol-5-vDmethanone
N N'
The title compound is prepared from 1-methyl-1H-benzotriazole-5-carboxylic acid and cis~ 1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 53% of theory; LC (method 4): tR = 1.90 min; Mass spectrum (EST*): m/z = 347 [M+Hf.
Example 53 (c/'s-7-Methoxy-2,3,4a,5,6,10b-hexahvdro-1 H-benzorf]quinolin-4-vD-( 1 -methvl-1 H-indol-3-yl)methanone
The title compound is prepared from 1-methyl-1H-indole-3-carboxylic acid and c/s-7-methoxy1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 82% of theory; LC (method 1): tR = 4.39 min; Mass spectrum (ESI+): m/z = 375 [M+Hf.
Example 54 (3-Fluoro-4-hvdroxv-phenvD-(c/s-2.3.4a,5.6.10b-hexahydro-1 H-benzofflquinolin-4-vOmethanone
OH
The title compound is prepared from 3-fluoro-4-hydroxy-benzoic acid and c/s1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used}. Yield: 40% of theory; LC (method 4): tR = 1.94 min; Mass spectrum (ESI+): m/z = 326 [M+Hf.
130
Example 55 (c/s-2,3,4a,5.6,10b-Hexahvdro-1H-benzoffîquinolin-4-vl)-(2-methvl-3H-benzoimidazol-5-vl)methanone
The title compound is prepared from 2-methyl-3H-benzoimidazole-5-carboxylic acid and c/s1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used] and isolated as its trifluoroacetic acid sait. Yield: 59% of theory; LC (method 4): tR = 1.64 min; Mass spectrum (ESI+): m/z = 346 [M+Hf.
Example 56 (4-Amino-3-chloro-phenyl )-(c/s-2,3,4a,5.6,10b-hexahydro-1 H-benzofflquinolin-4-vlÎ-methanone
The title compound is prepared from 4-amino-3-chloro-benzoic acid and c/s-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2(7-aza-1H-benzotriazo!-1-yl)-1l113,3-tetramethyluronium hexa-fiuorophosphate is used]. Yield: 52% of theory; LC (method 4): tR = 1.99 min; Mass spectrum (ESI+): m/z = 341/343 (Cl) [M+H]+.
Example 57 (2-Amino-3H-benzoimidazoÎ-5-yl )-(cis-2,3,4a,5,6.10b-hexahvdro-1 H-benzofflquinolin-4-vl)methanone
The title compound is prepared from 2-amino-3H-benzoimidazole-5-carboxylic acid and cis1,2,3,4,4a,5,6,10b-octahydro-benzo[f|quÎnolrne following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used] and isolated as its trifluoroacetic acid sait. Yield: 58% of theory; LC (method 4): tR = 1.66 min; Mass spectrum (ESI+): m/z = 347 [Μ+ΗΓ.
131
Example 58
Benzothiazol-6-vl-(c/s-2,3,4a,5.6,10b-hexahvdro-1H-benzo|flquinolin-4-v0-methanone
The title compound is prepared from benzothiazole-6-carboxylic acid and 0/5-1,2,3,4,48,5,6,10^ octahydro-benzo[f]quinoline following a procedure analogousto that described in Example 1 [2(Z-aza-IH-benzotriazol-l-yO-I.I.S.a-tetramethyluronium hexa-fluorophosphate is used]. Yield: 24% of theory; LC (method 4): tR = 1.97 min; Mass spectrum (ESI+): m/z = 349 [M+H]*.
Example 59 (4-Chloro-3-hvdroxv-phenyl )-(c/s-2,3,4a. 5.6,1 Ob-hexahydro-1 H-benzoff|quinolin-4-yl)methanone
The title compound is prepared from 4-chloro-3-hydroxy-benzoic acid and c/s1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinolinefollowing a procedure analogousto that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 46% of theory; LC (method 4): tR = 1.99 min; Mass spectrum (EST): m/z = 342/344 (Cl) [M+H]+.
Example 60 (c/s-2,3,4a,5.6,1Qb-Hexahvdro-1H-benzorf1quinolin-4-vl)-(3H-imidazo]4,5-blpvridin-5-yl)methanone
The tille compound is prepared from 3H-imidazo[4,5-b]pyridine-5-carboxylic acid and c/s1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used] and isolated as ils trifluoroacetic acid sait. Yield: 40% of theory; LC (method 4): tR = 1.83 min; Mass spectrum (EST): m/z = 333 [M+Hf.
132
5-(c/s-2,3.4a,5,6,10b-Hexahvdro-1H-benzo[f|quinoline-4-carbonyl)-1,3-dihydro-benzoimidazol-2Example 61 one
The title compound is prepared from 2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid and c/s-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 14% of theory; LC (method 4): tR = 1.89 min; Mass spectrum (ESI*): m/z = 348 [M+H]4.
Example 62 (c/s-2,3,4a,5,6,10b-Hexahvdro-1 H-benzo[flquinolin-4-yl)-(3-methyl-3H-benzoimidazol-5-vl)methanone
The title compound is prepared from 3-methyl-3H-benzoimidazole-5-carboxylic acid and c/s1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1l3,3-tetramethyluronium hexafluorophosphate is used], Yield: 91% of theory; LC (method 4): tR = 1.65 min; Mass spectrum (ESI4): m/z = 346 [M+H]4.
Example 63 (3-Amino-4-fluoro-phenyl)-(c/s-2,3,4a,5,6,10b-hexahvdro-1H-benzo[flquinoiin-4-vl)-methanone
NH.
The title compound is prepared from 3-amino-4-fluoro-benzoic acid and c/s-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-fluorophosphate is used). Yield: 47% of theory; LC (method 4): tR = 1.94 min; Mass spectrum (ESI4): m/z = 325 [M+H]4.
133
Example 64 (c/s-2,3,4a,5,6l10b-Hexahvdro-1H-benzo[f1quinolin-4-yl)-imidazo[1.2-a1pyridin-7-yl-methanone
The title compound is prepared from imidazo[1,2-a]pyridine-7-carboxylic acid and c/sI.Z.S^/a.S.ejOb-octahydro-benzo^quinoline foliowing a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-y!)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 95% of theory; LC (method 4): tR = 1.59 min; Mass spectrum (ESl*): m/z = 332 [M+Hf.
Example 65 (c/$-2.3.4a.5,6.10b-Hexahvdro-1H-benzofflquinolin-4-vl)-(1H-indazol-5-yl)-methanone
The title compound is prepared from 1 H-indazole-5-carboxylic acid and 0/5-1,2,3,4,48,5,6,10boctahydro-benzo[f]quinoline foliowing a procedure analogous to that described in Example 1 [2(7-aza-1H-benzotriazol-1“yl)-1,1,3,3-tetramethyluronium hexa-fluorophosphate is used]. Yield: 39% of theory; LC (method 4): tR = 1.94 min; Mass spectrum (ESl·): m/z = 332 [M+Hf.
Example 66
5-(c/s-2,3,4a,5.6,10b-Hexahvdro-1H-benzo[f]quinoline-4-carbonvl)-3,3-dimethyl-1,3-dihvdro-
The title compound is prepared from 3,3-dimethyt-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid and cÀs-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline foliowing a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 19% of theory; LC (method 4): tR = 1.95 min; Mass spectrum (ESl*): m/z = 375 [M+Hf.
134
Example 67 (4-Amino-phenvl)-(c/s-2.3,4a,5,6,10b-hexahvdro-1H-benzo[flauinolin-4-yl)-methanone
The title compound is prepared from 4-amino-benzoic acid and c/s-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 66% of theory; LC (method 4): tR = 1.81 min; Mass spectrum (EST): m/z = 307 [M+Hf.
Example 68 (c/s-2,3,4a,5,6,10b-Hexahvdro-1H-benzoiflquinolin-4-yl)-(4-hvdroxv-phenyl)-methanone
The title compound is prepared from 4-hydroxy-benzoic acid and c/s-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 28% of theory; LC (method 4): tR = 1.93 min; Mass spectrum (ESI+): m/z = 308 [M+Hf.
Example 69 (ο/3-2.3.43,5,6,106-Η6Χ3ΐΊν0Γθ·1Η436ηζο[ί|ουίηοΙΐη-4-νΙΜ1Η-ίη8οΙ-5-νΟ-ΠΊ61ΐΊ3ηοη6
The title compound is prepared from 1H-indole-5-carboxylicacid and c/s-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 51% of theory; LC (method 4): tR = 1.99 min; Mass spectrum (EST): m/z = 331 [M+Hf.
Example 70 (c/s-2,3,4a.5,6,10b-Hexahydro-1H-benzo[f1quinolin-4-vl)-(1H-indol-3-vl)-methanone
The title compound is prepared from 1H-indole-3-carboxylic acid and c/s-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-
135 (7-aza-1 H-benzotriazol-1 -yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 43% of theory; LC (method 4): tR = 2.01 min; Mass spectrum (ESl*): m/z = 331 [M+H]*.
Example 71 (3,5-Dichloro-4-hvdroxv-phenvl)-fc/s-2,3,4a,5,6,10b-hexahvdrO“1H-benzo[flquinolin-4-yl)methanone
The title compound is prepared from 3,5-dichloro-4-hydroxy-benzoic acid and cis1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1 H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 26% of theory; LC (method 4): tR = 2.03 min; Mass spectrum (ESl*): m/z = 376/378/380 (2 Cl) [M+H]*.
Example 72 (1H-Benzotriazol-5-vl)-(c/s-2,3,4a,5,6,10b-hexahvdro-1H-benzo[flquinolin-4-yl)-methanone
The title compound is prepared from 1 H-benzotriazole-5-carboxylic acid and cis1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1 H-benzotriazol-1 -yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 58% of theory; LC (method 4): tR = 1.90 min; Mass spectrum (EST): m/z = 333 [M+H]*.
Example 73 (c/s-2,3,4a,5.6.10b-Hexahvdro-1H-benzo[f]quinolin-4-vl)-(1-methvl-1H-indol-3-vl)-methanone
The title compound is prepared from 1-methyl-1H-indole-3-carboxylic acid and c/s1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1 H-benzotriazol-1-yl )-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 28% of theory; LC (method 4): tR = 2.05 min; Mass spectrum (ESl*): m/z = 345 [M+H]*.
136
Example 74 (c/s-2,3,4a,5,6,10b-Hexahydro-1 H-benzofflquinolin-4-yl)-(3-hvdroxy-4-nnethoxy-phenyl)methanone
The title compound is prepared from 3-hydroxy-4-methoxy-benzoic acid and c/sI.Z.SAAa.S.ô.lOb-octahydro-benzoffiquinolinefollowing a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 42% of theory; LC (method 4): tR = 1.93 min; Mass spectrum (EST): m/z = 338 [M+Hf.
Example 75 (3-Chloro-4-hydroxy-phenvl)-(c/s-2,3.4a.5.6,1 Ob-hexahvdro-1H-benzo|flquinolin-4-yl)methanone
The title compound is prepared from 3-chloro-4-hydroxy-benzoic acid and c/s1,2,3,4,48,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 42% of theory; LC (method 4): tR = 1.98 min; Mass spectrum (ESI+): m/z =342/344 (CI) [M+H]+.
Example 76 (3-Amino-4-chloro-phenyl)-(c/s-2.3,4a,5,6,10b-hexahydro-1H-benzo]f]quinolin-4-vl)-methanone
The title compound is prepared from 3-amino-4-chloro-benzoic acid and c/s-1,2,3,4,48,5,6,10boctahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-fluorophosphate is used]. Yield: 46% of theory; LC (method 4): tR = 1.28 min; Mass spectrum (ESI+): m/z = 341/343 (Cl) [M+H]+.
137
Example 77 (3-Amino-4-methyl-phenvl)-(c/s-2.3,4a,5,6.10b-hexahvdro-1H-benzofflquinolin-4-yl)-methanone
The title compound is prepared from 3-amino-4-methyl-benzoîc acid and c/s-1,2,3,4,4a,5,6,10boctahydro-benzo[f|quinoline following a procedure analogous to that described in Example 1 [2(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-fluorophosphate is used], Yield: 95% of theory; LC (method 4): tR = 1.85 min; Mass spectrum (ESΓ): m/z = 321 [M+H]+.
Example 78 t4-Amino-3-methoxY-phenvl)-(c/'s-2,3,4a,5<6,10b-hexahvdro-1H-benzo[flquinolin-4-yl)methanone
The title compound is prepared from 4-amino-3-methoxy-benzoic acid and c/s1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 64% of theory; LC (method 4): tR = 1.84 min; Mass spectrum (ESI+): m/z = 337 [M+Hf
Example 79 (4-Amino-3-fiuoro-phenvl)-(c/s-2,3,4a,5,6,10b-hexahydro-1H-benzo[f|quinolin-4-vD-methanone
The title compound is prepared from 4-amino-3-fluoro-benzoic acid and c/s-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2(7-aza-1H-benzolriazol-1-yl)-1,1l3,3-tetramethyluronium hexa-fluorophosphate is used], Yield: 64% of theory; LC (method 4): tR = 1.94 min; Mass spectrum (EST): m/z = 325 [M+H]+.
Example 80
6-(c/s-2.3.4a,5,6,10b-Hexahvdro-1H-benzo[f|quinoline-4-carbonylMH-quinoxalin-2-one
138
The title compound is prepared from 2-oxo-1,2-dihydro-quinoxaline-6-carboxylic acid and c/s1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 19% of theory; LC (method 4): tR = 1.92 min; Mass spectrum (EST): m/z = 362 [M+Hf.
Example 81 (c/s-7-Hvdroxy-2.3,4a,5.6.10b-hexahvdro-1H-benzoFflquinolin-4-yl)-(1-methvl-1H-indol-3-vll· methanone
The title compound is prepared from (c/s-7-methoxy-2,3,4a,5,6,10b-hexahydro-1Hbenzo[f]quinolin-4-yl)-(1-methyl-1H-indol-3-yl)-methanone following a procedure analogous to that described in Example 7. Yield: 10% of theory; LC (method 1 ): tR = 3.58 min; Mass spectrum (ESf): m/z = 361 [M+Hf.
Example 82 (1 H-Benzoimidazol-5-yl)-f c/s-8-benzyl-2,3,4a,5,6,10b-hexahvdro-1H-benzo|f]quinolin-4-vlÎmethanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and a mixture of c/s-
8-benzyl-1,2,3,4,43,5,6,1 Ob-oclahydro-benzo[f]quinoline and c/s-8-cyclohexylmethyl1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline (ca. 30:70) following a procedure analogous to that described in Example 1 and separated from the also formed Example 83 by HPLC on reversed phase (MeOH/H2O/NH4OH). Yield: 12% of theory; LC (method 1): tR = 3.35 min; Mass spectrum (ESI+): m/z = 422 [M+H]+.
Example 83 (1H-Benzoimidazol-5-vl)-(c/s-8-cvclohexylmethyl-2,3.4a.5.6,10b-hexahydro-1H-benzoff|quinolin-
139
The title compound is prepared from IH-benzoimidazole-5-carboxylic acid and a mixture of c/s8-benzyl-1,2,3,4,4a,5,6,Wb-oclahydro-benzo[f|quinoline and c/s-8-cyclohexylmethyl1,2,3,4,4a,5,6t10b-octahydro-benzo[f]quinoline (ca. 30:70) following a procedure analogous to that described in Example 1 and separated from the also formed Example 82 by HPLC on reversed phase (MeOH/H20/NH40H). Yield: 50% of theory; LC (method 1 ): tR = 4.06 min; Mass spectrum (EST): m/z = 428 [M+Hf
Example 84 (1 H-Benzoimidazol-S-yD-fc/s-IO-hvdroxvmethyl^.SAa.S.e.lOb-hexahydro-IH-benzofflquinolin4-yl)-methanone
The title compound is prepared from c/s-4-(1H-benzoimidazole-5-carbonyl)-1,2,3,4,4a,5,6,10boctahydro-benzo[f]quinoline-10-carboxylic acid methyl ester following a procedure analogous to that described in Example 34. Yield: 46% of theory; TLC: rr = 0.27 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1); Mass spectrum (ESC): m/z = 362 [M+H]*.
Example 85 (1H-Benzoimidazol-5-ylÎ-[cis-10-(4-methoxv-benzvlÎ-2,3,4a,5.6.10b-hexahvdro-1HbenzoÎflquinolin-4-yll-methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and c/s-10-(4methoxy-benzyl)-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 17% of theory; LC (method 1): tR = 3.21 min; Mass spectrum (Ε5Γ): m/z = 452 [M+Hf.
Example 86 (1 H-Benzoimidazol-5-yl)-(cjs-6,6-dimethvl-2,3,4a,5.6,10b-hexahydro-1 H-benzofflquinolin-4-yl)methanone
140
The title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and c/s-6,6-dimethyl1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 58% of theory; LC (method 1): tR = 2.84 min; Mass spectrum (ESI+): m/z = 360 [M+Hf.
Example 87 c/s-4-(1H-Benzoimidazole-5-carbonvl)-1,2,3,4,4a,5,6,10b-octahvdro-benzo[flquinoline-10carboxylic acid amide
The title compound is prepared from c/s-4-(1H-benzoimidazole-5-carbonyl)-1,2,3,4,4a,5,6,10boctahydro-benzo[f]qurnoline-10-carboxylic acid and ammonia (7 mol/L in methanol) following a procedure analogous to that described in Example 1. Yield: 58% of theory; TLC: η = 0.24 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1 ); Mass spectrum (EST): m/z = 375 [M+H]+.
Example 88 c/s-4-(1H-Benzoimidazole-5-carbonyl)-1,2,3,4,4a,5,6,10b-octahvdro-benzoif1quinoline-10carbonitrile
Thetitlecompoundis preparedfrom c/s-4-(1H-benzoimidazole-5-carbonyl)-1,2,3,4,4a,5,6, 10boctahydro-benzo[f]quinoline-10-carboxylic acid amide following a procedure analogous to that described in Example 42. Yield: 66% of theory; TLC: rf = 0.45 (silica gel, CH2CI2/ MeOH/32% aqueous NH3 90:10:1); Mass spectrum (Ε3Γ): m/z = 357 [M+Hf.
Example 89 ( 1 H-Benzoimidazol-5-vl)4c/s-8-(4-methoxy-phenoxv)-2,3,4a,5,6110b-hexahydro-1 Hbenzorf|quinolin-4-yll-methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and c/s-8-(4methoxy-phenoxy)-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 72% of theory; LC (method 1): tR = 3.16 min; Mass spectrum (EST): m/z = 454 [M+Hf.
141
Example 90 trans-4-( 1 H-Benzoimidazole-5-carbonyl)-1,2,3.4,4a,5,6.10b-octahydro-benzo[flquinoline-9carbonitrile
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and trans1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline'9-carbonitrile following a procedure analogous to that described in Example 1. Yield: 18% of theory; LC (method 1): tR = 2.49 min; Mass spectrum (ESP): m/z = 357 [M+H]*.
Example 91 c/s-4-(1H-Benzoimidazole-5-carbonvl)-1,2,3.4,4a,5,6.10b-octahvdro-benzoff|quinoline-9carbonitrile
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and c/s1,2,3,4,48,5,6,10b-octahydro-benzo[f]quinoline-9-carbonitrile following a procedure analogous to that described in Example 1. Yield: 64% of theory; LC (method 1); tR = 2.40 min; Mass spectrum (ESP): m/z = 357 [M+Hf.
Example 92 ( 1 H-Benzoïrnidazol-S-yD-ic/s-l 0-(6-methyl-pyridazin-3-vloxv)-2,3,4a,5.6.10b-hexahvdro-1 Hbenzoff|quinolin-4-vll-methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylicacid and c/s-10-(6-methylpyridazin-3-yloxy)-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline following a procedure analogous to that described in Example 1. Yield: 17% of theory; LC (method 1 ): tR = 2.39 min; Mass spectrum (ESP): m/z = 440 [M+H]+.
142
Example 93 (1H-Benzoimidazol-5-vl)-(c/s-2,3,4,4a,9,9a-hexahvdro-indeno[2.1-blpyridin-1-vn-methanone
The tille compound is prepared from 1H-benzoimidazole-5-carboxylic acid and cis2,3,4,4al9,9a-hexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1. Yield: 60% of theory; LC (method 1): tR = 2.44 min; Mass spectrum (ESl*): m/z = 318 [M+Hf; 1H NMR (400 MHz, DMSO-d6, mixture of rotamers) d 1.20-1.34 (m, 1H), 1.41-1.56 (m, 1H), 1.56-1.71 (m, 1H), 1.92-2.02 (m, 1H), 2.68-3.11 (m, 3H), 3.11-3.27 (m, 1H), 3.47-5.43 (very broad signais, 2H), 7.07-7.30 (m, 5H), 7.54-7.62 (m, 1 H), 7.64-7.72 (m, 1H), 8.29(s, 1H), 12.51-12.65 (m, 1H).
Example 94 (1H-Benzoimidazol-5-vl)-l(4a-/?.9a-S)-2.3.4,4a,9,9a-hexahvdro-indenof2.1-b1pyridin-1-vllmethanone
The title compound is obtained by chromatographing a racemic mixture of (1H-benzoimidazol-5yl)-(c/s-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl)-methanone (100 mg) on chiral phase (column: 1x ASH 250 x 10 mm, 250 pm; mobile phase: methanol containing 0.2% diethylamine/sc carbon dioxide 25:75; flow rate: 10 mL/min). Yield: 47 mg; LC (method as above on chiral phase): tR = 2,35 min; Mass spectrum (EST): m/z = 318 [M+H]*; for 1H NMR see Example 94.
Example 95 (1H-Benzoimidazol-5-vl)-[(4a-S,9a-R)-2.3,4,4a, 9,9a-hexahvdro-indenof2.1-b1pvridin-1-vl1methanone
The title compound is obtained by chromatographing a racemic mixture of (1H-benzoimidazol-5yl)-(c/s-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl)-methanone (100 mg) on chiral phase (column: 1x ASH 250 x 10 mm, 250 pm; mobile phase: methanol containing 0.2%
143 diethylamine/sc carbon dioxide 25:75; flow rate: 10 mL/min). Yield: 44 mg; LC (method as above on chiral phase): îr = 1.98 min; Mass spectrum (EST): m/z = 318 [M+Hf; for 1H NMR see Example 94.
Example 96
4-(c/s-2,3,4.4a,9.9a-Hexahvdro-indeno[2,1-b]pvridine-1-carbonvD-benzamide
The title compound is prepared from terephthalamic acid and c/s-2,3,4,4a,9,9a-hexahydro-1Hindeno[2,1-b]pyridine following a procedure analogous to that described in Example 1. Yield: 50% of theory; LC (method 1): tR = 3.07 min; Mass spectrum (ESf): m/z = 321 [M+Hf.
Example 97 ca. 1:1 mixture of cis-(1H-Benzoimidazol-5-vlM6-bromo-2.3.4.4a,9,9a-hexahvdro-indenor2,1blpyridin-1 -vl)-methanone and c/s-( 1 H-Benzoimidazol-5-vl)-(7-bromo-2.3.4,4a,9,9a-hexahydroindeno[2.1 -blpyridin-1 -vl)-methanone
N />
N
A part of the impure mixture obtained in Step 4 of Intermediates 34 and 35 is purified by HPLC on reversed phase (acetonitrile/water) to give a ca. 1:1 mixture of the title compounds. Mass spectrum (ESI+): m/z = 396/398 (Br) [M+Hf.
Example 98 c/s-1 -( 1 H-Benzoimidazole-5-carbonvl)-2.3.4,4a,9,9a-hexahvdro-1 H-indenof2,1 -blpyridine-6carboxylic acid
The title compound is prepared from a ca. 1:1 mixture of c/s-1-(1H-benzoimidazole-5-carbonyl)2,3,4,4al9,9a-hexahydro-1H-indeno[2,1-b]pyridine-6-carboxylic acid methyl ester and c/s-1-(1Hbenzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1 - b] pyridine -7-carboxylic acid methyl ester following a procedure analogous to that described in Example 35 and
144 separated from Example 99 by HPLC on reversed phase (MeCN/H2O). Yield: 4% of theory: Massspectrum (EST): m/z = 362 [M+Hf.
Example 99 c/s-1-(1H-Benzoimidazole-5-carbonvl)-2.3.4,4a.9.9a-hexahvdro-1H-indeno[2,1-blpyridine-7carboxylic acid
The title compound is prepared from a ca. 1:1 mixture of c/s-1-(1H-benzoimidazole-5-carbonyl)2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1-b]pyridine-6-carboxylic acid methyl ester and c/s-1-(1Hbenzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine -7-carboxylic acid methyl esterfollowing a procedure analogous to that described in Example 35 and separated from Example 98 by HPLC on reversed phase (MeCN/H2O). Yield: 5% of theory; Mass spectrum (EST): m/z = 362 [M+Hf.
Example 100 c/s-1-(1H-Benzoimidazole-5-carbonvl)-2.3.4,4a.9.9a-hexahvdro-1H-indenof2,1-blpvridine-6carboxylic acid amide
The title compound is prepared from c/s-1-(1H-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridine-6-carboxylic acid and ammonia (0.5 mol/L in 1,4-dioxane) following a procedure analogous to that described in Example 1. Yield: 64% of theory; LC (method 1): tR = 1.64min; Massspectrum (EST): m/z = 361 [M+H]*.
Example 101 c/s-1-(1H-Benzoimidazole-5-carbonyl 1-2,3,4,4a,g.ga-hexahvdro-IH-indenofë.l-blpyridine-?-
145
The title compound is prepared from c/s-1-(1H-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridine-7-carboxylic acid and methylamine (2 mol/L in tetrahydrofuran) following a procedure analogous to that described in Example 1. Yield: 19% of theory; LC (method 1): tfi = 1.86 min; Mass spectrum (ESC): m/z = 375 [M+H]+.
Example 102 (cÂs-2,3.4.4a,9.9a-Hexahvdro-indenoÎ2.1-blpvridin-1-vl)-(1H-imidazof4,5-b1pvridin-5-vlÎmethanone
N />
N
The title compound is prepared from 1H-imidazo[4,5-b]pyridine-5-carboxylic acid and c/s2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1“b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,34etramethyluronium hexafluorophosphate is used]. Yield: 74% of theory; LC (method 3): tR = 2.10 min; Mass spectrum (ESI+): m/z = 319 [M+H]*.
Example 103
6-(c7s-2.3,4.4al9.9a-Hexahvdro-indenof2,1-blpyridine-1-carbonvl)-3H-benzothiazol-2-one
The title compound is prepared from 2-oxo-2,3-dihydro-benzothiazole-6-carboxylic acid and c/s2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 74% of theory; LC (method 3): tR = 2.28 min; Mass spectrum (ESC): m/z= 351 [M+H]*.
Example 104 (c/s-2,3,4.4a.9.9a-Hexahvdro-indenor2.1-blpvridin-1-vll-imidazoÎ1.2-alpvridin-6-yl-methanone
The title compound is prepared from imidazo[1,2-a]pyridine-6-carboxylic acid and c/s2,3,4,4a,9.9a-hexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3’tetramethyluronium hexa-
146 fluorophosphate is used], Yield: 85% of theory; LC (method 3): tR = 1.81 min; Mass spectrum (ESI*): m/z =318 [M+H]*.
Example 105 ( 1 H-Benzoimidazol-5-vl)-(trans-10b-ethyl-2,3,4a,5,6,1 Qb-hexahydro-1 H-benzoiflauinolin-4-yl)methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and trans-10b-ethyl1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline foilowing a procedure analogous to that described in Example 1. Yield: 44% of theory; TLC; rf = 0.42 (silica gel, CH2CI2/MeOH/32% aqueous NH3 90:10:1 ); Mass spectrum (ESI*): m/z = 360 [M+H]*.
Example 106 c/s-1 -(1H-8enzoimidazole-5-carbonvl)-2.3.4.4a.9.9a-hexahydro-1H-indeno[2.1-blpvridine-6carbonitrile
The title compound is prepared from cis-1-(1H-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridine-6-carboxylic acid amide foilowing a procedure analogous to that described in Example 42. Yield: 64% of theory; LC (method 1): tR = 2.33 min; Mass spectrum (Ε3Γ): m/z = 343 [M+H]*; for ’H NMR see Example 108.
The title compound is also obtained as follows:
Aflask charged with a stir bar, zinc cyanide (0.32 g), trifluoromethanesulfonic acid c/s-1 -(1trifluoromethanesulfonyl-1H-benzoimidazole-5-carbonyl )-2,3,4,4a,9,9a-hexahydro-1Hindeno[2,1-b]pyridin-6-yl ester (mixture of isomers regarding sulfonyl group attachment at N-1 or N-3 of the benzimidazole, 1.08g), and N,N-dimethylformamide (5 mL) is sparged with argon for 10 min. Tetrakis(triphenylphosphine)palladium(0)(0.31 g) is then added and the resulting mixture is heated to 100 °C and stirred at this température for 2 h. After cooling to room température, 1 -hydroxybenzotriazole hydrate (0.45 g) and water (1.5 mL) are added and stirring is continued at room température for 3 h. Ethyl acetate, lîttle methanoi, and saturated aqueous NazCC>3 solution are added and the mixture ïs filtered over Celite. The aqueous phase of the filtrate is separated and neutralized with 2 M aqueous citric acid and extracted with ethyl acetate. The organic phases are combined and washed with brine and dried (Na2SO4). The solvent is evaporated and the residue is chromatographed on silica gel
147 (dichloromethane/methanol 96:4-»90:10) to give the title compound as a solid. Yield: 0.42 g (68% of theory).
Example 107 (4a-R9a-S)-1 -(1H-Benzoimidazole-5-carbonyl )-2,3,4,4a,9,9a-hexahydro-1H-indenof2,1blpvridine-6-carbonitnle
The title compound is obtaîned by chromatographing a racemic mixture of c/s-1-(1Hbenzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1 -b]pyridine-6-carbonitrile (600 mg)on chiral phase (SFC; column: Daicel ASH 250 x 20 mm, 5 pm; mobile phase: isopropanol containing 0.2% diethylamine/sc carbon dioxide 25:75; flow rate: 90 mL/min; 40 °C). Yield: 112 mg; LC (préparative SFC on chiral phase as above): tR = 8.45 min; Mass spectrum (ESI+): m/z = 318 [M+H]*; for ’H NMR see Example 108.
Alternatively, the compound is obtaîned from (1H-benzoimidazol-5-ylH(4a-R,9a-S)-6-bromo2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl]-methanonefollowing a procedure analogous to that described in Example 148. Yield: 26% of theory.
Alternatively, the title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and (4aR,9a-S)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine-6-carbonitrile following a procedure analogous tothat described in Example 1. Yield: 81% of theory.
The title compound is also prepared as follows:
1-Hydroxybenzotriazole monohydrate (138.0 g), 1-(dimethylaminopropyl)-3-ethylcarbodîimide hydrochloride (172.7 g), and triethylamine (262 mL) are added in the given order to a solution of
H-benzoimidazole-5-carboxylic acid (146.1 g) and (4a-/?,9a-S)-2,3,4,4a,9,9a-hexahydro-1Hindeno[2,1-b]pyridine-6-carbonitrile (149.0 g) in N,N-dimethylformamide (600 mL) at room température. The mixture is stirred at room température overnight. Water (1.5 L) and dichloromethane (1.5 mL) are added and the organic phase is separated and the aqueous phase is extracted with dichloromethane (750 mL). The combined organic phase is washed with mol/L aqueous NaOH solution (750 mL), 2 mol/L aqueous hydrochloric acid (630 mL), and water (3x 1.5 L) and concentrated at below 50 °C. Ethyl acetate (700 mL) is added to the residue and the resulting mixture is heated to obtain a homogeneous solution. The solution is cooled to room température overnight and the precipitate is separated by filtration and washed with ethyl acetate (2x 100 mL). The precipitate is dried under vacuum at 50 °C for 5 h to give the title compound as a white solid. Yield: 208.0 g (84% pure, >99% ee).
The title compound is also prepared as follows:
148 (4a-R,9a-S)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine-6-carbonitrile (19.8 g) and 40 ml 2-methyltetraherofuran are added to a 500 ml reactor with overhead agitator, followed by addition of water(200 ml) and Na2CO3 (21.2 g, 200 mmol, 2 eq). A slurry of 1Hbenzoimidazole-5-carboxylic acid chloride in 2-methyltetrahedrofuran (19.8 g, 110 mmol, 1.1 eq, in 200 ml 2-methyltetrahedrofuran) is added slowly over a period of 3 h, and the resulting twophase reaction mixtureis stirred for another 3 h. The aqueous phase is removed, and the the organic organic phase is washed with 10% brine. The solution is concentrated at ~50 °C under reduced pressure, and solvent is switched to 250 mL ethyl acetate. A slurry forms at this stage and the reaction mixture is cooled to room température and stirred for 2 h. The precipitate is separated by filtration and washed with ethyl acetate (2x 15 mL). The precipitate is dried under vacuum at 50 ’C for 5 h to give the title compound as a white solid. Yield: 34.4 g (86% wt as ethyl acetate solvaté, 86% yield, >99% ee).
The hydrogen chloride sait of (4a-R,9a-S)-1-(1H-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridine-6-carbonitrile is obtained in two different crystalline modifications:
Crystal form I: f4a-/?,9a-S)-1-(1H-Benzoimidazole-5-carbonvlÎ-2.3,4.4a,9,9a-hexahvdro-1H-indenof2,1b1pvridine-6-carbonitrile*hydroqen chloride
Hydrochloric acid (5-6 mol/L in isopropanol, 1.46 mL) is added dropwise to a stirred solution of (4a-R,9a-S)-1-(1H-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1b]pyridine-6-carbonitrile (2.10 g) in éthanol (10 mL) at room température. A seed crystal is added, and stirring is continued at room température for 2 h and at 0 ’C for another 2 h. The precipitate is separated by filtration (the filtrate is used to préparé crystal form II, see below), washed with little éthanol, and dried (60 ’C) to give an orange-colored solid (1.60 g), The solid is redissolved in éthanol (250 mL) and charcoal (1 g) is added to the solution. The mixture is stirred for 5 min and then filtered. The filtrate is concentrated to ca. 100 mL and a seed crystal is added. The solution is stirred at room température for 2 h and at ca. -10 ’C for 30 min. The precipitate is separated by filtration (the filtrate is used to préparé crystal form II, see below) and dried (60 ’C) to give the title compound as a colorless, crystalline solid (0.90 g); mp (onset) = 252 ’C.
The seed crystals are prepared as follows: hydrochloric acid (5-6 mol/L in isopropanol, 40 pL) is added to a stirred solution of (4a-R,9a-S)-1-(1H-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridine-6-carbonitrile (63 mg) in éthanol (0.5 mL). The resulting solution is stirred at room température overnight. The precipitate is separated by filtration, washed with little cold éthanol, and dried to give a colorless solid (30 mg).
149
Crystal Form I can also be prepared by the following procedure:
A solution of (4a-R,9a-SJ-1-(1H-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1Hindeno[2,1-b]pyridine-6-carbonitrile (1.5 g) in éthanol (3.92g) is prepared by heating to 50 °C.
The solution is then cooled to ambient température within 30 mins. The solution is charged with aqueous HCl (36.5 wt%; 0.4 g) and aged until the slurry forms. The slurry is filtered and dried under vacuum at ~ 25 °C.
Crystal form II: (4a-R9a-S)-1-(1H-Benzoimidazole-5-carbonvn-2,3,4,4a,9,9a-hexahvdro-1H-indenof2.1blDvridine-6-carbonitrile*hvdroQen chloride
The filtrâtes of the above mentioned préparation of crystal form I are concentrated, combined, and taken up in ethyl acetate (75 mL). The resulting mixture is stirred at 50 °C for 4 h. The suspension is cooled to room température, the precipitate is separated by filtration, washed with ethyl acetate (20 mL), and dried (60°C) to give a colorless solid (0.58 g). This solid (0.58 g) together with a residue (ca. 1 g) obtained by concentration of a filtrate from a repeat préparation of crystal form I are stirred in éthanol at room température overnight. The precipitate is separated by filtration and dried (60 °C) to give the colorless, crystalline form II of the title compound (0.65 g); mp (onset) = ca. 240 C. This procedure may be scaled up to the multigram, hundred gram oreven kilogram scale.
Crystal form II is also obtained by the following procedure:
A reaction vessel charged with (4a-R,9a-S)-1-(1H-benzoimidazole-5-carbonyl)-2,3l4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridine-6-carbonitrile (331.5 g) and isopropanol (331.5 g) is heated at 75 ’C until a homogeneous solution is formed. 5.12 mol/L HCl in isopropanol (29.7 g) is added followed by isopropanol (5 g) to rinse the addition vessel. (4a-R,9a-S)-1-(1HBenzoÎmidazole-5-carbonyl)-2,3l4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine-6-carbonitrile hydrochloride (crystal form II; 19.88 g; the seeds are milled and slurried in 30 g isopropanol for ca. 1 h) is added followed by isopropanol (20 g) to rinse the addition vessel. The solution is aged for 1 h and then 5.12 mol/L HCl in isopropanol (171.3 g) is added over 4 h. The mixture is cooled to 0-5 °C over 1 h and aged at this température for 30 min. The precipitate is separated by filtration, washed with heptane (0-5 °C), and dried under vacuum at 65 °C for 8 h. Yield: 368.9 g (yield: 95%; corrected forseed charge).
Crystal form II is also obtained by the following procedure:
Crystal form 1(150 mg) and absolute éthanol (0.6 mL) are stirred at room température for one week. The precipitate is separated by filtration, washed with little absolute éthanol and dried at 40eC.
Crystal Form II can also be prepared by the following procedure:
150
A solution of (4a-R,9a-S)-1 -(1 H-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1 Hindeno[2,1-b]pyridine-6-carbonitrile (26.07 g) in 200 proof absolute éthanol (104.30g) is prepared by heating to 50 °C. The solution is charged with 4.587 g HCl in 200 proof absolute éthanol (6.55 N) at 50 °C. 3.605 g Form II mîlled seed slurry is added (seed slurry is prepared by mixing 0.782 g mîlled Form II with 2.823 g EtOH) and âge at 50 °C for more than 2 hrs. The solution is charged with 5.045g HCl in EtOH (6.55 N) over 2 hrs, then cooled to 0 °C over 1 hr. The solution is aged at 0 qC for more than 1 hr. The crystals are separated by filtration and dried at 70 °C under vacuum for more than 12 hrs. This procedure may be scaled up to the multi-gram, hundred gram or even kilogram scale.
X-Ray Powder Diffraction - XRPD
X-ray powderdiffraction analyses for samples of Form I and Form II were conducted on a Bruker AXS X-Ray Powder Diffractometer Model D8 Advance, using CuKa radiation (1.54A) in parafocusing mode with a graphite monochromator and a scintillation detector. The pattern was obtained by scanning over a range of 2’ - 35° 2T, step size of 0.05° 2T, step time of 4 sec per step. ExemplaryXRPD spectraof Form I and Form II may be found in Figures 1 and 5, respectively.
Solîd-state NMR-SSNMR 13C Solid-state NMR (SSNMR) data for samples of Form I and Form II was acquired on a Bruker Avance III NMR speclrometer (Bruker Biospin, Inc., Billerica, MA) at 9.4T (1Η=400.46 MHz, 13C=100.70 MHz). Samples were packed in 4 mm O.D. zirconia rotors with Kel-F® drive tips.
A Bruker model 4BL CP BB WVT probe was used for data acquistion and sample spinning about the magic-angle (54.74°). Sample spectrum acquistion used a spinning rate of 12kHz. A standard cross-polarization puise sequence was used with a ramped Hartman-Hahn match puise on the proton channel at ambient température and pressure. The puise sequence used a 5 millisecond contact puise and a 30 second recycle delay. Two-pulse phase modulated (tppm) decoupling was also employed in the puise sequence. No exponential line broadening was used prior to Fourier transformation of the free incution decay. Chemical shifts were referenced using the secondary standard of adamantane, with the upfield résonance being set to 29.5 ppm. The magic-angle wasset using the 79Br signal from KBr powder at a spinning rate of 5 kHz. Exemplary 13C SSNMR spectra of Form I and Form II may be found in Figures 2 and 6, respectively.
TGA
TGA analysis was performed with a Perkin Elmer Pyris 1 TGA instrument, SN 537N9120103, using general procedure, 002-GP-00342. Samples were heated from RT (~25°C) to 300 °C and
151 the weight loss calculated from RT to 150 ’C. Exemplary TGA traces of Form l and Form II may be found in Figures 4 and 8, respectively. Results are reported below.
Sample ID | %Weight Loss | Ave. % IVt Loss |
Form II | 0.041 | 0.05 |
0.066 | ||
Form I | 2.050 | 2.09 |
2.125 |
DSC
DSC analysis was performed with a Diamond DSC instrument, SN 536N6102101, using general procedure, 002-GP-00343. Samples were heated from 25°C to 300°C and the thermal events determined. Exemplary DSC traces of Form I and Form II may be found in Figures 3 and 7, respectively. Results are reported below. Form I also showed a thermal event at 67.4°C possibly due to loss of surface water as sample showed evidence of hygroscopicity.
Sample ID | Onset ofMelt w/Decomp. (°C) |
Form II | 235.5 |
Form I | 231.7 |
Example 108 (4a-S.9a-R)-1-(1H-Benzoimi'dazole-5-carbonvl)-2.3,4,4a,9,9a-hexahvdro-1H-indenof2.1blpyridine-6-carbonitrile
The title compound is obtained by chromatographîng a racemic mixture of c/s-1-(1Hbenzoimidazole-5-cafbonyl)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine-6-carbonitrile (600 mg) on chiral phase (SFC; column: Daîcel ASH 250 x 20 mm, 5 pm; mobile phase: isopropanol containing 0.2% diethylamine/sc carbon dioxide 25:75; flow rate: 90 mL/min; 40 °C) in ca. 90% eepurity (Example 108/Example 107 ca. 95:5). Yield: 115 mg; LC (préparative SFC on chiral phase as above): tR = 6.00 min; Mass spectrum (ESl*): m/z =318 [M+H]+; ‘H NMR (400 MHz, DMSO-d6, mixture of rotamers) d 1.22-1.35 (m, 1 H), 1.42-1.56 (m, 1 H), 1.57-1.69 (m, 1H), 1.96-2.06 (m, 1 H), 2.86-3.18 (m, 3H), 3.20-ca. 3.29 (m, 1H), ca. 3.62-5.58 (very broad signais, 2H), 7.19-7.31 (m, 1H), 7.41-7.49 (m, 1 H), 7.54-7.74 (m, 4H), 8.29 (s, 1 H), 12.60 (broad s, 1H).
152
Example 109 (2-Amino-benzothiazol-6-vl)-(c/s-2,3,4,4a,9.9a-hexahydro-indeno[2,1-b]pyridin-1-vl)-methanone
The title compound is prepared from 2-amino-benzothiazole-6-carboxylic acid and cis2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 63% of theory; LC (method 4): tR = 1.76 min; Mass spectrum (ESI+): m/z = 350 [M+Hf.
Example 110 (c/s-2,3,4,4a,9,9a-Hexahydro-indeno[2,1-b]pyridin-1-vl)-(3-hydroxv-4-methvl-phenvl)methanone
The title compound is prepared from 3-hydroxy-4-methyl-benzoic acid and 0/5-2,3,4,43,9,98hexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1 H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-fluorophosphate is used]. Yield: 45% of theory; LC (method 4): tR = 1.98 min; Mass spectrum (ESI+): m/z = 308 [M+Hf.
Example 111 (3-Amino-4-methoxv-phenvlKcis-2,3,4.4a,9,9a-hexahydro-indenof2.1-blpvridin-1-yl)-methanone
The title compound is prepared from 3-amino-4-methoxy-benzoic acid and 0/5-2,3,4,43,9,93hexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1 H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-fluorophosphate is used]. Yield: 77% of theory; LC (method 4): tR = 1.75 min; Mass spectrum (ESI+): m/z = 323 [M+Hf.
153
Example 112 (c/s-2,3.4,4a,9,9a-Hexahvdro-indeno[2,1-blpvridin-1-vl)-(2-methvl-1H-indol-5-vl)-methanone
The title compound is prepared from 2-methyl-1H-indole-5-carboxylic acid and c/s2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 39% of theory; LC (method 4): tR = 2.01 min; Mass spectrum (ESI+): m/z = 331 [M+H]+.
Example 113
5-(c/s-2,3,4.4a,9,9a-Hexahvdro-indeno[2,1-blovridine-1-carbonvl)-1-methvl-1,3-dihvdrobenzoimidazol-2-one
The tille compound is prepared from 1-methyl-2-oxo-2,3-dihydro-1H-benzoimidazole-5carboxylic acid and c/s-2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate is used]. Yield: 27% of theory; LC (method 4): tR = 1.89 min; Mass spectrum (EST): m/z = 348 [M+H]+.
Example 114 (c/s-2.3.4.4a,9,9a-Hexahvdro-indenor2.1-b1pvridin-1-vn-(1H-indol-6-vl)-methanone
The title compound is prepared from 1H-indole-6-carboxylic acid and c/s-2,3,4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1 H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 41% of theory; LC (method 4): tR = 2.00 min; Mass spectrum (EST): m/z = 317 [M+Hf.
154
Example 115
5-(0/5-2,3,4,48,9,9a-Hexahvdro-indeno[2.1-blpvridine-1-carbonvlM,3-dihydro-indol-2-one
The title compound îs prepared from 2-oxo-2,3-dihydro-1 H-indole-5-carboxylic acid and c/s2,314,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine foliowing a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 29% of theory; LC (method 5): tR = 0.98 min; Mass spectrum (ESl·): m/z = 333 [M+Hf.
Example 116
6-(c/'s-2,3.4.4a,9,9a-Hexahydro-indeno[2,1-blpyridine-1-carbonvl)-1.3-dihvdro-indol-2-one
The title compound is prepared from 2-oxo-2,3-dihydro-1 H-indole-6-carboxylîc acid and c/s2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine foliowing a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 34% of theory; LC (method 4): tR = 1.88 min; Mass spectrum (ESI+): m/z = 333 [M+Hf.
Example 117 (c/s-2.3.4,4a.9,9a-Hexahvdro-indeno[2,1-blpvridin-1-vl)-(1-methyl-1H-benzoimidazol-5-vDmethanone
The title compound is prepared from 1-methyl-1H-benzoimidazole-5-carboxylic acid and c/s2,3,4,4a,9,9a-hexahydro-1H-indeno[2l1-b]pyridine foliowing a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 90% of theory; LC (method 4): tR = 1.62 min; Mass spectrum (ESl·): m/z = 332 [M+Hf.
155
Example 118 (cis-2,3,4,4a,9,9a-Hexahvdro-indeno[2,1-b1pyridin-1-vlH1-methYl-1H-benzotriazol-5-vOmethanone
N ,N
N
The title compound is prepared from 1-methyl’1H-benzotriazole-5-carboxylic acid and c/s2l314,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 65% of theory; LC (method 4): tR = 1.88 min; Mass spectrum (ESI+): m/z = 333 [M+H]+.
Example 119 (1H-Benzoimidazol-5-vD-(c/s-7-hvdroxy-2,3.4,4a,9,9a-hexahvdro-indenof2.1-blpvridin-1-yl)methanone
The title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and c/s2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-7-ol following a procedure analogous to that described in Example 1. Yield: 18% of theory; LC (method 1): tR = 1.97 min; Mass spectrum (ESI+): m/z = 334 [M+H]+.
Example 120 (c/s-2l3.4,4a,9,9a-Hexahvdro-indenor2.1-b1pvridin-1-vl)-(4-hvdroxv-3-methvl-phenvl)-methanone
The title compound is prepared from 4-hydroxy-3-methyl-benzoic acid and c/s-2,3,4,4a,9,9ahexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-fluorophosphate is used]. Yield: 35% of theory; LC (method 4): tR = 1.92 min; Mass spectrum (EST): m/z = 313 [M+H]*.
156
Example 121 (c/s-Z.S.^a.g.ga-Hexahvdro-indenoiZ.I-blpvridin-l-ylMZ-methvl-IH-benzoimidazol-S-yl)methanone
The title compound is prepared from 2-methyl-1H-benzoimidazole-5-carboxylic acid and c/'s2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 (2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 89% of theory; LC (method 5): tR = 0.95 min; Mass spectrum (ESL): m/z= 332 (M+HJ*.
Example 122 (4-Amino-3-chloro-phenyl)-( c/s-2,3,4,4a,9,9a-hexahvdro-indenoi2.1-b1pvridln-1-yl)-methanone
The title compound is prepared from 4-amino-3-chloro-benzoic acid and c/s-2,3,4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridîne following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 38% of theory; LC (method 4): tR = 1.96 min; Mass spectrum (ESI+): m/z = 327/329 (Cl) [M+Hf.
Example 123
The title compound is prepared from 1 H-indazole-6-carboxylic acid and c/'s-2,3,4,4a,9,9ahexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 5% of theory; LC (method 4): tR = 1.92 min; Mass spectrum (EST): m/z = 318 [M+Hf.
157
Example 124 (2-Amino-1H-benzoimidazol-5-vn-(c/s-2,3.4,4a.9.9a-hexahvdro-indenof2,1-b1pvridin-1-vl)methanone
The title compound is prepared from 2-amino-1H-benzoimidazole-5-carboxylic acid and cis2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1 H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 71% of theory; LC (method 4): tR = 1.64 min; Mass spectrum (ESl·): m/z = 333 [M+H]*.
Example 125
Benzothiazol-6-vl-(c/'s-2.3,4.4a,9,9a-hexahYdro-indenof2,1-blpyrÎdin-1-vn-methanone
The title compound is prepared from benzothiazole-6-carboxylic acid and c/s-2,3,4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1 H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 36% of theory; LC (method 4): tR = 1.94 min; Mass spectrum (ESl·): m/z = 335 [M+Hf.
Example 126 (4-Chloro-3-hvdroxv-phenvl)-(c/s-2.3.4,4a.9.9a-hexahydro-indeno[2.1-b1pvridin-1-vl)-methanone
The title compound is prepared from 4-chloro-3-hydroxy-benzoic acid and c/s-2,3,4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 44% of theory; LC (method 4): tR = 1.97 min; Mass spectrum (EST): m/z = 328 [M+Hf.
158
Example 127 (c/s-2,3.4,4a,9,9a-Hexahydro-indenof2,1-blpvridin-1-vl)-(1H-imidazor4,5-blpvrÎdin-6-yl)methanone
The tille compound is prepared from 1H'imidazo[4,5-b]pyridine-6-carboxylic acid and cis2,3<4,4a(9,9a-hexahydro-1 H-indeno^J-blpyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 71% of theory; LC (method 4): tR = 1.79 min; Mass spectrum (EST): m/z = 319 [M+Hf.
Example 128
5-(c/s-2,3,4,4a,9.9a-Hexahvdro-indeno[2,1-blpvridine-1-carbonyl)-1,3-dihvdro-benzoimidazol-2-
N >0
N
H
The title compound is prepared from 2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid and c/s-2,3,4l4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 11% of theory; LC (method 4): tR = 1.86 min; Mass spectrum (ESL): m/z= 334 [M+Hf.
Example 129 (c/s-2,3,4,4a,9,9a-Hexahvdro-indeno[2.1-blpvridin-1-vlH3-methyl-3H-benzoimidazol-5-vl)methanone
The title compound is prepared from 3-methyl-3H-benzoimidazole-5-carboxylic acid and c/s2,3l4l4al9,9a-hexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that describedin Example 1 [Z-fy-aza-IH-benzotriazol-l-ylfl.I.S.S-tetramethyluronium hexafluorophosphate is used]. Yield: 94% of theory; LC (method 4): tR = 1.62 min; Mass spectrum (ESI+): m/z= 332 [M+Hf.
159
Example 130
O-Amino^-fluoro-phenvIKcis^.S^^a.g.ga-hexahydro-indeno^.l-blpvndin-l-vO-methanone
The title compound is prepared from 3-amino-4-fluoro-benzoic acid and c/s-2,3,4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 ^-(T-aza-IH-benzotriazol-l-yO-I.I.S.S-tetramethyluronium hexafluorophosphate is used]. Yield: 68% of theory; LC (method 4): tR = 1.91 min; Mass spectrum (ESI4): m/z = 311 [M+H]+.
Example 131 (c/s-2,3,4,4a,9.9a-Hexahvdro-indeno[2,1-blpyridin-1-vl)-imidazof1,2-alpyridin-7-yl-methanone
The title compound is prepared from imidazo[1,2-a]pyridine-7-carboxylicacid and c/s2,3,414al9,9a-hexahydro-1H-indeno[2l1-b]pyridine following a procedure analogous to that described in Example 1 ^-(T-aza-IH-benzotriazol-l-yO-U.S.S-tetramethyluronium hexafluorophosphate is used], Yield: 18% of theory; LC (method 4): tR = 1.56 min; Mass spectrum (EST): m/z = 318 [M+H]4.
Example 132 (c/s-2,3,4,4a.9,9a-Hexahvdro-indeno[2.1-blpvridin-1-vD-(1H-indazol-5-vl)-methanone
The title compound is prepared from 1H-indazole-5-carboxylic acid and c/s-2,3,4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 31% of theory; LC (method 4): tR = 1.91 min; Mass spectrum (ESI4): m/z = 318 [M+H]+.
160
Example 133 (4-Amino-phenyl)-(c/s-213,4,4a,9,9a-hexahvdro-indeno[2,1-blpyridin-1-vl)-methanone
The title compound is prepared from 4-amino-benzoic acid and c/s-2,3,4,4a,9,9a-hexahydro-1Hindeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-azaIH-benzotriazol-l-yO-I.I.S.S-tetramethyluronium hexafluorophosphate is used]. Yield: 70% of theory; LC (method 4): tR = 1.77 min; Mass spectrum (ESP): m/z = 293 [M+Hf.
Example 134 (c/s-2.3,4,4a,9,9a-Hexahydro-indenoi2,1-blpvridin-1-vl)-(4-hydroxv-phenyl)-methanone
The title compound is prepared from 4-hydroxy-benzoic acid and c/s-2,3,4,4a,9,9a-hexahydro1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 25% of theory; LC (method 4): tR = 1.91 min; Mass spectrum (ESP): m/z = 294 [M+H]+.
Example 135 (c/s-2,3,4,4a,9,9a-Hexahydro-indeno[2.1-b1pvridin-1-vl)-(1H-indol-5-yl)-methanone
The titfe compound is prepared from 1 H-indole-5-carboxylic acid and 0/3-2,3,4,48,9,93hexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 43% of theory; LC (method 4): tR = 1.97 min; Mass spectrum (EST): m/z = 317 [M+H]+.
Example 136 (c/s-2.3,4.4a,9,9a-Hexahvdro-indenof2.1-b1pvridin-1-vl)-(lH-indol-3-vl)-methanone
161
The title compound is prepared from 1 H-indole-3-carboxylîc acid and c/'s-2,3,4,4a,9,9ahexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 35% of theory; LC (method 4): tR = 1.99 min; Mass spectrum (ESI+): m/z= 317 [M+H]+.
Example 137 (3.5-Dichloro-4-hvdroxv-phenvl)-(c/s-2,3,4,4a,9,9a-hexahvdro-indenof2,1-b1pvridin-1-vl)methanone
OH
Cl
The title compound is prepared from 3,5-dichloro-4-hydroxy-benzoic acid and c/s-2,3,4,4a,9,9ahexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 32% of theory; LC (method 4): tR = 2.01 min; Mass spectrum (ESI+): m/z = 362/364/366 (Cl) [M+H]+.
Example 138 (1H-Benzotriazol-5-vl)-(c/s-2.3.4.4a.9.9a-hexahvdro-indeno|2,1-blpvridin-1-vD-methanone
The title compound is prepared from 1H-benzotriazole-5-carboxylic acid and c/s-2,3,4,4a,9,9ahexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 19% of theory; LC (method 4): tR = 1.87 min; Mass spectrum (ESI+): m/z = 319 [M+H]*.
Example 139 (c/s-2,3.4.4a,9.9a-Hexahvdro-indenor2.1-blpvridin-1-vl)-(1-methvl-1H-indol-3-vl)-methanone
The title compound is prepared from 1-methyl-1H-indole-3-carboxylic acid and c/s2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-bjpyridine following a procedure analogous to that
162 described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 26% of theory; LC (method 4); tR = 2.02 min; Mass spectrum (EST): m/z = 331 [M+Hf.
Example 140 (c/s-2,3,4,4a,9,9a-Hexahvdro-indenoi2,1-blPvridin-1-vl)-(3-hvdroxv-4-methoxy-phenvll· methanone
The title compound is prepared from 3-hydroxy-4-methoxy-benzoic acid and c/s-2,3,4,4a,9,9ahexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-lH-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 45% of theory; LC (method 4): tR = 1.91 min; Mass spectrum (ESC): m/z = 324 [M+Hf.
Example 141
The title compound is prepared from 3-chloro-4-hydroxy-benzoic acid and c/3-2,3,4,4a,9,9ahexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-fluorophosphate is used], Yield: 32% of theory; LC (method 4): tR = 1.96 min; Mass spectrum (ESC): m/z = 328/330 (Cl) [M+Hf.
Example 142 (3-Amino-4-chloro-phenvl)-(c/s-2l3,4,4a,9,9a-hexahvdro-indenor2.1-b1pvridin-1-vl)-methanone
The title compound is prepared from 3-amino-4-chloro-benzoic acid and c/s-2,3,4,4a,9,9ahexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used], Yield: 43% of theory; LC (method 4): tR = 1.97 min; Mass spectrum (ΕΘΓ): m/z = 327/329 (Cl) [M+Hf.
163
Example 143 (3-Amino-4-methvl-phenvn-(c/s-2,3.4.4a.9.9a-hexahvdro-indeno[2,1-b]pvridin-1-vO-methanone
The title compound is prepared from 3-amino-4-methyl-benzoic acid and c/s-2,3,4,4a,9,9ahexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-{7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 63% of theory; LC (method 4): tR = 1.81 min; Mass spectrum (EST): m/z = 307 [M+H]*.
Example 144 (4-Amino-3-methoxv-phenvl)-(c/‘s-2,3,4,4a.9,9a-hexahvdro-indenoi2,1-blpvridin-1-vl)-nnethanone
The title compound is prepared from 4-amino-3-methoxy-benzoic acid and c/s-2,3,4,4a,9,9ahexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-fluorophosphate is used]. Yield: 59% of theory; LC (method 4): tR = 1.80 min; Mass spectrum (EST): m/z = 323 [M+H]*.
Example 145 (4-AminQ-3-fluoro-phenvlMc/s-2.3,4,4a.9.9a-hexahydro-indenor2,1-b1pvridin-1-yl)-methanone
The title compound is prepared from 4-amino-3-fluoro-benzoic acid and c/s-2,3,4,4a,9,9ahexahydro-1 H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 62% of theory; LC (method 4): tR = 1.91 min; Mass spectrum (ESI+): m/z = 311 [M+H]*.
164
Example 146 (1H-Benzoimidazol-5-vl)-(c/s-4-methvl-2.3,4,4a.9.9a-hexahydro-indeno[2,1-b1pvridin-1-vl)methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and c/s-4-methyl2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1. Yield: 16% of theory; LC (method 1): tR = 2.68 min; Mass spectrum (ESI4): m/z = 332 [M+H]4.
Example 147
6-(c/s-2,3,4,4a,9,9a-Hexahvdro-indeno[2.1-b]Dvridine-1-carbonvl)-1H-guinoxalin-2-one
The title compound is prepared from 2-oxo-1,2-dihydro-quinoxaline-6-carboxylic acid and c/s2l3,4l4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1 [2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate is used]. Yield: 45% of theory; LC (method 4): tR = 1.89 min; Mass spectrum (ESI4): m/z = 346 [M+H]4.
Example 148 (4a-fîl9a-S)-1-(1H-Benzoimidazole-5-carbonvl)-2l3.4,4a.9,9a-hexahydro-1H-indeno[2,1blDvridine-7-carbonitrile
Aflask charged with a stir bar, zinc cyanide (94 mg), (1H-benzoimidazol-5-yl)-[(4a-R,9a-S)-7bromo-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl]-methanone (0.30 g), and N,Ndimethylformamide (2 mL) is sparged with argon for 10 min. Tetrakis(triphenylphosphine)palladium(O) (0.10 g) is then added and the resulting mixture is heated to 100 °C and stirred at this température overnight. After cooling to room température, methanol is added and the resulting mixture is filtered. The filtrate is concentrated and water is added to the residue. The
165 aqueous mixture is extracted with ethyl acetate, the combined extracts are dried (Na2SO4), and the solvent is evaporated. The residue is purified by HPLC on reversed phase (acetonitrile/water/trifluoroacetic acid) to give the title compound as its trifluoroacetic acid sait. Yield: 0.09 g (25% of theory); LC (method 1 ): tR = 2.31 min; Mass spectrum (ESI+): m/z = 343 [M+Hf.
Example 149 (4a-f?,9a-S¾-(1H-Beπzoimidazol·5-vl)-(6-methoxv-2,3,4,4a,9,9a-hexahvdro-indenoF2.1-b1pyridin1-vl)-methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and (4a-R,9a-S)-6methoxy-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1. Yield: 89% of theory; LC (method 1): tR = 2.43 min; Mass spectrum (ESf): m/z = 348 [M+Hf.
Example 150 (4a-/?,9a-S)-(1H-Benzoimidazol-5-vl)-(6-hvdroxv-2,3,4,4a,9,9a-hexahvdro-indeno[2,1blpyridin-1 -ylTmethanone
The title compound is prepared from (4a-R,9a-S)-(1H-benzoimidazol-5-yl)-(6-methoxy2,3,4l4al9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl)-methanone following a procedure analogous to that described in Example 7. Yield: 78% of theory; LC (method 1): tR = 1.89 min; Mass spectrum (EST): m/z = 334 [M+Hf.
Example 151 (c/s-7-Amino-2.3,4.4a,9,9a-hexahvdro-indeno[2.1-blpvridin-1-vl)-(1H-benzoimidazol-5-yl)methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and c/s2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-7-ylamine following a procedure analogous to
166 that described in Example 1. Yield: 30% of theory; LC (method 1): tR = 0.79 min; Mass spectrum (ESF): m/z = 333 [M+H]+.
Example 152 (4a-/?,9a-S)-1-(7-Methyl-1H-benzoimidazole-5-carbonyl)-2.3,4,4a,9,9a-hexahvdro-1Hindenof2,1-b|pvridine-6-carbonitrile
The title compound is prepared from 7-methyl-1 H-benzoimidazole-5-carboxylic acid and (4aR9a-S)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine-6-carbonitrile following a procedure analogous to that described in Example 1. Yield: 53% of theory; LC (method 6): tR = 1.05 min; Mass spectrum (EST): m/z = 357 [M+H]+.
Example 153 (4a-R.9a-S)-1-(6-Methvl-1 H-benzoimidazole-5-carbonyl)-2,3,4.4a. 9.9a-hexahvdro-1 Hindenof2,1-b1pyridine-6-carbonitrile
The title compound is prepared from 6-methyl-1H-benzoimidazole-5-carboxylic acid and (4a/?,98-5)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine-6-carbonitrile following a procedure analogous to that described in Example 1. Yield: 69% of theory; LC (method 6): tR = 0.99 min; Mass spectrum (ESI+): m/z = 357 [M+Hf.
Example 154 c/s-1-(1H-Benzoimidazole-5-carbonvD-2.3,4,4a,9.9a-hexahvdro-1H-indenof2.1-blpyridine-6carboxylic acid methvl ester
A flask charged with a stir bar, trifluoromethanesulfonic acid c/s-1-(1-trifluoromethane-sulfonyl1H-benzoimidazole-5-carbonyl)-2,3,4,4a.9,9a-hexahydro-1H-indeno[2,1-b]pyridin-6-yl ester (mixture of isomers regarding sulfonyl group attachment to N-1 or N-3 of the benzimidazole, 0.50g), triethylamine (0.18 mL), N.N-dimethylforrnamide (2 mL), and methanol (1 ml) is sparged with argon for 5 min. [1,T-Bis(diphenylphosphino)ferrocene]-dichloropalladium dichloromethane
167 complex (53 mg) is added and the mixture is sparged with carbon monoxide for another 5 min. The mixture is then heated to 70 eC under carbon monoxide atmosphère (4 bar) and shaken at this température overnight. After cooling to room température, the mixture is filtered and the filtrate is concentrated under reduced pressure. The residue is chromatographed on silica gel (dichloromethane/methanol 1:0—>9:1 ) to afford the title compound. Yield: 0.27 g (87% of theory); LC (method 1): tR = 2.43 min; Mass spectrum (ESI*): m/z = 376 [M+H]*.
Example 155 (1H-Benzoimidazol-5-vlÎ-(c/s-6-ethvnvl-2,3,4,4a,9,9a-hexahvdro-indeno[2,1-blpyridin-1-vl)methanone
A flask charged with a stir bar, trifluoromethanesulfonic acid c/s-1-(1-trifluoromethane-sulfonyl1H-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-6-yl ester (mixture of isomers regarding sulfonyl group attachment to N-1 or N-3 of the benzimidazole, 0.20 g) and Ν,Ν-dimethylformarnide (2 mL) is sparged with argon for 5 min. Copper(l) iodide (13 mg), Pd(PPh3)2CI2 (25 mg), triethylamine (0.31 mL), and trimethylsilylacetylene (0.14 mL) are added in the given order, the vessel is sealed, and the resulting mixture is heated to 60 ’C. After stirring the mixture at 60 °C overnight, it is cooled to room température and aqueous K2CO3 solution is added. The resulting mixture is extracted with ethyl acetate, the combined extract is dried (Na2SO4), and the solvent is evaporated. The residue is chromatographed on silica gel (dichloromethane/methanol 1:0->9:1) to afford the trimethylsilylated title compound which is taken up in methanoi (3 mL) and treated with saturated aqueous K2CO3 solution at room température for 2 h. The mixture is then concentrated, water is added to the residue, and the resulting mixture is extracted with ethyl acetate. The combined extract is dried (Na2SO4) and concentrated. The residue is chromatographed on silica gel (dichloromethane/methanol 1:0->9:1 ) to afford the title compound. Yield: 0.03 g (26% of theory); LC (method 1 ): tR = 2.65 min; Mass spectrum (ESl·): m/z = 342 [M+H]4.
Example 156 (1H-Benzoimidazol-5wl)-(c/s-6-hvdroxvmethvl-2,3,4,4a,9,9a-hexahvdro-indeno[2,1-blpvridin-1-
vl)-methanone
168
The title compound is prepared from c/s-1-(1H-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9ahexahydro-IH-indeno^.l-bJpyridine-e-carboxylic acid methyl ester following a procedure analogous to that described in Example 34. Yield: 30% of theory; LC (method 1 ): tR = 1.87 min;
Mass spectrum (ESC): m/z = 348 [M+H]*.
Example 157 (1H-Benzoimiciazol-5-vl)-ic/s-6-(1-hvdroxv-1-methvl-ethvl )-2,3,4l4al9,9a-hexahydro-indeno[2,1blpyridin-1 -yll-methanone
The title compound is prepared from c/s-1-(1H-benzoimidazole-5-carbonyl)-2,3,4,4a.9,9ahexahydro-1H-indeno[2,1-b]pyridine-6-carboxylic acid methyl ester following a procedure analogous to that described in Example 41 except for using MeLi instead of MeMgBr. Yield: 21% of theory; LC (method 1): tR= 2.13 min; Mass spectrum (ESC): m/z = 376 [M+H]*.
Example 158 (1H-Benzoimidazol-5-vl)-(c/s-6-phenyl-2,3,4.4a,9.9a-hexahvdro-indeno[2,1-blpvridin-1-yl)methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and c/s-6-phenyl2l3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1. Yield: 63% of theory; LC (method 1): tR = 3.28 min; Mass spectrum (ESC): m/z = 394 [M+H]*.
Example 159 (1H-Benzoimidazol-5-vl)-(c/s-6-phenvlethvnyl-2.3,4.4a.9.9a-hexahvdro-indeno[2.1-blpyridin-1vl)-methanone
The title compound is prepared from c/s-1-(1-trifluoromethane-sulfonyl-1H-benzoimidazole-5carbonylJ^.S^^a.g.Oa-hexahydro-IH-indeno^.l-bJpyridin-e-yl ester (mixture of isomers regarding sulfonyl group attachment to N-1 or N-3 of the benzimidazole) and phenylacetylene
169 following a procedure analogous to that described in Example 155; in case the sulfonyl group on one of the benzimidazole nitrogens is not completely removed after the reaction, the mixture is treated with 1-hydroxy-benzotriazole and water. Yield: 24% of theory; LC (method 1): tR = 3.58 min; Mass spectrum (ESI+): m/z = 418 [M+H]+.
Example 160 (1H-Benzoimidazol-5-vl)-(c/s-6-furan-3-yl-2,3,4,4a,9,9a-hexahydro-indeno[2,1-blpyridin-1-vl)methanone
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and c/s-6-furan-3-yl2,3,4,4a,9,9a-hexahydro-1 H-indeno[2,1 -bjpyridine following a procedure analogous to that described in Example 1. Yield: 14% of theory; LC (method 1): tR = 2.89 min; Mass spectrum (ESI+): m/z = 384 [M+H]+.
Example 161 dH-Benzoimidazol-5-vl)-(c/s-6-DroD-1-vnvl-2,3,4l4a,9,9a-hexahvdro-indenoi2,1-blDvridin-1-yl)methanone
The title compound is prepared from c/s-1-(1-trifluoromethane-sulfonyl-1H-benzoimidazole-5carbonyl)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-6-yl ester (mixture of isomers regarding sulfonyl group attachment to N-1 or N-3 of the benzimidazole) and propyne following a procedure analogous to that described in Example 155; in case the sulfonyl group on one of the benzimidazole nitrogens is not completely removed after the reaction, the mixture is treated with 1-hydroxy-benzotriazole and water. Yield: 30% of theory; LC (method 1): tR = 2.92 min; Mass spectrum (ESC): m/z = 356 [M+H]+.
Example 162 (1H-Benzoimidazol-5-vl)-fc/s-6-(Trnethvl-1 H-pvrazol-4-y0-2,3,4,4a,9,9a-hexahvdro-indenof2,1b]pvridin-1-yl1-methanone
170
The title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and c/s-6-(1-mehyl1H-pyrazol-4-yl)-2,3,4,4a,9,9a-hexahydrO’1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1. Yield: 78% of theory; LC (method 1): tR = 2.35 min;
Mass spectrum (ESI+): m/z = 398 [M+Hf.
Example 163 ( 1 H-Benzoimidazol-5-vlHc/s-6-methvl-2.3,4.4a,9,9a-hexahvdro-indenof2,1 -blpyridin-1 -vDmethanone
The title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and c/s-6-methyl2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine following a procedure analogous to that described in Example 1. Yield: 60% of theory; LC (method 1): tR = 2.75 min; Mass spectrum (ESf): m/z = 332 [M+Hf.
Example 164 (1H-Benzoimidazol-5-yll4cis-6-(tetrahydro-pvran-4-vl)-2,3,4,4a,9,9a-hexahvdro-indenol2.1 blpyridin-1-yll-methanone
A mixture of (1H-benzoimidazol-5-yl)-[6-(3,6-dihydro-2H-pyran-4-yl)-2,3,4,4al9,9a-hexahydroindeno[2,1-b]pyridin-1-yl]-methanone (48 mg), 10% palladium on carbon (10 mg), and methanol (3 mL) is shaken under hydrogen atmosphère (5 bar) at room température overnight. The catalyst is then separated by filtration and the filtrate is concentrated. The residue is purified by chromatography on silica gel (dichloromethane/methanol 1:0-+9:1 ) to afford the title compound. Yield: 15 mg (31% of theory); LC (method 1): tR = 2.63 min; Mass spectrum (EST): m/z = 402 [M+Hf.
Example 165 (1H-Benzoimidazol-5-vl)-(c/s-6-cyclopentvl-2.3,4.4a,9.9a-hexahvdro-indeno|2.1-b1pyridin-1-vDmethanone
171
The title compound is prepared from (1H-benzoimidazol-5-yi)-(6-cyclopent-1-enyl-2,3.4,4a(9,9ahexahydro-indeno[2,1-b]pyridin-1-yl)-methanone following a procedure analogous to that described in Example 164. Yield: 50% of theory; LC (method 1): tR = 3.53 min; Mass spectrum (ESl*): m/z = 386 [M+H]*.
Example 166
N-[ç/s-1-(1 H-Benzoimidazole-5-carbonvl 1-2,3,4,4a,9,9a-hexahydro-1H-indeno|2.1-blDvridin-7vll-acetamide
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and N-(c/s2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-7-yl)-acetamide following a procedure analogous to that described in Example 1. Yield: 34% of theory; LC (method 1 ): tR = 1.97 min; Mass spectrum (ESl*): m/z = 375 [M+H]*.
Example 167
N-[c/s-1-(1H-Benzoimidazole-5-carbonvl)-2,3,4,4a,9,9a-hexahvdro-1H-indeno[2,1-b]pvridin-7-
H N
N />
The title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and N-(c/s2,3,4,4a,9,9a-Hexahydro-1H-indeno[2,1-b]pyridin-7-yl)-methanesulfonamide following a procedure analogous to that described in Example 1. Yield: 7% of theory; LC (method 1 ): tR = 2.07 min; Mass spectrum (ESl*): m/z = 411 [M+H]*,
Example 168 (1H-Benzoimidazol-5-vl)-(c/s-6-hydroxv-7-nitro-2,3,4,4a<9,9a-hexah¥dro-indenor2,1-b]pvridin-1-
vl)-methanone
172
The title compound is prepared from 1H-benzoimidazole-5-carboxylic acid and c/s-7-nitro2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridin-6-ol following a procedure analogous to that described in Example 1. Yield: 32% of theory; LC (method 1): tR = 2.43 min; Mass spectrum (ESI+): m/z = 379 [M+HJ*.
Example 169 (c/s-7-Amino-6-hvdroxy-2,3.4.4at9,9a-hexahvdro-indenor2.1-blpvridin-1-vD-(1H-benzoimidazol·
5-vD-methanone
A mixture of (1H-benzoimidazol-5-yl)-(c/s-6-hydroxy-7-nitro-2,3,4,4a,9,9a-hexahydro-indeno[2,1b]pyridin-1-yl)-methanone(O.56 g), 10% palladium on carbon (50 mg), and methanol (10 mL) is shaken under hydrogen atmosphère (1 bar) at room température for 3 h. The catalyst is separated by filtration and the filtrate is concentrated. The residue is chromatographed (dichloromethane/methanol 1:1 —>7:3) to give the title compound. Yield: 0.32 g (63% of theory); LC (method 1 ): tR = 0.65 min; Mass spectrum (ESI+): m/z = 349 [M+Hf.
Example 170 (1H-Benzoimidazol-5-vl)-(c/s-2-methvl-4b,5.6.7,8a.9-hexahvdro-3-oxa-1,8-diazacvclopentafblfluoren-8-vÎ)-methanone
(c/s-7-Amino-8-hydroxy-2,3,4,4a,9,9a-hexahydro-indeno[2,1-b]pyridin-1-yl)-(1H-benzoimidazol5-yl)-methanone (0.10 g) in triethyl orthoformate (0.5 mL) is stirred at 60 DC for 2 h. After cooling to room température, the mixture is concentrated and the residue is chromatographed on silica gel (dichloromethane/methanol 1:0—>7:3) to afford the title compound. Yield: 64% of theory; LC (method 1): tR = 2.28 min; Mass spectrum (ESI*): m/z = 373 [M+Hf.
173
Example 171
HH~Benzoimidazo[-5-vl)-(c/s-4b,5l6,7,8a,9-hexahydro-3-oxa-1,8-diaza-cvclopenta[b1fluoren-8yl)-methanone
A mixture of (cîs-7-amÎno-8-hydroxy-2,3,4,4a,9,9a-hexahydro-indeno[2l1-b]pyridin-1-yl)-(1Hbenzoimidazol-5-yl)-methanone (100 mg), 4-toluenesulfonic acid hydrate (5 mg), triethyl orthoformate (40 pL), and methanol (1 mL) is stirred at 60 °C for 2 h. After cooling to room température, the mixture is concentrated and the residue is dissolved in ethyl acetate. The resulting solution is washed with 1 M NaOH solution, dried (NaaSO^), and concentrated to give the title compound. Yield: 50 mg (49% of theory); LC (method 1 ): tR = 2.24 min; Mass spectrum (ESl*): m/z = 359 [M+Hf.
Example 172 (1H-Benzoimidazol-5-vl)-(c/.s-6-methoxv-7-methyl-2,3,4,4a.9,9a-hexahvdro-indeno[2,1-blpyridin1-vl)-methanone
The title compound is prepared from 1 H-benzoimidazole-5-carboxylic acid and c/s-6-methoxy-7methyl-2,3,4,4a,9,9a-hexahydro-lH-indeno[2,1-b]pyridinefollowing a procedure analogous to that described in Example 1. LC (method 7): tR = 1.04 min; Mass spectrum (ESl*): m/z = 362 [M+H]*.
Example 173 (1H-Benzoimidazol-5-vl)-(c/s-6-hvdroxv-7-methvl-2.3.4.4a,9.9a-hexahvdro-indenor2.1-blpvridin1-vl)-methanone
The title compound is prepared from (IH-benzoïmidazol-S-ylXc/s-e-methoxy-T-methylZ.S^^a.g.Ga-hexahydro-indenop.l-bJpyridin-l-ylJ-methanone following a procedure analogous
174 to that described in Example 7. LC (method 7): tR = 0.82 min; Mass spectrum (ESI ): m/z - 348 [M+HJ*.
Examples 174 and 175 (4a-f?,9a-S)-1 -(1H-Benzoimidazole-5-carbonvl)-7-methvl-2.3,4.4a.9.9a-hexahvdro-lHindeno[2,1-blpvridine-6-carbonitriie (174) and (4a-S,9a-f?)-1-(1H-Benzoimidazole-5-carbonyl)-7methvl-2,3,4,4a.9,9a-hexahvdro-1H-indeno[2.1-blDvridine-6-carbonitrile (175) (The absolute configuration of the two compounds is arbitrarily assiqned)
The title compounds are prepared from trifluoromethanesulfonic acid c/s-7-methyl-1-(1trifluoromethanesulfonyl-1 H-benzoimidazole-5-carbonyl)-2,3,4,4al9,9a-hexahydro-lHindeno[2,1-b]pyridin-6-yl ester (mixture of isomers regarding sulfonyl group attachment at N-1 or N-3 of the benzimidazole) and zinc cyanide following a procedure analogous to that described in Example 106; the title compounds are separated by SFC on chiral phase.
(4a-Rl9a-S)-1-(1H-Benzoimidazole-5-carbonyl)-7-methyl-2,3,4,4a,9,9a-hexahydro-1Hindeno[2,1-b]pyridine-6-carbonitrile (174): LC (method 7): tR =0.88 min; Mass spectrum (ESI+): m/z = 357 [M+H]4, 379 [M+Na]4.
(4a-S,9a-/?)-1-( 1 H-Benzoimidazole-5-carbonyl)-7-methyl-2,3,4,4a,9,9a-hexahydro-1 Hindeno[2,1-b]pyridine-6-carbonitrile (175): LC (method 7): tR =0.88 min; Mass spectrum (ESI*): m/z = 357 [M+H]4, 379 [M+Na]4.
Examples 176 and 177 (4a-R9a-S)-1 -(1H-Benzoimidazole-5-carbonyl)-5-methvl-2,3l4.4a.9,9a-hexahvdro-1 Hindeno[2.1-b1pyridine-6-carbonitrile (176) and (4a-S.9a-R)-1-(1H-Benzoimidazole-5-carbonyl)-5methvl-2,3.4.4a.9,9a-hexahvdro-1H-indeno[2.1-blpyridine-6-carbonitrile (177) (The absolute configuration of the two compounds is arbitrarilv assiqned)
The title compounds are prepared from trifluoromethanesulfonic acid c/s-5-methyl-1-(1trifluoromethanesulfonyl-1 H-benzoimidazole-5-carbonyl )-2,3,4,4a,9,9a-hexahydro-1Hindeno[2,1 -b]pyridin-6-yl ester (mixture of isomers regarding sulfonyl group attachment at N-1 or
N-3 of the benzimidazole) and zinc cyanide following a procedure analogous to that described in Example 106; the title compounds are separated by SFC on chiral phase. (4a-Rl9a-S)-1-(1H-Benzoimidazole-5-carbonyl)-5-methyl-2,3,4(4al9,9a-hexahydro-1Hindeno[2,1-b]pyridine-6-carbonitrile (176): LC (method 7): tR =0.89 min; Mass spectrum (EST): 5 m/z = 357 [M+Hf, 379 [M+Naf.
(4a-S(9a-R)-1-(1H-Benzoimidazole-5-carbonyl)-5-methyî-2l3,4,4a,9,9a-hexahydro-1Hindeno[2,1-b]pyridine-6-carbonitrile (177): LC (method 7): tR =0.89 min; Mass spectrum (EST): m/z = 357 [M+Hf, 379 [M+Naf.
176
Some examples of formulations will now be described in which the term active substance dénotés one or more compounds according to the invention, including the salts thereof. In the case of one of the combinations with one or additional active substances as described previously, the term active substance” also includes the additional active substances.
Example A
Tablets containing 100 mg of active substance
Composition:
tablet contains:
active substance | 100.0 mg |
lactose | 80.0 mg |
corn starch | 34.0 mg |
polyvinylpyrrolidone | 4.0 mg |
magnésium stéarate | 2.0 mg |
220.0 mg |
Method of Préparation:
The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50°C it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.
Weight of tablet: 220 mg
Diameter; 10 mm, biplanar, facetted on both sides and notched on one side.
Example B
Tablets containing 150 mg of active substance
Composition:
tablet contains:
active substance | 150.0 mg |
powdered lactose | 89.0 mg |
corn starch | 40.0 mg |
colloïdal silica | 10.0 mg |
polyvinylpyrrolidone | 10.0 mg |
magnésium stéarate | 1.0 mg |
300.0 mg |
177
Préparation:
The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. Thegranules, dried at45°C, are passed through the same screen again and mixed with the specified amount of magnésium stéarate. Tablets are pressed from the mixture.
Weight of tablet: 300 mg die: 10 mm, fiat
Example C
Hard gélatine capsules containing 150 mg of active substance
Composition:
capsule contains:
active substance | 150.0 mg | |
corn starch (dried) | approx. | 180.0 mg |
lactose (powdered) | approx. | 87.0 mg |
magnésium stéarate | 3.0 mg | |
approx. | 420.0 mg |
Préparation:
The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gélatine capsules.
Capsule filling: approx. 320 mg
Capsule shell: size 1 hard gélatine capsule.
Example D
Suppositories containing 150 mg of active substance
Composition:
suppository contains: active substance polyethyleneglycol 1500 polyethyleneglycol 6000 polyoxyethylene sorbitan
150.0 mg
550.0 mg
460.0 mg monostearate 840.0 mg
2,000.0 mg
178
Préparation:
After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moutds.
Example E
Ampoules containing 10 mg active substance
Composition:
active substance 10.0 mg
0.01 N hydrochloric acid q.s.
double-distilled water ad 2.0 mL
Préparation:
The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonie with common sait, filtered stérile and transferred into 2 mL ampoules.
Example F
Ampoules containing 50 mg of active substance
Composition:
active substance 50.0 mg
0.01 N hydrochloric acid q.s.
double-distilled water ad 10.0 mL
Préparation:
The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonie with common sait, filtered stérile and transferred into 10 mL ampoules.
Claims (39)
- We claim:1. A compound represented by the following structural formula:wherein at least 50 % by weight of the compound is crystalline.
- 2. A compound represented by the following structural formula:wherein at least 50 % by weight of the compound is a single crystalline form.
- 3. A compound represented by the following structural formula:wherein at least 99% by weight of the compound is a single crystalline form.
- 4, The compound of any one of Claims 1-3, wherein at least 50 % by weight of the compound is crystalline Form I.
- 5. The compound of any one of Claims 2-4, wherein the single crystalline form is characterized by at least three x-ray powder diffraction peaks at 2T angles selected from 12.5°, 12.9°, 14.8°, 20.0°, 22.2° and 26.1°.
- 6. The compound of any one of Claims 2-4, wherein the single crystalline form is characterized by at least four x-ray powder diffraction peaks at 2T angles selected from 12.5°, 12.9°, 14.8°, 20.0°, 22.2° and 26.1°.180
- 7. The compound of any one of Claims 2-4, wherein the single crystalline form is characterized by at least five x-ray powder diffraction peaks at 2T angles selected from 12.5°, 12.9°, 14.8°, 20.0°, 22.2° and 26.1°.
- 8. The compound of any one of Claims 2-4, wherein the single crystalline form is characterized by x-ray powder diffraction peaks at 2T angles 12.5°, 12.9°, 14.8°, 20.0°, 22.2° and 26.1°.
- 9. The compound of any one of Claims 2-4, wherein the single crystalline form is characterized by at least three x-ray powder diffraction peaks at 2T angles selected from 12.5°, 14.8°, 22.2° and 26.1°.
- 10. The compound of any one of Claims 2-4, wherein the single crystalline form is characterized by x-ray powder diffraction peaks at 2T angles 12.5°, 14.8°, 22.2° and 26.1°.
- 11. The compound of any one of Claims 2-4, wherein the single crystalline form is characterized by major x-ray powder diffraction peaks at 2T angles 12.5°, 14.8°, 22.2° and 26.1°.
- 12. The compound of any one of Claims 2-4, wherein the single crystalline form is characterized by the x-ray powder diffraction pattern of FIG. 1.
- 13. The compound of any one of Claims 2-12, wherein the single crystalline form is characterized by at least ten 13C solid-state nuclear magnetic résonance peaks at chemical shïfts selected from 170.3 ppm, 146.5 ppm, 142.8 ppm, 135.0 ppm, 130.6 ppm, 128.1 ppm, 122.1 ppm, 116.7 ppm, 115.6 ppm, 112.8 ppm, 109.8 ppm, 107.6 ppm, 44.6 ppm, 43.3 ppm, 41.4 ppm, 30.3 ppm, 26.3 ppm and 23.9 ppm.
- 14. The compound of any one of Claims 2-12, wherein the single crystalline form is characterized by 13C solid-state nuclear magnetic résonance peaks at chemical shifts of 170.3 ppm, 146.5 ppm, 142.8 ppm, 135.0 ppm, 130.6 ppm, 128.1 ppm, 122.1 ppm,116.7 ppm, 115.6 ppm, 112.8 ppm, 109.8 ppm, 107.6 ppm, 44.6 ppm, 43.3 ppm, 41.4 ppm, 30.3 ppm, 26.3 ppm and 23.9 ppm.
- 15. The compound of any one of Claims 1-3, wherein the compound is crystalline Form II.181
- 16. The compound of any one of Claims 2, 3 or 15, wherein the single crystalline form is characterized byx-ray powder diffraction peak at 2T angles 13.7°, 17.6°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°.
- 17. The compound of any one of Claims 2, 3 or 15, wherein the single crystalline form is characterized x-ray powder diffraction peaks at 2T angles 13.7°, 17.6°, 19.7,21.3°, 21.9*, 23.3°, 25.6° and 26.5°.
- 18. The compound of any one of Claims 2, 3 or 15, wherein the single crystalline form is characterized byx-ray powderdiffraction peaks at 2T angles 13.7°, 17.6°, 19.7, 20.9, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°.
- 19. The compound of any one of Claims 2, 3 or 15, wherein the single crystalline form is characterized byx-ray powderdiffraction peaks at 2T angles 13.7°, 17.6°, 19.3, 19.7, 20.9, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°.
- 20. The compound of any one of Claims 2, 3 or 15, wherein the single crystalline form is characterized byx-ray powderdiffraction peaks at 2T angles 13.3°, 13.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°.
- 21. The compound of any one of Claims 2, 3 or 15, wherein the single crystalline form is characterized by at least seven x-ray powder diffraction peaks at 2T angles selected from 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7e, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°.
- 22. The compound of any one of Claims 2, 3 or 15, wherein the single crystalline form is characterized by at least eight x-ray powder diffraction peaks at 2T angles selected from 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°.
- 23. The compound of any one of Claims 2, 3 or 15, wherein the single crystalline form is characterized by at least nine x-ray powder diffraction peaks at 2T angles selected from 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°.
- 24. The compound of any one of Claims 2, 3 or 15, wherein the single crystalline form is characterized by at least ten x-ray powder diffraction peaks at 2T angles selected from 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7’, 20.9°, 21.3°, 21.9°, 23.3°, 25.6’ and 26.5°.182
- 25. The compound of any one of Claims 2, 3 or 15, wherein the single crystalline form is characterized by at least eleven x-ray powder diffraction peaks at 2T angles selected from 13.3°, 13.7’, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°.
- 26. The compound of any one of Claims 2, 3 or 15, wherein the single crystalline form is characterized by x-ray powder diffraction peaks at 2T angles selected from 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°.
- 27. The compound of any one of Claims 2, 3 or 15, wherein the single crystalline form is characterized by major x-ray powder diffraction peaks at 2T angles selected from 13.7°, 17.6°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°.
- 28. The compound of any one of Claims 2, 3 or 15, wherein the single crystalline form is characterized by x-ray powder diffraction pattern of FIG. 5.
- 29. The compound of any one of Claims 2, 3 or 15-28, wherein the single crystalline form is characterized by at least ten 13C solid-state nuclear magnetic résonance peaks at chemical shifts selected from 172.6 ppm, 147.1 ppm 144.1 ppm, 132.9 ppm 129.6 ppm, 125.9ppm 121.2 ppm, 119.5 ppm, 117.7 ppm, 114.6 ppm, 110.2 ppm, 45.1 ppm, 42.4 ppm, 32.6 ppm, 28.3 ppm and 24.4 ppm.
- 30. The compound of any one of Claims 2, 3 or 15-28, wherein the single crystalline form is characterized by 13C solid-state nuclear magnetic résonance peaks at chemical shifts of 172.6 ppm, 147.1 ppm 144.1 ppm, 132.9 ppm 129.6 ppm, 125.9 ppm 121.2 ppm, 119.5 ppm, 117.7 ppm, 114.6 ppm, 110.2 ppm, 45.1 ppm, 42.4 ppm, 32.6 ppm, 28.3 ppm and 24.4 ppm.
- 31. A pharmaceutical composition comprising the compound of any one of Claims 1-30 and a pharmaceutically acceptable carrier or diluent.
- 32. A compound or pharmaceutical composition according to any one of the preceding claims, for the treatment or prévention of diseases or conditions which can be influenced by inhibiting the enzyme 11B-hydroxysteroid dehydrogenase (HSD) 1.
- 33. The compound of claim 32, wherein the disease or condition which can be influenced by inhibiting the enzyme 11B-hydroxysteroid dehydrogenase (HSD) 1 is a metabolic disorder.183
- 34. A method for producing crystalline form I of a compound represented by the following structural formula (II):the method comprising:dissolving a free base represented by the following structural formula (III):protonating the dissolved free base with hydrochloric acid; and allowing crystalline form I to form by cooling the dissolved protonated free base (e.g., at a température below about 30°C.
- 35. A method for producing crystalline form II of a compound represented by the following structural formula (II):the method comprising:contacting a compound represented by structural formula (II) with éthanol to form a suspension, and stirring the suspension for a period of time sufficient to form crystalline form II.
- 36. A method for producing crystalline form II of a compound represented by the following structural formula (II):the method comprising184 dissolving a compound represented by structural formula (II) in ethyl acetate at a température above about 40°C; and allowing crystalline form II to form by cooling the dissolved compound (e.g., at a température below about 15°C).
- 37. A method for producing crystalline form II of a compound represented by the following structural formula (II):the method comprising:dissolving a free base represented by the following structural formula (lll):in isopropanol at a température above about 40°C;protonating the free base with hydrochloric acid; and allowing crystalline form II to form by cooling the dissolved protonated free base (e.g., at a température below about 15°C).
- 38. A method for producing crystalline form II of a compound represented by the following structural formula (II):the method comprising dissolving a free base represented by the following structural formula (lll):185 protonating the dissolved free base with hydrochloric acid and maintaining the dissolved protonated free base at a température above 40°C for at least two hours; and allowing crystallineform II to form by cooling the dissolved protonated free base (e.g., ata température belowabout 15’C).
- 39. A method according to claim 35 or claim 38, wherein the éthanol is 200 proof absolute éthanol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USPCT/US2010/055586 | 2010-11-05 | ||
US61/484,995 | 2011-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16399A true OA16399A (en) | 2015-10-07 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9663470B2 (en) | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | |
US9120769B2 (en) | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | |
CA2704628C (en) | Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | |
CA2711757C (en) | Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | |
CA2738453C (en) | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | |
CA2735204C (en) | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | |
AU2017209935A1 (en) | New substituted cyanoindoline derivatives as NIK inhibitors | |
TW202200574A (en) | Bcl-2 inhibitor | |
KR20230019431A (en) | Iminosulfanone inhibitor of ENPP1 | |
OA16399A (en) | Crystalline forms of hydrochloride salt of (4AR, 9A-S)-1-(1H-benzoimidazole-5-car-bonyl)-2, 3, 4, 4A 9, 9A-hexahydro-1H-indeno[2, 1-B] pyridine6-carbonitrile and their use as HSD 1 inhibitors. | |
OA16619A (en) | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydro benzoquinoline. |